Effects of serotonin signaling on behavior and gene transcription. A journey through postnatal brain development by Kroeze, Y.L.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/183318
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Effects of serotonin signaling on 
behavior and gene transcription 
A journey through postnatal brain development
Yvet Kroeze
The research presented in this thesis was carried out at the Department of Cognitive 
Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Neuroscience, 
Radboud university medical center, Nijmegen, the Netherlands, with financial support from 
the Donders Centre for Neuroscience and the Dutch Brain Foundation (grand number 
2013(1)-24).
ISBN: 978-94-6284-130-7
Lay-out: Yvet Kroeze
Cover design: Promotie In Zicht, Arnhem
Printed by:  Ipskamp Printing, Enschede
© Yvet Kroeze, 2017
All rights reserved. No part of this thesis may be reported or transmitted, in any form or by 
any means, without permission of the author.
Effects of serotonin signaling on 
behavior and gene transcription 
A journey through postnatal brain development
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op vrijdag 2 februari 2018
om 12.30 uur precies
door
Yvet Laura Kroeze
geboren op 19 oktober 1985
te Almelo
Promotor:  
Prof. dr. J.H.L.M. van Bokhoven
Copromotoren:  
Dr. J.R. Homberg
Dr. H. Zhou
Manuscriptcommissie:
Prof. dr. L.T. Kozicz (voorzitter)
Prof. dr. R.J. Verkes
Prof. dr. M.J.H. Kas (Rijksuniversiteit Groningen)  
Table of Contents
Chapter 1 General introduction and outline of the thesis
Chapter 2 The genetics of selective serotonin reuptake inhibitors
  Pharmacol Ther. 2012 Dec;136(3):375-400
Chapter 3 Long-term consequences of chronic fluoxetine exposure on the 
expression of myelination-related genes in the rat hippocampus
 Transl Psychiatry. 2015 Sep; 5(9): e642
Chapter 4 Perinatal reduction of functional serotonin transporters results 
in developmental delay
  Neuropharmacology. 2016 Oct;109:96-111
Chapter 5 Transcriptome analysis identifies multifaceted regulatory 
mechanisms dictating a genetic switch from neuronal network 
establishment to maintenance during postnatal prefrontal 
cortex development
  Cereb Cortex. 2017 Jan 19. doi: 10.1093/cercor/bhw407 
Chapter 6 Genetic inactivation of the serotonin transporter dysregulates 
expression of neurotransmission and myelination genes in the 
postnatal medial prefrontal cortex of the rat
  In preparation
Chapter 7 General discussion and future perspectives
Chapter 8 English summary
  Nederlandse samenvatting
Chapter 9 Dankwoord
  Curriculum Vitae
  List of publications
  List of abbreviations 
  Donders series
 
7
37
85
115
147
185
217
239
243
251
257
259
261
262

1
General introduction
and outline of the thesis
8Chapter 1
9General introduction
1
Affective disorders
Affective disorders are a set of psychiatric diseases which typically affect mood. The main 
types of affective disorders are major depressive disorder (further called depression in 
this chapter), anxiety-related disorders and bipolar disorder. Affective disorders are among 
the leading causes of burden worldwide. Depression and anxiety-related disorders were, 
respectively, the second and sixth leading cause of years lived with disability in 20101,2. 
The 12 month prevalence of depression, bipolar disorder and anxiety-related disorders 
are respectively, 6.9 percent, 2.6 percent and 18 percent of all U.S. adults3,4. Pregnancy is 
a period with high risk for depression, particularly for women with pre-existing psychiatric 
disorders. The number of women that are depressed during pregnancy ranges between 7% 
and 26%5-8. Depression is often caused by experiencing unavoidable stress, while anxiety is 
caused by stressors which are avoidable and which are not present at that moment. The 
symptoms for each affective disorder can vary greatly, but there are some common signs. 
Depression is characterized by prolonged sadness, anxiety, lack of energy, lack of interest in 
normal activities (anhedonia), suicidal thoughts and major changes in eating and sleeping 
habits. Bipolar disorder is defined by unusual and chronic mood swings with during the 
depressive phase symptoms similar to those during depression and during the (hypo)manic 
phase people feel extremely positive and active with symptoms like, less sleep and feelings 
of exaggerated self-confidence, irritability, aggression, self-importance and impulsiveness. 
There are different types of anxiety-related disorders, which are all characterized by feelings 
of nervousness, anxiety and fear. All these symptoms can have a strong impact on people’s 
daily life. The Diagnostic and Statistical Manual of Mental Disorders, fifth revision (DSM-5)9 
and the International Classification of Diseases10 are the current standards by which affective 
disorders are classified and which provides the language by which clinicians, researchers, 
and public health officials communicate about mental disorders. Patients can be diagnosed 
for a specific affective disorder while displaying variable sets of symptoms, see Box 1. As a 
consequence, patients can vary considerably in clinical presentation. Besides the symptom-
based diagnosis of affective disorders there are also studies focusing on discovering new 
markers for the diagnosis of affective disorders, such as endophenotypes11,12. 
Box 1: DSM-5 Criteria
Major Depressive episode
A. Five or more of the following symptoms have been present and documented during 
the same two-week period and represent a change from previous functioning; at least 
one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure:
1. Depressed mood most of the day, nearly every day
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day 
3. Significant weight loss when not dieting or weight gain, or decrease or increase in 
appetite nearly every day
10
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Brain regions involved in affective disorders 
Years ago, a couple of brain structures were suggested to be responsible for emotion and 
emotional expression. This became known as the ‘limbic system,’ based on the ‘grand lobe 
limbique’ of Broca13. Limbic refers to an edge or border and in this case indicates the structures 
around the medial edge of the cerebral hemisphere. There is no universal agreement on the 
total list of structures which comprise the limbic system, but the best known limbic structures 
are the hypothalamus, the amygdala and the hippocampus. In addition, the prefrontal cortex 
(PFC) is a cortical region which has intensive neural connections with limbic structures and 
is implicated in emotion and affective disorders. I will briefly discuss the functions of these 
4. Insomnia or hypersomnia nearly every day
5. Psychomotor agitation or retardation nearly every day 
6. Fatigue or loss of energy nearly every day
7. Feelings of worthlessness or excessive or inappropriate guilt nearly every day 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing suicide
B. The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning
C. The episode is not attributable to the physiological effects of a substance or to another 
medical condition.
Generalized Anxiety Disorder
A. Excessive anxiety and worry, occurring more days than not for at least 6 months, about a 
number of events or activities
B. The individual finds it difficult to control the worry
C. The anxiety and worry are associated with three (or more) of the following six symptoms 
(with at least
some symptoms having been present for more days than not for the past 6 months):
1. Restlessness, feeling keyed up or on edge
2. Being easily fatigued
3. Difficulty concentrating or mind going blank
4. Irritability
5. Muscle tension
6. Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying                        
    sleep)
D. The anxiety, worry, or physical symptoms cause clinically significant distress or impairment 
in social, occupational, or other important areas of functioning
E. The disturbance is not attributable to the physiological effects of a substance or another 
medical condition 
F. The disturbance is not better explained by another medical disorder
11
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brain regions and their relation with affective disorders, with the main focus on the PFC and 
the hippocampus, since these structures are used for molecular experiments in this thesis.
The amygdala has a primary role in emotional reactions and also in the processing of 
memory and decision-making14,15. The cortical projections of the amygdala are widespread, 
but the strongest connections are with the medial PFC (mPFC)16. The hypothalamus 
contains a number of small nuclei with a variety of functions, amongst others, controlling 
body temperature, hunger, fatigue, sleep, circadian rhythms and response to stress. The 
hypothalamus links the nervous system to the endocrine system via the pituitary gland 
(hypophysis). With regard to stress, the paraventricular nucleus of the hypothalamus 
secretes corticotropin-releasing hormone, which is involved in a stress response via the 
hypothalamic–pituitary–adrenal axis (HPA axis), leading to the release of corticosterone17,18. 
The hippocampus plays important roles in spatial navigation, learning and the consolidation 
of information for long- and short-term memory. Although learning and memory is the main 
role of the hippocampus, it is strongly connected to parts of the brain that are involved 
in emotional behavior, like the amygdala19. The glutamatergic pyramidal and granule cells 
represent 90% of hippocampal neurons and the remaining 10% are primarily γ-aminobutyric 
acid (GABA)-producing interneurons19,20. In addition, receptors from other neurotransmitters, 
such as serotonin21-23, are also present in the hippocampus. The laminae that make up the 
hippocampus consist of the dentate gyrus (DG), the cornu Ammonis (CA) and the hilus 
(also called CA4). The cornu Ammonis can be divided into three regions, termed CA1–CA3, 
based on pyramidal neuron morphology and sensitivity to anoxia19. The DG consists of three 
layers of neurons; molecular, granular and polymorphic layer. The granular layer is most 
prominent and contains granule cells that project to the CA3 region24. The DG is one of the 
two brain regions where adult neurogenesis takes place. In patients with depression a smaller 
hippocampal volume has been observed25. Volume reductions of the hippocampus might be 
the result of remodeling of key cellular elements, involving retraction of dendrites, decreased 
neurogenesis in the DG and loss of glial cells26-30. Adult neurogenesis in the DG has been shown 
to be reduced in depressed patients and can be increased by antidepressant treatment31. 
The PFC, as a conglomerate of subregions, is implicated in a plethora of cognitive functions, 
such as working memory, attention, arousal, decision making, moderating social behavior, 
behavioral inhibition, and motivation32. Each subregion of the PFC has its own specific role in 
cognition. The dorsolateral PFC (DLPFC) is involved in working memory; the ventrolateral PFC 
(VLPFC) plays a role in decision making and goal-directed behavior; the orbitofrontal cortex 
(OFC) signals the valence of predictive stimuli, and the mPFC exerts control over emotion and 
motivation32-35. The PFC is affected in many, if not all, neuropsychiatric disorders. For example, 
in several subregions of the PFC a reduction in gray matter volume has been observed in 
depression and bipolar disorder, with the most prominent volumetric abnormality reported 
in the anterior cingulate cortex (ACC) of the mPFC36. Furthermore, decreased mPFC neuronal 
activity is associated with depression- and anxiety-like behaviors in mice37. Recent evidence 
indicates that the mPFC is critical for the extinction of fear. Moreover, a dorsal-ventral 
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distinction is apparent within the mPFC, such that the rodent prelimbic cortex drives the 
expression of fear, whereas the rodent infralimbic cortex suppresses these behaviors after 
extinction. Posttraumatic stress disorder (PTSD) patients exhibit disturbed extinction of fear 
and a decreased activity within the ventral mPFC is observed in these patients when exposed 
to traumatic reminders38-40. 
The serotonergic system
Aberrant serotonin (5-hydroxytryptamine, 5-HT) signaling in the brain is associated with 
affective disorders41-43. Decades ago, studies showed that low extracellular 5-HT levels in 
the brain and a diminished activity of the serotonergic pathway play a causal role in the 
pathophysiology of depression44. Anxiety-related disorders and bipolar disorder are also 
associated with decreased serotonergic signaling45,46. 5-HT is a neurotransmitter primarily 
found in the gastrointestinal tract, blood platelets, and the central nervous system (CNS). 
Production of 5-HT takes place in the brain and the intestines. 5-HT can be found widely 
across the body and can influence a variety of body and psychological functions. 5-HT cannot 
cross the blood-brain barrier; therefore 5-HT that is used in the brain must be produced there. 
Brain-derived 5-HT plays a role in several psychological functions like mood, sleep, sexual 
activity, emotions and appetite. In the brain 5-HT is produced by the serotonergic neurons 
located in the raphe nuclei in the brainstem, which project to nearly all brain regions47. The 
majority of projections arise from the dorsal and median raphe nuclei48, which innervate 
the amygdala, basal forebrain, hypothalamus, thalamus, caudate-putamen, cerebral cortex, 
and part of the hippocampus47. Most (95%) of the 5-HT in the body is located in the gut49. 
The gut is surrounded by enterochromaffin cells, which release 5-HT in response to food in 
the lumen, resulting in contraction around the food. Besides peristalsis, 5-HT can mediate 
vasoconstriction and perception of pain or nausea through activation of a diverse family of 
5-HT receptors in the gastrointestinal tract50. Recent studies also suggest that gut-derived 
5-HT influences bone metabolism51. In the blood, 5-HT is derived from enterochromaffin cells 
of the intestine, but its plasma concentration is primarily regulated by circulating platelets52. 
5-HT acts as a vasoconstrictor to stop bleeding when platelets bind to damaged tissue and 
release 5-HT upon activation53. 
 5-HT belongs to the group of classical monoamines. Classical monoamines consist 
of histamine, catecholamines (epinephrine, norepinephrine, dopamine) and tryptamines 
(serotonin, melatonin), which all contain one amino group that is connected to an aromatic 
ring by a two-carbon chain (-CH2-CH2-). 5-HT is synthesized from tryptophan (Figure 1). 5-HT 
is taken up into storage vesicles and can be released from these vesicles into the extracellular 
space, where it can activate subtypes of the 5-HT receptor. At present, 16 different 5-HT 
receptor subtypes have been identified: 5-HT
1A, 1B, 1C, 1D, 1E, 1F
, 5-HT
2A, 2B, 2C
, 5-HT
3A, 3B
, 5-HT
4
, 
5-HT
5A
, 
5B,
 5-HT
6
 and 5-HT
7
. Each receptor can activate its own signal transduction pathway 
inside the postsynaptic neuron. The 5-HT3A and 3B receptors are ligand-gated ion channel 
receptors, while all others are G-protein coupled receptors. Each 5-HT receptor is associated 
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with different functions, as shown in Table 1, which is a consequence of the different locations 
and downstream pathways of each receptor. The 5-HT transporter (5-hydroxytryptamine 
transporter, 5-HTT) facilitates the reuptake of 5-HT from the synaptic cleft back into the 
presynaptic neuron. Within the presynaptic neuron, 5-HT would either be taken up by the 
storage vesicles or degraded by monoamine oxidase A (MAO-A) (Figure 1).  
Serotonin-related gene polymorphisms in affective disorders 
Genetic variations, such as mutations and polymorphisms, contribute to the etiology of 
affective disorders. Bipolar disorder is highly heritable with genetic influences explaining 60–
85% of the risk76, while depression and anxiety-related disorders have a considerably lower 
heritability of, respectively, 37%77 and 30-40%78. A polymorphism is a natural variation in a DNA 
sequence which occurs with fairly high frequency in the general population. Polymorphisms 
in genes coding for components of the serotonergic pathway are extensively studied in 
relation to affective disorders. A well-studied polymorphism is the 5-HTT-linked polymorphic 
region (5-HTTLPR). 5-HTTLPR is located in the promoter region of 5-HTT (SLC6A4 gene) about 
1kb upstream of the transcription start site79. The long (L) allele contains 16 repeats of a 20-
23 bp repetitive sequence, whereas the short (S) allele contains 14 repeats. The deletion of 2 
repeats is located 1212-1255 bp upstream of the transcription start site80,81. The S-allele is very 
common in the Caucasian population, with an allele frequency of around 40%. Frequencies 
differ between ethnicities, with lower S-allele frequencies in African-Americans (20-25%82) and 
higher frequencies in Asian populations (75-80%83,84). The S-allele is associated with reduced 
transcription of the SLC6A4 gene. The S/S and the S/L genotypes both show an approximately 
two-fold lower transcriptional efficiency compared to the L/L genotype, which implies that 
the S-allele is dominant over the L-allele regarding expression of the SLC6A4 gene.81,85. S-allele 
carriers have an increased risk of developing anxiety, depression and aggression85-88. The 
higher expression of the L-allele may be due to an A/G single nucleotide polymorphism (SNP) 
within the 5-HTTLPR of the L-allele, rs25531 (g.28564346A>G, dbSNP allele frequencies: A: 
86%, G: 14%, all genomic locations are based on GRCh37.p13), resulting in the La (L-like) 
and Lg (S-like) allelic variants89. The Lg allelic carriers have 5-HTT levels more similar to 
S-allele carriers and are associated with greater depression severity compared with the 
higher expressing La-allele90. In addition to 5-HTT, SNPs in 5-HT receptors are also associated 
with affective disorders. The HTR1A gene, encoding for the 5-HT1A receptor, contains a SNP, 
rs6295 (g.63258565G>C), which is related to the pathophysiology of affective disorders. The 
G variant of the rs6295 polymorphism in the promoter region of HTR1A has been associated 
with higher expression of 5-HT1A receptors, depression, completed suicide and less stressors 
preceding the need of hospitalization for bipolar disorder91,92. Genotype frequencies of the 
HTR2A polymorphism rs6313 (g.47469940C>T) are associated with suicidal behavior (T-allele) 
and schizophrenia (CC genotype)93,94. The C-allele is associated with lower mRNA and lower 
protein expression93. Tryptophan hydroxylase 2 (TPH2) is considered as a rate-limiting enzyme 
in 5-HT biosynthesis. It catalyses the conversion of tryptophan to 5-hydroxytryptophan (Figure 
14
Chapter 1
5-HT1/5
5-HTT
5-HT
5-HT2
5-HT3
5-HT4/6/75-HT1a
Gs
AC
Gi
Gq
AC
PLC
AADC
TPH
MAOTRYP
5-HIAA
5-HTP
ATP
cAMP
ATP
cAMP
PIP2
IP3    +  DAG
Na+      
  K+
Figure 1. Schematic overview of the serotonergic system in the central nervous system. Serotonin 
(5-hydroxytryptamine, 5-HT) is synthesized by the conversion of tryptophan (TRYP) to 5-hydroxytryptophan (5-HTP) 
catalyzed by tryptophan hydroxylase (TPH), followed by conversion of 5-HTP to 5-HT catalyzed by aromatic amino 
acid decarboxylase (AADC). 5-HT is taken up into storage vesicles and can be released from these vesicles into 
the synaptic space, where it can activate subtypes of the 5-HT receptor (1–7). Each can activate its own signal 
transduction pathway inside the postsynaptic neuron. 5-HT is taken up into the presynaptic neuron by the 5-HT 
transporter (5-HTT). Within the presynaptic neuron, 5-HT is taken up by the storage vesicles or degraded by 
monoamine oxidase (MAO). 5-HIAA, 5 hydroxyindolacetic acid; AC, adenylate cyclase; ATP, Adenosine triphosphate; 
cAMP, Cyclic adenosine monophosphate; PLC, Phospholipase C; DAG, diacylglycerol; IP3, inositol-1,4,5-trisphosphate; 
PIP2, phosphatidylinositol-4,5-bisphosphate.
Table 1. Biological processes and disorders associated with 5-HT receptors 
Receptor Receptor function and associated dysfunctional phenotypes  
5-HT1A Sleep
54, Pain55, Anxiety56, Depression56, Aggression57
5-HT
1B
Vasoconstriction58, Bone mass59, Aggression57
5-HT1D Vasoconstriction
58 
5-HT2A Urinary bladder contractions
60, Depression61, Anxiety43, Schizophrenia62
5-HT
2B
Cardiovascular functioning63,64
5-HT2C Appetite
65, Bone mass66, Depression67, Schizophrenia68
5-HT3 Emesis
69
5-HT
4
Movement of food70, Learning & memory71, Depression71
5-HT
5A
Memory consolidation72 
5-HT
6
Cognition73, Depression42, Anxiety42
5-HT
7 Sleep
74, Circadian rhythm74, Thermoregulation74, Vasodilation75, Locomotion, 
Pain75, Depression74,75
Note: Not for all receptors a function is known (yet), therefore several receptors are missing in this table 
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1). The A-allele of the TPH2 SNP rs120074175 (g.72425324G>A) showed an association with 
depression95. TPH1, sharing 70% homology in amino acid sequence with TPH2, is expressed in 
the gastrointestinal tract and pineal gland and is an important factor in the 5-HT synthesis96. 
It was found that the C-allele of the rs2108977 SNP (g.18040596T>C) of TPH1 conferred a 
protective effect against the development of PTSD97 and depression98. The rs1137070 SNP 
(g.43603391T>C) in MAOA, encoding for the mitochondrial enzyme catalyzing oxidative 
deamination of 5-HT, is associated with depression. The T-allele appeared with a significantly 
higher frequency in depressed female patients than in the control group99. However there are 
also several studies showing no association between SNPs in serotonergic genes and affective 
disorders100-103. 
Gene-environment interactions in affective disorders
It is becoming increasingly evident that the vulnerability to affective disorders is dependent 
on the interplay of the genome and the environment, also called gene-environment 
interactions. Environmental factors like stress, abuse, diet and trauma contribute to the 
etiology of affective disorders. Some people are more resilient to a certain environmental 
trigger than others, which can (at least partly) be explained by their genetic background. 
Genetic variants, such as the SNPs mentioned in the previous paragraph, confer differential 
susceptibility to a particular environmental factor. A mechanism by which environmental 
factors can influence gene expression is epigenetics. Epigenetics refers to modifications 
that occur on top of genetics (epi means on top of), which are modifications that influence 
gene expression without changing the DNA code. Examples of epigenetic modifications 
are DNA methylation and histone modifications. In addition, non-coding RNAs (ncRNAs) 
can influence gene expression (Figure 2). DNA methylation, a relatively stable mark, mainly 
occurs at cytosines present in cytosine-phosphate-guanine (CpG) sites and is catalyzed by 
DNA methyltransferases (DNMTs)104. In mammals, most patterns of DNA methylation are 
established during embryonic development by DNMT3A and DNMT3B and maintained by 
a DNMT1-mediated copying mechanism when cells divide105. DNA methylation of cytosines 
(5-methylcytosine, 5mC) is generally associated with repression of gene expression104. 
Aberrant DNA methylation patterns in the brain are linked to affective disorders106,107. 
Genome-wide twin studies showed aberrant DNA methylation in peripheral blood of 
depressed patients107. In addition, bipolar disorder is associated with aberrant DNA 
methylation observed in blood and brain tissue using several gene-specific and genome-wide 
approaches108. Anxiety has been shown to be associated with higher global levels of DNA 
methylation in the blood109. Also increased gene-specific DNA methylation was observed 
in saliva of older women with anxiety and depression110. Whether these DNA methylation 
changes are cause or consequence of the phenotype is unknown. 5-hydroxymethylcytosine 
(5hmC), created by oxidation of 5-methylcytosine (5mC) by TET proteins, is thought to be an 
intermediate step in the active demethylation process. However, there is increasing evidence 
that 5hmC is not simply an intermediate step, but also exerts its own regulatory functions such 
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as promoting genome stability, marking sites of DNA damage, regulation of gene expression 
and tissue differentiation111,112. 5hmC is highly abundant in the brain113. There are a few 
recent studies showing a potential link between 5hmC and early-life stress114 and early-life 
stress-induced anxiety115. Furthermore, lower 5hmC levels were observed in blood samples 
of bipolar disorder patients116. Histone modifications are more reversible epigenetic marks104 
and comprise acetylation, methylation, phosphorylation and ubiquitination104. The type of 
modification and the position on the histone protein determine whether the modification 
leads to a more open or a more condensed chromatin structure, which is associated with 
transcriptional activation or repression, respectively117. Especially histone acetylation has 
been shown to correlate with affective disorders118. Several studies showed increases in 
histone deacetylase 5 (HDAC5) levels in the blood of depressed patients119,120, while brain 
levels of HDAC5 are shown to be reduced in depressed patients121,122. Increased histone H3 
acetylation and decreased levels of HDAC2 in the nucleus accumbens have been observed in 
postmortem brain tissue from depressed patients122. ncRNAs have emerged as key regulators 
of protein-coding gene expression. ncRNAs can be short (< 200 nucleotides) or long (< 200 
nucleotides) and are further subdivided based on their genomic origin and mechanism of 
action123. Small ncRNAs can regulate transcription by guiding Argonaute protein complexes 
to complementary nascent RNA scaffolds and then mediating the recruitment of histone and 
DNA methyltransferases124. Long ncRNAs can regulate transcription by recruiting polycomb 
proteins, which remodel chromatin125 and by acting as enhancers123,126,127. Several long and 
DNA 
methylation
Histone
SNPs
Mutations
Family, work and social environmentFamily, work and social environment
Drugs/ alcohol abuse
Hormonal changes
Trauma
Diet
Childhood abuse / neglect
Environmental factors Genetic factors
Epigenetics Genetics
C G
CG
TT
A A
GT
A C
Non-coding 
RNAs
M
A
M
Figure 2. Environmental and genetic factors associated with affective disorders. Environmental factors influencing 
affective disorders are drugs/alcohol abuse, childhood abuse/neglect, trauma, hormonal changes (mostly 
postpuberal), diet, family and conditions at home, school, office including a wide array of factors such as socio-
economic status, IQ, education, etc. (Epi)genetic factors include mutations (insertions and deletions of nucleotides 
causing frame shifts and substitutions), Single nucleotide polymorphisms (SNPs) and epigenetic regulation by non-
coding RNAs, DNA (hydroxy)methylation, histone modifications (acetylation, phosphorylation, methylation etc. of 
histone tails protruding from the nucleosome). M: methylation, A: acetylation 
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short ncRNAs have been implicated in neurodevelopment, brain function and neurological 
diseases128-130, however the role of ncRNAs in affective disorders is largely unknown. The most 
studied ncRNAs are microRNAs (miRNA, a short ncRNAs) and a few are found to be associated 
with bipolar disorder131, anxiety-related disorders132 and depression133.  
Epigenetic regulation of several serotonergic genes has been associated with 
affective disorders. Both increased and decreased DNA methylation of the SLC6A4 (encoding 
for 5-HTT) promoter have been associated with depression106. An increase in TPH2 promoter 
methylation was associated with depression and suicide134. Htr1a (encoding for 5-HT1A) 
promoter methylation was increased in mice subjected to unpredictable chronic mild stress 
to induce a depression-like phenotype135. Furthermore, aberrant DNA methylation of SLC6A4, 
HTR1A and HTR2A is associated with bipolar disorder108. While several studies investigate DNA 
methylation, there are hardly any studies investigating the effect of histone modifications of 
serotonergic genes in affective disorders. There is one study showing increased acetylation of 
histone H3 at the promoter of the MAOA gene in rats exposed to peripuberty stress136. Also 
some serotonin-related non-coding RNAs are linked to affective disorders. MiR-16, which 
targets 5-HTT, was significantly lower in cerebrospinal fluid (CSF) from depressed patients 
compared to controls. Another 5-HTT associated miRNA, miR-135, was found to control the 
onset of co-existing depression and anxiety symptoms in mice137,138 as well as the response 
to antidepressant treatment137,138. In addition, miR-96 targets 5-HT
1B
 and is associated with 
aggression-related disorders139. The discovered (epi)genetic contributors and their pathways 
can be used in the treatment of affective disorders. 
Treatment of affective disorders 
Treatment of affective disorders consists of drug administration and therapy. Drugs used 
for treatment of depression and anxiety-related disorders are selective serotonin reuptake 
inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine 
reuptake inhibitors (NRIs), tricyclic antidepressants (mostly replaced by other drugs due 
to unpleasant side effects) and monoamine oxidase inhibitors (MAOIs). All drugs act by 
increasing the availability of (extracellular) monoamines, either by blocking the reuptake in 
the presynaptic neuron or by inhibition of 5-HT degradation. Recently several clinical trials 
with new drugs acting on the glutamate system (mostly acting on N-methyl-D-aspartate 
(NMDA) receptors) are conducted in depressed patients and their results are promising140. 
The treatment of depression in people with bipolar disorder is similar to that for people 
who develop depression without episodes of mania. In addition, the (hypo)manic period in 
bipolar disorder is treated with mood stabilizers141, antipsychotics141 and sedatives142. Besides 
medication, different therapies are used for the treatment of affective disorders such as 
psychotherapy143, exposure therapy144 and electro-convulsive therapy145. 
Among the most frequently prescribed drugs for affective disorders are SSRIs. 
SSRIs are best known as antidepressants, but they are also used in the treatment of anxiety-
related disorders, like obsessive compulsive disorder, social anxiety, panic disorders146 and 
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occasionally PTSD147. SSRIs block the 5-HTT resulting in an increased level of 5-HT in the 
synaptic cleft148-150. The currently available SSRIs are citalopram (Cipramil®), escitalopram 
(Lexapro®), fluoxetine (Prozac®), fluvoxamine (Fevarin®), paroxetine (Seroxat®) and sertraline 
(Zoloft®). Some SSRIs, like fluvoxamine and fluoxetine have varying degrees of selectivity 
for the 5-HT, norepinephrine and dopamine transporters, whereas others (e.g. citalopram, 
escitalopram, paroxetine and sertraline) have high affinity for the 5-HTT and only weak 
affinity for the noradrenaline and dopamine transporters151.  Besides the positive effects on 
affective disorders, clinical studies have shown that there are many side effects upon chronic 
administration of SSRIs, like sexual dysfunction152, suppression of rapid eye movement 
sleep153, nausea154,155, decreased appetite156 and aggression/violence157,158, indicating that 
further optimization of chronic treatment of affective disorders is still needed. In addition, 
it takes weeks of treatment with SSRIs before clinical effects are noticed, which also needs 
optimization159. 
SSRI exposure during development 
While numerous trials have shown robust safety of SSRIs and positive effects on treatment 
of affective disorders in adults, there are alarming studies showing that perinatal and 
adolescent SSRI exposure have negative effects on development and behavior. The highest 
risk for women to suffer from depression is during the childbearing years160. They may 
become pregnant while being treated for depression or may require antidepressants to 
fight depression during pregnancy161-163. Depression is associated with an increased risk of 
preterm delivery, low birth weight, higher impulsivity, maladaptive social interactions, and 
behavioral and emotional difficulties164,165. Treatment of depression is therefore important 
for these women and accordingly around 25% of the women treated for depression continue 
antidepressant use, and another 0.5% start with antidepressant drugs during the pregnancy, 
with SSRIs as the most frequently used antidepressants161. SSRIs can cross the placenta and 
are found in breast milk, thereby reaching the (unborn) child166,167. Studies have shown that 
perinatal SSRI exposure can increase the risk for neonatal withdrawal symptoms (including 
continuous crying, restlessness, fever, tremors, rigidity, respiratory distress, feeding 
difficulties, sleep disturbance, hypoglycemia, and seizures) which are temporary and are 
usually resolved within two weeks168,169. In addition, an increased risk for preterm birth170, low 
birth weight5,171, defects in motor behavior172,173, autistic-like behavior as well as persistent 
pulmonary hypertension174,175 and congenital heart defects166,176 are observed in children 
perinatally exposed to SSRIs. Rodent studies investigating long-term effects of SSRIs showed 
that perinatal SSRI exposure increases the risk for anxiety and depression-like symptoms 
in adulthood177-179. Furthermore, there is increasing evidence that SSRI treatment during 
childhood and the adolescent period is associated with negative effects, such as increased 
risk for suicidal ideation, agitation, reduced social behavior180, depression and anxiety181-185. 
However, it is important to keep in mind that in children and adolescents SSRIs also have 
beneficial effects186-188. Unlike fetuses, children and adolescents usually receive SSRIs for 
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the treatment of harmful mental states and in these situations no treatment at all will most 
likely lead to more severe health problems. Together, these data show that SSRIs exert age-
dependent effects with negative outcomes during early-life. 
5-HT function and signaling during neurodevelopment 
The paradoxical negative effects of perinatal reduction in functional 5-HTT (perinatal SSRI 
exposure and S-allele carriers) compared to functional 5-HTT reduction only during adulthood 
(adult SSRI treatment), might be related to the neurotrophic function of 5-HT. 5-HT can 
promote neurodevelopmental processes like neuronal outgrowth, synaptogenesis and 
migration processes189-193. In addition, 5-HTT shows a more widespread distribution during 
neurodevelopment, which might contribute to the different effects observed after perinatal 
5-HTT reduction compared to adult 5-HTT reduction194. During development 5-HTT is not 
only present on 5-HT neurons from the raphe nuclei, but also on non-serotonergic neurons. 
Mice studies show that at mid-gestation (embryonic day 10.5) expression of 5-HTT begins 
in the 5-HT neurons of the raphe nuclei, and subsequently emerges in the non-serotonergic 
neurons of the sensory system (thalamus, retina, somatosensory cortex) and corticolimbic 
regions (hippocampus, E14–E15). Expression in the PFC starts around birth. During the 
second postnatal week 5-HTT expression in non-serotonergic neurons ends rapidly194. It has 
been proposed that the transient broader 5-HTT expression during the perinatal period may 
serve to maintain stable 5-HT levels important for developmental processes. The thyroid 
hormone is shown to be involved in repression of the transient 5-HTT expression195,196. 
Studies in humans and non-human primates are limited, but show that in human embryos 
of gestational week 8–11 5-HTT is expressed in fibre tracts of the non-serotonergic internal 
capsule and optic tract197, and at midgestation 5-HTT appears in all major sensory afferents 
(dorsal root ganglia, retinal ganglion cells, cochlear nucleus and olfactory nerves) in non-
human primates198. Regions where the transient 5-HTT is co-expressed with 5-HT receptors 
could be important for brain development. 5-HTT is co-expressed with 5-HT2A and 5-HT2C in 
the mPFC and downstream pathways of these receptors are involved in dendritic maturation 
and cell death199-201. Furthermore, co-expression of 5-HTT and presynaptic 5-HT
1B
 is observed 
in the thalamocortical axons (TCAs)202-205. 5-HT
1B
 is linked to protein kinase A mediated 
signaling which can play a role in the response of axons to guidance factors, such as netrins 
and ephrins206,207. The transient broader expression of 5-HTT and the neurotrophic effects of 
5-HT together ensure that the consequences of reduced functional 5-HTT can be different 
depending on the developmental stage of occurrence.  
Neurodevelopment and altered 5-HT signaling
In order to unravel the developmental consequences of increased extracellular 5-HT, as seen 
in S-allele carriers and perinatal SSRI exposure, it is important to know what developmental 
processes occur during the neonatal stage and during infancy and adolescence. Environmental 
input and molecular events of gene expression changes are essential for normal brain 
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development, and disruption of either can fundamentally alter neural network formation, 
potentially leading to neurodevelopmental disorders (see Box 2). Here we give an overview of 
the main developmental processes taking place during fetal and postnatal brain development. 
In addition, the effects of 5-HT on several of these processes are mentioned. For comparison 
of experimental data between humans and rodents we have to take into account that rodents 
are born more immature compared to humans in terms of brain maturation208. See Table 2 
for an overview of developmental processes across comparable ages in humans and rodents.
Neurodevelopment and altered 5-HT signaling during the human fetal period 
Much of brain development in the human fetal period (gestational week 8 till birth) centers 
around the processes of neuron production, migration and differentiation. Beginning on 
embryonic day 42, cell division of neural progenitor cells located in the ventricular zone (VZ) 
begins to shift from symmetrical (two neural progenitor cells) to asymmetrical (one neural 
progenitor and one neuron)209. The new progenitor cell remains in the VZ and continues 
to divide, while the postmitotic neuron leaves the VZ to take its place in the developing 
neocortex. Because of the greater distances, neurons require radial glial guides to support 
their migration210. Radial glial guides (which are neural progenitor cells211,212) in the VZ extend 
a basal process that attaches to the pial surface of the brain, which forms a scaffold along 
which neurons can migrate. The earliest produced neurons migrate to the deepest cortical 
layers and subsequently migrating neurons migrate to successively more superficial layers 
creating an inside out order of migration213. Once the young neurons have reached their 
target region of the cortex, they start to develop axons and dendrites that allow them to 
communicate with other neurons. The growth cone, a dynamic, actin-supported extension 
of a developing neurite, is involved in axon branching and outgrowth214 and samples the 
environment for guidance molecules. Guidance molecules direct the axon toward its target 
and can be attractive, signaling movement toward a source, or repulsive, guiding movement 
away from a source. Once the axon has reached its target, connections with the target cell 
are formed, called synapses, which are essential for communication in the nervous system.  
During the fetal stage there is the period of transient widespread 5-HTT expression 
and 5-HT can influence fetal neurodevelopmental processes like neuronal outgrowth and 
migration189-193. As a consequence, deregulation of 5-HT signaling in this period might have 
a widespread effect on brain development. Rodent studies have shown that early-life SSRI 
treatment and genetic inactivation of 5-HTT result in defects in the somatosensory cortex and 
the corticolimbic system. In rodents the primary somatosensory cortex contains ‘‘barrels’’ 
in layer IV which correspond to functional inputs from whiskers on the contralateral snout 
in a one-to-one relationship215. The centre of a barrel contains projection targets of TCAs 
that conduct sensory information and form terminal clusters in layer IV. The ‘walls’ of the 
barrels consist of neurons in layer IV that organize around the terminal clusters from TCAs 
and receive synaptic contacts194. Early-life SSRI treatment and genetic inactivation of 5-HTT 
causes impaired innervation of cortical layer IV by reduced arborisation (formation of a 
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treelike shape) of TCA clusters, diffuse barrel patterns and dendritically smaller spiny stellate 
cells with a reduced spine density in the somatosensory systems194,205,216,217. A corticolimbic 
circuit regulated by the serotonergic system is the connection between the dorsal raphe 
nucleus, mPFC and the amygdala, which is involved in stress-related reactions80,218-220. Genetic 
inactivation of 5-HTT leads to increased dendritic spine densities in pyramidal cells of the 
amygdala and abnormally increased dendritic branching in pyramidal neurons of the PFC194,221. 
  
Neurodevelopment and altered 5-HT signaling during postnatal 
neurodevelopment 
In the human postnatal period, neurogenesis continues to take place in a very limited degree 
and is restricted to two brain regions, the subventricular zone (SVZ, lies adjacent to the VZ) 
and the subgranular zone (SGZ) in the DG of the hippocampus. At gestational week 7–8 the 
SVZ forms above the VZ223,224. In this zone new neurons continue to emerge and migrate in 
the direction of the olfactory bulb, where they differentiate into interneurons. In the DG the 
newly formed neurons migrate from the SGZ only as far as the nearby granular layer225. These 
two forms of neurogenesis appear to continue throughout adult life but produce only a small 
percentage of the neuronal population226. The functional relevance of adult neurogenesis 
is uncertain227, but there is evidence that hippocampal adult neurogenesis is important for 
learning and memory228. Many factors may affect the rate of hippocampal neurogenesis. 
Exercise and an enriched environment have been shown to promote the survival of neurons 
and the integration of newborn cells into the existing hippocampus229,230. On the other 
hand, chronic stress and aging can result in a decreased neuronal proliferation226,231. It has 
been shown that 5-HT depletion reduces the rate of neurogenesis in the adult DG, whereas 
increased levels of 5-HT and activation of 5-HT1A, 5-HT2A and 5-HT2C receptors increase 
neurogenesis in the DG232. Adult neurogenesis in the DG has been shown to be reduced 
Box 2: Neurodevelopmental disorders
Neurodevelopmental disorders are psychiatric conditions originating in childhood that involve 
serious impairments in different areas of the central nervous system. The main neurodevelopmental 
disorders are autism spectrum disorder (ASD), intellectual disability (ID), schizophrenia (SCZ) and 
attention deficit (hyperactivity) disorder (AD(H)D). ASD is a disorder characterized by impairments 
in three core domains; reciprocal social interaction, communication (verbal and nonverbal) and 
restricted and repetitive behavior. ID is characterized by significant limitations in both intellectual 
functioning (e.g. learning, reasoning, problem solving) and in adaptive behavior (conceptual, 
social, and practical skills that are learned and performed by people in their everyday lives). 
SCZ is characterized by delusions and hallucinations and by poor emotional responsiveness, 
and disorganized thinking and speech. AD(H)D is characterized by inattention, hyperactivity/
impulsivity and motivational/emotional dysregulation. All four neurodevelopmental disorders are 
associated with disturbed developmental processes, such as proliferation of neuronal progenitor 
cells (ASD, ID, SCZ), migration of neurons (ID, ASD), axon guidance (ASD, AD(H)D), synaptogenesis 
(ASD, ID, AD(H)D) and pruning (SCZ)222. 
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in depressed patients and can be increased by 5-HT-related antidepressants (SSRIs, MAO 
inhibitors)30.
In contrast to neurogenesis, gliogenesis (the proliferation and migration of glial 
progenitors) occurs largely in the postnatal period. Glial progenitors proliferate in the 
forebrain SVZ and migrate outwards into other brain regions. Subsequent differentiation 
of glial progenitors results in function-specialized glial lineages consisting of astrocytes, 
oligodendrocytes, ependymal cells and microglial cells233. The peak in overall gliogenesis 
occurs around birth (with each specific glial lineage having its own peak at a different time 
point) and gliogenesis continues until adulthood. Astrocytes, the most abundant type of glial 
cells in the CNS, regulate the external chemical environment of neurons by removing excess 
potassium ions, and by recycling neurotransmitters released during synaptic transmission233. 
Ependymal cells line the spinal cord and the ventricular system of the brain. These cells 
are involved in the creation, secretion and circulation of CSF and make up the blood-CSF 
barrier234. Oligodendrocytes produce myelin, which insulates axons to facilitate electric 
signal transduction (Box 3)233. Finally, microglial cells are specialized macrophages capable of 
removing cellular and foreign debris within the CNS233. Glial progenitors persist indefinitely 
in the adult brain in a wide anatomical distribution, and can differentiate in response 
to injury235. There are a few studies showing an effect of 5-HT on glial cell development. 
Oligodendrocyte development and myelination  can be influenced by 5-HT levels in vitro236. 
Furthermore, myelin sheath formation is disturbed in rats perinatally exposed to SSRIs, with 
the strongest effects seen after postnatal exposure (Postnatal day (PND)8–21)237. Postnatal 
SSRI treatment has been shown to affect astrocyte development, with the strongest effects 
seen after treatment during the peri-adolescence period (PND 21-35)238,239.
Another process that continues after birth is synapse formation. The cerebral cortex 
produces most of its synaptic connections after birth in a massive burst of synapse formation 
known as the exuberant period, which is important for the formation of brain networks240. 
This period of synaptic exuberance varies in different parts of the cerebral cortex. Synaptic 
density peaks in the human primary visual cortex as early as 8–12 months of age, compared to 
2–4 years of age in the PFC241. The number of synapses plateaus at levels nearly twice as high 
as those observed in the adult brain, and then gradually declines to adult levels across the 
period of childhood and adolescence242. Every experience excites certain neural circuits and 
leaves others inactive. Those that are consistently turned on over time will be strengthened, 
while those that are rarely excited will be eliminated243. The elimination of unused synapses 
is called synaptic pruning. Synaptic pruning streamlines children’s neural processing, making 
the remaining circuits work more quickly and efficiently. The pruning process is completed 
first in primary sensory regions and last in frontal and parietal regions244. 5-HT is involved in 
the regulation of synaptogenesis and synaptic pruning191,245,246. 5-HT can disturb pruning by 
its capability to inhibit the activation of microglia via 5-HT2 receptor activation, resulting in a 
reduced uptake of synaptic particles247. 5-HTT-/- mice display increased spine densities during 
adulthood, which can be a result from pruning deficits248. 
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Table 2. Developmental processes across comparable ages in humans and rodents
Human Rodent Developmental milestone
23-32 wk gestation PND1-3 Establishment of the blood-brain barrier249,250
Immune system development251
36-40 wk gestation PND7-10 Peak brain growth spurt252,253
Peak in gliogenesis254,255
Increasing axonal and dendritic density253,256,257
Oligodendrocyte maturation and onset of myelination258
Consolidation of immune system251
0-1 year old PND12-13 End of transient wide-spread 5-HTT expression194* 
2-3 year old PND20-21 Brain reaches 90-95% of adult weight252,259,260
Peak in synaptic density at 50% > adult levels261,262
Peak in myelination rate263
4-11 year old PND25-35 Fractioning/specialization of prenatal cortex neural networks 
(structural maturation)264
Maximum volume of grey matter and cortical thickness265,266
12-18 year old PND35-49
Reduced synapse density, reaching a plateau at adult levels261,267
Ongoing myelination: increasing white matter volume257,259 
Refinement of cognitive dependent circuitry  (by pruning and 
myelination)268
20 + year PND60+ Adult levels of synaptic density261
Ongoing myelination and declining grey matter269,270
Note: Table adjusted from Semple and colleagues241.  PND: postnatal day. * Based on rodent studies.
The 5-HTT knockout rodent
Studying behavior and gene expression across development is time-consuming and rather 
complicated in humans since their life-time is relatively long and environmental factors 
cannot be controlled very well. To circumvent these limitation, rodents are often used for 
these kind of studies. The 5-HTT knockout (5-HTT-/-) rat and mouse are frequently used for 
studying the effects of increased 5-HT signaling. Both 5-HTT-/- rats and 5-HTT-/- mice show 
reduced 5-HT uptake (synaptosomes and primary neurons)271-273 and increased extracellular 
5-HT levels across the brain271,274-276. In addition, reduced firing of raphe neurons, decreased 
expression and sensitivity of 5-HT1A inhibitory autoreceptors and increased 5-HT1B receptor 
sensitivity have been observed in 5-HTT-/- mice and rats274,277-280. 5-HTT-/- rats and mice show 
a rather mild phenotype, they reach normal age (Homberg, unpublished findings) and show 
normal coat and whisker condition281. Phenotype differences are present in both 5-HTT-/- mice 
and rats, but are not often readily apparent at first glance. Both 5-HTT-/- rats and 5-HTT-/- 
mice show anxiety and depression-like behavior. They show anhedonia and behavioral 
despair179,282, as reflected by reduced sucrose preference and increased immobility in the 
forced swim test126,233281. Increased anxiety-like behavior is observed in the elevated plus-
maze, open field, light dark exploration and novelty suppressed feeding test177,179,282,283. The 
anxiety and depression-like behavior observed in these 5-HTT-/- rodents resembles the effects 
seen in the 5-HTTLPR S-allele carriers and in early-life SSRI exposed humans and rodents. 
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Both 5-HTT-/- rats and 5-HTT-/- mice display reduced social behavior284,285. With regard to 
cognitive functioning, 5-HTT rats show impaired object recognition, but show better strategy 
set-shifting and perform better in a rodent version of the lowa gambling task286-288. In addition, 
both 5-HTT-/- rats and 5-HTT-/- mice show improved reversal learning289-291. There are no studies 
that have investigated behavior across developmental stages in 5-HTT-/- rodents.
Genome-wide gene expression analysis
While several studies reported behavioral and structural consequences of 5-HTT down-
regulation during development, the molecular mechanisms contributing to these 
developmental changes are poorly understood. Studying gene expression during development 
might reveal important new insights and might potentially lead to new targets for treatment 
of 5-HT-related disorders. Gene expression analysis can be performed for specific genes 
using quantitative PCR techniques or genome-wide using RNA sequencing (RNA-seq). Since 
several chapters in this thesis include RNA-seq experiments, the RNA-seq procedure and 
transcriptional changes that can be detected with this technique will be explained here. 
For RNA-seq, messenger RNA (mRNA) is isolated from brain tissue and converted into 
complementary DNA (cDNA). Subsequently, this cDNA is fragmented and adapters are ligated 
to the fragments. Fragments around 300 base pairs are selected and used for sequencing. 
Figure 3 shows the (Illumina) sequencing steps that occur in the sequencer. The sequences of 
these fragments (reads) are mapped to the reference genome and the number of fragments 
Box 3: Myelination
Oligodendrocyte progenitor cells (OPC) are the glial progenitors important for myelination, which 
is the production of a fatty white substance that surrounds the axon, called myelin. Upon reaching 
their destination, OPCs begin to differentiate by extending processes and increasing myelin 
protein expression. The processes then begin to form membrane wraps around nearby axons. 
Between gestational weeks 20 and 28 in humans, mature myelin is detected first in subcortical 
regions and later in cortical regions. Myelin enhances the speed and fidelity of the transmission 
of information encoded in action potentials that propagate along neurons292. Because myelination 
of an axon has dramatic functional consequences for how fast neurons will transmit their 
signals, myelination is likely to have a role in modulating network activity in the brain293. There is 
evidence that myelin sheath formation is regulated by experience during development and also 
in adult life294-296. The dynamic extent of myelin may serve as a form of plasticity to adapt brain 
function to environmental stimuli. Structural components of CNS myelin are myelin basic protein 
(MBP), proteolipid protein (PLP), myelin associated glycoprotein (MAG), myelin and lymphocyte 
protein (MAL), myelin oligodendrocyte glycoprotein (MOG) and 20,30-cyclic nucleotide 
30-phosphodiesterase (CNPase)297,298, with MBP and PLP as the most abundant proteins167,168. 
These components are important for myelin formation and myelin compaction298. In addition, 
several other components are associated with oligodendrocyte differentiation and myelination, 
like amongst others, oligodendrocyte transcription factor 1 and 2 (OLIG1/OLIG2), Sry-related 
HMG-Box gene 10 (SOX10)299,300, ciliary neurotrophic factor (CNTF)301 and transferrin (TF)302. 
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Figure 3. Illumina (Solexa) sequencing. Basic processes of sequencing (adapted from https://www.illumina.com/ 
documents/products/techspotlights/techspotlight_sequencing.pdf). 
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per kilobase per million mapped reads is calculated per gene or exon. The more reads 
mapped to a specific region, the higher the expression of that region. Differences in gene 
expression between developmental time points or different genetic models can be analyzed. 
Expression of protein-coding genes as well as expression of ncRNAs can be analyzed using 
RNA-seq. Protein-coding genes, which only account for a minority of cellular transcriptional 
output303, are the best annotated genes and the function of the majority of these genes 
is known. Non-coding RNAs are less well annotated and their function is often unknown. 
In the RNA-seq method described above there is a selection for 300 bp fragments and 
therefore small ncRNAs, such as most of the miRNAs, are not detected using this method. 
Another transcriptional mechanism that can be investigated by RNA-seq is alternative exon 
usage, which is a commonly used mechanism for increasing coding diversity within genes. In 
this process, particular exons of a gene may be included within or excluded from the final, 
processed mRNA. Consequently, the proteins translated from alternatively spliced mRNAs 
will contain differences in their amino acid sequence and, often, in their biological functions. 
Alternative exon usage comprises alternative promoter usage (5’ exon), alternative splicing of 
internal exons and alternative 3’ exon usage. 
Aim and outline of the thesis
The aims of this thesis are to elucidate the transcriptional changes occurring across postnatal 
mPFC development and to unravel the behavioral and molecular consequences of aberrant 
5-HT signaling across development in the absence of adverse environmental conditions. 
Behavior and morphological consequences of aberrant 5-HT signaling are the main focus of 
most studies and the amount of molecular studies is still limited. While most molecular studies 
focus on the effects of SSRIs on gene expression immediately after the last administration 
(short-term/ acute effects), the long-term effects of adult SSRI exposure on (genome-wide) 
gene expression are unclear. In addition, the paradoxical effects of SSRI exposure during early-
life and adulthood on adult anxiety and depression-like behavior would suggest that adult gene 
expression is affected in opposite direction after early-life compared to adult SSRI exposure, 
a presumption that remains to be investigated. Furthermore, there is ample evidence that 
perinatal exposure to SSRIs (causing pharmacological blockade of 5-HTT) has negative effects 
on behavior in adulthood, but besides the transient withdrawal symptoms, information about 
the effect on the development of CNS-controlled behavior in early-life and their long-term 
consequences is lacking. Data about development of CNS-controlled behavior is also missing 
for individuals with inherited 5-HTT down-regulation. In addition, gene expression analysis at 
different developmental time points in a model of reduced functional 5-HTT expression will 
contribute to linking gene expression to the observed behavioral changes.
In chapter 2, we summarized the effects of SSRIs on gene expression in the brain. The 
main groups of genes affected by SSRIs are genes encoding serotonin receptors, components 
of non-serotonergic neurotransmitter systems, neurotrophic factors, hypothalamic hormones 
and inflammatory factors.
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In chapter 3, we investigated whether the paradoxical effect of SSRI exposure during 
early-life and adulthood on adult anxiety and depression-like behavior is also observed on 
gene expression level. We treated rats with fluoxetine or methylcellulose (control group) at 
adulthood and measured anxiety-like behavior in the novelty suppressed feeding test. We 
have performed genome-wide gene expression analysis in the hippocampus of these rats 40 
days after fluoxetine treatment and found several differentially regulated myelin genes. In 
addition, we examined the expression of several myelin genes in the hippocampus of adult 
rats postnatally (PND1-21) exposed to fluoxetine using reverse transcription quantitative PCR 
(RT-qPCR). 
In chapter 4, we investigated the effects of reduced 5-HTT expression during early-
life on behavior across development. We performed several behavior experiments in rats 
perinatally exposed to fluoxetine and rats perinatally exposed to methylcellulose (control 
group). In addition, we performed the same tests in 5-HTT-/- and 5-HTT+/+ rats. Behavior 
experiments included body weight, eye opening, motor-related behavior, reflex development, 
olfactory function, grooming behavior, sensorimotor gating, object directed behavior and 
novel object recognition, and were performed during the first three postnatal weeks and 
repeated during adolescence and adulthood if possible. 
In chapter 5, we examined expression changes during postnatal development in 
the PFC, a region frequently involved in affective disorders. We performed genome-wide 
expression analysis in the mPFC at five developmental time points from infancy till adulthood 
and analyzed developmental changes in coding-gene expression, long intergenic non-coding 
RNA expression and alternative exon usage. We provide a data resource of temporal gene 
expression in the developing mPFC from infancy to adulthood. 
In chapter 6, we investigated the molecular mechanisms contributing to the 
structural and behavioral changes in the mPFC related to inherited 5-HTT down-regulation. 
We examined differentially expressed coding-genes in the mPFC of 5-HTT-/- rats compared 
to 5-HTT+/+ rats at five time points across postnatal development. In addition, DNA (hydroxy)
methylation levels (5(h)mC) were measured at the same five developmental time points. 
Finally, chapter 7 provides a general discussion and future perspectives regarding 
the research described in this thesis.
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Abstract
Selective serotonin reuptake inhibitors (SSRIs) are among the most widely prescribed drugs in 
psychiatry. Based on the fact that SSRIs increase extracellular monoamine levels in the brain, 
the monoamine hypothesis of depression was introduced, postulating that depression is 
associated with too low serotonin, dopamine and noradrenaline levels. However, several lines 
of evidence indicate that this hypothesis is too simplistic and that depression and the efficacy 
of SSRIs are dependent on neuroplastic changes mediated by changes in gene expression. 
Because a coherent view on global gene expression is lacking, we aim to provide an overview 
of the effects of SSRI treatment on the final targets of 5-HT receptor signal transduction 
pathways, namely the transcriptional regulation of genes. We address gene polymorphisms 
in humans that affect SSRI efficacy, as well as in vitro studies employing human-derived 
cells. We also discuss the molecular targets affected by SSRIs in animal models, both in vivo 
and in vitro. We conclude that serotonin transporter gene variation in humans affects the 
efficacy and side effects of SSRIs, whereas SSRIs generally do not affect serotonin transporter 
gene expression in animals. Instead, SSRIs alter mRNA levels of genes encoding serotonin 
receptors, components of non-serotonergic neurotransmitter systems, neurotrophic factors, 
hypothalamic hormones and inflammatory factors. So far little is known about the epigenetic 
and age-dependent molecular effects of SSRIs, which might give more insights in the working 
mechanism(s) of SSRIs.
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2
Introduction
Selective serotonin reuptake inhibitors (SSRIs) are among the most widely prescribed drugs 
in psychiatry. Besides serving as antidepressants, they are also used in the treatment of 
anxiety-related disorders (obsessive compulsive disorder, social anxiety, panic disorders)1, 
autism2, eating disorders3, and occasionally posttraumatic stress disorder4. SSRIs increase 
the extracellular serotonin (5-hydroxytryptamine; 5-HT) levels in the synaptic cleft by 
blocking the serotonin transporter (5-HTT), a Na+/Cl- inward rectifying transporter5 located 
on presynaptic nerve terminals. This increase in extracellular levels of 5-HT is consistently 
shown in several brain regions by performing microdialysis followed by high-performance 
liquid chromatography6-11. The amount of increase can differ between studies, which might 
be caused by differences in SSRI treatment, brain region or timepoint of measurement. 
For example, it is shown that acute SSRI treatment results in a transient 5-HT increase, 
while repeated treatment increases baseline 5-HT levels8. There is no evidence that the 
SSRI-induced increase in extracellular serotonin is caused by blocking the serotonin break 
down or increasing serotonin synthesis. Due to negative feedback mechanisms caused by 
activation of inhibitory autoreceptors (discussed below), serotonin synthesis and release is 
even decreased7. Some SSRIs (fluvoxamine (Luvox), fluoxetine (Prozac)) have varying degrees 
of selectivity for the 5-HTT, norepinephrine and dopamine transporters, whereas others 
(e.g. citalopram (Celexa), s-citalopram (Lexapro), paroxetine (Paxil), and sertraline (Zoloft)) 
have high affinity for the 5-HTT and only weak affinity for the noradrenaline and dopamine 
transporters12. Based on the fact that SSRIs increase extracellular 5-HT levels in the brain, 
the monoamine hypothesis of depression was introduced, postulating that depression is 
associated with too low 5-HT (and dopamine and noradrenaline) levels13. This hypothesis has 
governed the depression field for several decades. However, there is accumulating evidence 
that this hypothesis is too simplistic. For instance, SSRI treatment results in desensitization 
of the 5-HT1A autoreceptors and thereby cause an increase in raphe firing
14. In both animal 
and clinical studies it has been found that SSRI-5-HT1A antagonist co-administration leads to 
enhanced antidepressant responses15,16. A recent study has also shown that a 5-HT1A receptor 
siRNA conjugated to the SSRI citalopram had antidepressant effects in mice17. These findings 
suggest that the antidepressant effects of SSRIs at least depend on 5-HT1A receptor function. 
The process is rather complex and probably goes beyond the serotonin system. For instance, 
5-HT1A receptor activation results in a decreased release of glutamate
18. The monoamine 
hypothesis is also not in line with the finding that depletion of the 5-HT precursor tryptophan 
does not induce depression-like mood symptoms in healthy subjects19. 
 In addition, there are several lines of evidence from rodent studies that in utero 
or neonatal exposure to SSRIs leads to paradoxical autism-, anxiety- and depression-
like symptoms in later life20. There is evidence that the 5-HTT expression pattern at early 
developmental stages is more widespread and it is shown that early life SSRI treatment can affect 
neurodevelopment21. Both, more widespread 5-HTT expression and neurodevelopment, can 
contribute to the paradoxical effects, however the exact mechanisms causing the differences 
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at behavioral level are still not clear. Furthermore, SSRIs increase risks of “possible suicidal 
ideation and suicidal behavior” by about 80%, and of “agitation and hostility” by about 130% 
in children with major depressive disorder (MDD)22. Consistent with these observations, 
animal experimental studies have shown that adolescent SSRI exposure leads to anxiety- 
and depression-related symptoms23,24. Taken together, a massive amount of data aiming to 
elucidate the working mechanism(s) of SSRIs has been generated, but simultaneously the 
findings have raised more questions than they answered. While it is clear that an increase in 
5-HT per se does not increase mood state, it is still obscure what mechanisms do contribute 
to the therapeutic and side effects of SSRIs. Understanding these mechanisms is not only 
of high interest from a fundamental point of view, but also will lead to improvement of the 
treatment of disorders characterized by mood disturbances. 
 To understand SSRI mechanisms it is critical to comprehend 5-HT-mediated 
signaling. Up to now, 16 different 5-HT receptor subtypes have been identified: 5-HT
1A, 1B, 
1C, 1D, 1E, 1F
, 5-HT
2A, 2B, 2C
, 5-HT
3A, 3B
, 5-HT
4
, 5-HT
5A, 5B
, 5-HT
6
 and 5-HT
7
. All of them are G-protein 
coupled receptors, except for the 5-HT3A and 3B receptors which are ligand-gated ion channel 
receptors25. The presynaptic 5-HT
1B 
receptor is expressed in rodents and auto-regulates 5-HT 
release, while the 5-HT1D receptor fulfils this purpose in humans
25. The presynaptic inhibitory 
5-HT1A autoreceptor is located in the raphe nuclei and regulates the firing of serotonergic 
raphe neurons that project to widespread regions in the brain, as well as to the spinal cord. 
The 5-HT1A and 5-HT1B/D receptors, as all other 5-HT receptors, are also found postsynaptically. 
Since SSRIs have indirect (increasing serotonin) and direct (SSRI dependent affinity for 
receptors like 5-HT2
26 and 5-HT1A
27) effects on 5-HT receptors, 5-HT receptor agonists/
antagonist are widely used to determine via which 5-HT receptor an SSRI effect is caused. 
Each receptor drives specific intracellular signalling pathways, targeting transcription factors 
to regulate transcription of multiple genes involved in components of the serotonergic and 
other neurotransmitter systems as well as in neurotrophic and developmental functions. 
In addition, 5-HT-receptor linked intracellular signalling pathways may target epigenetic 
processes like DNA methylation and histone acetylation/methylation. These epigenetic 
modifications influence the transcriptional machinery, and thereby provide another 
means by which SSRIs can affect a wide array of central processes. Given the multiple 5-HT 
receptors and their coupling to various signal transduction pathways and genomic targets 
(e.g. transcription regulators), which change across developmental stages and in response 
to external stimuli like stress or pharmacological agents, it may not be surprising that the 
mechanisms underlying SSRI effects are far more complex than the monoamine hypothesis 
suggests. 
Here we aim to provide an overview of the effects of SSRI treatment on the final 
targets of 5-HT receptor signal transduction pathways, namely the transcriptional regulation 
of genes (Table 1). We address gene polymorphisms in humans that affect SSRI efficacy, as 
well as in vitro studies employing human-derived cells. We also discuss the molecular targets 
affected by SSRIs in animal models, both in vivo and in vitro (see Box 1 for the (dis)advantages 
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Chapter 2
of the biological materials). By presenting data into pathways, an overview is generated of 
pathways affected by SSRIs that could help to elucidate the working mechanisms of SSRIs. In 
addition, we propose a few research directions which might give more insights in the working 
mechanisms of SSRIs. 
Serotonergic system
Since the serotonergic system (Box 2 and Figure 1) is the main target of SSRIs, polymorphisms 
in genes involved in this system likely influence SSRI responsiveness. Furthermore, studies in 
animals (in vivo as well as in vitro) also show interactions between SSRIs and the serotonergic 
system. Below, we will describe the effects of SSRIs on the 5-HTT gene, 5-HT receptor genes 
and genes involved in 5-HT synthesis and downstream signaling pathways.
Human-polymorphisms
The serotonin transporter
One genetic factor modifying SSRI effects is the common serotonin transporter promoter 
polymorphism (5-hydroxytryptamine transporter-linked polymorphic region; 5-HTTLPR). The 
short (S) allele is associated with reduced transcription of the SLC6A4 gene compared to the 
long (L) allele. The L-allele bears an A/G single nucleotide polymorphism (SNP), resulting in 
the La (L-like) and Lg (S-like) allelic variants216. In the treatment of generalized anxiety disorder 
it was found that the SSRI escitalopram had no efficacy in the La- group versus moderate 
efficacy in the La+ group, due to a higher placebo response in La- subjects191. Thus, the 
5-HTTLPR S-like allelic variants appear to be associated with poor SSRI responsiveness. This 
was confirmed by several other studies using SSRIs in Korean33,217, Chinese29,30, Japanese205 
and Caucasian28,31,32,122,170,171,192,203,204 depressed patients, particularly in females172,173,218. 
Moreover, S-allele carriers were found to respond worse to fluoxetine in personality disorder 
Box 1: Biological material
Studies addressing the working mechanisms of SSRIs are performed in humans and animals (e.g. 
rodents, fish) both in vivo and in vitro. Each of these approaches has its own advantages and 
disadvantages. Given that gene expression is highly tissue specific, experimental animals provide 
the advantage of the accessibility of the brain. Moreover, SSRI treatment (dosage, duration, age of 
treatment, etc.) and environmental conditions can be more tightly controlled. On the other hand, 
behavioral models for depression are debated because of their lack of construct validation, thus 
a clear link to neurobiological substrates. Although experimental animals provide the advantage 
of the accessibility of the brain, dissected brain areas are still very heterogenous regarding cell 
type. Cell systems overcome this caveat, although in vitro findings require validation in vivo. 
Furthermore, there are obvious ethical limitations with using human brain tissue. An exception 
would be the use of postmortem brain tissue, but this tissue delivers ‘static’ information, whereas 
gene expression and regulatory mechanisms are dynamic. To overcome these limitations 
peripheral cell lines have been used. In addition, there are a lot of studies on the association of 
gene polymorphisms in humans to SSRI efficacy. 
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patients characterized by impulsive-aggressive behavior219, and SSRI treatment in healthy 
subjects diminished the perception of sad and fearful pictures, but only in 5-HTTLPR L-allele 
carriers193. These and other studies have been evaluated in several meta-analyses and 
reviews of Kato and Serretti220, Serretti and coworkers221-223, and Weizman and Weizman224. 
Furthermore, a meta-analysis by Porcelli and colleagues225 suggested an ethnic-specific 
effect of mixed antidepressants in which the Asians show a smaller effect of 5-HTTLPR on 
remission and response rates compared to Caucasians. The overall poor responsiveness to 
SSRIs in S-allele carriers may relate to reduced 5-HTT availability, but no clear association 
has been reported between 5-HTT genotype and central 5-HTT binding226. Alternatively, it 
may be explained by increased sensitivity to SSRI-induced side effects227,228. For instance, 
evidence shows that Dutch depressed patients with the 5-HTTLPR S/S or S/L genotype exhibit 
an increased risk of adverse events in response to SSRI treatment, especially general adverse 
events (dermatologic reactions, weight change and fatigue)229. 
Yet, several studies could not find an association between the 5-HTTLPR, either two- 
or tri-allelic, and SSRI responsiveness159,173,230,231. Potentially, differences in types of SSRIs, 
length of drug treatment, dose, evaluation methods, etc. may explain such discrepancies. 
Finally, no association was found between a variable number of tandem repeats (VNTR) in 
the second intron of the SLC6A4 gene (STin2) and SSRI efficacy in depressed patients173,232, 
although Chinese30 and Asian patients28 with the STin2 12/12 genotype – which is associated 
with higher SLC6A4 gene expression233 - showed a superior reduction of depressive scores in 
response to SSRI treatment. 
Serotonin synthesis
The efficacy of SSRIs is also influenced by polymorphisms in genes encoding proteins involved 
in 5-HT synthesis. For instance, a SNP (rs7163862, A:63%, T:37%, TT haplotype) in the 
promoter of the GCHFR (GTP-cyclohydrolase I feedback regulator) gene, regulating the 5-HT 
and dopamine synthesis cofactor tetrahydrobiopterin (BH4), reduced the responsiveness to 
fluoxetine34. Because the TT haplotype is associated with reduced gene transcription, this 
finding may imply that SSRI effects are diminished in individuals synthesizing relative low 
amounts of 5-HT. L-tryptophan hydroxylase 2 (TPH2) is the rate-limiting enzyme involved in 
5-HT synthesis and exclusively found in the brain. Studies reported that the number of TPH2 
Box 2: Serotonergic system
Serotonin (5-HT) is synthesized from the amino acid L-tryptophan by the rate-limiting enzyme 
L-tryptophan-hydroxylase (TPH), resulting in the formation of 5-hydroxytryptophan (5-HTP)234. 
5-HT is subsequently obtained by removal of a carboxyl group catalyzed by the enzyme 5-hydroxy-
tryptophan-decarboxylase. 5-HT is, like other neurotransmitters, stored in storage and release 
vesicles via the vesicular monoamine transporter (VMAT). When released in the synapse, 
serotonin exerts its effects through 16 distinctive 5-HT receptors. Furthermore, 5-HT reuptake in 
the presynaptic neuron occurs via the serotonin transporter (5-HTT). 
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rs2171363 (C:40%,T:60%) heterozygote carriers was higher in responders than non-responders 
to fluoxetine and citalopram35, and that the TPH2 C allelic variant of the rs10897346 (C>T) 
SNP, which is completely associated with functional Pro312Pro polymorphism affecting TPH2 
expression, was associated with an increased risk for non-responding to SSRIs235. However, 
another study did not observe an association between TPH2 gene and SSRI efficacy236 
(Binder et al., 2004). Although it remains to be established how these polymorphisms affect 
TPH2 gene transcription, the studies suggest that SSRI effects are dependent on brain 5-HT 
synthesis, and thereby 5-HT levels. The other TPH isoform, TPH1, mainly found in peripheral 
tissues, has not been associated with fluoxetine and venlafaxine treatment outcomes237, 
although the response to citalopram126 and paroxetine178 treatment were worse in depressed 
patients carrying the TPH1 A/A and A/C genotypes (rs1800532; c.218C>A, A:33%, C:67%) 
compared to those with the TPH1 C/C genotype. These mixed findings for TPH1 imply that 
particularly central 5-HT levels are relevant for SSRI effects. 
Serotonin receptors
When 5-HT has been released in the synaptic cleft, its signal is transmitted to the genome 
through 5-HT receptors. In view of the finding that a progressive desensitization of serotonin 1A 
(5-HT1A), and also 1B (5-HT1B), autoreceptors enhances the action of SSRIs
238,239, the association 
between HTR1A (5-HT1A receptor gene) and HTR1B (5-HT1B receptor gene) polymorphisms 
and SSRI responses have been thoroughly investigated. Villafuerte and coworkers127 analyzed 
the influence of functional polymorphisms in HTR1A (rs6295, rs1364043, rs1423691 and 
rs10042486) and HTR1B (rs6296, rs6297, rs6298, rs130058, rs11568817 and rs1221366) 
in depressed patients treated with citalopram, and found that depressed homozygotes for 
the G-allele at rs1364043 (G:32%, T:68%) in HTR1A and the C-allele at rs6298 (c.129C>T; 
C:71%, T:29%) in HTR1B showed a better response to citalopram over time. Furthermore, 
depressed homozygotes for the G-allele at rs6295 (-1019C/G; C:48%, G:52%) in HTR1A and 
at rs6296 in HTR1B showed significantly lower response rates36-38. It is possible that a higher 
baseline level of expression of these two receptors interferes with SSRI efficacy, as the HTR1A 
rs6295 G-variant prevents binding of a transcription repressor (NUDR/DEAF-1) in the raphe 
nuclei240. In addition, binding to HTR1B is increased in subjects homozygous for a G in the 
rs6296 (c.861G>C; C:36%, G:64%) polymorphism241. These findings raise the hypothesis that 
genetic variants enhancing 5-HT1A and 5-HT1B expression/function decrease desensitization of 
both receptors by SSRIs and ultimately drug responses. Reduced SSRI efficacy has also been 
noted in a population of anxiety patients, in which the GG HTR1A genotype of the rs6295 
polymorphism was strongly associated with diminished changes in panic attack frequency 
following paroxetine or sertraline treatment159. However, also negative studies for HTR1A gene 
polymorphisms and their association with SSRI effects exist242-245. Also Arias and colleagues246 
did not find an association between the rs6295 polymorphism in the HTR1A gene and clinical 
outcome or remission after citalopram treatment. However, they found a combined genetic 
effect of HTR1A and SLC6A4 genes to influence the clinical outcome of depressive patients. 
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When considering the remission status, an increase of patients carrying the risk genotype 
combination (S/S-G/G) was found among subjects who did not reach remission. 
 Regarding HTR2A polymorphisms, rs7997012 and rs6311, in interaction with gender, 
explained 14% of chance in depression scores after SSRI treatment39. In another study, two 
functional HTR2A SNPs (-1438A/G: rs6311 and c.102C>T: rs6313) and two functionally 
undefined HTR2A SNPs (rs7997012 and rs1928040) were associated with the therapeutic 
response to SSRIs in Japanese MDD patients40. The association between the HTR2A 
rs7997012 polymorphism and the outcome of citalopram has also been shown by several 
others128-130,174,175,220,246. These findings may be consistent with reports that 5-HT2A receptor 
blockade leads to rapid antidepressant effects in rodents247. Notably, the pharmacogenetic 
effects of the c.102C>T HTR2A polymorphism may be dependent on ethnicity, as HTR2A 
T-allele carriers in a Japanese sample showed selective and slower score reductions than 
C-allele carriers in delusion and activity symptoms, whereas in an Italian sample C-allele 
carriers showed a slower and selective score reduction compared with T-allele carriers in 
somatic anxiety175. It may also be dependent on the interaction between the HTR2A gene 
and a new marker (rs1954787; C:50%, T:50%) in the GRIK4 gene, which codes for the kainic 
acid-type glutamate receptor KA1. The effect size of the GRIK4 marker alone was modest, 
but homozygous carriers of the treatment-response-associated marker alleles of both the 
GRIK4 and HTR2A genes were 23% less likely to experience non responsiveness to treatment 
relative to participants who did not carry any of these marker alleles249. On the other hand, 
also negative findings regarding HTR2A gene polymorphisms and their association with 
SSRI effects exist. Illi and colleagues244 could not find an association between an HTR2A 
polymorphism (rs6313) and major depressive disorder or SSRI response.
Other 5-HT receptor polymorphisms implicated in the pharmacogenetic effects 
of SSRIs are those located in HTR2C (5-HT2C receptor gene), HTR3A (5-HT3A receptor gene) 
and HTR6 (5-HT
6 
receptor gene). In alcoholic patients, HTR2C Ser23 alleles were associated 
with significantly higher adrenocorticotropic hormone (ACTH) responses under placebo 
administration and these responses were reduced in the citalopram treated group131. 
Furthermore, nausea, a side effect of SSRI (paroxetine) treatment occurring in approximately 
30% of patients, was significantly associated with an insertion/deletion polymorphism 
(-100_-102AAG) in the HTR3B receptor gene in a small cohort of 72 Japanese patients with 
anxiety or depression-related disorders. In other words, patients homozygous for the -100-
102AAG insertion allele had a lower risk of developing nausea compared to other patients176. 
This finding may coincidence with the efficacy of 5-HT3 receptor antagonists in the prevention 
of chemotherapy induced nausea in cancer patients250. Finally, the association between SSRI 
efficacy and the HTR6 gene has been studied, but none out of five HTR6 polymorphisms 
(rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997) were associated with SSRI 
responsiveness in a population of Japanese depressed patients251. 
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Figure 1. Schematic overview of the serotonergic system. Serotonin is synthesized by the conversion of tryptophan 
(TRYP) to 5-hydroxytryptophan (5-HTP) catalyzed by tryptophan hydroxylase (TPH), followed by conversion of 5-HTP 
to 5-hydroxytryptamine (5-HT, serotonin) catalyzed by aromatic aminoacid decarboxylase (AADC). 5-HT is taken 
up into storage vesicles and can be released from these vesicles into the synaptic space, where it can activate 
subtypes of the 5-HT receptor (1-7). Each can activate its own signal transduction pathway inside the postsynaptic 
neuron. 5-HT is taken up into the presynaptic neuron by the 5-HT transporter. Within the presynaptic neuron, 5-HT 
would either be taken up by the storage vesicles or degraded by monoamine oxidase (MAO). Selective serotonin-
reuptake inhibitors (SSRIs) inhibit the 5-HT transporter. 5-HIAA, 5 hydroxyindolacetic acid; AC, adenylate cyclase; PLC, 
Phospholipase C; DAG, diacylglycerol; IP3, inositol-1,4,5-trisphosphate; PIP2, phosphatidylinositol-4,5-bisphosphate. 
Animals-in vivo studies
The serotonin transporter
Surprisingly, whereas the 5-HTTLPR has been linked to SSRI efficacy in numerous human 
pharmacogenetic studies, rodent studies have reported conflicting findings on Slc6a4 
(encoding 5-HTT) expression: Slc6a4 mRNA levels were either unaffected in the rat dorsal 
raphe nucleus (DRN) following 21 days of SSRI treatment134,252-254, or 4-8 week SSRI treatment 
normalized increased stress-induced Slc6a4 mRNA levels in the rat midbrain43,44. 
Serotonin transporter knockout animals 
Given that the 5-HTTLPR S-allele in humans increases the vulnerability for anxiety and 
depression, 5-HTT knockout rodents are considered as valuable and reliable models for the 
5-HTTLPR. As such, they show a disturbed serotonergic system. Extracellular 5-HT levels are 
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increased, and tissue 5-HT levels255,256 and 5-HT1A receptor sensitivity are reduced
257-261. The 
5-HTT knockout rodents also show increased anxiety by spending less time in the center of 
the open field261-264, spending less time on the open arm in the elevated plus maze261-263,265 and 
by showing increased latency to start eating in the novelty-suppressed feeding test261,263,266. 
Furthermore, 5-HTT knockout rodents show an increase in immobility in the forced swim 
test261,262,266 and reduced sucrose preference261,265, which are characteristics of behavioral 
despair and anhedonia, respectively. In addition, 5-HTT knockout rodents show impaired 
social behavior256,264,267,268. These depressive-like traits as a result of knock-down of the 5-HTT 
again pinpoint the importance of the serotonergic system in depression. However, the positive 
relationship between central 5-HT levels and depression in these animals undermines the 
monoamine hypothesis of depression.
Serotonin synthesis
Of interest, the Tph2 gene, the rate-limiting enzyme involved in 5-HT synthesis in the brain, 
undergoes changes in expression in response to SSRIs. For instance, whereas chronic mild 
stress (CMS), a procedure to induce depression-like symptoms in rats269 had no effect on Tph2 
mRNA levels, treatment for 4 weeks with citalopram (30 mg/kg/day) down-regulated Tph2 
mRNA levels in the DRN134. Likewise, Dygalo and colleagues43 reported that chronic fluoxetine 
treatment (25 mg/kg/day per os (p.o.), 14 days) significantly reduced Tph2 mRNA levels in 
the rat brainstem. However, long-term treatment of rats with another SSRI, sertraline (10 
mg/kg, i.p., 2 weeks), was associated with an up-regulation of mRNA and protein TPH levels 
in the DRN, as determined by in situ hybridization and immunocytochemistry, respectively160. 
Furthermore, Heydendael and Jacobson45 showed an increase in DRN Tph2 gene expression 
in mice after fluoxetine treatment (5 mg/kg, i.p.) for 5 weeks. The discrepancies between 
studies showing decreased and increased Tph2 mRNA levels in response to chronic SSRI 
treatment may be due to differences in factors like SSRI type, treatment duration, route of 
administration, rat strain, and/or mRNA detection method. Of interest, Kim and colleagues160 
showed that the up-regulation of Tph gene expression in the DRN by sertraline was 
attenuated by the protein kinase A (PKA) inhibitor N-[2-(p-bromocinnamylamine)-ethyl]-5-
isoquinolinesulfonamine, suggesting that a mechanism involving the PKA signaling pathway 
might at least in part mediate the therapeutic action of sertraline. This finding matches 
reports that long-term antidepressant administration leads to PKA nuclear translocation270 
and increased expression of cAMP-response element-binding protein (CREB)55. The human 
TPH gene contains a cAMP-responsive element in its promoter271, and its gene expression272-274 
is up-regulated by cAMP, which may also be the case in rodents.
Serotonin receptors and signaling pathways
Regarding the involvement of 5-HT receptors in SSRI-mediated molecular mechanisms in 
experimental animals, it was found that 24 h after a 2-3 week treatment with fluoxetine (8 
mg/kg i.p., daily) there was a significant decrease in Htr1a mRNA levels in the anterior raphe 
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area (comprising the median and dorsal raphe nuclei) and a significant increase in Htr1b 
mRNA levels in the striatum and the cerebral cortex. Electrophysiological recordings in brain 
slices showed that chronic fluoxetine treatment reduced the potency of the 5-HT1A agonist 
8-hydroxy-2-(di-n-propylamino)tetralin to inhibit neuronal activity in the DRN, but did not 
affect 5-HT1A-evoked responses of CA1 pyramidal cells in the hippocampus. The decrease in 
Htr1a mRNA levels in the anterior raphe suggests that fluoxetine-induced desensitization of 
5-HT1A autoreceptors involves changes at the transcription level
14. The regulation of 5-HT
1B
 
receptor transcripts by SSRI treatment was also addressed in another rat study. It was found 
that chronic (8 weeks) fluoxetine (5 mg/kg/d) and paroxetine (5 mg/kg/d) administration 
to rats via subcutaneous osmotic minipumps reduced DRN Htr1b mRNA by 36% and 27%, 
respectively, whereas sertraline (10 mg/kg/d) had a no significant effect. After 3-14 days 
of drug washout, DRN Htr1b mRNA levels in SSRI treated rats were no longer different 
from controls. Htr1b mRNA levels in hippocampus were not affected by SSRI drugs at any 
time point. These results confirm that SSRI antidepressants selectively reduce presynaptic 
Htr1b mRNA levels, and that this effect is maintained for at least 8 weeks of antidepressant 
treatment, but reverses rapidly after discontinuation46. Chronic SSRI (fluoxetine) treatment 
has also been reported to down-regulate Htr2c mRNA expression in the mouse prefrontal 
cortex, which became significant after 3 weeks of treatment and persisted after a fourth 
week of drug withdrawal. In the hippocampus, fluoxetine induced a threefold up-regulation 
of Htr2c mRNA levels by the 2nd and 3rd week, returning to the baseline level after drug 
withdrawal. These robust changes in Htr2c mRNA levels were associated with slight changes 
in Htr2c RNA editing47. Htr2c receptor mRNA editing may be strain specific, as only BALB/c, 
but not C57BL/6 and 129Sv, mice showed significant site-specific increases in Htr2c pre-mRNA 
editing, leading to an increase in the pool of mRNA encoding receptors with reduced function 
in response to chronic fluoxetine treatment. Chronic stress exposure blocked this effect of 
fluoxetine, suggesting that Htr2c receptor mRNA editing is involved in the chronic effects of 
fluoxetine275. Overall, the 5-HT2C findings are consistent with the view that fluoxetine acts as 
a competitive and reversible antagonist of 5-HT2C receptors
48. Interestingly, there is a physical 
interaction between PTEN - a negative regulator of the PI3-kinase pathway converging on 
molecules capable of influencing morphogenesis, growth, and neuronal function, including 
mTOR, GSK-3beta, CREB, and NF-kappa-B - and the 5-HT2C receptor: the phosphatase activity 
of PTEN regulates the activity of this receptor276. Hence, it is possible that alterations in Htr2c 
mRNA levels induced by chronic SSRI treatment are associated with changes in a cascade of 
intracellular signaling components regulating the expression of genes involved in neuronal 
morphogenesis.  
5-HT receptors targeted by SSRIs are linked to cAMP-PKA and PLC-PKC pathways 
converging on CREB. As such, 5-HT2C receptors stimulate, through Gαq, phospholipase C (PLC) 
activity, which subsequently promotes the release of diacylglycerol and inositol triphosphate, 
which in turn stimulate protein kinase C (PKC) activity and Ca2+ release. In this context, a 
study assessing whole brain kinase expression using Affymetrix gene chips in rats treated 
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with placebo 3 and 21 days, fluoxetine 3 and 21 days, and citalopram 21 days revealed that 
PKC-delta, PKC-gamma, stress-activated protein kinase, cAMP-dependent protein kinase beta 
isoform, Janus protein kinase, and phosphofructokinase M were all down-regulated50. These 
findings fit well with the studies above demonstrating Htr2c down-regulation in response to 
chronic SSRI treatment. Furthermore, long-term citalopram (10 mg/kg, i.p.), but not single-
dose administration, increased the adenylyl cyclase (AC) type 1 mRNA in the hippocampus, 
whereas type 2 mRNA was unaffected. However, long-term citalopram treatment did not 
increase AC type 1 protein, basal or forskolin-stimulated AC activity, but GTP increased 
AC activity in the hippocampus. This may indicate enhanced AC/G protein coupling. Thus, 
citalopram may increase cAMP signaling by acting on components of the AC system without 
affecting the protein level of the AC type 1136. A role for cAMP signaling is further supported 
by the finding that rolipram, a selective inhibitor of cAMP-specific phosphodiesterases type 
4 (PDE4), has antidepressant efficacy in behavioral models of depression and in clinical 
trials. PDE4 metabolizes cAMP277, and by inhibiting cAMP breakdown PDE4 inhibitors can 
potentiate signaling through the cAMP system. In situ hybridization analysis indicated that 
chronic fluoxetine treatment (5 mg/kg, i.p., 21 days) significantly increased Pde4a1, but not 
Pde4a5 or Pde4a10, mRNA levels in frontal and parietal cortices. Fluoxetine also increased 
Pde4a10 levels in the hippocampus. The differential up-regulation of Pde4a splice variants 
suggests compensatory region-specific responses to the antidepressant-induced increase 
in cAMP signaling51. Another study analyzing the mRNAs coding for PDE4A, PDE4B, PDE4D, 
and the five known PDE4D splice variants using in situ hybridization in response to acute (1 
day) and chronic (14 days) fluoxetine (3 mg/kg day) treatment in rats revealed that single 
fluoxetine administration increased the density of Pde4d1 mRNA in frontal and hippocampal 
regions. Chronic fluoxetine treatment increased Pde4a mRNA levels in the hippocampus and 
decreased Pde4a levels in the anterior cingulate cortex. Furthermore, chronic fluoxetine was 
associated with mostly increased Pde4d(5) mRNAs in areas including the subiculum, dorsal 
part of medial geniculate nucleus, parabigeminal nucleus, pontine nuclei, vestibular nuclei, 
area postrema, and cerebellum52,53. Takahashi and coworkers52 showed that the expression 
of PDE4A and PDE4B, but not PDE4D, mRNA and immunoreactivity were significantly 
increased in rat frontal cortex by 14-day administration of sertraline (10 mg/kg, i.p.) and 
fluoxetine (5 mg/kg, i.p.). They also found that antidepressant administration significantly 
increased the expression of Pde4b mRNA in the nucleus accumbens, a brain region thought 
to mediate pleasure and reward that could also contribute to the anhedonia often observed 
in depressed patients. In contrast, expression of Pde4a and Pde4b were not influenced by 
short-term treatment (1 or 7 days). The changes in cAMP-specific phosphodiesterases may 
be linked to CREB, a well-known transcription factor linked to G-protein coupled receptors 
and cAMP signaling. Specifically, chronic administration of the PDE inhibitors rolipram 
or papaverine increased expression of Creb mRNA in hippocampus, an effect also found 
following chronic SSRI treatment. These effects were associated with increased levels of CRE 
immunoreactivity and of CRE binding activity. Increased expression and function of CREB 
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suggest that specific target genes are regulated by sertraline (10 mg/kg, i.p.) or fluoxetine (5 
mg/kg, i.p.) treatment55. 
In further support of the findings that SSRIs affect gene transcription via CRE, it 
was found that chronic (14 days), but not acute, fluoxetine (10 mg/kg, i.p.) administration 
to transgenic mice with a CRE-LacZ reporter gene construct significantly increased CRE-
mediated gene transcription, as well as the phosphorylation of CREB in the cerebral cortex, 
hippocampus, amygdala, and hypothalamus278. Whereas these findings overall show that 
SSRI treatment leads to up-regulation of the cAMP-CREB pathway (with increased PDE4 levels 
being indicative of higher levels of cAMP available for breakdown), it has been reported that 
citalopram (25 mg/kg, i.p.) and fluoxetine (10 mg/kg, i.p.) treatment (21-25 days) completely 
abolished the increase in CRE/CREB-directed transcription in the hippocampus induced by 
chronic psychosocial stress56. A similar finding was obtained by Abumaria and coworkers134. 
This finding contributes to the debate whether CREB is antidepressive, or pro-depressive279. 
Serotonin receptors and signaling pathways in knockout animals 
Knockout rodents have further increased insights in the molecular targets of SSRIs: like 
polymorphisms in humans, genetic background of rodents influences the efficacy and side 
effects of SSRIs. As such, it has been reported that citalopram induced a dose-dependent 
inhibition of rapid eye movement (REM) sleep 2-6 h after injection, which was observed in 
wild-type and 5-HT
1B
-/- mice, but not in 5-HT1A
-/- mutants. This REM sleep inhibition was fully 
antagonized by pretreatment with the 5-HT1A antagonist WAY 100635, but only partially with 
the 5-HT
1B
 antagonist GR 127935, indicating that the action of the SSRI citalopram on sleep 
in the mouse is essentially mediated by 5-HT1A receptors
135. Another study showed that a 
mouse model bearing a loss of function mutation in G(alpha)i2 (G184S), a regulator of G 
protein signaling (RGS) coupled to 5-HT1A receptors, exhibited spontaneous antidepressant- 
and anxiolytic-like behavior, as well as increased cortical and hippocampal phosphorylation of 
glycogen synthase kinase-3beta, a constitutively active pro-apoptotic kinase that is inhibited 
through phosphorylation in response to 5-HT, SSRIs, and 5-HT1 receptor agonists. These mice 
were 5-10 times more responsive to the antidepressant-like effects of the SSRI fluvoxamine 
(30 mg/kg i.p.), suggesting that endogenous RGS proteins suppress the antidepressant-
like effects of SSRIs211. In 14-day old 5-HT2C receptor mutant mice with a heterozygous 
mutation of the beta-endorphin gene (2CREnd mice) acute fluvoxamine (10 and 30 mg/kg) 
administration exerted anorexic effects, whereas fluvoxamine had no effect on food intake 
in age-matched wild-type mice and 5-HT2C receptor mutant mice. These results suggest 
that acute fluvoxamine-induced feeding suppression requires a concerted perturbation 
of the 5-HT2C receptor and beta-endorphin signalling
210. In another study, Nonogaki and 
colleagues280 showed that fluvoxamine together with pharmacological inactivation of 5-HT2C 
receptors (without mutation of the beta-endorphin gene) exerts appetite suppression and 
that these effects were attenuated in the presence of a selective 5-HT
1B
 receptor antagonist, 
suggesting that activation of 5-HT
1B
 receptors and blockage of 5-HT2C contribute to the 
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appetite-suppressing effects. Finally, it has been reported that acute administration of three 
SSRIs (citalopram (3 mg/kg, s.c.), fluoxetine (5 mg/kg, s.c.), paroxetine (1 mg/kg, s.c.)), but 
not the tricyclic antidepressant desipramine (2 mg/kg, s.c.), had a significantly stronger REM 
sleep suppressive effect in 5-HT
7
-/- mice compared to 5-HT
7
+/+ mice. In contrast, REM sleep was 
similarly affected in 5-HT
7
+/+ mice and 5-HT
7
-/- mice after treatment with the 5-HT1A receptor 
agonist ipsapirone and the 5-HT1A receptor antagonist WAY-100635. These findings indicate 
that the 5-HT
7
 receptor augments the effect of various acutely administered SSRIs on REM 
sleep suppression and that this effect is distinct from those mediated via 5-HT1A receptors
49. 
Animals-in vitro studies
The serotonin transporter and serotonin synthesis
Animal in vitro studies addressing the effects of SSRIs on the serotonergic system are limited. 
An expression microarray analysis of citalopram-treated serotonergic neurons revealed 
that antidepressant treatment did not alter Slc6a4 mRNA expression, whereas evidence 
by confocal microscopy was obtained for citalopram-induced 5-HTT internalization. These 
data suggest that 5-HTT trafficking from and to the cell membrane is regulated at the post-
transcriptional level281, a finding also reported by Iceta and coworkers282 and matching in 
vivo rodent findings. Another study using RBL-2H3 cells showed an increase in mRNA and 
protein levels of TPH by sertraline, as determined by Northern blot and immunoblot analyses, 
respectively. This was accompanied by increases in the levels of TPH enzymatic activity and 
total 5-HT levels160. This increase in TPH level by SSRI treatment corresponds well with part 
of the in vivo studies. However, as mentioned above, there are also in vivo studies showing a 
decrease in TPH expression. 
Dopamine, norepinephrine, GABA, glycine and glutamate system
5-HT does not function in isolation, but interacts with many other neurotransmitter systems, 
including the dopamine (DA), norepinephrine (NE), GABA, glycine and glutamate systems 
(Box 3). Microdialysis studies in vivo have clearly shown that exposure of the striatum or 
nucleus accumbens to 5-HT results in increased release of DA283,284. The NE system is activated 
after administration of 5-HT receptor antagonists in the locus coeruleus of rats, showing an 
interaction between the 5-HT and NE pathways285. Allain and colleagues286 showed that 5-HT 
interacts with the gamma-aminobutyric acid (GABA) system, by controlling the maturation 
of the GABA phenotype in the ventral spinal cord via 5-HT
1B
 receptors. A modulatory effect 
of 5-HT on the glycine response was shown in the rat sacral dorsal commissural nucleus by 
Xu et al.287. Furthermore, an interaction between glutamate receptor mGLU5 and the 5-HT2A 
receptor was shown in mice288. 
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Human-polymorphisms
In line with evidence that the serotonergic and dopaminergic systems interact289, it has been 
found that the Met allele of the Val(108/158)Met polymorphism (rs4680) in the catechol-
O-methyltransferase (COMT) gene was associated with a faster onset of therapeutic effects 
of fluvoxamine and paroxetine in a population of depressed patients212,290. The COMT 
Val(108/158)Met polymorphism was not associated with a 4-week fluoxetine therapeutic 
response, but association analysis showed that patients with the COMT(Val/Val) genotype 
had poorer responses in the eighth week291. However, also negative findings for COMT 
Val(108/158)Met gene variance have been obtained292-294. Another SNP (rs13306278; 
C:92%, T: 8%), located in the distal promoter region of COMT, showed significant association 
with remission in depressed patients treated with citalopram or escitalopram. Alternation 
in the ability of the variant sequence to bind nuclear proteins might affect transcription 
regulation295. Others showed that the dopamine transporter (DAT) VNTR polymorphism 
can influence rapid response to antidepressant therapy. There was a significantly smaller 
number of rapid responders among homozygous carriers of the DAT1 9-repeat allele (9/9) 
than among heterozygous (9/10) and homozygous (10/10) carriers of the 10-repeat allele296. 
Polymorphisms in the dopamine D2 and D4 receptors were not associated with SSRI efficacy
297. 
Regarding the glycine system, a metabolic assay of plasma samples from escitalopram 
remitters and nonremitters showed that glycine, as an inhibitory neurotransmitter, was 
Box 3: Dopamine, norepinephrine, GABA, glycine and glutamate system
Dopamine (DA) is a neurotransmitter synthesized from tyrosine via tyrosine hydroxylase 
(TH) catalysis to levodopa (L-DOPA), and subsequent decarboxylation by dopa decarboxylase 
(DDC) to DA. It can activate five known types of DA receptors (D1, D2, D3, D4, and D5), which 
downstream pathways are involved in many processes, like motivation, sleep, mood and learning. 
DA is de-activated by reuptake by the presynaptic neuron and is broken down by the enzymes 
catechol-O-methyl transferase (COMT) and monoamine oxidase (MAO). Norepinephrine (NE) is 
a neurotransmitter synthesized from DA by DA β-hydroxylase and released from noradrenergic 
neurons in the locus coeruleus. The actions of NE are carried out via the binding to adrenergic 
receptors (α1, α2, β1, β2 and β3). Glutamate is the most abundant excitatory neurotransmitter, 
which plays a role in synaptic plasticity. Glutamate binds to α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid receptors (AMPARs), metabotropic glutamate receptors (mGluRs), 
kainate receptors and NMDA receptors (NMDARs) activating downstream pathways, like the BDNF 
pathway (see Box 4) and the calcium signaling pathway312. Glutamate also serves as the precursor 
for the synthesis of the inhibitory gamma-aminobutyric acid (GABA) in GABA-ergic neurons, which 
is catalyzed by glutamate decarboxylase (GAD). GABA acts at inhibitory synapses by binding to 
specific transmembrane receptors, GABAA and GABAB, and plays a role in regulating neuronal 
excitability throughout the nervous system and muscle tone. Glycine is a neurotransmitter which 
can exert both inhibitory and excitatory functions. When glycine receptors are activated, chloride 
ions enter the neuron and the cell undergoes a hyperpolarization, but glycine is also involved in 
the activation of NMDA receptors as a co-agonist of glutamate. 
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negatively associated with treatment outcome, an effect that was associated with the 
rs10975641 SNP in the glycine dehydrogenase gene139. Given that glycine/N-Methyl-D-
aspartic acid (NMDA) receptor functional antagonists enhance the antidepressant-like action 
of 5-HT298, and that oral glycine administration enhances 5-HT release in the prefrontal 
cortex299, it may be that 5-HT and glycine synergistically mediate the (neuroplastic) effects 
of SSRIs. 
No association could be found between purinergic receptor P2X, ligand-gated ion 
channel 7 (P2RX7) gene polymorphisms and MDD or remission after SSRI treatment300, 
whereas these polymorphisms have been suggested to be associated with MDD301. P2RX7 
is an ATP-gated non-selective cation channel activated by high concentrations of ATP (>100 
μM)302. P2RX7 is localized on glutamatergic nerve terminals and plays a significant role in 
ATP-evoked glutamate efflux303. Furthermore, P2RX7 mediates the influx of Ca2+ and Na+ 
ions and the release of proinflammatory cytokines. However, a polymorphism in another 
glutamatergic gene, GRIK4, in combination with an HTR2A polymorphism is associated with 
SSRI response249. The rs5443 (c.825C>T; C:52%, T:48%) polymorphism in the G-protein beta3 
subunit (GNB3) gene - a key modulator of signal transduction – shown to be involved in 
dopamine receptor availability - is associated with SSRI responsiveness304. Lin and colleagues245 
showed that carriers of the C-allele responded better to SSRI treatment than those with the 
T/T variant. Conversely, others showed that subjects with GNB3 T/T variants showed better 
response to fluoxetine305, fluvoxamine and paroxetine treatment209. In addition, there are also 
studies showing no association between the rs5443 polymorphism and SSRI response306. 
Yet, glycogen synthase kinase-3beta (GSK3B) TAGT carriers showed a poorer 
response to chronic fluoxetine and citalopram treatment61. GSK3B is a constitutively active 
serine/threonine kinase that phosphorylates cellular substrates and thereby regulates a 
wide variety of cellular functions, including development, metabolism, gene transcription, 
protein translation, cytoskeletal organization, cell cycle regulation, and apoptosis307. GSK3B 
is regulated by several neurotransmitter systems, including serotonergic308, dopaminergic309, 
cholinergic and glutamatergic systems310. No correlation between the norepinephrine 
transporter T182C/G1287A polymorphisms and SSRI response was observed30,33.
There are also studies showing evidence for the involvement of the glutamate 
system on sexual dysfunction, a well-known side effect of SSRI treatment. For instance, 
sexual dysfunction as side effect of citalopram treated in a cohort of Caucasian depressed 
patients was associated with single nucleotide polymorphisms in ionotrophic α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamatergic receptor genes: GRIA3 
(ionotrophic AMPA 3) and GRIK2 (ionotropic kainate 2) were associated with decreased 
libido, GRIA1 (ionotrophic AMPA 1) was associated with difficulty achieving orgasm, and 
GRIN3A (ionotropic N-methyl-D-aspartate 3A) was associated with difficulty achieving 
erection. Surprisingly, no associations between sexual dysfunctions and serotonergic genes 
were found138. Furthermore, Thomas and colleagues60 showed evidence for an association 
between the adrenergic beta-1 receptor gene (ADRB1) Ser49Gly (rs1801252; A:85%, G:15%) 
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and Arg389Gly (rs1801253; C:69%, G:31%) variants and cardiovascular side effects. There 
was a significant interaction between Arg389Gly variant status and fluoxetine and paroxetine 
treatment in relation to systolic blood pressure and heart rate.
Human-lymphoblasts
A study in human lymphoblasts focused on G protein-coupled receptor kinases (GRKs). Blood 
platelets derived from unmedicated depressed patients were characterized by reduced 
GRK2 mRNA levels and chronic SSRI treatment normalized platelet GRK2. Furthermore, 
GRK2 up-regulation discriminated between responder and non-responder patients59. GRK2 
is a ubiquitous protein kinase of the GRK family, which phosphorylates the beta adrenergic 
receptor and related G-protein-coupled receptors311. A study in human mononuclear 
leukocytes also showed alleviation of decreased GRK2 mRNA levels by antidepressant 
treatment137.
Animals-in vivo
Besides studies in humans, the effect of SSRIs on other neurotransmitter systems has also 
been investigated in animals in vivo. In rats, chronic (21 days) fluoxetine treatment failed 
to affect dopamine D3 receptor mRNA levels on the nucleus accumbens shell, although an 
up-regulation was seen after 42 days of treatment63. In addition, repeated administration of 
citalopram (10 mg/kg, p.o., 14 days) resulted in an increase in the level of D1 (Drd1) mRNA in 
the striatum and in the core region of nucleus accumbens140. Furthermore, mRNA levels of 
tyrosine hydroxylase (Th), the enzyme mediating DA synthesis, were increased by 70-150% 
in the locus coeruleus after 2 weeks of fluoxetine treatment, and by 71-115% after 8 weeks 
of treatment64. An increase in Th mRNA levels after fluoxetine treatment (5 weeks, 5 mg/kg) 
was also reported by Heydendael and Jacobson45. Thus, overall, chronic SSRI treatment may 
lead to up-regulation of DA neurotransmission. Given that NE is synthesized from DA, it is 
expected that SSRIs affect the expression of noradrenergic genes as well. However, citalopram 
(10 mg/kg, i.p., 14 days) failed to affect the expression of alpha1A and alpha1B subtypes of 
the adrenergic alpha1-A receptor in the rat prefrontal cortex, as measured by Northern blot 
analysis and RT-PCR, respectively313. 
Knockout animals
Yet, mice lacking the dopamine beta-hydroxylase gene (Dbh-/-), converting DA into NE, did 
not respond to the antidepressant effects of fluoxetine, sertraline, and paroxetine in the tail 
suspension test, whereas citalopram was equally effective at reducing immobility in mice 
with and without NE. Restoration of NE using L-threo-3,4-dihydroxyphenylserine reinstated 
the behavioral effects of paroxetine in Dbh-/- mice, thus demonstrating that the reduced 
sensitivity to antidepressants is related to NE function68. In mice lacking GABA Type A chronic 
but not subchronic treatment with fluoxetine (~4 mg/kg/day in drinking water) normalized 
anxiety-like behavior in the novelty suppressed feeding test, but not depression-related 
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behavior in the forced swim, tail suspension, and sucrose consumption tests69. This reduced 
sensitivity to fluoxetine in the GABA Type A knock out indicates that GABA is important for the 
anti-depressive effects of fluoxetine.
Animals-in vitro
Data on the monoamine and excitatory/inhibitory neurotransmitter systems interacting with 
SSRIs are limited for in vitro animal studies. Yet, interesting is the finding that in cultured 
mouse astrocytes fluoxetine up-regulated the kainate receptor Grik2 mRNA levels and its 
RNA editing. This effect was associated with abolishment of glutamate-mediated increases 
in intracellular Ca(2+) and ERK(1/2) phosphorylation, due to the 5-HT
2B
 receptor agonism 
of fluoxetine, as assessed by small interfering RNA manipulation71. This suggests that the 
fluoxetine-induced effects on the glutamatergic system are mediated via the HT
2B
 receptor.
Neuroplasticity factors
The serotonergic system also strongly interacts with brain-derived neurotrophic factor (BDNF), 
in a synergic manner314. BDNF is one of the targets, but also regulators, of the cAMP-CREB 
pathway, as well as a key factor in neuroplasticity and neurogenesis (Box 4). In addition, we 
will discuss some other neuroplasticity factors that might be influenced by SSRIs, like vascular 
endothelial growth factor (VEGF), dysbindin, synaptophysin, growth-associated protein-43 
(Gap-43) and the Kv4.2 gene. VEGF participates in physiological and pathological processes 
of angiogenesis and studies of recent years have revealed neurotrophic and neuroprotective 
potential of VEGF in the nervous system. Furthermore, VEGF might play a role in the strong 
positive correlation between the incidence of cardiovascular diseases and depression315. 
Dysbindin is a protein that has a possible biological role in synaptic signaling and plasticity, and 
localization in the brain. The dysbindin complex is found in axon bundles and is a component 
of the dystrophin glycoprotein complex involved in glutamatergic neurotransmission316, 
which may play an important role in the antidepressant potential of SSRIs. Synaptophysin is a 
synaptic vesicle glycoprotein which plays an essential role in synaptic plasticity317. Gap-43 is a 
growth and plasticity factor which is expressed at high levels in neuronal growth cones during 
development and axonal regeneration and is phosphorylated after long-term potentiation 
and after learning318,319. The Kv4.2 gene  (KCND2) encodes for an essential subunit of voltage-
gated A-type potassium channels that is involved in dendritic signal integration and synaptic 
plasticity320. 
Human-polymorphisms
The human BDNF gene bears the common Val66Met (rs6265; A:18%, G:82%) polymorphism, 
in which G>A substitution in nucleotide position 196 results in a valine (Val) to methionine 
(Met) change at amino acid position 66, with BDNF secretion being reduced in 66Met BDNF 
neurons322. A significant association of Val/Met heterozygous genotype and increased SSRI 
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response rate was found in several studies323-325. However, Chi and colleagues326 reported 
that patients with the Val/Val genotype had significantly higher chances to be responders 
to venlafaxine treatment (serotonin-norepinephrine reuptake inhibitor) and that fluoxetine 
treatment was not associated with the Val66Met polymorphism. Furthermore, a study in 
Korean MDD patients showed that the Val66Met polymorphism is associated with citalopram 
efficacy143, with Met-allele carriers responding better to citalopram treatment. In addition, 
Met-allele carriers showed a lower incidence of side effects including insomnia and decreased 
libido77. Moreover, there are studies showing no association between SSRI treatment and the 
Val66Met polymorphism325. The inconsistencies in results may be explained, at least partially, 
by ethnicity327 and differences between antidepressants. Most studies that revealed significant 
association between the Val66Met polymorphism and antidepressants treatment response 
were based on Asian populations, whereas Caucasian studies showed no association. Another 
study showed that two BDNF polymorphisms (rs908867 and rs1491850) with unknown 
functions were associated with SSRI treatment outcome in obsessive compulsive disorder 
patients78. In depressed patients receiving SSRI treatment the BDNF rs962369 polymorphism 
was associated with increased suicidal ideation, by interacting with variants in BDNF and 
NTRK2, the gene encoding the BNDF receptor196. A haplotype analysis further revealed 
that p75(NTR) TCT carriers had a more unfavorable response to SSRI therapy79. Of interest, 
the rs2227684-G (A:43%, G:57%) and rs7242-T (G:43%, T:57%) alleles of the plasminogen 
activator (tPA) inhibitor type 1 (PAI-1) gene were found to be associated with depression 
in Chinese patients, and the haplotype derived from the rs2227631-G (A:41%, G:59%) and 
rs1799889-4G (-:35%, G:65) polymorphisms was lower in responders than non-responders to 
fluoxetine or citalopram treatment80. The activity of the tPA–plasminogen system is dependent 
on the generation of a protease, plasmin, which is generated from an inactive precursor, 
plasminogen, through the action of tPA. Plasmin is the most significant protease involved 
in the cleavage of proBDNF in the brain328, and because proBDNF has biologically opposite 
effects to BDNF329, the proteolytic processing of proBDNF by the tPA–plasminogen system 
thus represents a powerful means of controlling the direction of BDNF action. Therefore, the 
finding that both BDNF and PAI-1 genes influence the efficacy of SSRIs confirms that these 
factors are functioning in a pathway. Taken together, these findings support the interaction 
between the serotonergic and BDNF-tPA systems. 
This interaction might be quite specific, as no association between SSRI efficacy 
and vascular endothelial growth factor (VEGF) was found in Japanse depressed patients330. 
However, there are studies showing interactions between SSRIs and other neuroplasticity 
factors. The dysbindin gene (dystrobrevin-binding-protein 1, DTNBP1) SNP rs760761 showed 
a trend of difference between responders and non-responders (4th week) to SSRI treatment 
in depressed patients144. 
Human-lymphoblasts
In a study in which cultured human neuroblastoma SH-SY5Y cells were treated with fluoxetine 
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(as well as other classes of antidepressant drugs) for 6, 24 and 48 hours, no changes in BDNF 
mRNA levels were noted331. Furthermore, one study employed a genome-wide profiling 
approach (microarrays) in human lymphoblastoid cell lines (LCLs), and it was found that 
increased paroxetine LCL growth inhibition was associated with a 36-fold down-regulation of 
CHL1, a gene coding for a neuronal cell adhesion protein implicated in correct thalamocortical 
circuitry, schizophrenia and autism. Several additional genes implicated in synaptogenesis 
and/or in psychiatric disorders, including ARRB1 (arrestin, β1, G-protein-coupled receptor-
mediated synaptic transmission), CCL5 (chemokine [C–C motif] ligand 5, chemoattractant 
for blood cells), ENDOD1 (endonuclease domain containing 1, Associated with CNS myelin), 
ENPP2 (ectonucleotide pyrophosphatase/ phosphodiesterase 2, Regulates myelin formation), 
FLT1 (FMS-related tyrosine kinase 1, receptor implicated in synaptic transmission), GABRA4 
(gamma-aminobutyric acid receptor A, involved in GABAergic neurotransmission), GAP43 
(growth-associated protein 43, Regulates neurite outgrowth and plasticity), and SPRY2 
(Regulates FGF2 signaling), also displayed more than 1.5-fold lower basal expression in the 
paroxetine-sensitive LCLs181. Thus, it appears that the SSRI paroxetine particularly affects 
the expression of plasticity-associated genes, whereas 5-HT related genes (SLC6A4, 5-HT 
receptor genes and other candidate genes related to 5-HT signaling221) mostly addressed in 
pharmacogenetic studies are not affected. Notably, although lymphocytes and other human 
cell lines are thought to potentially act as a neural probe for studying psychiatric disorders332, 
these findings should be considered with caution given that gene expression and regulatory 
mechanisms can be highly tissue specific. 
Animals-in vivo
To assess the time-dependent effects of SSRIs on Bdnf gene expression, rats were treated with 
fluoxetine (10 mg/kg, p.o.) for 4, 7, 14 and 21 days. Four days of fluoxetine treatment induced 
decreases in Bdnf mRNA (hippocampus, medial habenular and paraventricular thalamic 
nuclei), 7 days of treatment showed a non-significant increase in Bdnf mRNA, and there 
were marked and region-specific increases following 14 days of treatment. BDNF protein 
levels remained unaltered until 21 days of fluoxetine treatment, when the numbers of BDNF 
Box 4: BDNF
Brain-derived neurotrophic factor (BDNF) is synthesized through proteolytic cleavage of proBDNF 
by the tPA/plasmin cascade. ProBDNF and mature BDNF (mBDNF) have been shown to elicit 
opposite effects by activating two distinct receptor-signaling systems. The biological function of 
BDNF is mediated by the TrkB receptor. Upon binding, BDNF triggers TrkB dimerization followed 
by autophosphorylation and the recruitment of a series of intracellular proteins that primes 
subsequent activation of several signaling pathways. In contrast, proBDNF binds p75NTR, resulting 
in the activation of several signaling molecules, including NF-kB, JNK and RhoA. The outcomes are 
opposite to those mediated by BDNF-TrkB. Antidepressant drugs are thought to increase BDNF 
levels, and thereby to increase neurogenesis and other pro-neuronal functions 321. 
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immunoreactive cells were increased, reaching significance in the pyramidal cell layer of CA1 
and CA3 regions of Ammon’s horn, but not in the other sub-regions of the hippocampus. In 
contrast to the time dependent and biphasic response of the Bdnf gene to fluoxetine, activity-
regulated, cytoskeletal-associated protein (Arc) mRNA showed a gradual increase during the 
14-day course of treatment81. Also citalopram (10 mg/kg) treatment led to increases only: 
after short-term (2 days) treatment Bdnf mRNA was increased in the CA2 region of the 
hippocampus, and when combined with exercise, Bdnf mRNA levels increased in the CA4 
and dentate gyrus after 2 weeks of treatment145. Again another study revealed a reversed 
biphasic BDNF response. Seven days of treatment with the SSRI escitalopram (10 mg/kg, i.p.) 
increased mRNA levels (as measured using the RNase protection assay) of BDNF in the rat 
prefrontal cortex, which was confirmed at protein level and associated with increased protein 
levels of phospho-ERK1/2 and p38 MAPK, signaling components linked to BDNF. Moreover, 
Carf (calcium responsive transcription factor) mRNA levels, a transcription factor of activity-
dependent BDNF expression, were increased, possibly through activation of p38 MAPK and 
ERK1/2. At 21 days of treatment with escitalopram, Bdnf and Carf mRNA, and phospho CREB 
levels were decreased in the hippocampus, while phospho-p38 MAPK levels were increased in 
the hippocampus195. SSRI effects on Bdnf mRNA expression are thus region-specific, although 
some studies failed to show any changes in Bdnf mRNA levels in the dentate gyrus upon 
chronic fluoxetine treatment86,333,334. SSRIs also affect other neuroplasticity factors in rodents. 
As such, a transient increase in synaptophysin mRNA was observed in the hippocampus, and 
in the CA3 region a reduction of Gap43 mRNA was observed after fluoxetine treatment (10 
mg/kg, i.p.) for 7 and 14 days86. Overall it appears that SSRIs increase mRNA levels of Bdnf 
and synaptophysin, which most likely allow beneficial neuroplastic changes in, among others, 
the hippocampus.   
Knockout animals  
In BDNF+/- mice the SSRI paroxetine (8 mg/kg, i.p., acute) failed to increase hippocampal 
extracellular 5-HT levels, while it produced robust effects in wild-type littermates, suggesting 
that BDNF+/- mice show genetic resistance to serotonergic antidepressant drugs183 and that 
5-HT and BDNF interact synergistically. In support, fluvoxamine (50 and 100 pmol) significantly 
decreased 5-HT clearance in hippocampal slices of BDNF+/+ mice, but not in BDNF+/- mice183,213. 
Furthermore, mice carrying a knockout of the Kv4.2 gene (Kcnd2) - which codes for an essential 
subunit of voltage-gated A-type potassium channels – were resistant to the antidepressive 
effects of acute fluoxetine (30 mg/kg, i.p.) in the forced swim and tail suspension test87.
Hypothalamic system 
It has also been well established that depression is associated with alterations in the 
hypothalamus-pituitary-adrenal (HPA)-axis (Box 5). Besides the HPA axis, other hypothalamic 
processes like regulation of hunger and reproduction are also associated with depression and 
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antidepressants.
Human-polymorphisms
Studies investigating the association between SSRI treatment and SNPs in genes involved 
in the HPA-axis are rather limited. The rs242941 (G:68%, T:32%) G/G genotype of the 
corticotrophin-releasing hormone receptor 1 (CRHR1) gene was associated with fluoxetine’s 
therapeutic response in depressed patients characterized by high-anxiety93. G carriers 
of rs2270007 (C:79%, G:21%) of the CRHR2 gene showed a worse overall response to 
citalopram147. Furthermore, a SNP (rs10473984; G:87%, T:13%) within the CRHBP locus, 
encoding the CRH-binding protein which inactivates corticotrophin releasing factor (CRF), 
showed a significant association with both remission and reduction in depressive symptoms 
in response to citalopram. The T-allele of this SNP was associated with poorer treatment 
outcome in 2 out of the 3 ethnic subsamples (African-American and Hispanic), despite large 
differences in minor allele frequency. This association was more pronounced in patients with 
features of anxious depression148. 
Animals-in vivo
More data on SSRI effects of the expression of HPA-axis components have been obtained 
in experimental animals. Starting at the level of the paraventricular nucleus (PVN) in the 
hypothalamus, male mice acutely treated with fluoxetine (10 mg/kg) exhibited no changes 
in arginine vasopressin (Avp), oxytocin (Oxt) and Crf mRNA expression, but female wild-
type animals showed increased PVN Avp and Oxt mRNA levels95. Upon chronic fluoxetine 
treatment, amygdala Crf gene expression was decreased45, and Brady and colleagues64 
observed that chronic fluoxetine (5 mg/kg, i.p.) treatment for 2-8 weeks decreased Crf mRNA 
Box 5: Hypothalamic system
Upon stress exposure, the hypothalamus secretes corticotrophin releasing factor (CRF), 
arginine vasopressin (Avp) and oxytocin (Oxt), triggering the release of proopiomelanocortin 
(POMC) from the pituitary, that is cleaved in, among others, adrenocorticotropic-hormone 
(ACTH). ACTH, on its turn, stimulates the secretion of the stress hormones cortisol (humans) 
and corticosterone (rodents). Feedback control of the HPA-axis is mediated by glucocorticoid 
(GR) and mineralocorticoid (MR) receptors in selective brain areas. CRF is not only found in the 
hypothalamus, but also in cortical and limbic structures, in particular high levels are found in the 
central nucleus of the amygdala335 where it plays a role in stress response336 and addiction337. 
Besides the HPA axis, the hypothalamus is involved in many more processes. The hypothalamus 
regulates homeostasis; it has regulatory areas for thirst, hunger, body temperature, water 
balance, and blood pressure, and links the nervous system to the endocrine system. Furthermore, 
the hypothalamus is involved in the reproductive system by secretion of gonadotropin releasing 
hormone (GnRH). GnRH stimulates the release of follicle-stimulating hormone by the pituitary 
gland, which, in turn, stimulates the release of estrogens (by the follicles) or testosterone (by the 
testes). 
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levels by 30-48% in the PVN of the hypothalamus. The decreases occurred at 8 weeks but not 
at 2 weeks. Proopiomelanocortin (Pomc) mRNA levels in the anterior pituitary and plasma 
ACTH levels were not altered after 2 or 8 weeks of drug treatment. However, Jensen and 
colleagues150 showed that a daily treatment with citalopram (10 mg/kg, s.c.) for 14 days 
decreased the expression of Pomc mRNA in the anterior pituitary by 40%. Furthermore, it 
has been demonstrated that 5 mg/kg fluoxetine (i.p.) increased the level of mineralocorticoid 
receptor (MR) mRNA in the hippocampus after 8 weeks of drug administration64. In addition, 
mice treated with fluoxetine (5 mg/kg, i.p.) for 5 weeks showed decreased glucocorticoid 
receptor (GR) gene (Nr3c1) expression in the prefrontal cortex, amygdala, locus coeruleus 
and DRN45. Effects of fluoxetine on the expression of GRs may be age-dependent, as chronic 
(1 month) fluoxetine (10 mg/kg, p.o.) treatment increased Nr3c1 mRNA in the hippocampus 
of 4 months old rats, and MR (Nr3c2) mRNA levels in CA2 of 24 month old rats96. Together 
these data suggest that chronic SSRI exposure decreases the activity of the HPA-axis through 
enhancing GR/MR feedback regulation, although the decreased Nr3c1 mRNA levels found by 
Heydendael et al.45 may also reflect diminished corticosterone secretion due to decreased 
CRF and POMC levels and therefore a reduced need for feedback regulation.   
 The HPA-axis is implicated not only in stress responses, but also in feeding. In female 
goldfish, chronic fluoxetine treatment (5 µg/gr, 13 days) reduced body weight and food 
intake, and induced an up-regulation of both crf1 and neuropeptide Y (npy) mRNAs in the 
hypothalamus. In the telencephalon there was a decrease of npy mRNA and an increase in 
amphetamine-regulated transcript (CART)-1 mRNA. No changes in tachykinin mRNA were 
observed in either the hypothalamus or telencephalon104. NPY exerts orexogenic effects 
and is under inhibitory regulation of CRF338. Their up-regulation may therefore reflect a 
compensatory mechanism to counteract the decrease in food intake. Chronic fluoxetine (10 
mg/kg, i.p., 2 weeks) administration in male obese Zucker rats decreased food intake along 
with increased Pomc expression and reduced melanocortin receptor 4 (Mc4r) expression 
in the hypothalamus, without changes in Agouti gene related peptide (Agrp) mRNA levels. 
These findings indicate that the melanocortin system is involved in the anorectic mechanism 
of fluoxetine100. 
 Again another hypothalamic system is the reproductive system driven by gonadal 
hormones. A female goldfish study showed that fluoxetine (5 µg/gr, 14 days) significantly 
reduced the expression of estrogen receptor (ER)beta1 mRNA in both the hypothalamus 
and the telencephalon, and ERalpha mRNA in the telencephalon. Fluoxetine had no effect 
on the expression of ERbeta2 mRNA in the hypothalamus or telencephalon. Microarray 
analysis identified isotocin, a neuropeptide that stimulates reproductive behavior in fish, as 
a candidate gene affected by fluoxetine treatment. Real-time RT-PCR verified that isotocin 
mRNA was down-regulated in the hypothalamus and the telencephalon. Intraperitoneal 
injection of isotocin (1 μg/g) increased plasma estradiol, providing a potential link between 
changes in isotocin gene expression and decreased circulating estrogen in fluoxetine-injected 
fish105. An association between estradiol and SSRI treatment was also observed in a study 
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in which rats were ovariectomized and supplemented with estradiol (E(2)) and thereafter 
withdrawn from the E(2) supplementation in half of the animals. It was found that in acute 
sertraline-treated (10 mg/kg, i.p.) rats, E(2) decreased Htr2a receptor mRNA, and E(2)-
withdrawal increased Htr1a, Htr2a and Htr2c receptor mRNA. These effects were not seen 
after imipramine (tricyclic antidepressant; TCA) treatment339, implying that E(2) synergizes 
behaviorally and neurochemically with acute SSRI administration.
Knockout animals
When the acute effects to 10 mg/kg fluoxetine (s.c.) on HPA-axis activation and the 
associated release of vasopressin (which together with CRF stimulates the secretion of ACTH 
from the anterior pituitary) were measured in Avpr1b knockout mice and wild-type controls, 
significantly attenuated plasma ACTH and CORT levels were noted in the knockout mice 
compared to their control counterparts. Avp, Oxt and Crf mRNA expression in the PVN did not 
change in acute fluoxetine (10 mg/kg, s.c.) -treated male Avpr1b knockout or wild-type mice. 
In contrast, fluoxetine treatment increased PVN Avp mRNA levels in female Avpr1b wild-type 
but not knockout animals. PVN Oxt mRNA levels increased in fluoxetine-treated female mice 
of both genotypes. The data suggests that the Avpr1b gene is required to sex-dependently 
drive the HPA axis response to acute antidepressant treatment95. In glucocorticoid receptor-
impaired mice hippocampal cell proliferation and BDNF mRNA expression were down-
regulated, and these alterations were reversed by chronic fluoxetine (10 mg/kg, i.p., 21 days) 
treatment. Fluoxetine did not reverse GR (Nr3c1) mRNA down-regulation, nor did it increase 
the survival of newly formed cells in the ventral part of the hippocampus340, which implies 
that the increase in Bdnf mRNA in fluoxetine exposed mice may be mediated by the activation 
of several pathways which are independent from GR, however this does not exclude that a 
link between GR and BDNF exists. 
Inflammatory system
Inflammation is an early response of the immune system to injury often caused by infection. 
An inflammatory response is produced by eicosanoids and cytokines, which are released by 
injured or infected cells and recruit immune cells to the site of infection and promote healing 
of any damaged tissue. Cytokines include interleukins (communication between white blood 
cells), chemokines (promoting chemotaxis) and interferons (anti-viral effects). Common 
eicosanoids include prostaglandins (fever and dilation of blood vessels) and leukotrienes 
(attracting leukocytes). Proinflammatory cytokines may provoke changes in brain structure 
and function, leading to the development of depression. Cytokines can directly modulate 
pathways implicated in the aetiology of depression, like neurotransmission, the HPA axis and 
hippocampal neurogenesis. Proinflammatory cytokines can down-regulate 5-HT synthesis 
by lowering the availability of tryptophan (the substrate for serotonin synthesis) through 
activation of indoleamine-2,3-dioxygenase (IDO)341-343, and increasing neurotoxic kynurenine 
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metabolites such as 3-hydroxy kynurenine and quinolinic acid344. In addition, it is shown that 
cytokines can enhance the reuptake of 5-HT345. Proinflammatory cytokines also reduces the 
synthesis346 and enhance the reuptake of dopamine347. The effect of cytokines on the HPA-axis 
has been attributed to glucocorticoid receptor (GR) resistance. Inflammatory cytokines and 
their signaling pathways including mitogen-activated protein kinases, nuclear factor-kappaB, 
signal transducers and activators of transcription, and cyclooxygenase have been found 
to inhibit GR function resulting in overactivity of the HPA-axis348. Furthermore, it has been 
shown that neuroinflammation inhibits neurogenesis349,350 and that inflammatory blockade 
with a non-steroidal anti-inflammatory drug restores neurogenesis349 .
Human-polymorphisms
Regarding inflammation, studies mainly address polymorphisms in interleukins. It is shown 
that MDD patients who were homozygous for the -511T allele (rs16944; T:53%, C:47%) of the 
interleukin-1 beta (IL-1β) gene had a trend of less severity of depressive symptoms and more 
favorable fluoxetine therapeutic response than -511C carriers351. Furthermore, Tadić and 
colleagues352 investigated the possible association of the IL-1β C-511T promoter polymorphism 
and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)n VNTR polymorphism with 
antidepressant response to paroxetine treatment. They show that patients homozygous for 
the IL-1β-511T-allele had a significantly faster and more pronounced response to paroxetine 
treatment than IL-1β-511C-allele carriers, while the IL-1Ra VNTR was not associated with 
paroxetine treatment response. Another genome-wide pharmacogenetics study showed an 
association between a polymorphism in the interleukin-11 gene (rs1126757) and response 
to escitalopram200. Finally, gene polymorphisms affecting SSRI efficacy were found in IDO, 
which is a gene associated with both the 5-HT pathway and the immune system. Two SNPs 
(rs2929115 and rs2929116), located between 26 kb and 28 kb downstream of the IDO2 gene, 
showed an association with citalopram response132. 
Human-lymphoblasts
In line with the inflammation hypothesis of depression, implying that inflammatory responses 
in the brain leads to depression-related symptoms344, it was found in leukocytes of depressed 
patients that mRNA expression of the cytokines IL-1beta, IL-6, (interferon) IFNgamma, (tumor 
necrosis factor) TNFalpha, and 5-HTT were higher compared to those of the healthy controls. 
The higher level of mRNA expressions of IFNgamma and 5-HTT diminished after fluoxetine 
treatment. Furthermore, there was a positive correlation between 5-HTT and cytokine 
mRNA expression in all participants, which suggested that pro-inflammatory cytokines and 
5-HTT might play critical roles in the pathogenesis of major depression and that their levels 
were affected by chronic treatment with 5-HTT inhibitors106. The cytokine-5-HT interaction 
in depression may be mediated by IDO, as mentioned before. Furthermore, one study 
employed a genome-wide profiling approach (microarrays) in human T-lymphocytes treated 
with paroxetine and sertraline and revealed down-regulation of CDC2 (Cell division cycle 2, 
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G1 to S and G2 to M), CDC6 (cell division cycle 6 homolog (Saccharomyces cerevisiae), TNFSF8 
(Tumor necrosis factor (ligand) superfamily,member 8), IL2RA (Interleukin 2 receptor, alpha 
Transcription factor Dp-1), LMAN1 (Lectin, mannosebinding, 1), STAT1 (Signal transducer 
and activator of transcription 1), which are involved in inflammation, as well as in gene 
proliferation, cancer and apoptosis165. Together, there is evidence that genes involved in the 
immune system are affected by SSRI treatment. However, it has to be taken into consideration 
that these studies are performed in lymphocytes and that gene expression and regulatory 
mechanisms can be highly tissue specific. 
Miscellaneous genetic effects of SSRIs
Human polymorphisms
Some miscellaneous effects of SSRIs have also been reported. It was found that polymorphisms 
in the CLOCK gene (rs3736544, rs1801260, rs3749474; GTT, GCC and TTC, respectively) were 
significantly associated with fluvoxamine’s therapeutic response in Japanese depressed 
patients214. This observation supports the idea that MDD is associated with disruptions 
in biological circadian rhythms, and that SSRIs have circadian properties. Furthermore, 
polymorphisms in pharmacokinetic genes (CYP2D6, ABCB1, CYP2C19, CYP3A4, CYP450, and 
CYP3A5) failed to affect the efficacy of SSRIs353-355. 
Animals-in vivo
Among the miscellaneous effects of SSRIs found in animal studies is the observation that 
chronic citalopram (30 mg/kg/day, 4 weeks, via drinking water) treatment prevented 
stress-induced up-regulation of synaptic vesicle glycoprotein 2b (Sv2b) and glial N-myc 
downstream-regulated gene 2 mRNA levels, involved in exocytosis of synaptic vesicles and 
neurite outgrowth, respectively. Furthermore, increased mRNA levels for neuron-specific 
enolase (NSE, Eno2 gene) were found in both stressed and unstressed citalopram treated 
animals in the dorsal raphe nucleus134. NSE has neurotrophic and neuroprotective effects 
on different types of cultured neurons356,357. The neuromodulator somatostatin, which 
inhibits the release of hormones from the pituitary gland and regulates dopamine release 
in the striatum358, was also found to be modulated by SSRI treatment. A single citalopram 
injection (10 mg/kg, i.p.) significantly reduced somatostatin levels in the striatum and nucleus 
accumbens after 4 but not 1, 8, or 24 h. No changes were found in hippocampus. In addition, 
it was found that the K+-evoked overflow of somatostatin-like immunoreactivity from striatal 
slices was significantly increased 1 h after a single injection of citalopram and was still higher, 
although not significantly, 4 h after the drug injection. Levels of preprosomatostatin mRNA 
were unchanged in striatum and accumbens 1 and 4 h after a single drug administration. 
When rats were treated with citalopram (10 mg/kg i.p.) twice daily for 14 days, the levels of 
somatostatin and its mRNA were significantly decreased in the striatum but not in other brain 
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regions 24 h after the last dose. No change was found in the basal or K+-evoked overflow of 
somatostatin-like immunoreactivity at 1, 4, and 24 h after the last drug injection156.
Age-dependent effects
Whereas the safety of SSRIs has been well established in adults, safety is not guaranteed in 
children and adolescents. Treatment during adolescence may increase the risk for suicide359 
and prenatal treatment results in adverse outcomes, such as premature birth360, neonatal 
cardiovascular abnormalities361, and pulmonary hypertension362. Furthermore, neonatal and 
adolescent SSRI exposure leads to paradoxical anxiety- and depression-like features in later 
life of rats and mice20,363. 
Animals-in vivo
To unravel the potential molecular mechanism underlying the age-dependent effects of 
SSRIs postnatal day 13, 21, 28 and adult rats were treated with escitalopram (2-15 mg/
kg, i.p.) for four days, twice a day and effects on BDNF and its receptor TrkB were studied. 
Bdnf mRNA and BDNF protein levels, as well as TrkB (Ntrk2) mRNA levels, were significantly 
increased in postnatal day 13 pups after escitalopram treatment as compared to control. 
However, desipramine, a TCA, failed to increase either Bdnf or Ntrk2 expression. The failure 
of desipramine to increase BDNF and TrkB levels in juvenile rats is consistent with the lack 
of efficacy of desipramine in children and adolescents and may relate to the fact that the 
serotonergic nervous system matures earlier than the noradrenergic system199. Another 
study focused on the neuronal PAS domain protein 4 (Npas4), one of the transcription factors 
regulating BDNF. The Npas4 gene expression was significantly decreased in animals that were 
exposed to chronic fluoxetine during gestation, but fluoxetine treatment of adult rats did not 
result in a significant change in the mRNA levels of the transcription factor88.
Animals-in vitro
Cultured cells are also highly informative to dissect the age (development)-dependent 
effects of SSRIs, as they allow the visualization of cell proliferation and differentiation. Using 
a mesencephalic neural cell line, mes-c-myc A1 (A1), producing 5-HT and expressing 5-HTT 
and both peripheral TPH1 and CNS-specific TPH2, it was reported that fluoxetine (10 μM) 
modulates the expression of serotonergic markers depending on the differentiation status of 
the cells. Interestingly, long-term (7 days), but not short-term (1 day), fluoxetine treatment 
selectively modulated mRNA levels of Tph2, only in differentiated A1 cells. Furthermore, 
SSRIs selectively decreased the proliferation rate of undifferentiated A1 cells, whereas they 
had no effects on NIH-3T3 fibroblasts proliferation, showing that the differentiation stage of 
cells influences SSRI responsiveness364. In embryonic stem (ES) cells, fluoxetine (0-1 µM) was 
found to decrease the viability of the cultured cells as well as their ability to differentiate into 
cardiomyocytes, possibly by inducing fluctuations in endodermal marker gene expression 
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(Gata6, Ttr, Afp, and Alb) during ES cell differentiation107. Fluoxetine (0-1 µM) treatment was 
also found to enhance the expression of glial marker genes (Gfap, Olig2, Dm20, and S100b) 
following neural differentiation, to increase the population of glial cells. The expression of 
neuronal markers during ES cell differentiation into neural cells (Tuj1, Syp, Th, and Nurr1), on 
the other hand, was inhibited by fluoxetine treatment, suggesting that fluoxetine facilitates 
the differentiation of mouse ES cells into glial cell lineage, which may affect fetal neural 
development65. 
In the human cerebellum, the proliferation of cerebellar granule cells continues until 
the 11th postnatal month and could be influenced in infants by breastfeeding-delivered SSRIs. 
To address this issue rat postnatal cerebellar neural progenitors were exposed to fluoxetine 
(0.001–20 mM) for 72 hours. RT-PCR and immunostaining revealed the expression of 5-HTT, 
5-HT1A receptors, TPH, and 5-HT, indicating that these cells are capable of producing 5-HT and 
controlling 5-HT release. Protracted in vitro fluoxetine treatment increased cell proliferation 
and differentiation. The proliferative effect of fluoxetine was abolished by the selective 5-HT1A 
receptor antagonist WAY-100635. Furthermore, fluoxetine induced activation of both CREB 
protein and extracellular signal-regulated protein kinases (ERK1/2), which was abolished 
by the selective inhibitor of MAP kinase kinase (MEK) 1,4-diamino-2,3-dicyano-1,4-bis(2-
aminophenylthio)butadiene (U0126), and increased cyclin D1 expression. All these effects 
were prevented by WAY-100635, indicating that rat postnatal cerebellum contains neural 
progenitors capable of proliferating and differentiating in response to fluoxetine exposure, 
possibly through the activation of 5-HT1A receptors
109.
In summary, SSRI treatment has differential effects on mRNA expression across age 
groups and cell stages. The effects on cell proliferation and differentiation may affect fetal 
neural development and plasticity. The age dependent behavioral effects as described above 
might be caused by these underlying molecular differences. However, the precise mechanisms 
causing the differences in molecular and behavioral effects across developmental stages are 
not clear and elucidating these mechanisms would be a great challenge. 
Regulation of gene expression
Studies discussed so far show that SSRI efficacy is modified by various polymorphisms in 
human genes, and that SSRIs alter the mRNA expression of multiple genes belonging 
to various pathways. What is not yet clear so far is whether the transcription of genes is 
under tight epigenetic and microRNA (miRNA) control. Epigenetic modifications represent 
modifications of DNA and histones that regulate various genomic functions occurring 
without changes in DNA sequence. DNA methylation involves the transfer of a methyl 
group to cytosine residues at cytosine-phosphate-guanosine units, which is catalyzed by the 
enzyme DNA methyltransferase. DNA methylation at specific gene promoters is an important 
mechanism to control gene transcription. Histone modifications which are mediated by 
histone acetyltransferases/deacetylases and histone methyltransferases/demethylases 
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determine the accessibility of the chromatin for the transcription machinery. Studies on 
the epigenetic mechanisms underlying the antidepressant potential effect of SSRIs are 
marginal, in contrast to those of TCA’s and selective noradrenaline reuptake inhibitors. One 
study reported that P11 (S100a10) mRNA levels were decreased in the prefrontal cortex 
of the Flinders Sensitive Line (genetic rodent model of depression), along with higher DNA 
methylation at its promoter. This hypermethylation was reversed to wild-type levels after 
chronic escitalopram treatment. Escitalopram caused hypomethylation of S100a10 and 
increased S100a10 gene expression, as well as a reduction in DNA methyltransferases (Dnmt1 
and Dnmt3a) involved in the maintenance of forebrain DNA methylation202. P11 is involved 
in the intracellular trafficking of transmembrane proteins to the cell surface365, including the 
5-HT
1B
 and 5-HT
4
 receptor, and thereby plays an important role in 5-HT signaling366. Studies 
investigating the epigenetic mechanisms underlying the antidepressant effects of TCA 
treatment are more abundant. Genome wide analysis in mice demonstrated that chronic 
defeat stress causes widespread and long-lasting changes in gene regulation, including 
alterations in repressive histone methylation (dimethylK9/K27-H3), which is reversed by 
imipramine treatment367. In another study, Tsankova and colleagues368 showed that in the 
hippocampus Bdnf gene expression is down-regulated, coincided with histone methylation of 
H3K27 after chronic social defeat stress. Chronic imipramine treatment reversed this down-
regulation with increasing acetylation of H3 at these promoters. Furthermore, they show that 
this hyperacetylation by chronic imipramine was associated with a selective downregulation 
of histone deacetylase 5 (Hdac5). One study showed evidence for SSRI-induced histone 
acetylation at the Bdnf promoter, although not in relation to depression369. Since TCAs and 
SSRIs both act on the serotonergic system370 and this system strongly interacts with BDNF, it 
is likely that SSRI treatment causes similar epigenetic changes at the Bdnf promoter. In line 
with the increase in H3 acetylation by antidepressant treatment, administration of HDAC 
inhibitors also resulted in antidepressant-like effects371. Furthermore, Sales et al.372 showed 
that (systemic and intra-hippocampal) administration of DNA methyltransferase inhibitors 
also results in antidepressant-like effects. 
miRNAs are short ribonucleic acid (RNA) molecules binding to complementary 
sequences on target messenger RNA transcripts (mRNAs), usually resulting in translational 
repression or target degradation and gene silencing. Their role in mediating SSRI effects was 
shown in an elegant study revealing that chronic fluoxetine treatment in mice led to increased 
miR-16 levels in serotonergic raphe neurons and reduced Slc6a4 expression. Furthermore, 
raphe exposed to fluoxetine were found to release the neurotrophic factor S100β, which 
turned on the expression of serotonergic functions in noradrenergic neurons of the locus 
coeruleus108. In addition, changes in the expression of determinants of mRNA translation 
may mediate SSRI effects. As such, chronic fluoxetine treatment (10 mg/kg, i.p.) induced 
hyperphosphorylation of eukaryotic elongation factor 2 (eEF2 - Thr56) in prefrontal cortex, 
hippocampus and dentate gyrus of rats and hyperphosphorylation of eukaryotic initiation 
factor 4E (eIF4E - Ser209) specifically in the dentate gyrus. Acute fluoxetine treatment had 
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no effect on translational factor activity373. In summary, SSRIs not only directly target 5-HT 
receptor linked signal transduction pathways and gene expression, they may also regulate 
gene expression by modifying miRNAs and epigenetic processes. 
Lessons from other antidepressants
We proposed several pathways which contribute to the antidepressant effects of SSRIs. 
In this section we will briefly discuss the effect of non-SSRI antidepressant drugs on these 
pathways. If a pathway is affected by several antidepressant drugs, it is more likely that this 
pathway plays a major role in inducing antidepressant effects. Tricyclic antidepressants (TCAs) 
and monoamine oxidase inhibitors (MAOIs) both influence the serotonergic system and 
also other neurotransmitter systems: MAOIs by blocking the enzyme monoamine oxidase 
which breaks down the neurotransmitters dopamine, serotonin, and norepinephrine, 
and TCAs by blocking the reuptake of norepinephrine and serotonin. This emphasizes the 
importance of the serotonergic system, and also the norepinephrine and dopamine systems, 
in inducing antidepressant effects. In addition, these non-SSRI antidepressants also affect 
some of the other pathways discussed in the previous sections. TCAs, like imipramine, can 
activate glial cell line-derived neurotrophic factor374 and increase the number of hippocampal 
synapses and neurons375, indicating neuroplastic effects. Furthermore, it is shown that TCA 
treatment reduces HPA-axis responsivity376 and inflammation377. In addition, TCAs induce 
epigenetic modifications. As mentioned before, imipramine can reverse stress-induced 
histone methylation (dimethylK9/K27-H3) and increase acetylation of H3. MAOIs, like 
tranylcypromine, are linked to neuroplasticity by increasing hippocampal BDNF expression320. 
Also, HPA-axis responsivity378 and the production of proinflammatory cytokines379,380 are 
reduced by MAOI treatment. Since SSRIs and these non-SSRI drugs are all directly affecting 
the serotonergic system, it is possible that the effects on other systems are “side effects” 
caused by downstream pathways of the serotonergic system and do not contribute to the 
antidepressant effect. Drugs or compounds with antidepressant effects not directly acting 
on the serotonergic system can give more insights into the antidepressant potential of these 
pathways. Regarding inflammation, there are a few studies showing that anti-inflammatory 
drugs can reduced depressive-like symptoms. For example, it is shown that cyclooxygenase 
inhibition - an enzyme that is responsible for formation of prostaglandins - is beneficial in 
treating depression381,382, however there are also studies showing negative results383. 
Furthermore, selective CRH1 antagonists, acting on HPA-axis signaling, show antidepressant 
effects384,385 and are also known for normalization of REM sleep386. Also, infusion of BDNF 
into the dentate gyrus of hippocampus in rats produced an antidepressant effect, showing 
evidence for the involvement of plasticity in antidepressant effects387. Finally, as mentioned 
before, epigenetic modifiers, like HDAC inhibitors and DNA methyltransferase inhibitors, 
exert antidepressant effects.
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Conclusion
Our review of current literature on the genetic targets of SSRIs provides several crucial 
insights:
1] 5-HTT gene (SLC6A4) variation in humans consistently influences the antidepressant 
efficacy of SSRIs, which makes sense for 5-HTT being the main target of SSRIs. More precisely, 
the low activity (short; S) variant of the 5-HTTLPR associated with reduced SLC6A4 gene 
transcription388 is linked to a poor responsiveness to SSRIs in depressed patients across 
ethnicities. In this context, it is striking that in animal studies Slc6a4 mRNA levels are generally 
not affected by chronic SSRI treatment. Rather, these studies reveal that posttranslational 
changes in 5-HTT modify SSRI responsiveness, for instance at the level of internalization. 
Taken together, this indicates that especially the amount of 5-HTT in the cell surface is linked 
to SSRI responsiveness.
2] Gene variations in many of the 5-HT receptor genes (HTR2C, HTR1A, HTR1B) are associated 
with antidepressant efficacy. In addition, in vivo animal studies showed down-regulation of 
Htr2c and presynaptic Htr1a and Htr1b mRNA levels by chronic SSRI treatment. Furthermore, 
the actions of SSRIs on sleep (5-HT
7
 and 5-HT1a), nausea (5-HT3b), feeding (5-HT2c, 5-HT1B) 
and gastrointestinal side effects (5-HT
2a)
 are essentially mediated by specific 5-HT receptors, 
indicating that 5-HT receptors and their different downstream pathways play a major role in 
the antidepressant and side effects of SSRIs.
3] Besides the serotonergic system, SSRIs can interact with other (neurotransmitter) 
systems, like the DA system, the HPA system and the immune system. DA neurotransmission 
is up-regulated by SSRIs, which is in line with the fact that SSRIs have a weak affinity for 
the DA transporter370. The activity of the HPA axis, involved in controlling stress responses, 
is down-regulated by SSRIs, which indicates that besides the serotonergic system the 
HPA-axis is an important contributor to the antidepressant effects of SSRIs. Furthermore, 
SSRIs influence the immune system by down-regulation of cytokines. It has been shown 
that proinflammatory cytokines play an important role in the development of depression 
by enhancing the reuptake of 5-HT345 and DA347 and reducing the synthesis of 5-HT (by 
influencing IDO342) and DA (by influencing BH4, a cofactor for tyrosine hydroxylase, the rate-
limiting enzyme in dopamine synthesis389). In addition to the modulation of neurotransmitter 
function, proinflammatory cytokines also activate the HPA axis by increasing the release of 
CRF348,390. In summary, down-regulation of the proinflammatory cytokines plays an important 
role in mediating the antidepressant effects of SSRI treatment by inhibition of the HPA axis, 
enhancing 5-HT and DA synthesis and inhibition of 5-HT and DA reuptake. The importance 
of proinflammatory cytokines in depression raises the question whether drugs that have a 
central anti-inflammatory action might foster a new generation of antidepressants.
4] SSRIs influence neuroplasticity by affecting the expression level of several neuroplasticity 
factors. In particular the effect of SSRIs on BDNF has been extensively studied. Polymorphisms 
in the BDNF gene and in other genes in the BDNF pathway are associated with SSRI treatment 
outcome and expression studies showed an increase in BDNF expression upon SSRI treatment, 
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which is time dependent and region specific. Since depression is shown to be associated with 
decreased plasticity391,392, SSRI-induced enhanced neuronal plasticity should contribute to the 
recovery from depression.
5] Little is known so far about the effects of SSRIs on epigenetic modifications. One study 
showed that SSRIs can reverse DNA hypermethylation, namely of the P11 gene (S100a10). 
In contrast, studies investigating the epigenetic effects of TCA treatment are more abundant 
and show that chromatin remodeling is an important mechanism in stress responses and 
antidepressant treatment. However, the exact mechanism by which stress and antidepressants, 
in particular SSRIs, converge on chromatin still needs to be elucidated. 
Figure 2. Pathways affected by SSRI treatment. Overview of the pathways affected by SSRI treatment. (1) The main 
target of SSRIs is the serotonin transporter. Blocking of this transporter will cause an increase in extracellular serotonin 
levels and subsequently an increase in activation of serotonin receptors and their downstream pathways. (2) SSRIs 
can also activate other neurotransmitter systems by low-affinity binding to other transporters. (3) SSRIs influence 
the inflammatory system by down-regulation of cytokines. (4) The activity of the HPA axis, involved in controlling 
stress responses, is down-regulated by SSRIs and also other hypothalamic processes, like regulation of hunger and 
reproduction, are influenced by SSRI treatment. (5) SSRIs influence neuroplasticity by affecting the expression level 
of several neuroplasticity factors. A well-known factor that is influenced by SSRI treatment is the brain derived 
neurotrophic factor (BDNF). In addition, the inflammatory system, the serotonin system, the dopamine system and 
the HPA axis are interacting with each other resulting in indirect effects (dashed lines). The down-regulation of the 
proinflammatory cytokines plays a role in mediating the antidepressant effects of SSRI treatment by inhibition of the 
HPA axis and influencing 5-HT and DA synthesis and reuptake.
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6] SSRI treatment has differential effects on mRNA expression across age groups and cell 
stages. SSRI-induced age-dependent effects are also shown at behavioral level and might be 
a consequence of these underlying molecular differences. The precise mechanisms causing 
the differences in molecular and behavioral effects across developmental stages are not 
clear. Possibly, age differences in 5-HT receptor expression and their downstream signaling 
pathways, as well as in epigenetic regulation, might play a role in these age-dependent effects. 
 In conclusion, SSRIs exert their antidepressive effects via a wide variety of pathways 
in addition to the serotonergic pathway (Figure 2). However, to obtain an overview of the 
exact molecular mechanisms contributing to the antidepressive effects, some unanswered 
questions still need to be elucidated. Especially studies investigating the molecular 
mechanisms underlying the age-dependent effects and studies addressing the epigenetic 
effects of SSRIs might give more insights in the working mechanism(s) of SSRIs. 
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Abstract
The selective serotonin reuptake inhibitor (SSRI) fluoxetine is widely prescribed for the 
treatment of symptoms related to a variety of psychiatric disorders. After chronic SSRI 
treatment, some symptoms remediate on the long-term, but the underlying mechanisms 
are not yet well understood. Here we studied the long-term consequences (40 days after 
treatment) of chronic fluoxetine exposure on genome-wide gene expression. During the 
treatment period, we measured body weight; and one week after treatment, cessation 
behavior in an SSRI-sensitive anxiety test was assessed. Gene expression was assessed in 
hippocampal tissue of adult rats using transcriptome analysis and several differentially 
expressed genes were validated in independent samples. Gene ontology analysis showed 
that upregulated genes induced by chronic fluoxetine exposure were significantly enriched 
for genes involved in myelination. We also investigated the expression of myelination-related 
genes in adult rats exposed to fluoxetine at early-life and found two myelination-related genes 
(Transferrin (Tf) and Ciliary neurotrophic factor (Cntf)) that were downregulated by chronic 
fluoxetine exposure. Cntf, a neurotrophic factor involved in myelination, showed regulation 
in opposite direction in the adult versus neonatally fluoxetine-exposed groups. Expression 
of myelination-related genes correlated negatively with anxiety-like behavior in both adult 
and neonatally fluoxetine-exposed rats. In conclusion, our data reveal that chronic fluoxetine 
exposure causes on the long-term changes in expression of genes involved in myelination, a 
process that shapes brain connectivity and contributes to symptoms of psychiatric disorders. 
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for the treatment of 
a variety of psychiatric disorders, such as depression1,2, bipolar affective disorder3, anxiety-
related disorders (obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD)) 
4,5, aggression6 and autism spectrum disorder (ASD)7,8. All these disorders have symptoms 
related to, among others, negative affectivity, which might be the symptom responsive to 
SSRI treatment. Clinical studies have shown that there are many side effects upon chronic 
administration of SSRIs, like sexual dysfunction9, suppression of REM sleep10, nausea11,12, 
decreased appetite13 and deterioration of symptoms (for example, aggression)14,15, indicating 
that optimization of chronic treatment of affective disorders is needed. In addition, some 
patients remain free of symptoms after discontinuation of SSRI treatment, whereas in others 
the symptoms reoccur16,17. Studies in generalized social anxiety disorder patients showed that 
within 24 weeks after discontinuation of SSRI treatment 40-50% of the patients (receiving 
placebo after stopping SSRI) relapsed18,19. For major depressive disorder, the cumulative 
probability of suffering a recurrence of major depression within 2 years after discontinuation 
of SSRIs was 60% for people aged 60 years or older20. Hence, the effects of SSRIs are not 
always sufficient to warrant long-term remission. To further improve the efficacy of SSRIs, 
there is an urgent need to unravel the mechanisms contributing to the long-term effects of 
chronic SSRI exposure. 
The primary target of SSRIs is the serotonin transporter (5-HTT); its blockade by 
SSRIs leads to increases in extracellular serotonin (5-HT) levels. According to classic literature, 
chronic rises in 5-HT levels would contribute to the therapeutic effects of SSRIs21, acting 
through 5-HT receptors. For example, antagonism of 5-HT2C and 5-HT7 results in significantly 
increased therapeutic effects of SSRIs22-25 and SSRI/5-HT1A antagonist co-administration leads 
to increased extracellular 5-HT levels and enhanced antidepressant responses26,27. However, 
these and other 5-HT receptors are also implicated in the side effects of SSRIs, like sexual 
dysfunction (5-HT1A)
28, sleep disturbances (5-HT
7
29 and 5-HT1A
30), nausea (5-HT
3B
31) and 
decreased appetite (5-HT2C
32, 5-HT
1B
33). Although 5-HT receptors have a key role in the short-
term effects of chronic SSRI exposure, it is likely that pathways downstream of the receptors 
are important for the long-term effects of chronic SSRI exposure.
Recently, several gene expression studies in rodents have shown that SSRI exposure 
can affect a wide variety of pathways in addition to the serotonergic system. It has been 
shown that SSRI treatment during adulthood alters gene expression levels of hypothalamic 
hormones, neurotrophic factors, inflammatory factors and components of non-serotonergic 
neurotransmitter systems34-36. Especially the inflammatory factors might play a central role 
in mediating the effects of SSRIs, because downregulation of proinflammatory cytokines can 
inhibit HPA axis function (facilitating stress reduction), enhance 5-HT and dopamine synthesis 
and inhibit 5-HT and dopamine reuptake34. Yet, these findings reflect short-term effects (24 
hours after the last treatment) of chronic SSRI exposure. The long-term consequences of SSRI 
exposure on gene expression are so far not well understood and might provide additional 
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information about the long-term adaptations that contribute to the remediation of disease 
symptoms after stopping medication. 
Studies addressing the long-term consequences of perinatal SSRI exposure may 
provide hints regarding potential mechanisms by which SSRIs exert their long-term effects. In 
humans and rodents, there is evidence that perinatal SSRI exposure increases the likelihood 
of symptoms related to autism37-41 in the offspring. This seemingly contrasts the use of SSRIs in 
the treatment of autism during adulthood. In addition, in rodents perinatally exposed to SSRIs 
there is evidence for ‘paradoxical’ anxiety- and depression-like symptoms at adulthood42-44. 
Because adult and perinatal SSRI exposure is associated with comparable effects on the 
serotonergic system, like increases in 5-HT levels, reductions in 5-HT transporter expression45,46 
and desensitization of 5-HT1A receptors
47,48, the ‘paradoxical’ outcomes of perinatal SSRI 
exposure cannot be explained by 5-HT levels (alone). Critically, during development, 5-HT 
not only acts as neurotransmitter, but also as a neurotrophic factor. Specifically, during early 
brain development, 5-HT steers neurodevelopmental processes like neuronal outgrowth 
and migration processes49-51. Studies have shown that 5-HT affects embryonic interneuron 
migration51 and also affects organization of axonal projections of excitatory spiny stellate 
and pyramidal cells in the barrel cortex52. These data show that 5-HT affects the outgrowth 
and migration of non-serotonergic neurons. As the brain is highly plastic during early 
development, rises in 5-HT levels induced by perinatal SSRI exposure can have outcomes 
that are substantially different from adult SSRI exposure. Nonetheless, studies focusing on 
early-life SSRI exposure could lead to potential targets of the long-term chronic SSRI exposure 
during adulthood. For example, SSRI exposure during brain development can disturb myelin 
sheath formation at adulthood40 and there is also evidence that SSRI treatment at adulthood 
can cause changes in white matter microstructure, which consists mainly of myelinated 
axons53. Furthermore, both adult and developmental SSRI exposure can affect hippocampal 
neurogenesis at adulthood54,55. 
To more concretely elucidate the long-term effects of chronic SSRI exposure during 
adulthood, we investigated the long-term consequences of chronic fluoxetine (12 mg/kg) 
versus vehicle treatment during adulthood (postnatal day (PND) 67-88) on gene expression 
in the hippocampus, a brain region that is highly responsive to SSRIs55,56 and implicated in 
psychiatric disorders characterized by affective changes like anxiety57,58, bipolar affective 
disorder59, aggression60 and depression61. It has for example been shown that the hippocampus 
is directly involved in the mediation of unconditioned anxiety-related responses in animals57. 
We measured body weight during treatment, as fluoxetine is known to exert anorectic 
effects62,63. In addition, we measured anxiety-like behavior in the novelty-suppressed feeding 
test (NSFT), which is highly sensitive to SSRIs42,43,64-66. We studied genome-wide gene expression 
using transcriptome analysis (RNA-seq) in hippocampal tissue of fluoxetine and vehicle-
exposed rats 40 days after the last treatment. Differentially regulated genes were validated 
by quantitative reverse transcription PCR (RT-qPCR) analysis using independent samples. 
Gene ontology analysis showed that the majority of upregulated genes had a function in 
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myelination. To assess whether genes involved in myelination were also affected by early-life 
exposure to fluoxetine, we performed qPCR analysis on genes involved in myelination in a 
group of rats neonatally exposed to fluoxetine or vehicle. Finally, we performed correlational 
analysis between anxiety-like behavior and messenger RNA (mRNA) expression.
Materials and methods
Animals 
Male Wistar rats (Rattus norvegicus) were obtained from Charles River (Cologne, Germany) 
and used for experiments after at least seven days of acclimatization. All animals were 
housed per two in standard Macrolon® type 3 cages in temperature-controlled rooms 
(21°C±1°C) under a standard 12/12-h day/night cycle (lights on at 07:00 a.m.) with food 
(Sniff, long cut pellet, Bio Services, Uden, The Netherlands) and water available ad libitum. 
Environmental conditions (for example, housing, light conditions (80 lux), noise level) were 
carefully controlled as these conditions can strongly influence stress levels in rats67,68. Three 
groups of animals were used in this study. In each group, the rats were randomly assigned 
to a treatment. The investigator was not blinded to the group allocations when performing 
the experiments, because effects of fluoxetine on the body weight and behavior were clearly 
visible. Group 1 was treated at adulthood with fluoxetine or vehicle (n = 12 per treatment), 
used for body weight measurements during treatment, tested in the NSFT and decapitated 
to collect hippocampal tissue for RT-qPCR validation; group 2 was treated at adulthood with 
fluoxetine or vehicle (n = 4 per treatment) and used for RNA-seq experiments. Finally, group 
3 consisted of adult female Sprague Dawley rats neonatally exposed to fluoxetine or vehicle 
(PND 1 to 21) via osmotic minipumps implanted in the mothers. Their hippocampal tissue 
was obtained from Maastricht University (fluoxetine n = 6, vehicle n = 7) and used for RT-
qPCR analysis. Figure 1 provides a schematic representation of the experimental timeline for 
each group. For behavior experiments, 12 animals per group were used, because this is the 
minimum required to achieve sufficient statistical power to establish significant differences 
(α = 0.05 and β = 0.20). For genome-wide gene expression analysis we used two biological 
replicates. All experiments were carried out according to the guidelines for the Care and Use 
of Mammals in Neuroscience and Behavioral Research (National Research Council 2003), the 
principles of laboratory animal care, as well as the Dutch law concerning animal welfare.
Drug treatment 
Rats from group 1 and 2 received fluoxetine (12 mg/kg/day, as used by Olivier and colleagues42) 
or vehicle by oral gavage from PND 67 to 88 in a volume of 5 ml/kg. Fluoxetine was purchased 
from the Pharmacy of the Radboud University Nijmegen Medical Centre, The Netherlands 
and dissolved in distilled water. As a vehicle, 1% methylcellulose (Genfarma B.V. Maarssen, 
The Netherlands) was used, which was the constituent of the fluoxetine pills. Body weight 
was monitored daily throughout the treatment. Rats from group 3 received fluoxetine via 
the milk of the dams. Minipumps were implanted subcutaneously in the dorsal region of the 
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dams on PND1 and filled with either fluoxetine–HCl (Fagron, Belgium) dissolved in vehicle 
(50% propylenediol in saline; 5 mg/kg/day), or with vehicle, as previously described69. 
Novelty-suppressed feeding test (NSFT)
The NSFT was performed as described before42. In short, after food deprivation, male rats 
(PND 95) of group 1 were placed in one corner of an open arena (50×50 cm) containing clean 
wood chip bedding with in the center a filter paper containing a food pellet. The latency (s) to 
start an eating episode was recorded (maximum time was 900 s). After each rat the arena was 
cleaned with ethanol (70%) and dried thoroughly to prevent transmission of olfactory cues.
Transcriptome sequencing
Rats within group 2 were sacrificed at PND 128, brains were removed and stored at -80°C. The 
hippocampus was dissected by punching from 300 micron frozen brain slices, and tissue from 
two rats was pooled for total RNA isolation and cDNA synthesis. DNA samples were prepared for 
RNA-seq by end repair, adapter ligation, size selection and amplification. After quality control 
of DNA libraries, samples were sequenced (36 bp, single read) with the Illumina Genome 
Analyzer IIx platform. Sequences were aligned to the rat rn4 reference genome70 and further 
analyzed using Genomatix software (www.genomatix.de). The Database for Annotation, 
Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) was used for 
gene ontology (GO) analysis. RNA-seq validation was performed by RT-qPCR analysis in an 
independent group of rats (group 1). See supplementary information for detailed information 
about the transcriptome analysis and primer sequences (Supplementary Table 1).
Quantitative Reverse Transcription PCR 
Hippocampal tissue of rats within group 3 was crunched in liquid nitrogen. RNA was isolated 
(RNeasy lipid tissue kit; QIAGEN, Venlo, The Netherlands) and cDNA was synthesized 
using iScript cDNA Synthesis Kit (Bio-Rad, Veenendaal, The Netherlands) according to 
manufacturer’s protocols. The qPCR reactions were performed in 7500 Fast Real Time PCR 
System (Applied Biosystems, Foster City, CA, U.S.A) using the SYBR Green fluorescence 
quantification system (GoTaq® qPCR Master Mix, Promega, Leiden, The Netherlands). See 
supplementary information for detailed information about the RT-qPCR method.
Statistical analysis
Statistical analysis of the data was carried out using the IBM Corp. Statistical Package for the 
Social Sciences (SPSS) version 20.0 (IBM Corp, Armonk, NY, USA). The Shapiro-Wilk test was 
used to check for normal distributions. Independent samples t tests were used for normally 
distributed data (corrected p-value was used when equal variance was not assumed) and 
Mann-Whitney U tests for non-normal distributions. Body weight was analyzed by repeated 
measures analysis of variance (ANOVA) and further analyzed per day using independent 
samples t tests. Spearman correlations were performed for the correlational analysis between 
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behavior tests and mRNA expression. Outliers (data points further than 3 interquartile ranges 
from the nearer edge of the box plot) were excluded from the analysis. Independent samples 
t tests and correlations were performed two-sided. No adjustments for multiple comparison 
was applied for the RNA-seq. We performed qPCR validations afterwards to validate the RNA-
seq results. The level of statistical significance was set at p<0.05 in all tests. 
PND67 PND88
NSF test
PND95
Drug treatment
Body weight measurements
PND120
Sacriced for qPCR
Group 1
Group 2
Group 3
PND67 PND88
Drug treatment
Body weight measurements
PND128
Sacriced for RNA-seq
PND1 PND21 PND140
Drug treatment
PND196
Sacriced for qPCRBehavior tests see Boulle et al., submitted
PND161
(Open eld test, elevated zero maze & forced swim test)
Figure 1. Schematic representation of experimental timeline. Male Wistar rats, group 1 (n=12 per treatment) 
and 2 (n=4 per treatment), were treated with fluoxetine or vehicle from postnatal day (PND) 67 to 88. During the 
treatment period body weight was measured every day. In group 1, anxiety-like behavior was tested on PND 95 using 
the novelty-suppressed feeding test (NSFT). Groups 1 and 2 were sacrificed by decapitation on PND 120 and PND 
128, respectively and used for mRNA expression analysis using hippocampal tissue. Group 3 (fluoxetine n=6, vehicle 
n=7) was used to investigate the effect of chronic fluoxetine exposure on hippocampal mRNA expression in Sprague 
Dawley rats. For neonatal exposure dams were treated during the postpartum period from PND 1 to 21. At PND 21, 
pups were weaned and group-housed for further examination (two rats per cage). Anxiety- and depression-related 
behavior was analyzed from PND 140 onwards (in the order as written in the figure) and rats were sacrificed by 
decapitation at PND 196. mRNA, messenger RNA; qPCR, quantitative PCR.
Results
Body weight and anxiety-like behavior in response to adult fluoxetine exposure
Body weight was measured daily during the treatment period. All rats received a daily oral 
administration of fluoxetine or vehicle from PND 67 to 88 (Figure 1). As shown in Figure 
2A, starting weight in group 1 was not different between fluoxetine and vehicle groups 
(t
(1,22)
=0.26; p=0.796). Repeated measures ANOVA revealed that fluoxetine significantly 
reduced adult body weight gain (F
(1,22)
=43.37; p<0.01). Independent samples t tests indicated 
that the reduction in body weight gain was significant (p<0.05) from day 4 of the treatment 
and further on. Vehicle-exposed rats grew on average from 295.5 g on the first day of 
treatment to 350.3 g on the last day of treatment, while fluoxetine-exposed rats grew on 
average from 294.8 g on the first day of treatment to 320.2 g on the last day of treatment (see 
Supplementary Table 2 for all body weight values). Similar results were obtained for group 2 
(data not shown). Anxiety-like behavior was measured one week after treatment using the 
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NSFT. We found that adult fluoxetine-exposed rats exhibited a shorter latency to start eating 
compared to vehicle-exposed animals (t
(1,19)
=2.32; p<0.05; Figure 2B, Supplementary Table 
2). Both decreased weight gain during chronic fluoxetine exposure71 and a shorter latency to 
start eating in the NSFT after chronic fluoxetine exposure64-66,72 are consistent with previous 
findings in stressed and unstressed rats. 
Figure 2. Fluoxetine in adult exposed Wistar rats reduces body weight and latency to start eating in a novel 
environment. A: Body weight in fluoxetine and vehicle treated (postnatal day (PND) 67 to 88) adult male rats (n=12/
group) measured during the treatment period. Data are presented as mean ± S.E.M. of body weight (g). B: Latency 
to start eating in a novel environment tested in fluoxetine and vehicle treated adult male rats on PND 95. Data are 
presented as mean + S.E.M. of latency (s) to start eating. *p<0.05
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Long-term consequences of adult chronic fluoxetine exposure on genome-wide 
mRNA expression patterns in the hippocampus 
To investigate which genetic pathways have a role in the long-term effects of chronic SSRI 
exposure, RNA-seq analysis was performed using hippocampal tissue of fluoxetine- and 
vehicle-exposed rats (two rats pooled per sample, two samples per treatment group). Genes 
with a fold change >1.5 fold and a p-value <0.05 were considered as differentially regulated 
genes. Analysis of the samples resulted in 258 genes that were significantly upregulated and 
218 genes that were significantly downregulated by fluoxetine treatment (Figure 3A, Online 
Supplementary Table 3). Some genes show overlap with a study in mice chronically treated 
with fluoxetine (see green marked genes in Online Supplementary Table 3)73.
To functionally categorize the differentially expressed genes, GO analysis was 
performed. The most significantly enriched GO-terms in the list of upregulated genes induced 
by adult fluoxetine treatment are all involved in glia cell development and myelination (Table 
1). Examples of upregulated genes involved in glia cell development are zinc finger protein 
488 (Znf488), proteolipid protein 1 (Plp1), ciliary neurotrophic factor (Cntf), NK6 homeobox 
2 (Nkx6-2) and POU class 3 homeobox 1 (Pou3f1). For the genes downregulated after adult 
fluoxetine treatment the most significantly enriched GO-term was ‘response to abiotic 
(non-living) stimulus’. An underlying and more specific GO-term that was also significantly 
enriched is ‘response to temperature stimulus (an abiotic stimulus)’, including genes such 
as adrenoceptor beta 2 (Adrb2), nitric oxide synthase 1 (Nos1), caspase 8 (Casp8), transient 
receptor potential cation channel, subfamily V, member 3 (Trpv3), interleukin 1 beta (Il1b), 
chemokine (C-X-C motif) ligand 12 (Cxcl12) and protein kinase C, delta (Prkcd). See Online 
Supplementary table 4 for a complete list of significantly enriched GO-terms including the 
genes linked to these terms.
Validation of the adult RNA-seq data was performed by RT-qPCR analysis in 
independent biological replicates (n=11-12 per treatment). For validation, we selected 
12 differentially regulated genes (five up- and seven downregulated) on the basis of 
p-value (p<0.05), fold change (>1.5) and expression profile using the WIG files. Five genes, 
olfactomedin 1 (Olfm1, U=31.00, p<0.05; downregulated), adenylate cyclase 1 (Adcy1, 
U=33.00, p<0.05; downregulated), neurotensin (Nts,U=25.00, p<0.05; upregulated), Cntf 
(U=26.00; p<0.05; upregulated) and claudin 11 (Cldn11, U=25.00, p<0.05; upregulated), 
showed a significant change in mRNA expression in the same direction as in the RNA-seq 
data (Figure 3B). Interestingly, three out of the five significantly upregulated genes in RNA-
seq were significantly upregulated in RT-qPCR analysis and the other two genes also showed 
a change in the right direction, that is, upregulation in the fluoxetine-exposed rats. However, 
the majority of the genes downregulated in the RNA-seq where not changed in the RT-qPCR 
analyses, indicating that the upregulated genes were more consistent among independent 
experiments. Of the upregulated genes, Cntf, Cldn11 and Tspan2 (p=0.17) are involved in 
myelination74-76, indicating that myelination is one mechanism involved in the long-term 
effects of SSRI exposure. 
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Figure 3. Gene expression in adult fluoxetine-exposed male Wistar rats. A: RNA-seq analysis was performed 
using hippocampal tissue of fluoxetine- and vehicle-exposed rats, two rats pooled per sample, two samples per 
treatment group. Fold change scatter plot showing fold change in expression (base mean) in fluoxetine-treated 
versus vehicle-treated rats (y-axis) against expression level (x-axis). Differentially regulated genes are genes with 
fold change threshold > 1.5 (log2 fold change > 0.58, blue dashed line) and p-value < 0.05 (colored in red). Red dots 
above the upper blue dashed line are upregulated genes (258 genes) and red dots below the lower blue dashed line 
are downregulated genes (218 genes). B: Validation of RNA-seq results by quantitative RT-PCR (RT-qPCR) analysis 
in independent biological replicates. Quantitative RT-PCR was performed on hippocampal RNA of adult fluoxetine 
and vehicle treated (postnatal (PND) day 67 to 88) rats (n=12 per treatment). Based on RNA-seq data, 7 genes 
downregulated (left side in figure) and 5 genes upregulated (right side in figure) by fluoxetine exposure were selected 
for RT-qPCR validation. Data are normalized for Ywhaz and Hprt mRNA levels and are presented as mean + S.E.M. of 
relative gene expression (% of vehicle group). Genes differentially expressed in RT-qPCR are marked with * (=p<0.05).
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Long-term consequences of neonatal chronic fluoxetine exposure on 
hippocampal mRNA expression
As GO analysis showed that upregulated genes are enriched for genes involved in 
myelination, we investigated whether myelin-linked genes were also affected in adult rats 
neonatally exposed to fluoxetine. We had access to hippocampal tissue of adult rats exposed 
to fluoxetine or vehicle from PND 1 to 21 and performed RT-qPCR analysis for several genes 
involved in myelination (based on Aston and colleagues77). Expression of Cntf, a gene also 
detected and validated in the RNA-seq experiment, was significantly reduced in response to 
neonatal fluoxetine exposure compared to vehicle (U=6.00, p<0.05). In addition, a significant 
reduction after fluoxetine exposure was found for transferrin (Tf, U=4.00, p<0.05; Figure 4). 
Consistent with the long-term effects on gene expression after chronic fluoxetine treatment 
during adulthood, these data show that genes associated with myelination are also involved 
in the long-term effects of neonatal SSRI exposure, but in the opposite direction.
Correlation between behavior and expression of myelination-related genes
To investigate whether the anxiolytic effect of chronic SSRI exposure (see section ‘Body weight 
and anxiety-like behavior in response to adult fluoxetine exposure’) is related to the altered 
expression of myelination-related genes, we performed a correlational analysis. Group 1 was 
used for both the NSFT and qPCR validations, which enables correlational analysis between 
latency to start eating and mRNA expression (Supplementary Figure 1). Interestingly, we 
found a negative correlation (r
(18)
=-0.529, p<0.05) between Cldn11 mRNA expression and the 
latency to start eating in the NSFT. In addition, we found a trend for a negative correlation 
between Tspan2 mRNA expression and latency to start eating (r
(18)
=-0.412, p<0.1). 
We also performed a correlational analysis using data (anxiety-like behavior 
in an open field test (OFT, results see Boulle and colleagues78) and expression analysis of 
myelination-related genes) derived from the neonatally fluoxetine-exposed rats (group 3). In 
the OFT, time spent in the corner (OFCo) and time spent in the center (OFCe) of the open field 
were measured, in which OFCo is a measure for anxiety-like behavior and OFCe a measure 
for anxiolytic-like behavior. We found that OFCo correlated negatively with mRNA expression 
of Cldn11 (r
(11)
=-0.736, p<0.05), Cnp (r
(11)
=-0.682, p<0.05), Plp1 (ex3-5) (r
(11)
=-0.827, p<0.05) 
and Plp1 (ex2-3) (r
(11)
=-0.800, p<0.05). In addition, Mag mRNA expression showed a trend 
for a negative correlation with OFCo (r
(11)
=-0.555, p<0.1). Finally, a trend for a positive 
correlation with OFCe was found for mRNA expression of Cldn11 (r
(11)
=0.582, p<0.1), Plp1 
(ex3-5) (r
(11)
=0.527, p<0.1) and Plp1 (ex2-3) (r
(11)
=0.536, p<0.1) and Mog (r
(11)
=0.573, p<0.1). 
See Supplementary Figure 1-3 for a complete overview of the correlation data. 
Taken together, these data indicate that a higher expression of myelination-related 
genes is linked to anxiolytic-like behavior in both the NSFT in adult fluoxetine-exposed rats 
and the OFT in the neonatally fluoxetine-exposed rats.
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Table 1. Significantly enriched GO-terms (biological process) affected by adult fluoxetine 
treatment
Factor DAVID ID GO-term # genes P-value Fold enrichment
Upregulated by 
fluoxetine
GO:0021782 Glial cell development 5 4.4E-4 13.7
GO:0010001 Glial cell differentiation 6 7.1E-4 8.4
GO:0042063 Gliogenesis 6 2.0E-3 6.7
GO:0042391 Regulation of membrane potential 8 2.5E-3 4.3
GO:0008366 Axon ensheathment 5 2.6E-3 8.6
GO:0007272 Ensheathment of neurons 5 2.6E-3 8.6
GO:0001508 Regulation of action potential 6 3.1E-3 6.0
GO:0033205 Cytokinesis during cell cycle 3 3.9E-3 30.8
Downregulated 
by fluoxetine
GO:0009628 Response to abiotic stimulus 15 8.2E-5 3.5
GO:0051931 Regulation of sensory perception 4 7.1E-4 22.1
GO:0051930 Regulation of sensory perception of pain 4 7.1E-4 22.1
GO:0009266 Response to temperature stimulus 7 7.7E-4 6.4
GO:0035239 Tube morphogenesis 8 1.3E-3 4.8
GO:0043044 ATP-dependent chromatin remodeling 3 2.3E-3 40.2
GO:0044236 Multicellular organismal metabolic process 4 2.8E-3 13.9
GO:0060562 Epithelial tube morphogenesis 6 4.0E-3 5.7 ??????????????????????????? ?? ????? ????? ??? ??? ?????? ???? ???? ???????????????? ?????????????????????????????????????????????
Figure 4. Hippocampal mRNA expression levels in neonatally fluoxetine-exposed female Sprague Dawley 
rats. Quantitative RT-PCR analysis was performed on hippocampal RNA of adult rats (fluoxetine n=6, vehicle n=7) 
neonatally exposed (postnatal day (PND) 1 to 21) to fluoxetine or vehicle. Data are normalized for Ywhaz and Hprt 
mRNA levels and are presented as mean + S.E.M. of relative gene expression (% of vehicle group). *p<0.05
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Discussion
In this study, we demonstrate, using a genome-wide approach, that 40 days after chronic 
fluoxetine treatment in adult rats mRNA levels of myelination-related genes were significantly 
upregulated in the hippocampus. Interestingly, in an independent group of rats we observed 
that chronic neonatal fluoxetine exposure downregulated myelination-related genes. 
We specifically observed that the myelination-related Cntf gene was upregulated in adult 
fluoxetine-exposed rats and downregulated in neonatally fluoxetine-exposed rats. In addition, 
we observed a negative correlation between expression of myelination-related genes and 
anxiety-like behavior in both the adult and neonatally fluoxetine-exposed rats. These data 
suggest that chronic SSRI exposure exerts its long-term effects, amongst others, by affecting 
myelination processes.
There are other studies in rodents showing genome-wide gene expression 
differences after adult fluoxetine treatment, but so far they all focused on short-term effects 
by investigating gene expression one day after the last fluoxetine administration73,79-81. 
The present finding that myelination-related genes were affected more than 40 days after 
chronic SSRI exposure, both in early-life and adulthood, is important given that it elucidates 
the neurobiological mechanisms contributing to the development of (early-life exposure) 
and recovery from (adult exposure) psychiatric disorders. Interestingly, there is overlap in 
differentially regulated genes between studies focusing on short-term effects and our study 
about long-term effects. For instance, Samuels and colleagues73 performed a microarray 
study using dentate gyrus tissue from 24 hours after treatment cessation of adult mice 
chronically treated with fluoxetine and identified 8 upregulated and 20 downregulated genes 
that overlap with our findings (see green marked genes in Online Supplementary Table 3). 
Genes affected in both short- and long-term studies might play a crucial role in inducing and 
maintaining the antidepressant state. It is not likely that effects of fluoxetine withdrawal are 
seen in our expression data, because these effects occur short after withdrawal and will not 
last for 40 days.
RNA-seq validation by qPCR showed that the upregulated genes were more consistent 
among independent experiments. We were unable to validate 5 out of the 7 downregulated 
genes, therefore we focused on the upregulated genes. The GO analysis of genes upregulated 
by chronic fluoxetine exposure in adulthood revealed that the majority of these genes have 
a function in myelination. In addition, we found a correlation between the latency to start 
eating in the SSRI-sensitive NSFT and gene expression of myelination-related genes (Cldn11, 
and a trend for Tspan2), which strengthens our findings. Interestingly, a wide range of 
psychiatric disorders responsive to SSRI treatment, including depression, bipolar affective 
disorder, autism, OCD, PTSD and ASD have been associated with defects in white matter, 
which consists mainly of myelinated axons82,83. A first link between mood disorders and myelin 
was shown by Aston and colleagues77. They studied gene expression in the temporal cortex 
of major depressive disorder patients and found a decreased expression of genes encoding 
structural components of myelin (for example, 2’,3’-cyclic nucleotide 3’ phosphodiesterase 
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(CNP), myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoproteinn (MOG), 
PLP1) and genes involved in myelin formation (e.g. TF, SRY (sex determining region Y)-box 
10 (SOX10)). We showed in our RNA-seq experiment that the SSRI fluoxetine increases the 
expression of genes linked to myelination in the hippocampus. Interestingly, we did not find 
the same genes as Aston and colleagues found in the temporal cortex (gene expression 
might be brain region dependent), but we did find genes (Cntf, Cldn11) influencing the 
same process. Genes interacting with each other (SOX10 and Cntf84) and genes with similar 
functions regarding myelination (PLP1 and Cldn1185) are found in the study by Aston and 
colleagues and our RNA-seq experiment. Moreover, in OCD patients, abnormalities of myelin 
integrity have been found that were partially reversed by SSRI treatment53. Taken together, 
these findings suggest that myelination is dysregulated in several psychiatric disorders and 
can be regulated by antidepressants, like fluoxetine. 
In hippocampal tissue of neonatally fluoxetine-exposed rats, we found that Cntf was 
downregulated, which directly opposed the finding that adult fluoxetine exposure upregulated 
this very same gene. Thus, the same gene, Cntf, was affected in opposite direction by chronic 
fluoxetine exposure in early-life and adulthood. This is consistent with the growing amount 
of experimental evidence that early-life SSRI exposure leads to ‘paradoxical’ autism-, anxiety- 
and depression-like symptoms in later life1,42-44. In agreement, our neonatally fluoxetine-
exposed rats showed increased depression-like behavior (forced swim test) at adulthood 
compared with the neonatally vehicle-exposed rats78. Furthermore, Boulle and colleagues 
showed that neonatal fluoxetine exposure decreased Bdnf IV expression in hippocampus78, 
while others observed increased Bdnf expression in hippocampus of adult fluoxetine-exposed 
rats 24 hours after treatment cessation86. Cldn11 expression, which was upregulated in the 
adult fluoxetine-exposed group, was not found to be regulated in the opposite direction 
(downregulated) in the neonatally fluoxetine-exposed group. 
The decrease in expression of the two myelin-linked genes after early-life fluoxetine 
exposure is in line with the findings of Simpson and colleagues40. They showed that early-life 
SSRI exposure (citalopram) disturbs myelin sheath formation and decreases interhemispheric 
connectivity by 50%. In addition, high levels of serotonin can lead to aberrant oligodendrocyte 
development and myelination deficits in vitro87. Our results of the RT-qPCR in hippocampus 
tissue of early-life fluoxetine-exposed rats suggest that gene expression of myelination-related 
genes was also affected by SSRIs. Notably, our adult and neonatally fluoxetine-exposed groups 
differed in fluoxetine dose, strain and gender, making it possible that the opposite finding 
was driven by these factors rather than neonatal versus adult fluoxetine exposure. However, 
our finding that expression of the myelination-related Cldn11 gene and anxiety correlated 
negatively in both the adult and neonatally fluoxetine exposed rats does not support this. 
Given that changes in myelination have been reported by others after both neonatal40 and 
adult53 SSRI exposure, it is more likely that our findings are the result of fluoxetine exposure 
at different ages. 
The Cntf gene, coding for ciliary neurotrophic factor, is the only gene differentially 
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regulated in all our experimental groups. CNTF is a neurotrophic factor produced by 
astrocytes, which supports the proliferation88 and survival89-91 of oligodendrocyte precursors 
and regulates myelination74. Studies have shown that CNTF can mediate stroke-induced 
adult CNS neurogenesis92 and that CNTF injection can increase remyelination in cuprizone-
induced multiple sclerosis mice93, supporting the role of CNTF as a neurotrophic factor and 
as a myelin regulator. In the hippocampus Cntf is strongest expressed in the dentate gyrus 
and CA1 regions94. The dentate gyrus is important for adult neurogenesis and therefore Cntf 
expression in this region fits well with its role in neurogenesis. Studies have shown that CNTF 
is essential for the formation and/or maintenance of the neurogenic subgranular zone in 
the adult dentate gyrus95. How fluoxetine targets myelination-related genes is still unclear. 
Based on literature, we propose a potential pathway, but this is highly speculative (see 
Supplementary Figure 4). In short, fluoxetine stimulates the 5-HT
2B
 receptor on astrocytes 
resulting in activation of its downstream signaling cascades96, which potentially can lead 
to release of CNTF. The released CNTF can activate astrocytes and these astrocytes then 
release an astrocyte specific factor (>30 kDa), which promotes proliferation and survival of 
oligodendrocyte precursor cells97 and maturation of oligodendrocytes90,98. Of further interest, 
Cntf-/- mice display increased anxiety- and depression-like behavior99. These findings are in 
line with the reduced Cntf expression we found in the group of rats exposed to fluoxetine 
at early-life, which also showed increased depression-like behavior78. Cldn11 expression is 
upregulated by adult chronic fluoxetine exposure and showed a negative correlation with 
anxiety-like behavior in the NSFT. In the neonatally fluoxetine-exposed rats, Cldn11 expression 
also showed a negative correlation with anxiety-like behavior (OFCo) in the open field test, 
despite the absence of significant differences between the treatment groups in the OFT and 
the expression analysis. Cldn11 codes for Claudin-11, which is a major component of myelin 
and forms tight junctions within myelin sheaths100. Downregulation of Cldn11 has been found 
in bipolar affective disorder patients101. Also Plp1 and Cnp showed a negative correlation with 
anxiety-like behavior (OFCo) in the open field test. Taken together, the correlations indicate 
that a higher expression of myelination-related genes results in anxiolytic-like behavior. 
In this study, we found that fluoxetine can cause long-term changes in the 
expression of myelination-related genes. However, a potential limitation of the present study 
is that we used a homogenate of hippocampus cells and there are different cell types in the 
hippocampus tissue. Selecting a specific cell type using fluorescence-activated cell sorting 
might give more insights in the gene expression per cell type, although it is notable that 
mRNA levels correlated with behavior. Another limitation of this study is that the fluoxetine 
dose differs between the prenatally (5 mg/kg/day) and adult (12 mg/kg/day) exposed groups. 
However, studies have shown that exposure to higher doses of fluoxetine early in life (10-20 
mg/kg/day) affects anxiety-like behavior (e.g. open field test) in the same way a seen for 5 
mg/kg102,103. Furthermore, studies using a lower dose of fluoxetine in adulthood (5 mg/kg/
day) showed a similar effect on anxiety-like behavior in the NSFT as shown in this study for 
12 mg/kg/day65. In the future it is relevant to explore whether fluoxetine exposure will give 
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similar results in models for psychiatric disorders responsive to SSRIs. Given that the effect of 
SSRIs in the NSFT is the same in healthy64,65 and stressed66,72 animals it is likely that also gene 
expression patterns will be similar. Finally, we measured gene expression, and it remains to 
be established whether our findings translate to changes in protein levels and myelination. 
As a next step in biology, evidence of changes in myelination will further support our findings. 
As such, it has already been demonstrated that SSRI treatment can have consequences for 
myelination40,53,104. 
In conclusion, we show that adult and neonatal chronic fluoxetine exposure cause 
on the long-term changes in hippocampal expression of ciliary neurotrophic factor and other 
genes linked to myelination, a process that shapes brain connectivity and could contribute to 
the remediation of symptoms of psychiatric disorders, like anxiety. 
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Supplementary materials and methods
RNA extraction and Double-Stranded cDNA Synthesis
Animals of group 2 were sacrificed at PND 128, brains were removed and immediately 
placed on dry ice and stored at -80°C. Hippocampal tissue was dissected in 8 consecutive 
slices of 200 µm using a 2 mm punch needle. Tissue from 2 rats was pooled for total RNA 
isolation with QIAzol (RNeasy lipid tissue kit; QIAGEN, Venlo, The Netherlands) according to 
the manufacturer’s recommendations. Total RNA was subjected to two rounds of poly(A) 
selection (Oligotex mRNA Mini Kit; QIAGEN), followed by DNaseI treatment (QIAGEN) and 
fragmentation by hydrolysis (5× fragmentation buffer: 200mM Tris acetate, pH8.2, 500mM 
potassium acetate and 150mM magnesium acetate) at 94°C for 90 s. Fragmented mRNA 
was purified (RNeasy MinElute Kit; QIAGEN) and used for cDNA synthesis with 5 μg random 
hexamers by Superscript III Reverse Transcriptase (Invitrogen Life technologies, Bleiswijk, 
The Netherlands). Double stranded cDNA synthesis was performed in second strand buffer 
(Invitrogen) according to the manufacturer’s recommendations and purified using the 
Minelute Reaction Cleanup Kit (QIAGEN) according to the manufacturer’s protocol. 
Sequencing
DNA samples were prepared for RNA-seq by end repair of 20 ng DNA as measured by Qubit 
dsDNA HS (Invitrogen). Adaptors were ligated to DNA fragments, followed by size selection 
(~300 bp) and 14 cycles of PCR amplification. Quality control of DNA libraries prepared for 
sequencing was made by qPCR and by running the products on a Bioanalyzer (Bio-Rad, 
Veenendaal, The Netherlands). Cluster generation and sequencing (36 bp, single read) was 
performed with the Illumina Genome Analyzer IIx (GAIIx) platform according to standard 
Illumina protocols. Samples were sequenced to a depth of approximately 15 million uniquely 
mapped tags per sample. Sequences were aligned to the rat rn4 reference genome with the 
Illumina Analysis Pipeline allowing one mismatch. Only the tags aligning to one position on 
the genome were considered for further analysis. The output data were converted to Browser 
Extensible Data (BED) files for downstream analysis and Wiggle (WIG) files for viewing.
Data analysis
RNA-seq data were analyzed using Genomatix software (www.genomatix.de). The number of 
sequence reads for each transcript was quantified and additionally a standardized normalized 
expression (NE) value per transcript was calculated (based on the number of reads located 
in the exons of the transcript and normalized to the length of the transcript and the density 
of the data set). NE values of vehicle and fluoxetine samples (group 2) were used to calculate 
fold change values for each transcript. Genes were identified as differentially expressed if they 
showed a DESeq1 p-value < 0.05 and fold change (FC) > 1.5 (among two biological replicates 
for both fluoxetine and vehicle treatment). The Database for Annotation, Visualization and 
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Integrated Discovery (DAVID, http://david.abcc .ncifcrf.gov/) was used for gene ontology (GO) 
analysis. 
Quantitative Reverse Transcription PCR
RNA-seq validation was performed by RT-qPCR analysis of selected genes using GoTaq® qPCR 
Master Mix (Promega Benelux b.v. Leiden, The Netherlands). Primers were designed using 
Primer3 online software (http://frodo.wi.mit.edu). See Supplementary Table 1 for primer 
sequences. Complementary DNA (cDNA) was synthesized using 1 μg of total RNA in a reverse 
transcription reaction using iScript cDNA Synthesis Kit according to manufacturer’s protocol 
(Bio-Rad). qPCR reactions were performed in a 7500 Fast Real Time PCR System (Applied 
Biosystems, Foster City, CA, U.S.A) using the SYBR Green fluorescence quantification system 
(GoTaq® qPCR Master Mix, Promega). Thermal cycling was initiated with incubation at 95°C 
for 10 min followed by 40 cycles of 95°C for 30 sec and 60°C for 1 min. To normalize the 
cDNA content of the samples, we used the comparative threshold cycle (CT) method2, which 
consists of the normalization of the number of target gene copies versus two endogenous 
reference genes Ywhaz and Hprt1. 
Supplementary Table 1. Primers used for quantitative PCR
Gene symbol Ref-seq number Forward primer Reverse primer
Olfm1 NM_053573.1 AGACCTCAGGCTCAAGGTTC CACCATGGACTTGTACTCACG
Grina NM_153308.4 AGGCTCTTCTGCGTCTTCC AACTCTTTTCATGGGACATGG
Syn2 NM_001034020.1 ATGCGGATGGAACCTACG GGATGAGCACGAAGTCTGG
Adcy1 NM_001107239.1 CTGTGTGGAGATGGGACTTG CACACGCATGTTCAGGTCTAC
Src NM_031977.1 GGAATCAGAGCGGCTACTTC TTTCACATTTAGGCCCTTGG
Tspan2 NM_022589.1 CAGCTCATTGGAATTGTTGG AGTTCCGTATTGCACAGCAG
Prkcd NM_133307.1 GCCTTTGTCCTGAATGTGG CCTTCCTCACCCATCTCATC
Cldn11 NM_053457.2 CGCATACAGGAAACCAGATG CTGGGGTGCTCCTTATTCTG
Cpne4 NM_001109003.1 TCATCCTCAAGATGCAATCC CCACCGTAAACAGCTTTGAG
Nts NM_001102381.1 CTGCTTGTCAGAAGGCTGAG GATCTGCCTCCAGGACTCTC
Sult5a1 NM_001201369.1 CAGAGTCACCCATCTTGGAC ACCAGAGTCAGGGCAAGTTC
Cntf NM_013166.1 CTTGCCACTGGTACACCATC TCGTTCAGACCTGACTGCTC
Egr2 NM_053633.1 TGCCCATGTAAGTGAAGGTC TGATCAGATGAACGGAGTGG
Igf1 NM_001082479.1 AAAGTCAGCTCGTTCCATCC TCTTGTTTCCTGCACTTCCTC
Plp1 (ex2-3) NM_030990.2 TCTCCAAAAACTACCAGGACTATG GGCCCCATAAAGGAAGAAG
Plp1 (ex3-5) NM_030990.2 TTTGGGAAAATGGCTAGGAC TGCAGATGGACAGAAGGTTG
Olig2 NM_001100557.1 TCACAGGAGGAACCGTGTC TGCTGGAGGAAGATGACTTG
Sox10 NM_019193.2 TCTTTGGGGTGGTTGGAG GCTGCTATCCAGGCTCACTAC
Mag NM_017190.4 AGACAATGGCAATCAGGATG TTTGTACCTCCAGGAACCTCTAC
Tf NM_001013110.1 GGAAAGTGCAGGCTTCTAGG CAGAGATGACACCAAGTGTTTG
Mog NM_022668.2 GAGGTTCTCGGATGAAGGAG CAGGGTTGATCCAGTAGAAGG
Cnp NM_012809.2 GGCAGAAGAATATGCCCAAC TCACAAAGAGGGCAGAGATG
Hprt1 NM_012583.2 GCAGACTTTGCTTTCCTTGG CGAGAGGTCCTTTTCACCAG
Ywhaz NM_013011.3 TTGAGCAGAAGACGGAAGGT GAAGCATTGGGGATCAAGAA
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Supplementary Figure 1. Correlations between latency to start eating in the novelty suppressed feeding test 
(NSFT) and expression of myelination-related genes in adult fluoxetine-exposed rats. Spearman correlations 
between latency to start eating (s) and expression of myelination-related genes (2ΔCT). A significant negative 
correlation was found for latency to start eating and expression of Cldn11 (p<0.05) and a trend for a negative 
correlation was found for latency to start eating and expression of Tspan2 (p<0.1). 
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Supplementary Figure 2. Correlations between time spent in the corner (OFCo) and expression of myelination-
related genes in neonatally fluoxetine-exposed rats. Spearman correlations between OFCo (s) and expression of 
myelination-related genes (2ΔCT).  A significant negative correlation was found for OFCo and expression of Cldn11, 
Cnp, Plp1_3_5 and Plp1_2_3 (p<0.05) and a trend for a negative correlation was found for Mag (p<0.1).
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Supplementary Figure 3. Correlations between time spent in the center (OFCe) and expression of myelination-
related genes in neonatally fluoxetine-exposed rats. Spearman correlations between OFCe (s) and expression of 
myelination-related genes (2ΔCT).  A trend for a positive correlation was found for OFCe and expression of Cldn11, 
Plp1_3_5, Plp1_2_3 and Mog (p<0.1).
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Supplementary Figure 4. Potential pathway for fluoxetine affecting myelination-related genes. It has been 
shown that fluoxetine can stimulate the 5-HT
2B
 receptor on astrocytes, which results in activation of its downstream 
signaling cascades3. The 5-HT
2B
 receptor is G
q/11 
protein coupled and stimulates the diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3) pathway (IP3-DAG). DAG is the physiological activator of protein kinase C (PKC), which in 
turn can activate the mitogen-activated protein kinase (originally called ERK, extracellular signal-regulated kinase) 
pathway (MAPK-ERK1/2)3. A third signal transduction pathway activated by fluoxetine-induced stimulation of the 
5-HT
2B
 receptor is the PI3K-AKT pathway3. Activation of these signal transduction pathways results in transcription 
factor activation and transcription of neurotrophic factors. MAPK-ERK1/2 activation by fluoxetine results in 
transcription of glial-derived nerve factor (GDNF)3, 4. In addition, transcription of brain derived neurotrophic factor is 
induced, but not through the MAPK-ERK1/2 pathway4. Possibly also transcription and release of ciliary neurotrophic 
factor (CNTF) is triggered by fluoxetine. The released CNTF can bind to the CNTF receptor triggering intracellular 
signaling through three major signal transduction pathways: JAK- STAT, MAPK-ERK1/2 and PI3K-AKT5. These signal 
transduction pathways all mediate different responses. Studies have shown that CNTF-activated astrocytes release 
an astrocyte specific factor (>30 kD), which promotes proliferation and survival of oligodendrocyte precursor cells6. 
Furthermore, studies have shown that CNTF can induce maturation of oligodendrocytes7, 8. An increase in the number 
of oligodendrocyte precursors and mature oligodendrocytes in our hippocampus tissue might explain the enhanced 
expression of myelination-related genes. It has been shown that the expression of NKX6.2 in oligodendrocytes is 
strongly induced after CNTF treatment (grey dotted line)9 and that PLP1 is required for transport and expression of 
SIRT2 in myelin (grey dotted line)10.
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Abstract
While there is strong evidence from rodent and human studies that a reduction in serotonin 
transporter (5-HTT) function in early-life can increase the risk for several neuropsychiatric 
disorders in adulthood, the effects of reduced 5-HTT function on behavior across developmental 
stages are underinvestigated. To elucidate how perinatal pharmacological and lifelong genetic 
inactivation of the 5-HTT affects behavior across development, we conducted a battery of 
behavioral tests in rats perinatally exposed to fluoxetine or vehicle and in 5-HTT-/- versus 
5-HTT+/+ rats. We measured motor-related behavior, olfactory function, grooming behavior, 
sensorimotor gating, object directed behavior and novel object recognition in the first three 
postnatal weeks and if possible the tests were repeated in adolescence and adulthood. We 
also measured developmental milestones such as eye opening, reflex development and body 
weight. We observed that both pharmacological and genetic inactivation of 5-HTT resulted 
in a developmental delay. Except for hypo-locomotion, most of the observed early-life effects 
were normalized later in life. In adolescence and adulthood we observed object directed 
behavior and decreased novel object recognition in the 5-HTT-/- rats, which might be related 
to the lifelong inactivation of 5-HTT. Together, these data provide an important contribution 
to the understanding of the effects of perinatal and lifelong 5-HTT inactivation on behavior 
across developmental stages. 
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Introduction
Serotonin (5-hydroxytryptamine; 5-HT) is an important neurotransmitter in the central 
nervous system, where it has various functions including the regulation of mood1, learning 
and memory2,3, appetite4 and sleep5,6. 5-HT is produced by serotonergic neurons in the raphe 
nuclei, which send their axons to regions throughout the brain. Serotonin transporters (5-
HTT) on serotonergic neurons facilitate the reuptake of extracellular 5-HT in the serotonergic 
neuron and thereby regulate extracellular 5-HT levels. In the adult brain 5-HTT is only expressed 
in the raphe neurons, but at early developmental stages (embryonic day 11 to postnatal 
day (PND)13 in rodents7) 5-HTT expression pattern is more widespread. The functional 
implication of the transient 5-HTT expression is not completely clear, but the idea is that 
it may serve to maintain stable 5-HT levels important for developmental processes. Hence, 
during neurodevelopment 5-HT acts not only as a neurotransmitter but also as a neurotrophic 
factor. Specifically, during early brain development 5-HT can promote neurodevelopmental 
processes like neuronal outgrowth, synaptogenesis and migration processes8-12. 
Alterations in the serotonergic system are involved in a variety of affective disorders, 
with depression as the most well-studied disorders in relation to 5-HT13,14. Most of the 
drugs prescribed for treatment of depression act on the serotonergic system and increase 
extracellular 5-HT levels to treat depression-like symptoms. Selective serotonin reuptake 
inhibitors (SSRIs) are the most frequently prescribed drugs for treatment of depression 
and act by blocking the serotonin transporter, resulting in increased levels of extracellular 
serotonin15-17. Besides their function as antidepressant, SSRIs are also prescribed for the 
treatment of anxiety-related disorders18,19 and autism spectrum disorders20,21. While a lot 
of studies focused on the ‘positive’ effects of increasing extracellular 5-HT levels in the 
mature brain, evidence is accumulating that increasing extracellular 5-HT levels in the 
developing brain is associated with ‘negative’ behavioral outcomes, resembling phenotypes 
of neuropsychiatric disorders. 
Pregnancy is a period with increased risk for depression. Accordingly, there is a 
substantial number of women taking SSRIs (prevalence between 7.4% and 14%22,23). It has 
been shown that antidepressants can pass from mother to child24 by crossing the placenta25 
and via breast milk26. The most reported effects in children perinatally exposed to SSRIs 
are neonatal withdrawal symptoms, which include continuous crying, irritability, jitteriness 
and/or restlessness; shivering; fever; tremors; hypertonia or rigidity; respiratory distress; 
feeding difficulty; sleep disturbance; hypoglycemia; and seizures 27. The onset of these 
symptoms ranges from several hours to several days after birth and the symptoms are usually 
resolved within 2 weeks27. In addition, a few human studies showed teratogenic effects, like 
an increased risk for preterm birth28, low birth weight23,29 as well as persistent pulmonary 
hypertension (PPHN)30,31, congenital heart defects32-35 and other congenital malformations33 
in the newborn. Given that serotonin is important for brain development, it is likely that also 
early-life behavior is affected after perinatal SSRI exposure. Indeed, there are a few human 
studies reporting developmental delay associated with 2nd and 3th trimester SSRI use, which in 
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most studies reflects a delay in gross motor function milestones (e.g. sitting and walking)36-38. 
Studies investigating longer term effects in children (up to 7 years of age) suggest persistent 
effects on motor function39 and language development40,41. Furthermore, there is evidence 
that perinatal SSRI exposure increases the likelihood of symptoms related to autism spectrum 
disorders42-44 in the offspring. However, there are also studies showing no effect of perinatal 
SSRI exposure on birth weight45,46, congenital malformations47-49 and neurodevelopmental 
behavior50,51.
A limitation of most human studies is that the type of SSRI, exposure period 
and dose are often mixed in this studies. Furthermore, environmental factors (including 
depression of the mother) might influence the development and behavior of the child, 
making long-term studies (up to adulthood) in humans challenging. To remedy this problem 
researchers use rodents to study the effects of developmental SSRI exposure in a more 
controlled environment and to focus on a specific SSRI type, dose and SSRI exposure period. 
In rodents treated with SSRIs during pregnancy also teratogenic effects have been shown, 
like a shortened gestational length52, delivery of smaller pups52,53, less weight gain in the 
pups53 and heart failure32. At the behavioral level most rodent studies focused on anxiety and 
depression-like behavior and showed that there is ample evidence that perinatal exposure 
to SSRIs results in ‘paradoxical’ anxiety- and depression-like symptoms in adulthood54-56. 
However, there are also studies showing that anxiety-like behavior can be decreased in 
adulthood after early-life SSRI exposure57. In addition, there are a few studies showing early-
life behavioral changes in perinatally SSRI-exposed rodents. Deiro and colleagues studied 
reflex development in rats exposed to SSRIs (sertraline or citalopram) during early-postnatal 
development and found a delay in development of several reflexes58,59. Also two studies using 
fluoxetine showed some early-life effects of perinatal SSRI exposure on reflex development60 
and muscle strength61. There are a few studies in rodents showing long-term effects up to 
adulthood. The most common long-term findings were (sensori)motor-related defects in 
adolescence62,63 and decreased locomotor activity55,64 and a reduction in sexual behavior in 
adulthood65-67. Furthermore, there is evidence that perinatal SSRI exposure increases the 
likelihood of symptoms related to autism spectrum disorders44,61,68.
Another example of an alteration in the serotonergic system already present in 
early-life is a variation in the promoter region of the serotonin transporter gene (SLC6A4). 
The short allelic variant (S-allele) of the serotonin transporter promoter-linked polymorphic 
region (5-HTTLPR), is associated with reduced 5-HTT protein availability and function69 
compared with the long (L) form. S-allele carriers have an increased risk for developing a 
variety of neuropsychiatric disorders, like depression70, anxiety71 and drug addiction72. To 
model life-long impairment of 5-HTT protein availability and function in rodents (as in the 
S-allele carriers) a 5-HTT knockout (5-HTT-/-) rat has been created73. These 5-HTT-/- rats also 
display increased anxiety74 and depression-like behavior74 and compulsive cocaine self-
administration behavior72. Despite the lifelong increase in extracellular 5-HT levels in the 
5-HTT-/- rats, the phenotype resembles the phenotype seen after perinatal SSRI exposure, 
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suggesting that the 5-HTT-/- phenotype is mainly caused by increased 5-HT levels in early-life. 
To the best of our knowledge there are no studies that have investigated behavior across 
developmental stages in S-allele carriers or in 5-HTT-/- rats. In sum, early-life inactivation of 
functional 5-HTT, by blocking 5-HTT using SSRIs or by genetic reduction of 5-HTT, leads in 
adulthood to phenotypes that are part of a variety of neuropsychiatric disorders. Whereas 
SSRI studies revealed that perinatal 5-HTT inactivation can have detrimental effects on early-
life behavior, with motor deficits as the most common finding, this remains to be studied 
for genetic 5-HTT inactivation conditions. Furthermore, it is unknown how behavior changes 
over developmental stages in individuals with perinatal or life-long 5-HTT inactivation. As the 
effects seen in rats with reduced 5-HTT function resemble the effects observed in humans 
with reduced 5-HTT function (e.g. depression, anxiety, autism and motor coordination), these 
rats are a good model for translational research.
To elucidate how perinatal pharmacological and life-long genetic inactivation of the 
5-HTT affects behavior across development, we conducted a battery of behavioral tests in rats 
perinatally exposed to fluoxetine or vehicle and in 5-HTT-/- versus 5-HTT+/+ rats. We performed 
tests for reflex development, motor-related behavior, olfactory function, grooming behavior, 
sensorimotor gating, object directed behavior and novel object recognition. In addition, 
we measured body weight and eye opening. Behavioral tests were performed in the first 
three postnatal weeks and several tests were repeated in adolescence and adulthood to see 
whether the early-life effects have long-term consequences.
Materials and methods
Animals
For perinatal fluoxetine and vehicle treatment, female Wistar rats were obtained from 
Harlan (Horst, The Netherlands) and housed in standard Macrolon® type 3 cages (42x26x20 
cm, Nijmegen, Gelderland, The Netherlands) in temperature-controlled rooms (21 °C ± 1 
°C) under standard 12-h light/dark cycle (lights on at 7:00 A.M.) with food (Sniff, long cut 
pellet, Bio Services, Uden, The Netherlands) and water available ad libitum. To assess the 
estrous stage, the cycle of female Wistar rats was measured daily in the late afternoon 
with an impedance checker (Impedance Checker MK-10B, Muromachi Kikai, Tokyo, Japan). 
When a female reached the estrous stage it was placed together with a male in a Macrolon 
type 3 cage (42×26×20 cm) with a wire gauze bottom. The next day the cage was explored 
for a vaginal plug, and if found, this day was considered as gestational day (GD) 1. From 
GD11 until 7 days after delivery dams were treated daily with 12 mg/kg fluoxetine or 1% 
methylcellulose (vehicle). The rats were randomly assigned to a treatment group. Pups were 
weaned at PND22. Three vehicle (n=16) and three fluoxetine-exposed (n=12) nests were 
used for experiments in early-life, adolescence and adulthood. Only the male pups were used 
for experiments and the following experiments were performed: body weight, eye opening, 
righting reflex, walking, swimming, negative geotaxis, vibrissa placing, bar holding, object 
directed behavior (ODB), novel object recognition (NOR), olfactory discrimination, grooming, 
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startle reflex and prepulse inhibition (PPI). 
5-HTT-/- rats (Slc6a41Hubr) were generated by ENU-induced mutagenesis75. Rats 
were housed in standard Macrolon® type 3 cages in temperature-controlled rooms (21 °C ± 1 
°C) under standard 12-h light/dark cycle (lights on at 7:00 A.M.) with food (Sniff, long cut pellet, 
Bio Services) and water available ad libitum. For experimental group 1, four 5-HTT+/+ (n=21) and 
three 5-HTT-/- (n=16) nests were used and the following experiments were performed: Body 
weight, eye opening, righting reflex, walking, swimming, negative geotaxis, vibrissa placing, 
olfactory discrimination and grooming. For experimental group 2, three 5-HTT+/+ (n=19) and 
three 5-HTT-/- (n=17) nests were used for experiments. The tests that were performed are 
body weight, bar holding, ODB, startle reflex and PPI. A third experimental group (group 3) 
was used for testing behavior in adolescence and in adulthood. Three 5-HTT+/+ (n=11) and 
three 5-HTT-/- (n=12) nests were used for body weight, grooming, ODB, NOR, startle reflex 
and PPI. In addition, a fourth group was used for measuring brain weight. Male rats were 
weighted and sacrificed by decapitation at four different time points, PND8, PND14, PND21 
and PND35. Brains were collected and brain weight was measured. For each time point 
three 5-HTT+/+ and three 5-HTT-/- nests were used. Brain material was used for molecular 
experiments (not in this paper). See Supplementary Figure 1 for the timetable of all groups. 
The investigator was not blinded to the group allocations when performing the experiments. 
Tests based on scoring (swimming, walking and vibrissa placing) were reanalyzed by a second 
researcher (blinded). All efforts were made to minimize animal suffering and to reduce the 
number of animals used. All experiments were carried out according to the guidelines for 
the Care and Use of Mammals in Neuroscience and Behavioral Research (National Research 
Council 2003), the principles of laboratory animal care, as well as the Dutch law concerning 
animal welfare.
Drug treatment 
Dams received fluoxetine (12 mg/kg/day, as used by Olivier and colleagues54) or vehicle by 
oral gavage (every morning) from GD11 to PND7 in a volume of 5 ml/kg. Fluoxetine was 
purchased from the Pharmacy of the Radboud University Nijmegen Medical Centre, The 
Netherlands and dissolved in distilled water. As a vehicle, 1% methylcellulose (Genfarma B.V. 
Maarssen, The Netherlands) was used, which was the constituent of the fluoxetine pills. 
Early postnatal morphological development 
Body weight of the rats was measured daily from PND2 to PND21 and on PND35 and PND70. 
Starting from PND13 eye opening was checked in the morning and in the afternoon. The rats 
scored (0) when both eyes were closed, (1) when one eye was open and (2) when both eyes 
were open. For measuring brain weight, rats were sacrificed on PND8, 14, 21 and 35. After 
collecting the brain, the weight of the brain was measured and corrected for body weight 
(brain/body mass index) which was measured right before decapitation. 
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Reflex testing
Four tests were used for investigating reflex development. Righting reflex was tested from 
PND2 to PND10. The rats were placed on its back and the time (in sec) till righting (turning 
to its belly) was measured. Negative geotaxis reflex was tested from PND4 to PND14. The 
rat was placed on a tilted surface (40°) with its head facing downwards and the time (in sec) 
till turning 180° (head facing upwards) was measured. After each rat the arena was cleaned 
with ethanol (70%) and dried thoroughly to prevent transmission of olfactory cues. Vibrissa 
placing was tested from PND6 to PND14. Vibrissa placing was tested as described by Deiro 
and colleagues58. In short, the rat was held by the tail, the head facing the edge of the table 
and vibrissae just touching the vertical surface. The rats showed the vibrissa reflex when 
it lifted its head and extended the fore limbs in the direction of the table. The scores were 
defined as follows: (1) when showing the reflex and (0) when the reflex was absent. Startle 
reflex was tested on PND21, 35 and 69, method see below (section acoustic startle reflex and 
prepulse inhibition).
Muscular strength and motor coordination
Swimming ability was tested by dropping the rats in a water tank from a height of around 20 
cm. The temperature of the water was 27°C (±1°C). The rat’s swimming behavior was scored 
as described by Schapiro and colleagues76 with small adaptations: (1) head is fully under 
water; (2) back of the head is above the water’s surface, but ears are still partially under water 
and nose is pointing downwards; (3) nose above the water’s surface, but ears still partially 
under water or (4) entire head remains above the water’s surface (see Supplementary Figure 
2). The experiment was performed daily between PND8 and PND14. Bar holding was tested 
daily from PND10 to PND19 and on PND21. Rats were placed with the forepaws on a wooden 
bar (3 mm or 5 mm in diameter, 40 cm long, 45 cm above the bench surface) and the time 
(in sec) till falling from the bar was scored (adapted from Deacon77�. If the rat touched one of 
the end columns with one forepaw it obtained the maximum time of 50 sec. Unstable walking 
was tested from PND3 to PND14 by placing a rat on a coarse surface for maximal 30 seconds. 
Shaking and unstable walking was noted as ‘present’ if it occurred at least once in this 30 
seconds. Scoring was as follows: (1) Shaking and unstable walking present, (0) no unstable 
walking and shaking, as described before by Balemans and colleagues78.
Olfactory discrimination
Olfactory discrimination was tested on PND8, 10 and 12. Each rat was placed in the center 
of an empty cage in a neutral position. On one side of the cage, fresh sawdust was placed, 
while on the other side bedding from the homecage (including several pieces of faeces) 
was placed. The side of the fresh sawdust was changed every day, to prevent bias caused 
by environmental cues. The time the rat needed to reach the bedding from its homecage 
(with their mothers odour) was measured. The experiment ended when the rat reached the 
bedding from its homecage or after 240 seconds. After each rat the arena was cleaned with 
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ethanol (70%) and dried thoroughly to prevent transmission of olfactory cues.
Grooming behavior
Grooming behavior was tested on PND14, 17, 21, 35 and 69. A rat was placed in a glass 
cylinder with a diameter of 25 cm and was given one minute to explore. After 1 min the rat 
was sprayed two times with water (+/- 27°C). The next five minutes grooming behavior was 
scored according to three properties: latency to grooming onset, total duration of grooming 
and total number of grooming episodes. This scoring method was adapted from Kalueff & 
Tuohimaa79. After each rat the arena was cleaned with ethanol (70%) and dried thoroughly to 
prevent transmission of olfactory cues.
Object directed behavior and novel object recognition
On PND20, 34 and 68 rats were tested for ODB and NOR. In the first trial three objects differing 
in color and shape were placed in the area (5 cm from the walls) and the rat was able to 
explore the objects for 7 minutes. Each rat was tested once and the same three objects were 
used for all rats counterbalanced for position. The time exploring each object was measured 
and ODB was calculated (exploration time most explored object/total exploration time80). 
After an intertrial interval of eight hours NOR was measured (in 5-HTT-/- and 5-HTT+/+ rats only 
performed in adolescence and adulthood) by replacing the object that was explored most 
in trial 1 by a new object. The rat was able to explore the objects for 7 minutes. The time 
exploring each object was measured and discrimination index (d2) was calculated (exploration 
time new object/total exploration time). Different sets of objects were used for the different 
developmental time points. Using a tracking system (EthoVision, Noldus, Wageningen, The 
Netherlands) the total distance moved was measured in both tests. After each rat the area 
was cleaned with alcohol (70%). 
Acoustic startle reflex and prepulse inhibition
On PND21, 35 and 69 startle reflex and prepulse inhibition experiments were performed 
in four acoustic startle chambers of San Diego Instruments (San Diego, USA) as described 
by Sontag and colleagues81. In short, rats were placed in a Plexiglas tube (PND21: 3.8 cm in 
diameter, 10.5 cm in length; PND35, 69: 8.2 cm in diameter, 25 cm in length) resting on a plastic 
frame. A piezoelectric accelerometer mounted under the tube detected and transduced 
the motion of the tube. Throughout the startle session, a background noise of 70 dB was 
maintained. The experiment started with a 5 min habituation session with background noise 
in the startle system. After this habituation period, ten blocks of five trials were delivered 
to measure prepulse inhibition. Each of these blocks consisted of one startle trial (120 dB, 
20 ms broad band burst), one no-stimulus condition, and three different prepulse-startle 
pairings, administered pseudorandomly. In these pairings, the prepulse was 3, 5, or 10 dB 
above background and always 20 ms broadband burst, followed by the 120 dB startle pulse 
100 ms later. The interval between two trials was between 10 and 20 s. The startle amplitude 
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was calculated as the mean of 10 delivered startle trials. The degree of prepulse inhibition (in 
percentage) was calculated according to the formula: 100 – (Average of startle amplitude on 
prepulse trial/ Average of startle amplitude on startle trial) × 100. 
Statistical analyses
Statistical analysis of the data was carried out using the IBM Corp. Statistical Package for 
the Social Sciences (SPSS) version 20.0 (IBM Corp, Armonk, NY, USA). Repeated measures 
analysis of variance (ANOVA) was applied on continuous data. Data were further analyzed 
per day using independent samples t tests (corrected p value was used when equal variance 
was not assumed). Mann-Whitney U tests were used for non-normal distributions. A 
Fisher’s exact test was performed on categorical data. For each behavior test p values were 
corrected for multiple testing (adjusted p value) using the Benjamini-Hochberg method82. 
Pearson (continuous data) and Spearman (for categorical and non-normal distributed data) 
correlations were performed for correlations between the different behavior tests. Outliers 
(data points further than 3 interquartile ranges from the nearer edge of the box plot) were 
excluded from the analysis. All tests were performed two-sided and the level of statistical 
significance was set at p<0.05 in all tests. The behavior in the 5-HTT-/- versus 5-HTT+/+ rats 
was assessed in three different groups and therefore no repeated measures ANOVA could 
be applied to the complete timeline up to adulthood. Separate tests were performed for 
adolescent and adult behavior. For consistency in data analysis, the same statistical analysis 
was used for the fluoxetine- versus vehicle-exposed group. The 5-HTT-/- and 5-HTT+/+ rats 
were not directly compared with the vehicle and fluoxetine-exposed rats since differences in 
handling (fixation and oral gavage, potentially causing stress) and differences in their genetic 
background (ordered by a company or own breeding) can affect development and behavior 
in the offspring83,84.
Results
Effect of genetic and pharmacological 5-HTT inactivation on early postnatal 
morphological development
Body weight of the offspring was followed from PND2 to PND21. In the fluoxetine- and 
vehicle-exposed group, repeated measures ANOVA revealed a significant age effect (F
(1.28, 
33.31)
=2653.41; p<0.05) and a significant treatment effect (F
(1,26)
=11.00; p<0.05), showing that 
early-life fluoxetine exposure significantly reduced body weight gain. Independent samples t 
tests indicated that the reduction in body weight gain was significant (p<0.05) from PND2 to 
PND14 and a trend was seen on PND15,16 and 21 (p<0.1). Body weight was also measured in 
adolescence (PND35) and adulthood (PND69). We found significantly reduced weights in the 
fluoxetine-exposed rats compared to vehicle-exposed rats (adolescence: t
(1,26)
= 2.11; p<0.05, 
adulthood: t
(1,26)
= 2.93; p<0.05) (Figure 1A). In 5-HTT-/- and 5-HTT+/+ rats (group 1) repeated 
measures ANOVA revealed a significant age effect (F
(1.41,46.67)
= 2234.31; p<0.05), genotype 
effect (F
(1,33)
=4927.80; p<0.05) and age x genotype interaction (F
(1.41,46.67)
=42.94; p<0.05). 
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Independent samples t tests indicated that the body weight of 5-HTT-/- rats was significantly 
reduced (p<0.05) compared to 5-HTT+/+ rats for all testing days (group 2 revealed similar 
results, not shown). Body weight was also measured in adolescence (PND35) and adulthood 
(PND69) and no significant differences were found (group 3) (Figure 1B). Eye opening was 
scored and showed no significant difference for both the 5-HTT-/- rats (group 1) and the 
fluoxetine-exposed rats compared to their controls (Figure 1C and D). In 5-HTT-/- and 5-HTT+/+ 
rats (group 4) brain weight was measured and corrected for body weight (brain/body mass 
index) on PND8, 14, 21 and 35. Independent samples t tests showed a significantly increased 
brain/body mass index in 5-HTT-/- rats compared to the 5-HTT+/+ rats on PND8 (t
(1,27)
=4.369; 
p<0.05) and PND14 (t
(1,27)
=5.110; p<0.05) and a trend on PND35 (t
(1,2)
=6.525; p<0.1) (Figure 
2A). As shown for group 2 and 3, body weight was also reduced in the 5-HTT-/- rats of group 4 
(data not shown). In addition, brain weight was significantly reduced in 5-HTT-/- rats compared 
to the 5-HTT+/+ rats on PND8 (t
(1,28)
=2.43; p<0.05), PND14 (t
(1,27)
=3.70; p<0.05) and PND35 
(t
(1,5)
=7.64; p<0.05) (Figure 2B). Unfortunately, we did not measure brain weight of rats 
sacrificed at PND70 and we have to keep in mind that the results of PND35 are based on 
a low number of animals. Brain weight was not measured in perinatally fluoxetine- versus 
vehicle-exposed rats. 
Effect of genetic and pharmacological 5-HTT inactivation on reflex development
Negative geotaxis was tested from PND4 to PND14. Rats perinatally exposed to fluoxetine 
or vehicle showed a significant age effect (F
(4.91,127.55)
=59.53; p<0.05) and treatment effect 
(F
(1,26)
=10.86;p<0.05) in the negative geotaxis test. Fluoxetine-exposed rats showed a 
significantly longer turning time compared to vehicle-exposed rats in repeated measures 
ANOVA, however independent samples t tests revealed no significant differences on separate 
days (Figure 3A). In the 5-HTT-/- and 5-HTT+/+ rats (group 1) repeated measures ANOVA also 
showed a significant age effect (F
(10,320)
=57.60; p<0.05), genotype effect (F
(1,32)
 = 45.00; 
p<0.05) and age x genotype interaction (F
(10,320)
=2.56; p<0.05). Independent samples t tests 
demonstrated that 5-HTT-/- rats show significantly (p < 0.05) longer turning times in the 
geotaxis experiment compared to 5-HTT+/+ rats on PND9 to PND12 (Figure 3B). In the vibrissa 
placing test (PND6 to PND14) perinatally fluoxetine-exposed rats showed a significant delay 
in developing the vibrissa placing reflex compared to vehicle-exposed rats on PND10 and 
PND11 (p<0.05) using a Fisher’s exact test (Figure 3C). The 5-HTT-/- rats (group 1) showed 
a significant delay in reflex development compared to 5-HTT+/+ rats on PND10 (p<0.05) 
using a Fisher’s exact test (Figure 3D). Vibrissa placing videos were re-analyzed by a second 
researcher resulting in similar results (data not shown). The righting reflex was tested from 
PND2 to PND10. In the rats perinatally exposed to fluoxetine or vehicle repeated measures 
ANOVA revealed an age effect (F
(1.43, 28.69)
=18.99; p<0.05), but no significant differences in 
turning time between the fluoxetine-exposed and vehicle-exposed rats (Figure 3E). In the 
5-HTT-/- and 5-HTT+/+ rats (group 1) repeated measures ANOVA demonstrated a significant 
age effect (F
(2.41,81.90)
=17.23; p<0.05) and a trend for a significant genotype effect (F
(1,34)
=3.75; 
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Figure 1. Effect of pharmacological and genetic inactivation of the 5-HTT on postnatal morphological development. 
Body weight in 5-HTT+/+ (n=21/n=11) and 5-HTT-/- (n=16/n=12) male rats (A) and in perinatally fluoxetine- (n=12) and 
vehicle-exposed (n=16) male rats (B) measured in early-life (postnatal day (PND) 2 to 21), adolescence (PND35) and 
adulthood (PND70). Data are presented as mean + S.E.M. of body weight (g). Eye opening in 5-HTT+/+ (n=21) and 
5-HTT-/- (n=16) male rats (C) and in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) male rats (D) scored 
from PND13 to PND16 twice a day ((0) both eyes closed; (1) one eye open; (2) two eyes open). Data are presented 
as mean ± S.E.M. of score. *p<0.05, #p<0.1.
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Figure 2. Effect of genetic inactivation of the 5-HTT on brain weight and brain/body mass index. Brain/body mass 
index (A) and brain weight (B) in 5-HTT-/- and 5-HTT+/+ male rats measured at four time points. Brain/body mass index: 
PND8 (5-HTT-/- n=14, 5-HTT+/+ n=16), PND14 (5-HTT-/- n=15, 5-HTT+/+ n=15), PND21 (5-HTT-/- n=10, 5-HTT+/+ n=6 and 
PND35 (5-HTT-/- n=2, 5-HTT+/+ n=2). Brain weight: PND8 (5-HTT-/- n=14, 5-HTT+/+ n=16), PND14 (5-HTT-/- n=15, 5-HTT+/+ 
n=14), PND21 (5-HTT-/- n=10, 5-HTT+/+ n=6 and PND35 (5-HTT-/- n=3, 5-HTT+/+ n=4). Data are presented as mean + 
S.E.M. of weight (g). *p<0.05, #p<0.1.
p<0.1). Independent samples t tests showed that 5-HTT-/- rats turned significantly slower 
on PND8 (t
(1,18.81)
=3.55; p<0.05) and showed a trend for turning slower on PND4, 7, 9 and 
10 (p<0.1) (Figure 3F). Startle reflex was assessed on PND21, 35 and 69. The perinatally 
fluoxetine-exposed rats showed a significant decrease in startle reflex compared to the 
vehicle-exposed rats on PND21 (U=52.00, p<0.05), a trend for an increase on PND35 (U= 
58.00, p<0.1) and a significant increase on PND69 (U=53.00, p<0.05) (Figure 3G). 5-HTT-/- rats 
(group 2) showed a significantly decreased startle reflex compared to 5-HTT+/+ rats on PND21 
(U=70.00, p<0.05), while no significant difference was found on PND35 and 69 (Figure 3H). 
In conclusion, both 5-HTT-/- and perinatally fluoxetine-exposed rats showed a delay in reflex 
development compared to control rats. 
Effect of genetic and pharmacological 5-HTT inactivation on muscular strength 
and motor coordination
Motor coordination was tested by scoring swimming ability daily between PND8 and PND14. 
Perinatally fluoxetine-exposed rats displayed an impaired swimming development compared 
to vehicle exposed rats on PND8, PND9 and PND14 (p<0.05) and a trend on PND13 (p<0.1) 
(Figure 4A). 5-HTT-/- rats (group 1) showed impaired swimming ability compared to 5-HTT+/+ 
rats on all days (p<0.05), as revealed by Fisher’s exact test (Figure 4B). Swimming videos 
were re-analyzed by a second researcher resulting in similar results (data not shown). Muscle 
strength was analyzed from PND10 to PND19 and on PND21 using a bar holding test. Repeated 
measures ANOVA in rats perinatally exposed to fluoxetine or vehicle showed a significant 
effect on age (F
(4.90,107.71)
=7.44; p<0.05), on treatment (F
(1,22)
=9.57; p<0.05) and a significant 
age x treatment interaction (F
(4.90,107.71)
=3.09; p<0.05). Independent samples t tests indicated 
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that the perinatally fluoxetine-exposed rats were able to hold the 3 mm bar significantly 
shorter (p<0.05) compared to the vehicle-exposed rats from PND10 to PND15 (Figure 4C). In 
the 5-HTT-/- and 5-HTT+/+ rats (group 2), repeated measures ANOVA showed a significant age 
effect (F
(6.24,205.88)
=25.34; p<0.05), genotype effect (F
(1,33)
=82.68; p<0.05) and age x genotype 
interaction (F
(6.24,205.88)
=9.72; p<0.05). Independent samples t tests demonstrated that 5-HTT-/- 
rats were able to hold the 3 mm bar significantly shorter compared to the 5-HTT+/+ rats on all 
test days (p<0.05) (Figure 4D). The 5 mm bar showed similar results (Supplementary Figure 3). 
Furthermore, tracking the rats for 14 minutes (in the ODB and NOR tests) showed significantly 
reduced locomotion (distance moved) in the perinatally fluoxetine-exposed rats compared to 
the vehicle-exposed rats on PND34 (t
(1,26)
=2.16; p<0.05). No significant treatment effect was 
found for locomotion in early-life (PND20) and adulthood (PND69) in this group (Figure 4E). 
The 5-HTT-/- rats (group 2 and 3) showed significantly reduced locomotion compared to the 
5-HTT+/+ rats on PND20 (t
(1,31)
=2.04; p<0.05) and PND69 (t
(1,21)
=2.25; p<0.05) and there was a 
trend for reduced locomotion in the 5-HTT-/- rats on PND34 (t
(1,21)
=2.00; p<0.1) (Figure 4F). 
In addition, we measured unstable walking from PND3 to PND14. The perinatally fluoxetine-
exposed rats showed no significant unstable walking after correcting for multiple testing 
(Figure 4G). The 5-HTT-/- rats (group 1) showed significantly more unstable walking compared 
to the 5-HTT+/+ rats from PND3 to PND9 and on PND13 (p<0.05), indicating that unstable 
walking was more visible in the 5-HTT-/- group (Figure 4H). Videos of the walking test were re-
analyzed by a second researcher resulting in similar results (data not shown). Taken together, 
both 5-HTT-/- and perinatally fluoxetine-exposed rats displayed defects in muscle strength and 
motor-related behavior.
Effect of genetic and pharmacological 5-HTT inactivation on olfactory 
discrimination
Olfactory function was tested on PND8, 10 and 12 using the olfactory discrimination task. In 
the rats perinatally exposed to fluoxetine or vehicle repeated measures ANOVA revealed a 
significant age effect (F
(1.15,24.06)
=10.48; p<0.05), treatment effect (F
(1,21)
=88.05; p<0.05) and 
age x treatment interaction (F
(1.15,24.06)
=4.62; p<0.05). Independent samples t tests showed a 
trend for an increased latency to reach the bedding from their homecage for the fluoxetine-
exposed rats compared to the vehicle-exposed rats on PND8 (t
(1,25)
= 2.32; p<0.1) and on 
PND10 (t
(1,25)
= 1.99; p<0.1) (Figure 5A). In the 5-HTT-/- and 5-HTT+/+ rats (group 1) repeated 
measures ANOVA demonstrated a significant age effect (F
(1.74,60.77)
=10.296; p<0.05), genotype 
effect (F
(1,35)
=26.495; p<0.05) and age x genotype interaction (F
(1.74,60.77)
=10.675; p<0.05). 
Independent samples t tests indicated that the latency to reach the bedding from their 
homecage is significantly increased in 5-HTT-/- rats compared to the 5-HTT+/+ rats on PND8 
(t
(1,35)
= 4.57; p<0.05) and on PND10 (t
(1,35)
= 2.43; p<0.05) (Figure 5B). Besides an increased 
latency to reach the bedding from their homecage, there were also 5-HTT-/- rats who walked 
to the fresh sawdust instead of to their homecage bedding on PND8 (n=3) and PND10 (n=3), 
while none of the 5-HTT+/+ rats showed this behavior. In conclusion, these data showed that
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Figure 3. Effect of pharmacological and genetic inactivation of the 5-HTT on reflex development. Negative geotaxis 
in 5-HTT+/+ (n=21) and 5-HTT-/- (n=16) male rats (A) and in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) 
male rats (B) was measured from postnatal day (PND) 4 to 14. Data are presented as mean ± S.E.M. of time turning 
180° (s). Vibrissa placement in 5-HTT+/+ (n=21) and 5-HTT-/- (n=16) male rats (C) and in perinatally fluoxetine- (n=12) 
and vehicle-exposed (n=16) male rats (D) was scored from PND6 to 14 ((0) no reflex; (1) reflex). Data are presented 
as mean ± S.E.M. of score. Righting reflex in 5-HTT+/+ (n=21) and 5-HTT-/- (n=16) male rats (E) and in perinatally 
fluoxetine- (n=12) and vehicle-exposed (n=16) male rats (F) was measured from PND2 to 10. Data are presented as 
mean ± S.E.M. of righting time (s). Startle reflex in 5-HTT+/+ (n=19/n=11) and 5-HTT-/- (n=17/n=11) male rats (G) and 
in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) male rats (H) was measured on PND21, 35 and 69. Data 
are presented as mean + S.E.M. of Avg startle amplitude. *p<0.05, #p<0.1. 
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Figure 4. Effect of pharmacological and genetic inactivation of the 5-HTT on motor function and muscle strength. 
Swimming development in 5-HTT+/+ (n=21) and 5-HTT-/- (n=16) male rats (A) and in perinatally fluoxetine- (n=12) and 
vehicle-exposed (n=16) male rats (B) was measured on postnatal day (PND) 8 to 14 (scoring: (1) head is fully under 
water; (2) back of the head is above water’s surface, but ears are still partially under water and nose is pointing 
downwards; (3) nose above the water’s surface, but ears still partially under water or (4) entire head remains above 
water’s surface). Data are presented as mean ± S.E.M. of score. Bar holding on a 3 mm bar in 5-HTT+/+ (n=19) and 
5-HTT-/- (n=17) male rats (C) and in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) male rats (D) was 
measured on PND10-19, 21. Data are presented as mean ± S.E.M. of time holding the bar (s). Distance moved in 
5-HTT+/+ (n=19/n=11) and 5-HTT-/- (n=17/n=12) (E) and in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) 
male rats (F) was measured on PND20, 34 and 69. Data are presented as mean + S.E.M. of distance moved per 
minute (cm/min). Unstable walking in 5-HTT+/+ (n=21) and 5-HTT-/- (n=16) male rats (G) and in perinatally fluoxetine- 
(n=12) and vehicle-exposed (n=16) male rats (H) was measured from PND3 to PND14. Scoring was as follows: (1) 
Shaking and unstable walking present, (0) no unstable walking and shaking. Data are presented as mean ± S.E.M. of 
walking score. *p<0.05, #p<0.1
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the development of olfactory function is delayed in 5-HTT-/- rats and a similar pattern is seen 
in perinatally fluoxetine-exposed rats.
Effect of genetic and pharmacological 5-HTT inactivation on grooming behavior 
Grooming behavior was assessed by scoring the total duration, latency and frequency on 
PND14,17,21, 35 and 69. In the rats perinatally exposed to fluoxetine or vehicle, repeated 
measures ANOVA revealed an age effect (F
(1.76,45.81)
=37.31; p<0.05) in early-life (PND14,17 and 
21), but no treatment effect or interaction was found. In adolescence (PND35) there was 
no significant difference, but in adulthood (PND69) the perinatally fluoxetine-exposed rats 
showed a significantly reduced grooming time (t
(1,25.49)
=2.37; p<0.05) (Figure 5C). No differences 
were found in frequency and latency of grooming in this group (Supplementary Figure 4A/C). 
In the 5-HTT-/- and 5-HTT+/+ rats (group 1) repeated measures ANOVA demonstrated an age 
effect (F
(1.48,50.16)
=22.07; p<0.05) and a genotype effect F
(1,34)
=37.63; p<0.05) in early-life 
(PND14,17 and 21). Independent samples t tests showed that the grooming time in 5-HTT-
/- rats was significantly shorter on all test days (p<0.05). Also in adolescence (PND35) the 
grooming time in 5-HTT-/- rats (group 3) was significantly shorter (t
(1,21)
=2.34; p<0.05), while 
there was no significant difference in adulthood (PND69) (Figure 5D). Likewise, there was a 
significant genotype effect (F
(1,34)
=8.23; p<0.05) and age x genotype interaction (F
(2,68)
=6.82; 
p<0.05) for the grooming latency. Independent samples t tests showed that the grooming 
latency in 5-HTT-/- rats was significantly increased on PND14 (t
(1,22.70)
=2.47; p<0.05) and a trend 
for an increase was seen on PND17 (t
(1,35)
=2.17; p<0.1). No differences in latency were seen 
in adolescence and adulthood (Supplementary Figure 4B). Frequency of grooming was also 
significantly reduced in the 5-HTT-/- rats compared to the 5-HTT+/+ rats on PND14 (p<0.05) and 
17 (p<0.05) and a trend for a reduction was seen on PND35 (p<0.1) using a Fisher’s exact test 
(Supplementary Figure 4D). In conclusion, grooming behavior was mainly affected in 5-HTT-
/- rats.
Effect of genetic and pharmacological 5-HTT inactivation on object directed 
behavior and novel object recognition 
Restricted/repetitive interests80 and cognition were assessed using the ODB and NOR test, 
respectively. No significant differences in ODB were found in early-life, adolescence and 
adulthood in rats perinatally exposed to fluoxetine or vehicle using independent sample t 
tests (Figure 5E). The 5-HTT-/- rats (group 3) showed significantly increased object directed 
behavior on PND34 (t
(1,15.15)
=3.24; p<0.05) and PND69 (t
(1,17)
=2.61; p<0.05) compared to 
5-HTT+/+ rats (group 3), while no difference was found on PND20 (group 2) (Figure 5F). For the 
NOR test no differences were found in rats perinatally exposed to fluoxetine or vehicle using 
independent samples t test (Figure 5G). The ability to discriminate old and new objects (as 
measured by the d2 index) was decreased in the 5-HTT-/- rats compared to 5-HTT+/+ rats (group 
3) on PND34 (t
(1,21)
=2.21; p<0.05) and PND69 (t
(1,19)
=2.20; p<0.05). This test was unfortunately 
not performed on PND20 (group 2) (Figure 5H). Taken together, rats lacking the serotonin 
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transporter showed object directed behavior and impaired object recognition in adolescence 
and adulthood. 
Effect of genetic and pharmacological 5-HTT inactivation on prepulse inhibition 
of the acoustic startle reflex in adolescence
Sensorimotor gating was assessed using PPI. In the rats perinatally exposed to fluoxetine or 
vehicle repeated measures ANOVA showed a significant effect of prepulse strength (dB) in 
early-life (PND21) and adulthood (PND69). The rats showed significantly more inhibition after 
a stronger prepulse at PND21 (F
(2,52)
=20.98; p<0.05) and PND69 (F
(2,52)
=17.20; p<0.05). No main 
effect of treatment or interaction was found. In adolescence (PND35) a trend for a significant 
prepulse x treatment interaction was found (F
(2,52)
=2.74; p<0.1). The fluoxetine-exposed rats 
showed a constant percentage of inhibition over all prepulse strengths, while an increase 
in inhibition was seen in the vehicle-exposed rats after a stronger prepulse. Independent 
samples t tests for each prepulse strength did not reveal a significant difference in PPI between 
the perinatally fluoxetine and vehicle-exposed rats after correcting for multiple testing. No 
main effect of treatment or prepulse strength was found in adolescence (Figure 6A,C,E). 
In the 5-HTT-/- and 5-HTT+/+ rats repeated measures ANOVA revealed a significant effect of 
prepulse strength (dB) in early-life (group 2), adolescence and adulthood (group 3). The rats 
showed significantly more inhibition after a stronger prepulse (PND21: F
(2,68)
=67.32; p<0.05, 
PND34: F
(2,40)
=82.29; p<0.05, PND69: F
(1.45, 30.41)
=44.15; p<0.05). Furthermore, in adolescence 
(PND34) a significant genotype effect (F
(1,20)
=6.46; p<0.05) and genotype x prepulse strength 
interaction (F
(2,40)
=4.97; p<0.05) was found. Independent samples t tests demonstrated that 
prepulse inhibition was stronger in 5-HTT-/- rats compared to 5-HTT+/+ rats for a prepulse of 
5 dB (t
(1,11.88)
=2.72; p<0.05) and 10 dB (t
(1,20)
=-2.83; p<0.05) above background noise (Figure 
6B,D,F). In conclusion, only in adolescence PPI is affected in 5-HTT-/- and perinatally fluoxetine-
exposed rats.
Analysis of correlations between aberrant behaviors
To investigate whether there is a correlation between the behaviors we measured, we 
performed a correlation analysis. Since numerous correlations could be performed, we 
decided to test only correlations between behavioral tests performed at the same day or if 
not possible with a maximum of one day difference. Overall, the correlations of behaviors 
in different tests in early-life were stronger in the 5-HTT knockout group compared to the 
fluoxetine group. We will only discuss part of the correlations here, for a complete list of 
correlation values see Online Supplementary Table 1. In rats perinatally exposed to fluoxetine 
or vehicle, body weight was positively correlated with swimming on PND9, 10, 11 and 13 and 
with bar holding on PND10 and a trend on PND12, 14 and 17. In the 5-HTT-/- and 5-HTT+/+ rats 
body weight was also positively correlated with swimming behavior from PND8 to PND14 
(p<0.05) and with bar holding on PND10 and PND13 to PND20 (p<0.05). A trend was seen 
with bar holding on PND11 and PND12 (p<0.1). Furthermore, in the 5-HTT-/- and 5-HTT+/+ rats 
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Figure 5.  Effect of pharmacological and genetic inactivation of the 5-HTT on olfactory function, grooming, 
restricted and cognitive behavior. Olfactory discrimination in 5-HTT+/+ (n=21) and 5-HTT-/- (n=16) male rats (A) and 
in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) male rats (B) was measured from postnatal day (PND) 
8 to 12. Data are presented as mean ± S.E.M. of latency to reach familiar sawdust (s). Grooming time in 5-HTT+/+ 
(n=21/n=11) and 5-HTT-/- (n=16/n=12) male rats (C) and in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) 
male rats (D) was measured on PND14, 17, 21, 35, 69. Data are presented as mean + S.E.M. of grooming duration 
(s). For the object directed behavior (ODB) test, time exploring each object was measured on PND20, 34 and 69 
in 5-HTT+/+ (n=19/n=11) and 5-HTT-/- (n=17/n=12) male rats (E) and in perinatally fluoxetine- (n=12) and vehicle-
exposed (n=16) male rats (F) and ODB was calculated (exploration time most explored object/total exploration time). 
Data are presented as mean + S.E.M. of ODB. For the novel object recognition (NOR) test, time exploring each object 
was measured in 5-HTT+/+ (n=11) and 5-HTT-/- (n=12) male rats (G) and in perinatally fluoxetine- (n=12) and vehicle-
exposed (n=16) male rats (H) on PND20, 34 and 69 and NOR was calculated (exploration time new object/total 
exploration time). Data are presented as mean + S.E.M. of NOR. *p<0.05, #p<0.1
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Figure 6. Effect of pharmacological and genetic inactivation of the 5-HTT on prepulse inhibition. Prepulse inhibition 
(PPI) of the acoustic startle reflex was measured in 5-HTT+/+ (n=19/n=11) and 5-HTT-/- (n=17/n=12) male rats on 
postnatal day (PND)21 (A), PND35 (C) and PND69 (E) and in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) 
male rats on PND21 (B), PND35 (D) and PND69 (F). PPI was calculated according to the formula: 100 – (Average of all 
startle amplitude on prepulse trial/ Startle amplitude on startle trial) × 100. Three different prepulses were tested; 
3, 5, or 10 dB above background noise. *p<0.05  
body weight was also positively correlated with startle reflex on PND21 (r
(36)
=0.391, p<0.05) 
and grooming time on PND17 (r
(35)
=0.385, p<0.05) and PND21 (r
(37)
=0.560, p<0.05). In 
addition, in the 5-HTT-/- and 5-HTT+/+ rats bar holding on PND21 was positively correlated with 
startle reflex (r
(36)
=0.41, p<0.05) on PND21 and locomotion on PND20 (r
(36)
=0.33, p<0.05). 
We also observed that in the 5-HTT-/- and 5-HTT+/+ rats swimming was positively correlated 
with grooming on PND14 (r
(37)
=0.570, p<0.05) and with vibrissa placing on PND9 (r
(37)
=0.36, 
p<0.05) and PND10 (r
(37)
=0.33, p<0.05) and a trend on PND13 (r
(37)
=0.31, p<0.1). A negative 
correlation was found between swimming and geotaxis on PND9 (r
(37)
=-0.39, p<0.05),10 (r
(37)
=-
0.33, p<0.05) and 11 (r
(37)
=-0.36, p<0.05). Later in life, we found in the 5-HTT-/- and 5-HTT+/+ rats 
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a negative correlation between grooming time and ODB in adolescence (r
(23)
=0.56, p<0.05) 
and a trend was seen in adulthood (r
(23)
=0.35, p<0.1). This negative correlation between ODB 
and grooming time was also found in the fluoxetine group, but only in adulthood (r
(28)
=-0.383, 
p<0.05).
Discussion
In this study, we demonstrate that both pharmacological (perinatal SSRI exposure) and genetic 
(knockout) 5-HTT inactivation result in a developmental delay. Specifically, we observed a 
delay in reflex development and olfactory function. In addition, we found defects in grooming 
and motor-related behavior and a decrease in body weight. Most of the observed early-life 
effects were normalized later in life. Interestingly, in adolescent and adult 5-HTT-/- rats, but 
not in fluoxetine-exposed rats, we observed object directed behavior and decreased novel 
object recognition. 
 We are the first to report the aberrant developmental time-course in early-life of 
5-HTT-/- rodents. We observed a delay in reflex development, as shown in the righting reflex, 
negative geotaxis, vibrissa placing and startle reflex. In addition, we found muscle and motor-
related changes in the 5-HTT-/- rats compared to the 5-HTT+/+ rats, like hypolocomotion, 
unstable walking, decreased bar holding time and lower swimming scores. Furthermore, 
olfactory discrimination and grooming development were delayed in the 5-HTT-/- rats. We 
also found a reduction in body weight in the 5-HTT-/- rats during early life, which has been 
shown before85. All differences seen in the reflex tests were normalized before adolescence 
(PND35). Regarding motor-related changes, the 5-HTT-/- rats showed hypolocomotion also 
during adolescence and adulthood. Unfortunately, walking and swimming behavior were not 
tested after PND14 and our bar holding setup did not give reliable results in adolescence due 
to the fact that the rats could see the ground (eyes open) and jumped off the bar. While most 
of the early-life differences were normalized in adolescence, differences in PPI, ODB and NOR 
were only seen later in life (adolescence and adulthood). Why we only see these differences 
later in life is unclear, but it might be related to the refinement of dendritic branching and 
synaptic connections which is occurring around adolescence86. Serotonin is involved in 
the regulation of synaptogenesis and the elimination of exuberant undesired connections, 
known as synaptic pruning10,87,88. It has been shown that 5-HTT-/- mice display increased spine 
densities during adulthood, which can be a result from pruning deficits89. Pruning is affected 
by serotonin’s capability to inhibit the activation of microglia via 5-HT2 receptor activation, 
resulting in reduced uptake of synaptic particles90. In addition, the 8 hour interval in the NOR 
test might be optimal for testing recognition memory later in life, but not for early-life (See 
also Reger et al.91). Increased object directed behavior in the 5-HTT-/- rats reflects repetitive/
restricted interests which is a sign of autistic-like behavior80. Increased PPI and decreased 
NOR (shown before in our adult 5-HTT-/- rats92) are seen in animal models for autism spectrum 
disorder93,94. This observation underscores the postulated link between early-life increased 
extracellular serotonin levels and autism spectrum disorder42-44. Serotonin is shown to be 
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modulating several pathways associated with autism spectrum disorder, like the mTOR 
pathway95-97, glutamate signaling98,99 and neurotrophin signaling100,101, which strengthens 
our autism-related behavior findings. An interesting example is the mTOR pathway. 
Hyperactivation of this pathway is associated with autism96,97. The serotonin receptor 5-HT6 
can form a complex with mTORC1 and activate the mTOR pathway, suggesting that increased 
serotonin signaling can also hyperactivate the mTOR pathway95. Furthermore, it has been 
shown that a hyperactivated mTOR pathway can cause pruning defects102 and both increased 
extracellular serotonin and autism spectrum disorder are associated with increased dendritic 
spine density caused by reduced developmental spine pruning102,103. However, there are also 
studies showing decreased PPI and increased grooming in autism spectrum disorder93,104-107, 
which are not seen in our 5-HTT-/- rats. Besides the behavior, we observed an increase in 
brain/body mass index in the 5-HTT-/- rats compared to the 5-HTT+/+ rats, which is also shown 
by Page and colleagues108 in 5-HTT+/- mice and is linked to autism spectrum disorder. Hence, 
more (behavioral) tests are needed to confirm whether the 5-HTT-/- rats display phenotypes 
of autism spectrum disorders. 
As mentioned in the introduction, there are several studies showing effects of 
perinatal SSRI exposure on neurodevelopmental behavior. While the results in human studies 
are often based on a combination of different SSRI types and exposure periods, animal 
studies have shown that the type of SSRI and exposure period might result in different 
behavioral outcomes57,109,110. We studied the effects of fluoxetine exposure from GD11 to 
PND7 on neurodevelopmental behavior. So far, studies using pre- and postnatal fluoxetine 
exposure reported a reduction in body weight111 and sexual behavior112,113 and an increase in 
anxiety111,114 and depression-like behavior111 in the offspring. We also observed the reduction 
in body weight in the fluoxetine-exposed rats from early-life till adulthood (the reduction 
was not significant from PND17 to PND21 probably because of increased variation in body 
weight). Furthermore, we found a delay in reflex development in the fluoxetine-exposed 
rats compared to the vehicle-exposed rats, as reflected by an increased turning latency 
in the negative geotaxis test, reduced vibrissa placing and decreased startle reflex. This 
delay corresponds well with findings of Deiro and colleagues, who found a delay in reflex 
development in rats postnatally (PND1-PND21) exposed to sertraline or citalopram58,59. 
Increased turning latencies in negative geotaxis were also shown by Zimmerberg and 
Germeyan61 in prenatally fluoxetine-exposed rats. In addition, the fluoxetine-exposed rats 
showed reduced performance in the bar holding test and swimming test in early-life, and 
they showed hypolocomotion in adolescence. Changes in motor-related behavior (bar 
holding, hypolocomotion) were observed before in rats postnatally exposed to fluoxetine60,62, 
indicating that 5-HT levels in the postnatal period are important for development of motor 
functions. As in the 5-HTT-/- rats, most of the early-life differences seen in the fluoxetine-
exposed rats where normalized at adolescent stage. In adolescence we found a trend for a 
treatment x prepulse interaction in PPI. In adulthood we found an increased startle reflex in 
the fluoxetine-exposed rats which might reflect anxiety-like behavior115. 
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We observed similar effects on reflex development and muscle/motor-related 
behavior in the perinatally fluoxetine-exposed rats and 5-HTT-/- rats. Overall, the effects on 
olfactory function, grooming and muscle and motor-related behavior were stronger in the 
5-HTT-/- rats compared to the fluoxetine-exposed rats. Differences between the two models 
might be caused by the fact that 5-HTT is only transiently blocked by fluoxetine, while it is lifelong 
absent in the 5-HTT-/- rats. In addition, fluoxetine has weak affinity for the norepinephrine and 
dopamine transporters116,117, which might also contribute to the effects on early-life behavior. 
Differences between the models are seen in adolescence and adulthood, which might be 
related to increased 5-HT levels in the 5-HTT-/- rats over their entire life span, whereas in 
the perinatally fluoxetine-exposed rats elevated levels are restricted to the perinatal period. 
Object directed behavior and a lower d2 in NOR were only seen in the 5-HTT-/- versus 5-HTT+/+ 
rats (in adolescence and adulthood). PPI in adolescence was affected in both 5-HTT-/- versus 
5-HTT+/+ and fluoxetine- versus vehicle-exposed rats, but in opposite direction. 5-HTT-/- rats 
showed a stronger increase in percentage inhibition by increasing prepulse strength compared 
to 5-HTT+/+ rats, while fluoxetine-exposed rats showed a trend towards a reduced increase in 
percentage inhibition by increasing prepulse strength compared to vehicle-exposed rats. The 
weak affinity of fluoxetine for the dopamine transporter might contribute to the decrease in 
PPI in the fluoxetine-exposed rats, as increased dopaminergic signaling can contribute to a 
decrease in PPI118,119. 
Rodents with impaired (early-life) 5-HTT function are often used as a model for 
depression and anxiety, however this depressive and anxious phenotype is mainly based on 
adult findings. As the focus of our study was on investigating neurodevelopmental behavior, 
we did not test anxiety and depression-like behavior across ages but it might very well be that 
the anxiety and depressive symptoms are only present later in life, while other symptoms are 
only present during early-life. We observed differences in motor-related behavior in early-
life, suggesting that early-life reduction in 5-HTT function might be a good model for motor 
disorders in early-life. Since the serotonergic system is involved in energy regulation120, it 
might be that rodents with impaired (early-life) 5-HTT function use their energy for different 
processes in early-life compared to adulthood. The development of motor function can be 
delayed, while other (unknown) functions are well- (or over) developed. 
We should note that additional factors might contribute to the results of some of 
the behavioral tests, complicating the interpretation of the findings. Especially differences 
in motor function can affect several behavior tests, like righting reflex, negative geotaxis, 
olfactory discrimination (but we do see that some of the 5-HTT-/- rats walk to the fresh sawdust) 
and startle reflex. We showed that there is a positive correlation between bar holding and 
startle reflex in the 5-HTT-/- and 5-HTT+/+ rats, indicating that the jumping in the startle test 
might be influenced by muscle strength. In addition, in the 5-HTT-/- and 5-HTT+/+ rats there 
was a significant negative correlation between swimming and negative geotaxis, suggesting 
that increased turning latency in the negative geotaxis test might be caused by defects in 
motor function. We also found a positive correlation between grooming and swimming 
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suggesting that grooming behavior is dependent on motor function. In the fluoxetine group 
no strong correlations between motor or muscle tests and other behavioral tests were found. 
Furthermore, correlational analysis showed that body weight is positively correlated with 
several behavioral test, like bar holding, swimming, grooming and startle reflex. A worse 
performance with a lower body weight in bar holding, swimming, grooming and startle reflex 
might reflect a delay in development of muscles causing the lower body weight.  
The strength of our study is that we performed a battery of behavior experiments 
under well controlled environments (temperature, noise level, type of SSRI, exposure period 
and dose) making it possible to monitor behavior across developmental stages. We used both 
perinatally SSRI-exposed and 5-HTT-/- rats to study different types of behavior, which enables 
direct examination of similarities and differences between these two models. However, 
there are also several limitations of the study. We performed multiple behavioral tests in 
the same group of rats. Repeated testing might influence the outcome of the tests (carry-
over effect), although we do think that most of the behavioral tests are very mild and the 
sequence of the behavior tests and the interval between the tests was always the same in the 
test and control group. Furthermore, we did not test motor-related behavior in adolescence 
and adulthood (except locomotion). Testing rotarod or bar holding under dimmed or red 
light conditions might be appropriate ways to study motor-related behavior later in life. In 
addition, we observed contradictory results regarding differences in brain weight. We found 
an increase in brain/body mass index, but a reduction in brain weight per se. While the brain/
body mass index is a commonly used measure, there are also studies looking at brain weight 
per se since body weight is a factor that can be influenced by various parameters (e.g. fat and 
muscles). It is important to mention that a lower brain weight per se, as seen in the 5-HTT-
/- rats, is linked to major depressive disorder121 and the serotonin system122,123. For mothers 
using SSRIs during pregnancy it is important to know whether SSRIs can cause livelong effects 
on neurodevelopmental behavior. In addition, testing neurodevelopmental behavior in the 
5-HTT+/- rat, which is argued to best model the human 5-HTTLPR S-allele, might provide 
valuable additional information. Lastly, it would be of interest to investigate whether prenatal 
stress increases the differences in early-life behavior between the 5-HTT inactivation models 
and their controls, as is seen for depression-like symptoms after early-life stress in relation to 
the 5-HTTLPR s/s (and s/l) genotype124-126.
In conclusion, we demonstrate that perinatal reduction of functional 5-HTT, by 
blocking 5-HTT using an SSRI or by genetically knocking out 5-HTT, results in a developmental 
delay. Strongest effects are observed in reflex development and motor-related behavior. 
Most of the early-life changes are normalized later in life, except for hypolocomotion. In 
adolescent and adult 5-HTT-/- rats we observe object directed behavior and decreased novel 
object recognition, which are not seen in the perinatally fluoxetine-exposed rats and might be 
related to the lifelong absence of 5-HTT. Together, these data provide important new insights 
into the effects of perinatal and lifelong 5-HTT inactivation on behavior across developmental 
stages. 
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Supplementary material
Supplementary Figure 1. Schematic representation of experimental timeline. Experiments performed in perinatally 
fluoxetine- and vehicle-exposed rats (A) and in 5-HTT+/+ and 5-HTT-/- rats (B). For perinatal fluoxetine exposure, 
dams were treated from gestational day (GD) 11 to 7 days after delivery. Male offspring was used for the following 
behavior tests: body weight, eye opening, righting reflex, swimming, negative geotaxis, vibrissa placing, grooming, 
bar holding, object directed behavior (ODB), novel object recognition (NOR), startle reflex and prepulse inhibition 
(PPI). At postnatal day (PND) 22, pups were weaned and group-housed for further examination (2 rats/cage). Male 
Wistar rats in group 1 (5-HTT+/+ n=21; 5-HTT-/- n=16) and 2 (5-HTT+/+ n=19; 5-HTT-/- n=17) were used to test early-life 
behavior from PND2 to PND21. Rats in group 1 were used for body weight, eye opening, righting reflex, swimming, 
negative geotaxis, vibrissa placing and grooming. Male Wistar rats in group 2 were used for body weight, bar holding, 
ODB, NOR, startle reflex and PPI. Male Wistar rats in group 3 (5-HTT+/+ n=11; 5-HTT-/- n=12) were used for testing 
adolescent (around PND35) and adult (around PND70) behavior. The following tests were performed: body weight, 
grooming, ODB, NOR, startle reflex and PPI. Male Wistar rats in group 4 were sacrificed at four different time points 
(PND8, 14, 21 and 35) and used for measuring brain weight.
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Supplementary Figure 2. Scoring of swimming development. Swimming development was scored according to the 
following scores: (1) head is fully under water; (2) back of the head is above water’s surface, but ears are still partially 
under water and nose is pointing downwards; (3) nose above the water’s surface, but ears still partially under water 
or (4) entire head remains above water’s surface. Scoring system is adapted from Schapiro and colleagues1.
Supplementary Figure 3. Bar holding (5mm). Bar holding on a 5 mm bar in 5-HTT+/+ (n=19) and 5-HTT-/- (n=17) male 
rats (A) and in perinatally fluoxetine- (n=12) and vehicle-exposed (n=16) male rats (B) was measured from PND10 to 
19 and 21. Data are presented as mean ± S.E.M. of time holding the bar (s). *p<0.05, #p<0.1
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Supplementary Figure 4. Grooming latency and frequency. Grooming latency (s) and number of grooming episodes 
in 5-HTT+/+ (n=21/n=11) and 5-HTT-/- (n=16/n=12) male rats (A,C) and in perinatally fluoxetine- (n=12) and vehicle-
exposed (n=16) male rats (B, D) was measured on PND14, 17, 21, 35, 69. Data are presented as mean + S.E.M. 
*p<0.05, #p<0.1
Supplementary references
1. Schapiro, S., Salas, M. & Vukovich, K. Hormonal effects on ontogeny of swimming ability in the rat: assessment 
of central nervous system development. Science 168, 147-50 (1970).
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Abstract
The prefrontal cortex (PFC) is one of the latest brain regions to mature, which allows the 
acquisition of complex cognitive abilities through experience. To unravel the underlying gene 
expression changes during postnatal development we performed RNA-sequencing (RNA-seq) 
in the rat medial PFC (mPFC) at five developmental time points from infancy to adulthood, 
and analyzed the differential expression of protein-coding genes, long intergenic non-coding 
RNAs (lincRNAs) and alternative exons. We showed that most expression changes occur in 
infancy, and that the number of differentially expressed genes reduces toward adulthood. 
We observed 137 differentially expressed lincRNAs and 796 genes showing alternative 
exon usage during postnatal development. Importantly, we detected a genetic switch from 
neuronal network establishment in infancy to maintenance of neural networks in adulthood 
based on gene expression dynamics, involving changes in protein-coding and lincRNA gene 
expression as well as alternative exon usage. Our gene expression datasets provide insights 
into the multifaceted transcriptional regulation of the developing PFC. They can be used to 
study the basic developmental processes of the mPFC and to understand the mechanisms 
of neurodevelopmental and neuropsychiatric disorders. Our study provides an important 
contribution to the ongoing efforts to complete the ‘brain map’, and to the understanding of 
PFC development. 
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Introduction
Cortical development is a molecularly orchestrated process that begins prenatally and 
continues postnatally until late adolescence, arguably throughout the lifespan1. It consists of 
a complex series of dynamic processes that operate throughout the course of development 
to promote new neural structures and functions. The birth, proliferation, migration, neuronal 
cell death, differentiation and target selection (axonal guidance) of neurons occurs mainly 
prenatally2-4. Postnatal developmental processes consist of dendritic growth, dendritic and 
axonal branching, synaptogenesis, synaptic pruning and myelination2,5-7. Homeostatic control 
and metabolic regulation are the main processes taking place in the adult brain8,9. 
The prefrontal cortex (PFC) is one of the last regions of the brain to reach 
maturation10. The PFC receives input from many regions including all cortical regions and 
is involved in the execution of cognitive and emotional functions, such as decision-making, 
planning, social interaction and impulse control11-15. The prolonged development of the PFC 
allows the acquisition of complex cognitive abilities through experience11. 
 The development of the PFC has often been studied in rodent models, because 
their development is faster than in humans, and it is easier to control environmental factors 
which can influence neurodevelopment. It has been shown that the sequence of key events 
in brain development is largely conserved between humans and rodents16,17, which makes 
rodents useful models for studying neurodevelopmental processes. However, it should be 
noted that rats are born more immature than humans in terms of brain maturation18. The 
first postnatal week in rats roughly corresponds to the third trimester of human gestation19. 
In addition, studies comparing rodent and primate PFC show that cortical areas are not 
only less segregated in rats compared to primates20, they are also less numerous overall21,22. 
Furthermore, some studies suggest that the relative size of the PFC is larger in humans than 
in other species10,23-25. These differences should be kept in mind when comparing rodent and 
human mPFC development.  
While postnatal morphological changes in the PFC are well studied, less is known 
about the molecular changes underlying this. Several studies focused on the expression 
changes of protein-coding genes related to neurotransmitter systems (serotonin, gamma-
aminobutyric acid (GABA), glutamate) and to neurotrophin signaling pathways (Trkb, Bdnf), 
showing different expression patterns during PFC development26-29. In addition, alternative 
exon usage is a process that occurs extensively in the nervous system to regulate receptor 
localization (e.g. Grin1, Grm1), axon guidance (e.g. Dscam) and synapse formation (e.g. 
Agrn, Nrxn1, Nrxn2, Nrxn3)30-32. Furthermore, long intergenic non-coding RNAs (lincRNAs) 
have been shown to be involved in neurodevelopmental processes, such as neural stem 
cell maintenance and differentiation (e.g. HOTAIRM), neurogenesis (e.g. RMST), gliogenesis 
(e.g. SOX8OT) and neural plasticity (e.g. NEAT2)33-36. LincRNAs have been implicated in the 
regulation of the expression of protein-coding genes37, especially of genes in their genomic 
vicinity38. While most studies have focused on individual genes, several recent studies 
investigated the expression of protein-coding genes in the PFC on a genome-wide level using 
150
Chapter 5
gene expression microarrays39-43. In addition, the Allen brain atlas provides PFC expression 
data from a large set of genes at different time points during mouse44, non-human primate45 
and human development46,47. So far, only one study investigated genome-wide alternative 
splicing in the human PFC during development using RNA-seq48 and there are no studies 
focusing on lincRNA changes during PFC development. It is likely that changes in expression of 
protein-coding genes and lincRNAs as well as in the alternative exon usage of protein-coding 
genes together regulate PFC development, and therefore it is important to investigate the 
combination of these gene regulation mechanisms during PFC development on a genome-
wide scale and in a temporal manner. 
In this study, we performed transcriptome analysis during medial PFC (mPFC) 
development in male Wistar rats. We used different developmental time points (infancy (PND8, 
PND14), (pre-) adolescence (PND21, PND35) and adulthood (PND70)) and studied genome-
wide protein-coding gene expression, lincRNA expression and alternative exon usage during 
development using RNA-sequencing (RNA-seq). We identify a genetic switch during mPFC 
development from neuronal network establishment in infancy to maintenance of neuronal 
networks in adulthood, which is supported by protein-coding and lincRNA gene expression 
dynamics as well as alternative exon usage patterns. Our study additionally provides a rich 
resource for future studies in neurodevelopmental and neuropsychiatric disorders.
Materials and methods
Animals
Wistar rats (Rattus norvegicus) were bred, reared and housed in individually ventilated cages 
(40x35x23, Greenline, Tecniplast, West Chester, Pennsylvania, USA) in temperature-controlled 
rooms (21 °C ± 1 °C) under standard 12-h light/dark cycle (lights on at 7:00 A.M.) with food 
(Sniff, long cut pellet, Bio Services, Uden, The Netherlands) and water available ad libitum. 
Pups were weaned at PND22. Male rats were sacrificed by decapitation at five different time 
points, PND8, PND14, PND21, PND35 and PND70. Three different nests per time point were 
used. All efforts were made to minimize animal suffering and to reduce the number of rats 
used. We used Wistar rats for this study because this is a commonly used rat strain in the 
laboratory. All experiments were carried out according to the guidelines for the Care and 
Use of Mammals in Neuroscience and Behavioral Research (National Research Council 2003), 
the principles of laboratory animal care, as well as the Dutch law concerning animal welfare.
RNA extraction and double-stranded cDNA synthesis
Five rat brain samples per time point were used for RNA extraction. mPFC tissue was 
dissected from seven (PND8 and 14) or eight (PND21, 35 and 70) consecutive slices of 200 
µm using a 2 mm punch needle. More information about the exact position of the punches is 
shown in Supplementary Figure 1. Total RNA was isolated with QIAzol (RNeasy lipid tissue kit; 
QIAGEN, Venlo, The Netherlands) according to the manufacturer’s recommendations. From 
each sample 2.5 μg RNA was used for rRNA depletion using the Ribo-Zero rRNA Removal Kit 
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(Human/Mouse/Rat, Epicentre, Madison, Wisconsin, USA) according to the manufacturer’s 
recommendations. RNA fragmentation reactions were performed using fragmentation 
buffer (5x; 200 mM Tris-Ac, 500 mM potassium-Ac, 150 mM Magnesium-Ac, pH 8.2) in a 
final concentration of 1x per reaction. Fragmentation reactions were incubated at 95°C for 
4 min on a thermal cycler and placed on ice for 10 min. Fragmented rRNA-depleted RNA 
was purified using ethanol precipitation. First and second strand synthesis was performed as 
described by Kouwenhoven and colleagues49. 
Sequencing
DNA samples were prepared for sequencing by end repair of 5 ng total DNA as measured 
by Qubit dsDNA HS (Invitrogen). NEXTflex adaptors (Bioo Scientific, Austin, Texas, USA) were 
ligated to the DNA fragments, followed by post-ligation cleanup using Agencourt AMPure XP 
beads (Beckman Coulter, Woerden, The Netherlands), library amplification by PCR (10 cycles) 
and size selection (∼300 bp) using Agencourt AMPure XP beads (Beckman Coulter). Quality 
control of DNA libraries prepared for sequencing was performed by qPCR and by running 
the products on a Bioanalyzer (Bio-Rad, Veenendaal, The Netherlands). Cluster generation 
and sequencing (50 bp, single end reads) was performed with the Illumina HiSeq 2000 
sequencer according to standard Illumina protocols. Samples were sequenced to a depth 
of approximately 29 million reads per sample. Reads were aligned to the rn4 rat genome 
assembly using the GSNAP program50, version 2012-07-20.
Differential expression analysis
Expression quantification was performed using the Cufflinks program and differential 
expression analysis was performed using the CuffDiff program51 version 2.2.1, using the 
Ensembl database52 version 69 rat transcriptome annotation. Cufflinks quantifies gene 
expression as Fragments per Kilobase per Million mapped reads (FPKM), which corrects 
for different transcript lengths and sample sequencing depths. These expression values 
are further normalized by CuffDiff across the samples in the experiment by scaling them 
according to the geometric mean of the samples. Based on these expression data, CuffDiff 
calculates differentially expressed genes between all pair-wise combinations of conditions 
(rat mPFC age in PNDs), taking replicates per condition into account and using a multiple 
testing-adjusted p-value of p<0.05. As CuffDiff uses sophisticated statistical models to 
calculate differentially regulated genes, no fold change or number of reads were required 
as cut-off to detect differentially regulated genes. Two outlier samples (WT14 21-3, WT21 
16-2) were excluded in the differential expression analysis. Clustering was performed using 
the Multi-Experiment Viewer53 version 4.9. Gene Ontology analysis was performed using the 
DAVID website54 and PANTHER55.
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Long intergenic non-coding RNA (lincRNA) analysis
Annotated lincRNAs were taken from the Ensembl database version 82 (rn6 rat genome 
assembly), and mapped to the rn4 rat genome assembly using the lift-over tool of the 
UCSC Genome Browser database56 due to the lack of lincRNA annotation in the Ensembl 
database version 69 (rn4 assembly). Only 2305 of the 3023 annotated lincRNAs that could be 
completely transferred to the rn4 assembly were used. Differentially expressed lincRNAs were 
determined using the Cuffdiff program with an adjusted p-value of p<0.05. The set includes all 
lincRNAs that are significantly differentially expressed between any two time points. Protein-
coding genes were taken from the Ensembl 69 (rn4) annotation, and the nearest genes to the 
lincRNAs were determined using the “closestBed” command of the BEDTools software suite57 
version 2.25.0. Correlation analysis and plotting were done using the R statistical software 
package (R Core Team (2015) R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria; URL: http://www.R-project.org/). Gene 
ontology analysis of the set of closest protein-coding genes was performed using the DAVID 
website54. Human orthologs of rat lincRNA-neighboring protein-coding genes were obtained 
using the Ensembl BioMart webtool58, using Ensembl database version 85. Nearest human 
genes to these protein-coding genes were mapped using the “closestBed” command using 
gene locations obtained from Ensembl BioMart (database version 85). Classification of these 
nearest genes into protein-coding or lincRNA genes was based on the Ensembl “biotype” 
annotation of the genes.
Alternative splicing analysis
Alternative splicing analysis was performed using the DEXSeq59 package (version 1.14.2) of 
the R Bioconductor Statistical Software Suite60. This software package identifies alternatively 
expressed exons after normalization for differences in total gene expression levels. The 
RGSC3.4 (rn4) rat transcriptome from Ensembl database52 version 69 was used for this 
analysis. Mapping of rat alternatively spliced exons to the hg19 human genome assembly 
was done using the UCSC genome browser56 lift-over tool, and overlap with human exons 
from the GENCODE61 version 19 annotation was done using the BEDTools “intersectBed” 
command.
Neuropsychiatric GWAS gene enrichment analysis
Genes associated with neuropsychiatric genome-wide association studies (GWAS) were 
obtained from the NHGRI-EBI GWAS Catalog62 (http://www.ebi.ac.uk/gwas/), spreadsheet 
version v1.0.1, downloaded on 22 August 2016. Genes were filtered using the GWAS Catalog 
trait ontology terms: “autism” (optionally followed by other words, e.g. “autism spectrum 
disorder”), “schizophrenia”, “bipolar depression”, “unipolar depression” and “attention 
deficit hyperactivity disorder”. GWASs combining multiple of these neuropsychiatric disorders 
were excluded. Ensembl BioMart was used to map the human GWAS genes to rat orthologs. 
For the enrichment analyses, rat cluster genes were first filtered for those that had human 
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orthologs according to Ensembl BioMart (database version 85).
Quantitative Reverse Transcription PCR
For validation of the RNA-seq, one gene per cluster (from k-means clustering) was selected 
for quantitative reverse transcription PCR (RT-qPCR). Primers were designed using Primer3 
online software (http://frodo.wi.mit.edu). See Supplementary Table 1 for primer sequences. 
Complementary DNA (cDNA) was synthesized using 500 ng of total RNA in a reverse 
transcription reaction using iScript cDNA Synthesis Kit according to manufacturer’s protocol 
(Bio-Rad, Veenendaal, The Netherlands). For the cDNA reaction we pooled five rat PFC samples 
for each time point. qPCR reactions were performed in a 7500 Fast Real Time PCR System 
(Applied Biosystems, Foster City, CA, U.S.A) using the SYBR Green fluorescence quantification 
system (GoTaq® qPCR Master Mix, Promega Benelux b.v. Leiden, The Netherlands). Thermal 
cycling was initiated with incubation at 95°C for 10 min followed by 40 cycles of 95°C for 30 sec 
and 60°C for 1 min. To normalize the cDNA content of the samples, we used the comparative 
threshold cycle (CT) method63, which consists of the normalization of the number of target 
gene copies versus the average of two endogenous reference genes, Gabbr1 and Kif5c (stable 
genes in the RNA-seq dataset throughout all ages based on the Coefficient of Variation (CV = 
stddev/mean)).
Results
Differentially expressed coding genes
We surveyed the gene expression changes that occured in the mPFC during rat postnatal 
development. Transcriptome analysis (RNA-seq) was performed in mPFC tissue of male Wistar 
rats sacrificed by decapitation at five different time points; PND8, PND14, PND21, PND35 and 
PND70. We performed pair-wise comparisons across all time points and observed a total of 
10336 differentially expressed genes at a multiple testing-adjusted p-value of p<0.05 using 
CuffDiff51 and the rat transcriptome from the Ensembl database52. More than 5000 genes 
are differentially regulated when gene expression is compared between PND8 and PND14 
(2638 and 2447, down- and up-regulated, respectively). This is the largest change across all 
comparisons between successive time points, and a continuous decrease in the number of 
differentially expressed genes with age was evident (Figure 1 and Online Supplementary Table 
2). This suggests that the majority of the postnatal expression changes between successive 
time points take place in the first three postnatal weeks. The numbers of up- and down-
regulated genes are similar for all pair-wise comparisons (Supplementary Table 3). 
Next, we investigated the functions of the differentially expressed genes between 
successive time points with gene ontology (GO) analysis64 using the NIH DAVID website54 
(Figure 1 and Online Supplementary Table 2). This analysis revealed that cell cycle (e.g. cyclin 
related genes, such as Ccna2 and Cdk4) and translational elongation genes (e.g. ribosomal 
proteins, such as Rpl18 and Rpl4) were significantly down-regulated during early development 
from PND8 to PND14 and from PND14 to PND21, while genes linked to transmission of nerve 
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impulse (e.g. neurotransmitter receptors, such as Grin2a and Gabrd) were up-regulated in 
the same developmental period. In addition, genes linked to myelination (e.g. Cldn11 and 
Mbp) are up-regulated from PND14 to PND21. Between PND21 and PND35, genes linked to 
cell adhesion (e.g. cadherins, such as Cdh5 and Pcdha13), vasculature development (e.g. 
collagens, such as Col1a1 and Col1a2) and cell migration (e.g. Reln and Dcx) were down-
regulated while genes linked to translational elongation (e.g. ribosomal proteins, such as 
Rps29 and Rpl5) were up-regulated. From adolescence (PND35) to adulthood (PND70) there 
was little change in gene expression (Figure 1) and no apparent enriched biological processes 
were detected in the GO analysis. Of interest, a shift from developmental processes (cell 
adhesion, neuron differentiation and cell migration) to maintenance (translational 
elongation, response to organic substance and metabolic processes) was detected between 
PND21 and PND35. We confirmed these findings using the alternative PANTHER55 GO analysis 
website, including the switch in gene expression from developmental processes to metabolic 
processes or maintenance during postnatal PFC development (see Online Supplementary 
Table 2). 
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Figure 1. Differential expression analysis between successive time points using RNA-seq. Number of differentially 
expressed genes (adjusted p<0.05) in the rat medial prefrontal cortex (mPFC) during development is shown in the 
bar graph. Top gene ontology (GO) terms for up- and down-regulated genes are shown under the graph. Top GO 
terms fit with mPFC development, as shown by the horizontal grey arrow.
To investigate the overall patterns of gene expression changes during rat mPFC 
development beyond changes between consecutive time points, we clustered the total set of 
10336 genes that changed significantly between any two time points into nine clusters using 
155
Gene regulation during PFC development 
5
k-means clustering (Multi-Experiment Viewer53). From these nine clusters several cluster 
pairs show mirrored patterns, namely clusters A and D, B and E, C and F, and G and H (Figure 
2). The mirrored patterns of gene expression suggest that these two gene groups are involved 
in complementary processes. For validation of the RNA-seq analysis, we performed RT-qPCR 
for one gene per cluster. The selected genes are linked to the GO-terms mentioned in Figure 
2. Our RT-qPCR validation showed that most of these genes have similar expression patterns 
to the RNA-seq data for all clusters (Supplementary Figure 2). In addition, we compared our 
gene expression data with human PFC expression data from Jaffe and colleagues65. Generally, 
we observed similar expression patterns for both human and rat genes in all gene clusters 
(see Supplementary Figure 3). To characterize the functions of the transcripts sharing 
common expression patterns during development, we performed a GO analysis using the NIH 
DAVID website on each cluster (Figure 2 and Online Supplementary Table 4). Consistent with 
the pair-wise comparisons, cell cycle genes are enriched in clusters D and E; both clusters 
show a continuous decrease in expression from the first postnatal week (PND8) until PND21, 
after which their levels either stabilize (cluster D) or continue to decline into adulthood 
(cluster E). These two clusters contain for example cyclins (e.g. Ccna2) and cyclin-dependent 
kinase enzymes (e.g. Cdk4 and Cdk6) which control the progression of cells through the cell 
cycle66,67. Additionally, RNA processing and, in particular, translational elongation genes 
are enriched in cluster D and H, both of which show a strong decrease in expression in the 
second postnatal week followed by either stable levels up to adulthood (cluster D) or a 
slow increase in expression after PND21 (cluster H). These terms, which are associated with 
protein production rate, are also enriched amongst genes that are down-regulated during 
the progression from infancy (PND21) to adolescence (PND35) in the consecutive time point 
comparisons (Figure 1). Furthermore, consistent with the pair-wise comparisons, GO terms 
related to inter-neuronal communication (ion transport, transmission of nerve impulse, 
cell-cell signaling and intracellular signaling cascade) are found in clusters A and G, which 
show increases in expression level during early development. Both clusters show a strong 
increase in expression in the second postnatal week, which is followed by either stable levels 
up to adulthood (cluster A) or a slow decline in expression after PND21 (cluster G). The two 
clusters contain, amongst others, neurotransmitter receptors, such as Grin2a and Gabrd, 
which are involved in the transmission of the neurotransmitters GABA and glutamate68-70. Cell 
adhesion genes were up-regulated from PND8 to PND14 and expression gradually decreased 
after that (cluster F). The decrease in expression is also shown in the consecutive time 
point comparison. This cluster contains, for example, cadherins, such as Cdh5 and Pcdh12, 
which play important roles in cell adhesion, forming adherens junctions between cells71. In 
contrast to the previous clusters that show enrichment of GO terms also enriched in the 
pair-wise comparisons, cluster B, which contains genes that increase gradually from the first 
postnatal week (PND8) until adulthood, is associated with genes involved in homeostasis 
(especially ion homeostasis) and protein phosphorylation. Finally, cluster I contained a 
relatively small set of genes with expression that oscillated in early postnatal development 
156
Chapter 5
but stabilized in adulthood, which were enriched for gliogenesis. This cluster contains for 
example Notch1, a receptor in the Notch signaling pathway, a pathway known to mediate 
prominent cellular events that result in gliogenesis72. We confirmed these DAVID GO analysis 
findings with the PANTHER GO analysis website, finding similar GO terms for each cluster 
(Online Supplementary Table 4). In summary, cluster analysis showed that expression of 
genes involved in protein phosphorylation, interneuronal communication and neuronal 
homeostasis is increasing during postnatal mPFC development, while expression of genes 
involved in cell proliferation is decreasing during neurodevelopment. Of interest, similar to 
the pair-wise comparison, the switch from neurodevelopmental processes to maintenance 
around PND21 was also observed in the cluster analysis. Clusters showing a decrease in 
expression after PND21 were related to transmission of nerve impulse (cluster G) and cell 
adhesion (cluster F), and clusters showing an increase in expression after PND21 were related 
to translational elongation (cluster H) and homeostasis (cluster B).
Next, we asked the question whether genes differentially regulated during mPFC 
postnatal development are relevant for neurodevelopmental and neuropsychiatric disorders. 
We found that indeed a number of the differentially regulated genes are known to have 
a function in (pre)frontal cortex development and are associated with disorders, such as 
intellectual disability, attention-deficit hyperactivity disorder, autism spectrum disorder and 
schizophrenia (See review by Schubert and colleagues10) (Table 1). The majority of these 
genes showed differential expression at the earliest time points (PND8-14 and PND14-21), 
which suggests that this early postnatal period is a more sensitive period for the onset of 
neurodevelopmental disorders compared to adolescence and adulthood. 
Furthermore, we examined the enrichment of genes identified by psychiatric GWAS 
studies in these clusters. Interestingly, we observed that genes with predominantly increasing 
expression levels during postnatal development (cluster A, B, C, F and G) are enriched for GWAS 
disease genes (adjusted p<0.05, Figure 2; Supplementary Figure 4 and Online Supplementary 
Table 5). These genes are associated with neurodevelopment-related processes (Clusters A, 
B, C, F & G), with different clusters being associated with different disorders (Supplementary 
Figure 4). Psychiatric GWAS genes are not enriched in gene clusters associated with the cell 
cycle or RNA processing (clusters D, E and H; Figure 2 and Supplementary Figure 4).    
Long intergenic non-coding RNAs
LincRNAs have been implicated in the regulation of genes in their genomic vicinity38 and they 
have been shown to be important in the dynamic nervous system. We therefore evaluated the 
expression patterns of annotated lincRNAs during mPFC development. Differential expression 
of lincRNAs across development was determined using the CuffDiff program51. We identified 
137 of the 2305 lincRNAs that showed differential expression (adjusted p<0.05) between any 
two time points across development (Online Supplementary Table 6). This proportion (6%) is 
lower than for the differentially expressed protein-coding genes (30%). This is likely, in part, 
due to the generally lower overall expression levels of lincRNAs (Figure 3A), which would
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Figure 2. K-means clustering analysis of differentially expressed genes. Differentially expressed genes were 
clustered in nine clusters. Graphs depict Z-score of the log-transformed FPKMs (fragments per kilobase per million 
mapped reads) per cluster against time (postnatal day, PND). Error bars indicate the standard deviation. The number 
of genes in the clusters is shown in the graphs. Top gene ontology (GO) terms are shown per cluster and p-values 
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make it more difficult to detect significant differences. As lincRNA expression has been found 
to be correlated to that of protein-coding genes in their genomic vicinity during mouse brain 
development133, we investigated the degree of expression correlation between lincRNAs and 
their nearest protein-coding genes during rat mPFC development. We found that, although 
the correlation is not clear for the full set of 2305 lincRNAs (Figure 3B), there is a clear positive 
correlation for the expression of the identified 137 differentially expressed lincRNAs and their 
neighboring protein-coding genes (Figure 3C). As lincRNAs are poorly annotated with respect 
to function, and given that they are frequently involved in the regulation of neighboring genes, 
we performed a GO analysis using the NIH DAVID website on the nearest protein-coding 
genes. Using the nearest protein-coding genes to all 2305 lincRNAs, GO analysis showed 
an enrichment of GO terms related to neuron differentiation/cell projection as well as 
positive regulation of gene expression (Table 2, Online Supplementary Table 6). Regulation 
of transcription and some terms related to development (e.g. positive regulation of cell 
differentiation and morphogenesis of a branching structure) were still present in the subset 
of 137 differentially expressed lincRNAs, although not significantly enriched (using Benjamini 
correction), probably due in part to the small number of genes (Online Supplementary Table 
6). Comparison of the 10336 differentially expressed coding genes with the 137 neighboring 
genes of the differentially expressed lincRNAs resulted in 71 coding gene-lincRNA pairs with 
both differentially expressed coding gene and differentially expressed lincRNA. Of these 71 
pairs, 32 pairs showed a strong correlation between coding genes and lincRNA expression 
(Pearson correlation (PCC) >0.75) (Online Supplementary Table 6). Strongly correlated 
differentially expressed coding gene-lincRNA pairs were present in almost all clusters, except 
cluster H. Among the 32 strongly correlated coding gene-lincRNA pairs, several coding genes 
are linked to neurodevelopment (e.g. Wnt5a134,135, Actr3b136 and Cbln1137) and to regulation 
of gene expression (e.g. Khdrbs2138, Abra139 and Fos140) (Figure 4). Most of the 32 strongly 
correlated lincRNA-neighboring gene pairs have an expression pattern that is linked to cluster 
A (n=10), B (n=8) and E (n=6), based on the coding genes (Online Supplementary Table 6). 
The enrichment of lincRNA-coding gene pairs in these clusters (which are also the largest 
coding gene clusters) suggests that, based on the cluster GO terms, most of these pairs are 
involved in neurodevelopment, homeostasis or cell cycle. Expression of lincRNA-coding gene 
pairs linked to neurodevelopment (cluster A) increases during the early postnatal period and 
becomes stable after PND21, while expression of lincRNA-neighboring gene pairs involved in 
homeostasis (cluster B) continues to increase after PND21. In addition, expression of lincRNA-
neighboring gene pairs involved in cell cycle processes (cluster E) decreases with time, 
suggesting reduced proliferation. These GO annotation patterns for the lincRNA-neighboring 
protein-coding genes suggest that around PND21 homeostatic processes start to exceed 
developmental processes. Given that lincRNAs are frequently involved in the regulation of 
neighboring genes, it is likely that the differentially expressed lincRNAs identified in this study 
are also important for this switch from development to maintenance.
To examine whether these rat lincRNAs are conserved in humans, we sought to 
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identify their corresponding human orthologs based on sequence similarity, but none of the 
2305 rat lincRNAs could be mapped to human lincRNAs. It is known that lincRNA sequences 
are poorly conserved across vertebrates, but that their genomic locations are more often 
retained141. We therefore compared the rat protein-coding genes neighboring these lincRNAs 
to their human orthologs to see if these also had neighboring lincRNAs. We found that 24.6% 
(375 out of 1527) of these human protein-coding orthologs did indeed have lincRNAs as 
their closest neighboring genes (Online Supplementary Table 6), indicating a higher level 
of conservation of lincRNA genomic location than sequence between the rat and human 
genomes.
 Taken together, a subset of lincRNAs show differential expression during mPFC 
development which correlate with the expression of neighboring neurodevelopmental 
protein-coding genes, suggesting that these lincRNAs are involved in the regulation of 
neurodevelopmental gene expression and thereby indirectly contribute to shaping the 
developing brain. 
Figure 3. Expression of lincRNA in the medial prefrontal cortex of the rat. (A) LincRNAs showed overall lower 
expression compared with coding genes on all five time points. Expression level is depicted as log10-transformed 
FPKM values (fragments per kilobase per million mapped reads) after adding a pseudocount of 0.01 to avoid infinite 
values. (B) Correlation between lincRNA expression and nearest coding gene expression using Pearson correlation 
for all 2305 expressed lincRNAs. (C) Correlation between lincRNA expression and nearest coding gene expression 
using Pearson correlation for the 137 differentially expressed lincRNAs. The 137 differentially expressed lincRNAs 
showed a clear positive correlation with the expression of their neighboring coding genes. PCC = Pearson Correlation 
Coefficient, DE = differentially expressed.
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Figure 4. Examples of coding gene-lincRNA pairs in the medial prefrontal cortex. Examples of coding gene-
lincRNA pair expression (FPKM) with Pearson correlation coefficient (PCC) >0.75. (A) Example cluster A; Fos and 
ENSRNOG00000057609 expression. (B) Example cluster B; Abra and ENSRNOG00000054328 expression. (C) Example 
cluster D; Khdrbs2 and ENSRNOG00000055308 expression. (D) Example cluster E; Cbln1 and ENSRNOG00000054562 
expression. (E) Example cluster F; Wnt5a and ENSRNOG00000058571 expression. (F) Example cluster G; Actr3b and 
ENSRNOG00000061925 expression. 
Table 2. Top 10 gene ontology terms for all lincRNAs expressed in the mPFC
GO term Count Benjamini Example genes
Neuron differentiation 81 7.71E-13 Cxcr4, Nrp1, Drd1a, Nrcam, Ntrk3 
Positive regulation of gene expression 83 2.21E-09 Fos, Abra, Shh, Runx2, Tcfap2b
Regulation of transcription from RNA polymerase II 
promoter 87 1.05E-08 Fos, Abra, Shh, Runx2, Tcfap2b
Positive regulation of transcription 80 1.21E-08 Fos, Abra, Shh, Runx2, Tcfap2b
Sensory organ development 49 1.71E-08 Ntrk2, Edn1, Nox3, Neurod1, Maf
Positive regulation of macromolecule metabolic 
process
106 4.30E-08 Fos, Abra, Dlx2, Egr2, Ntf3
Regulation of cell proliferation 91 5.45E-08 Htr2a, Igf1, Klf5, Sox2, Ptprm
Positive regulation of transcription from RNA 
polymerase II promoter
63 7.45E-08 Fos, Abra, Shh, Runx2, Tcfap2b
Positive regulation of macromolecule biosynthetic 
process
87 8.63E-08 Fos, Abra, Shh, Runx2, Tcfap2b
Positive regulation of transcription, DNA-dependent 70 1.11E-07 Fos, Abra, Shh, Runx2, Tcfap2b
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Alternative exon usage
Alternative exon usage is a process that occurs extensively in the nervous system142. We 
therefore surveyed alternative exon usage during rat mPFC development using the DEXSeq 
package59 of the R Bioconductor Statistical Software Suite60, which detects differentially 
expressed exons after correcting for differences in overall gene expression. At an adjusted 
p-value of p<0.05, we identified 1634 differentially expressed exons in 796 genes. Of these 
genes, 491 also showed differential gene expression across development. Functional analysis 
of the 796 genes using the DAVID website54 showed an enrichment of GO terms related to 
neuron differentiation/projection, neurotransmission and cytoskeleton organisation and 
the axon guidance pathway (Table 3 and Online Supplementary Table 7).
Of the genes with alternative exon usage, 166 showed differential expression 
of 5’ exons, and therefore differential promoter usage (Online Supplementary Table 7). A 
striking example is the protocadherin alpha gene cluster (Pcdha13), which is involved in the 
establishment of cell-cell connections and neuronal wiring in the brain143,144. This cluster has 
multiple alternative promoters that share the same 3’ exons, resulting in a set of transcript 
isoforms that differ only in their 5’ exons145. These alternative 5’ exons encode variants of 
the extracellular region of this neurodevelopmental transmembrane protein, while the 
common 3’ exons encode the common intracellular region143,146. For this gene cluster, the 
overall expression level decreases during mPFC development, but exons transcribed from 
the earlier promoters (exons E01, E02, E07), associated with longer genomic isoforms, are 
more strongly affected than those transcribed from the proximally located promoters (exons 
E11, E12, E13), leading to a quantitative shift in favor of the genomically shorter isoforms 
(Figure 5A). 585 of the 796 genes with alternative axon usage showed alternative splicing in 
internal exons (cassette exons or mutually exclusive exons). An interesting example of a gene 
with cassette exons is the neurotransmission-related gene synaptosomal-associated protein 
25 (Snap25). Two isoforms (isoforms A and B) exist, with nine amino acid residue differences 
between the two isoforms, including a re-localization of one of the four cysteine residues147. 
There is a switch from isoform A (incorporating exon E4) to isoform B (incorporating exon E5) 
during development (Figure 5B), which has also been shown in mice110. 252 genes harbored 
alternatively spliced 3’ exons. An example is Srgap2 (although the first 3’ exon does not reach 
the threshold of significance), which is involved in axon guidance. The shorter splice variants 
are more highly expressed in the later developmental stages (Supplementary Figure 5). It 
should be noted that the group of alternatively spliced internal exons might also contain 
genes with alternative promoter usage, since a promoter exon can also be an internal exon 
if it is an inner promoter; additionally, some of the alternative 3’ or 5’ exons might have 
ended up in the group of genes with internal exons if the first or last exon was not above the 
significance threshold.
Interestingly, the majority (1555 out of 1634, or 95%) of these alternatively spliced 
exons overlap with exon annotation in the human genome (Online Supplementary Table 7). 
Therefore, these exons could also be alternatively spliced in human PFC development. Indeed, 
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comparison with 24 genes reported by a previous study to be alternatively spliced during 
human PFC development48 shows a statistically significant overlap with our rat alternatively 
spliced genes, despite different experimental and analytical methodologies (9 out of 24 genes 
are present in our 796 alternatively spliced genes; p = 1.3 x 10-8, hypergeometric distribution 
test).
In summary, alternative exon usage occurs in neurodevelopmental genes during rat 
PFC development, suggesting that dynamic exon usage may be important for proper brain 
development. 
Table 3. Top 10 gene ontology terms alternative exon usage in the mPFC
GO category GO term Count Benjamini Example genes
Biological process Cell projection organization 42 3.27E-07 Snap25, Ctnna2, Robo2, Ncam2, Cdh23
Transmission of nerve impulse 37 3.64E-07 Snap25, Grik5, Grm5, Syn2, slc17a7
Neuron differentiation 47 7.12E-07 Snap25, Ctnna2, Robo2, Ncam2, Cdh23
Cellular component morphogenesis 42 7.55E-07 Snap25, Ctnna2, Robo2, Ncam2, Cdh23
Cell morphogenesis 38 3.29E-06 Snap25, Ctnna2, Robo2, Ncam2, Cdh23
Neuron development 38 4.75E-06 Snap25, Ctnna2, Robo2, Ncam2, Cdh23
Synaptic transmission 29 5.44E-06 Snap25, Grik5, Grm5, Syn2, slc17a7
Regulation of cytoskeleton organization 20 6.98E-06 Dst, Map4, Mapt, Rock2, Tpm1
Regulation of organelle organization 25 8.41E-06 Dst, Map4, Mapt, Rock2, Tpm1
Neuron projection development 31 3.73E-05 Snap25, Dcx, Robo2, Ncam2, Vcan
KEGG_PATHWAY Axon guidance 15 3.91E-02 Srgap2, Robo2, Rock2, Cxcl12, Pak1
Discussion
We provide a comprehensive resource of gene expression in the rat developing mPFC from 
infancy to adulthood, including differentially expressed protein-coding genes, lincRNAs 
and alternative exon usage in protein-coding genes. We show that most transcriptional 
changes occur in the first three postnatal weeks and the number of differentially regulated 
genes reduces toward adulthood. Besides providing a comprehensive resource, we 
describe expression patterns of different functional clusters of coding genes during mPFC 
development. We detected an expression pattern switch from genes involved in neuronal 
network establishment in infancy to those involved in neuronal homeostasis and maintenance 
in adulthood. This genetic switch is likely regulated by several parallel and/or complementary 
mechanisms including dynamic expression of protein-coding genes, lincRNAs and alternative 
exons. In addition, we show that several differentially regulated genes are known to be involved 
in neurodevelopmental and neuropsychiatric disorders and that specific clusters of genes 
are enriched for GWAS genes that are associated with developmental and neuropsychiatric 
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diseases, suggesting that the catalog of gene expression we generated in this study can also 
be used as a resource to study such disorders.
The gene expression patterns found in our rat mPFC developmental time course 
show substantial overlap with the gene expression patterns observed by Semeralul and 
colleagues41, who studied mouse PFC development at five time points (2, 3, 4, 5 and 10 
weeks old) using gene expression microarrays and found that the majority of expression 
changes occurred between postnatal weeks 2 and 4. This indicates that expression patterns 
of important pathways are highly conserved between rodents and therefore it is likely also 
conserved in different strains of rodents. Furthermore, in microarray studies of human39,148 
and non-human primates43, gene expression changes in PFC or neocortex are shown to be 
most obvious from birth through infancy, which is consistent with our RNA-seq time course 
data (Figure 1). In a human RNA-seq study of PFCs across six life stages65, gene expression 
generally showed similar patterns as in our rat study (Supplementary Figure 3), although the 
human expression data are noisier than the rat data (larger standard errors for the z-scores). 
The more homogeneous genetic background and more precisely synchronized ages of our 
rat mPFCs relative to the human post-mortem PFCs probably contributes to the difference in 
variability levels between our rat and the human RNA-seq data. Taken together, our rat mPFC 
RNA-seq analyses corroborate previous studies in different species of PFC gene expression 
during postnatal development, and highlight the conservation of gene expression dynamics 
during PFC postnatal development from rodents to humans.
Our GO analysis of the differentially expressed coding genes between successive 
time points and of the genes clustered in the k-means clustering showed several GO terms 
that match with neurodevelopmental processes taking place during PFC development, and 
with findings from other studies. The decrease in expression of genes involved in the cell 
cycle (PND8-14, PND14-21, cluster D and E), as also described in mice by Semeralul and 
colleagues41, is consistent with the decrease in production of new neurons and supportive 
cells as brain growth slows down and the brain matures. Mature neurons and supportive 
cells will enter a postmitotic state, which is in line with the decrease in expression of cell 
cycle control genes. Increased expression of genes involved in inter-neuronal communication 
(ion transport, transmission of nerve impulse, cell-cell signaling and intracellular signaling 
cascade, PND8-14, PND14-21, cluster A and G) coincides with the explosion of synapse 
formation during early brain development, known as exuberant synaptogenesis, which 
is important for the formation of brain networks11. Ion transport by ion channels plays an 
important role in intercellular communication. Ion transport is essential for the regulation 
of action potentials149. When an action potential arrives at the axon terminal, synaptic 
transmission occurs by the release of neurotransmitters, which bind to receptors on the 
postsynaptic neuron and activate downstream intracellular signaling cascades. Cell adhesion 
genes were up-regulated from PND8 to PND14 and expression gradually decreased after that 
(PND21-35, cluster F). The increase in expression may reflect synapse formation and ongoing 
migration of cells in early postnatal development that is guided by adhesion molecules150. 
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The decrease in expression of cell adhesion genes starting from PND14 was also found by 
Semeralul and colleagues41 in mouse PFC tissue and may reflect specification of neuronal 
networks by elimination of exuberant undesired connections, a process known as synaptic 
pruning. Synaptic pruning is a process that is strongest around adolescence in both rats and 
humans11,151. In rats it occurs around PND30 in the PFC11 and a recent paper demonstrated 
that effective axon pruning requires destabilization of cell adhesion152. However, there 
are also studies in primates showing that synaptic pruning might differ between layers153 
and studies reporting an earlier peak of synaptic density around birth and only a slight 
though significant decline in synapses by pruning till 20 years of age154. The up-regulation 
of myelination genes from PND14 to PND21 as rats approach adolescence may reflect the 
stabilization of synaptic networks after the early period of exuberant synaptogenesis and 
synaptic remodeling11,155. Genes involved in homeostasis (cluster B), a state mainly present 
in the developed adult brain, increased gradually from the first postnatal week (PND8) till 
adulthood. Furthermore, a strong shift from developmental processes (cell adhesion, 
neuron differentiation, cell migration) to maintenance (translational elongation, response 
to organic substance, glucose metabolism) is detected between PND21 to PND35. From 
PND35 to PND70 gene expression changes become less dynamic, as is reflected in the 
lowest number of differentially expressed genes, suggesting that developmental processes 
are mostly finished at this stage and maintenance and homeostasis become more important 
activities in the brain. Adolescence starts around PND35 and is characterized by shaping 
of cognitive and emotional functions by synaptic pruning11; however, we do not see many 
gene expression changes in the mPFC during this developmental stage. Possibly the gene 
expression changes that are needed for effective pruning, such as decreasing the expression 
of cell adhesion genes, take place before adolescence starts. In addition, pruning is highly 
dependent on environmental factors and more expression changes might occur if rats are 
exposed to a variety of environmental triggers instead of keeping the environment relatively 
stable. Finally, it is worth bearing in mind that while this study only focused on postnatal 
neurodevelopment, there is also a lot of neurodevelopment going on prenatally10.
The dynamic gene expression profile from infancy to adulthood implies that 
regulatory events of gene expression are important for the development of neuronal networks 
and that disturbance of these events (e.g. caused by environmental factors such as stress and 
drugs) might lead to abnormal functioning, often manifested in neurodevelopmental and 
neuropsychiatric disorders156,157. This is supported by the enrichment of genes associated with 
neuropsychiatric disorders amongst the genes that change in expression during postnatal rat 
mPFC development (Figure 2 and Supplementary Figure 4). In particular, genes that increase 
in expression during early life stages are associated with these disorders, while genes that 
decrease in expression do not show similar enrichments (Figure 2 and Supplementary Figure 
4). The former genes are generally associated with neurodevelopment-related processes 
while the latter are more associated with cell proliferation and housekeeping processes 
(Figure 2 and Supplementary Table 4).
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Besides protein-coding genes, we also investigated lincRNAs. LincRNAs are involved 
in regulating the expression of neighboring genes38, but so far they are poorly annotated 
(in rodents especially). There is one study describing eight lincRNAs that showed changes 
in expression during human cortex development; however, these lincRNAs had limited 
evolutionary conservation and were primate-specific158. Our rat mPFC-expressed lincRNAs 
similarly showed low sequence similarity with human genes, and none could be mapped to 
human lincRNAs based on sequence similarity. However, a quarter of the human orthologs 
of the rat protein-coding genes neighboring these lincRNAs were also located adjacent 
to lincRNAs, suggesting that these genes are also associated with lincRNA regulation in 
humans. lincRNAs can affect gene regulation in different ways and genomic location and 
RNA secondary structure are also often important for their function141. We found lincRNAs 
with neighboring genes involved in neurodevelopment showing a strong coexpression 
(Pearson Correlation Coefficient > 0.75), which suggests that these lincRNAs are involved 
in the regulation of expression of their neighboring gene and thereby also the regulation 
of neurodevelopmental processes. An example is lincRNA ENSRNOG00000058571 with its 
neighboring gene Wnt5a (Figure 4E). Both show a small increase in expression from PND8 to 
PND14 and a decline after PND14, which matches with the role of Wnt5a in the regulation 
of cell migration and adhesion through focal adhesion dynamics135. Another example is 
lincRNA ENSRNOG00000057609 with its neighboring gene Fos (Figure 4A), a transcription 
factor often used as a marker for neuronal activity. Fos knockout mice show impaired brain 
development159,160, suggesting that Fos has an as yet undefined role in neurodevelopment. 
Both, Fos and its neighboring lincRNA, show an increase in expression when new synapses 
are formed (PND8 till PND21) and subsequently a decrease in expression161. This is consistent 
with the switch from neurodevelopment to maintenance. Several studies have shown that 
lincRNAs can act as enhancer elements, promoting the transcription of their neighboring 
coding genes162-164. lincRNAs are also involved in epigenetic processes by recruiting and 
regulating chromatin-modifying complexes and in posttranscriptional regulation34,165. 
However, regulating the expression of the nearest protein-coding gene is only one of the 
functions of lincRNAs. There is also evidence that lincRNAs can work in trans rather than 
in cis, by regulating the expression of distant genes166. Using these different mechanisms, 
lincRNAs can affect a variety of processes in neurodevelopment. It will be of interest to 
functionally test the differentially regulated lincRNAs identified in this study and search for 
human counterparts. Besides lincRNAs, small non-coding RNAs, such as miRNAs, are also 
important in brain development167. However, we did not further investigate these small non-
coding RNAs as our RNA-seq protocol is not suited to their accurate quantification (due to size 
selection for 300 bp fragments).
Analysis of alternative exon usage resulted in 1634 differentially expressed exons 
in 796 genes. We found several genes involved in axon guidance, neuron differentiation/
projection, neurotransmission and cytoskeleton organisation, which are all processes that 
are highly important in early brain development. In human PFC development alternatively 
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spliced genes seem to play roles in neurotransmission and cytoskeleton organization as 
well48. As can be expected for protein-coding genes, there is good conservation between 
rat and human exons and almost all the rat alternatively spliced exons map to human exon 
annotation (Online Supplementary Table 7). In addition, a statistically significant 9 of the 
24 alternatively spliced genes that were validated in human PFCs48 are also present in our 
list of genes with alternative exon usage (p = 1.3 x 10-8, hypergeometric test). This suggests 
that there is similarity between human and rat alternative splicing during PFC development, 
although a thorough systematic analysis would be required to confirm this. While it is known 
that widespread splicing changes occur in brain development48, the functional implication 
of differential splicing is unknown for most of the variants. Some genes have been well 
studied, however, such as the protocadherin alpha gene cluster. This gene cluster is highly 
expressed during neurodevelopment (peak in first postnatal week), gradually concentrating 
in the synaptic region, with expression decreasing as the brain matures168,169. Chen and 
colleagues170 showed that the so-called C-type protocadherin isoforms (Pcdhac1 and Pcdhac2, 
incorporating exon 12 and 13, respectively), which have different properties compared with 
the A and B type isoforms, are primarily important for mediating neuronal survival, whereas 
the role of protocadherins in postnatal developmental processes like neuronal wiring, requires 
isoform diversity. This suggests that C-type isoforms are more important for maintenance 
later in life, while others are more involved in developmental processes, such as neuronal 
wiring, which correlates with our expression data. In our analysis, a higher expression of 
C-type isoforms is shown later in life (PND35 and PND70) compared with earlier time points, 
whereas some non-C-type isoforms were higher expressed at the earlier time points (PND8 
and PND14) (Figure 5A). Another interesting alternative splicing example is Snap25, encoding 
for synaptosomal-associated protein 25, which is a member of the SNARE complex involved 
in vesicular release of neurotransmitters. There is a switch from isoform A (incorporating 
exon E4) to isoform B (incorporating exon E5) during mPFC development (Figure 5B), as 
shown before in the brain110,171. A study using mice overexpressing isoform A showed that 
the isoform switch alters the facilitation of synaptic transmission. This study suggests that 
the assembly of different SNARE complexes affects membrane fusion properties and that the 
developmental switch between Snap25 isoforms alters the efficacy of synaptic transmission 
that may contribute to the solidification of developing neural circuitries172. The Srgap2 gene, 
involved in neuronal migration173, showed alternative 3’ exon usage. In humans, the SRGAP2 
gene has been duplicated three times in the human genome during evolution and one of 
the shorter variants dimerizes with the longer variant to inhibit its function174. It might be 
that the shorter splice variants in rats (although different from the human duplicates) have 
a similar function and therefore are expressed higher in later developmental stages during 
which neuronal migration and neuronal differentiation are less important (Supplementary 
Figure 5). However, for most genes, it is still unknown what the functions of the different 
variants are. Further research is needed to unravel the function of all the different transcript 
variants found during mPFC development in rats. 
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Changes in the expression of protein-coding genes, lincRNAs and changes in 
exon usage together facilitate neurodevelopment and the switch to maintenance. The 
overall expression of protein-coding genes can be affected by both lincRNA regulation 
and alternative exon usage. Abra, encoding for actin-binding Rho activating protein which 
acts as an activator of serum response factor-dependent transcription, is an example of a 
gene showing differential expression during development (Cluster B, Online Supplementary 
Table 4) that might be influenced by alternative exon usage and lincRNA regulation. Abra 
shows alternative exon usage (Online Supplementary Table 7) and is in the close proximity 
of a differentially expressed lincRNA showing a strong coexpression (Figure 4B). It will be of 
interest to investigate the function of this gene during postnatal brain development. 
Summarizing these results, we find a clear switch in gene expression patterns from 
regulation of network formation to maintenance around PND21. This switch is probably 
important for creating a mature PFC directed to the execution of cognitive and emotional 
tasks that is less susceptible to the environmental factors that shaped the PFC during 
development. The dynamic gene expression during PFC development shown in this study 
also emphasizes the developmental stage-specific nature of the expression of many PFC 
genes, highlighting the importance of taking developmental stage into consideration when 
studying specific genes involved in PFC development or related diseases.
 It should be noted that we used punched mPFC tissue (prelimbic and a little 
infralimbic) in our analysis, which is a mixture of different cell types. Nevertheless, we could 
detect gene expression in processes occurring in different cell types of the PFC. For example, 
from PND14 to 21 we observed an upregulation in expression of genes linked to myelination 
and genes involved in neurotransmission. Neurotransmission is a process occurring in 
neurons, while myelin is made by oligodendrocytes. Myelin forms a layer around the axons 
of neurons and increases the speed of neurotransmission. Our data suggest that from PND14 
to PND21 oligodendrocytes are relatively more important than at other time points where 
neuron-related processes are the major enriched GO-terms associated with differentially 
regulated genes. However, single cell RNA-sequencing175 or selecting a specific cell type using 
fluorescence-activated cell sorting might give more insight into PFC gene expression per cell 
type. Furthermore, a more comprehensive study involving different brain regions and other 
tissues would be required to determine whether the expression changes we found are PFC-
specific, cortex-specific or brain-specific. Another interesting direction for future research is 
the investigation of gene expression in layer-specific circuits during postnatal development 
for example in dorsolateral PFC layer three microcircuits, which are important for working 
memory and are linked to schizophrenia176. Furthermore, it would be interesting to investigate 
the link between gene expression changes and the development of PFC-dependent behavior, 
such as social behavior, emotion regulation, decision-making, and attention. The investigation 
of the functions of different splice variants of neurodevelopmental genes will also give 
valuable new insights into the role that alternative splicing plays in PFC development.
In conclusion, we provide a data resource of temporal gene expression in the 
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developing mPFC from infancy to adulthood. We showed that gene expression is dynamic 
during postnatal development and identified a clear genetic switch from neuronal network 
establishment in infancy to maintenance in adulthood. This genetic switch is likely controlled 
by complementary regulatory mechanisms of protein-coding gene expression, lincRNA 
expression and alternative exon usage. Together with other studies39-41,48,177, our study makes 
an important contribution to the effort of completing the ‘brain map’. Our multifaceted 
genome-wide gene expression dataset can be used to study the basic developmental 
processes of the mPFC and to understand the mechanisms of neurodevelopmental and 
neuropsychiatric disorders. 
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Supplementary material
Supplementary Figure 1: Punch location of samples used for RNA-seq. (A) Position of the 8 consecutive slices in 
the adult brain (coronal slices adapted from Paxinos & Watson). Circle shows punch area. (B) Slices of developmental 
periods including the punch area (coronal 200 micron brain sections from Khazipov and colleagues1). Dashed line 
corresponds to horizontal midline which was used for determination of punching location in PND8 and PND14 slices, 
since the brain regions were harder to distinguish due to lower myelin levels. Prl = prelimbic cortex, Il = infralimbic 
cortex, Cg1 = cingulate cortex, area 1, fmi = forceps minor of the corpus callosum. CPu = caudate putamen.
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Supplementary Figure 2: Comparison of RNA-
seq and RT-qPCR gene expression per cluster. 
Expression of RT-qPCR genes generally follows 
the same patterns as their corresponding 
RNA-seq clusters. Plots are shown for all 
clusters (A-I). Developmental time point is 
shown on the x-axis and z-score or 2^ΔCT is 
shown on the y-axis. Gene name or number 
of genes is shown above each graph. RT-qPCR 
gene expression is normalized by the average 
expression of two reference genes (Gabbr1, 
Kif5c). Error bars indicate the standard error 
of the mean.
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Supplementary Figure 3: Comparison of human 
and rat brain developmental gene expression 
per cluster. Expression patterns per cluster 
generally follow the same pattern in humans 
(data from Jaffe et al.2) and rats. Plots are shown 
for all clusters (A-I). Developmental time point is 
shown on the x-axis and z-score is shown on the 
y-axis. Error bars indicate the standard error of 
the mean.
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Supplementary Figure 4: Enrichment of neuropsychiatric disorder GWAS genes per cluster. Heatmap shows 
the -log10 transformation of the multiple testing-corrected p-value (q-value) for the enrichment of GWAS genes 
from each disorder (y-axis) in each cluster (x-axis). The hypergeometric distribution test was used to calculate the 
significance of the enrichment and multiple testing correction was done using the False Discovery Rate algorithm. 
The -log10 transformation facilitates visualization as it converts the exponential scale q-values to a linear scale (for 
instance q=10-1 and q=10-3 would correspond to 1 and 3 respectively after -log10 transformation).
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Supplementary Figure 5: Alternative splicing of 3’ exons in the medial prefrontal cortex of the rat. 
Graph shows expression per exon, corrected for overall expression level between time points. Colors 
represent the different time points during development in postnatal days (PND). Vertical purple dashed 
lines depict differentially expressed exons during development, caused by alternative exon usage. The 
upper x-axis depicts exon numbers. The y-axis shows normalized counts per exon after correcting for 
total transcript expression differences between the time points. The different isoforms are shown 
under the graph. The first one (gene model) represents the summary of all isoforms and the different 
isoforms are shown below. Differentially expressed exons are shown in purple. The lower x-axis (under 
the isoforms) shows the genomic location of the isoform. + or - behind the gene name represents the 
strand on which the gene is located. The Srgap2 gene is an example showing alternatively spliced 
3’exons (although first exon does not reach the threshold of significance). Exon E3 and E4 (genomically 
shorter splice variants) show higher expression in the later developmental stages compared to the early 
postnatal period. 
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Supplementary Table 1. Primers used for quantitative RT-PCR
Gene symbol Ensembl number Forward primer Reverse primer
Kcnh5 ENSRNOG00000009542 CACATACCAGGAGCACAAGG CAATGCCTTTGAAAATGTGG
Apoe ENSRNOG00000018454 GTTCCTCCAGCTCCTTTTTG CTGACCAGGTCCAGGAAGAG
Ptk2 ENSRNOG00000007916 GGCTGGTCATGACATACTGC TGAGACCATTCCCATCCTTC
Rbm3 ENSRNOG00000005387 GACCAGGGATATGGAAGTGG CCTGAGTAGCGGTCATAGCC
Fem1b ENSRNOG00000007077 CAGTGGCACCATCAATGAC CTCCACACCCCTCATCATC
Robo2 ENSRNOG00000029598 CGACATCAGTGATTTGCTCAG GCAGGGGTTGGAGTAAAAAG
Slc6a1 ENSRNOG00000006527 AACACCACCAACATGACCAG GGCTTGTCTAGCCCATCTG
Cpsf6 ENSRNOG00000005927 TCCCAAAGAATGAACTGCTTC TTGGTGATGATGTGGGTAAAG
Sox10 ENSRNOG00000011305 TCTTTGGGGTGGTTGGAG GCTGCTATCCAGGCTCACTAC
Gabbr1 ENSRNOG00000000774 TTTTCAGCCGCTTGGTTAG ACATCACCACGGAGATTGTC
Kif5c ENSRNOG00000004680 AAATTCAAAGGCGAGGAGAC GCACAGGCATTGTAGACCTG
Supplementary Table 3. Number of differentially expressed genes
  PND8 PND14 PND21 PND35 PND70
PND8 up -
 down  -     
PND14 up 2638 -
 down 2447  -    
PND21 up 3671 1677 -
 down 3597 1564  -   
PND35 up 4038 2486 725 -
 down 3889 2384 823  -  
PND70 up 4160 2809 1185 389 -
 down 4018 2711 1277 380  -
All other supplementary tables are available online 
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Abstract
Reduced expression of the serotonin transporter (5-hydroxytryptamine transporter, 5-HTT) in 
early-life has been associated with a delay in postnatal brain development and endophenotypes 
of a variety of neuropsychiatric and neurodevelopmental disorders in adolescence and 
adulthood. How a reduction in functional 5-HTT can disrupt neurodevelopment is still largely 
unknown. Here we studied genome-wide gene expression using transcriptome analysis 
(RNA-sequening, RNA-seq) and global levels of DNA (hydroxy)methylation (5(h)mC) using 
high-performance liquid chromatography-tandem mass spectrometry in 5-HTT wild-type (5-
HTT+/+) and 5-HTT homozygous knockout (5-HTT-/-) rats across life (postnatal day (PND) 8, 
14, 21, 35 and 70) in the medial prefrontal cortex (mPFC); a brain region with an extensive 
serotonergic innervation involved in several neuropsychiatric endophenotyes. We observed 
most gene expression changes in the mPFC during early postnatal life (PND8) and found at 
this time point an enrichment of genes linked to neuronal and developmental processes like 
neurotransmission, neuropeptide signaling and cell migration. Genome-wide 5(h)mC analysis 
showed a global increase in 5hmC in the mPFC during development in both genotypes and 
a significant increase in global 5hmC in 5-HTT-/- compared to 5-HTT+/+ rats at PND35. The 
differences in the regulation of gene expression in 5-HTT-/- versus 5-HTT+/+ rats during early 
postnatal life can dysregulate neurodevelopmental processes resulting in aberrant brain 
wiring and functioning. This might influence neurodevelopmental behavior and can result in 
lifelong consequences for executive functioning.
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Introduction
Serotonin (5-hydroxytryptamine; 5-HT) is an important neurotransmitter in the central nervous 
system, where it has various functions including the regulation of mood1, appetite2, sleep3,4 and 
learning and memory5,6. 5-HT is produced by serotonergic neurons in the raphe nuclei, which 
send their axons to regions throughout the brain. The serotonin transporter (5-HTT, encoded 
by SLC6A4) facilitates the reuptake of extracellular 5-HT in the presynaptic serotonergic 
neuron and thereby regulates extracellular 5-HT levels available for the activation of 5-HT 
receptors on the postsynaptic neuron. Besides its role as a neurotransmitter, 5-HT also acts 
as an important factor during neurodevelopment. 5-HT can promote neurodevelopmental 
processes, such as migration, neuronal outgrowth, and synaptogenesis7-11. In addition, 
while in the adult brain 5-HTT is only expressed in raphe neurons, 5-HTT expression is more 
widespread at early developmental stages. At mid-gestation (embryonic day 10.5 in mice12) 
expression of 5-HTT begins in the 5-HT neurons of the raphe nuclei, and subsequently 5-HTT 
expression emerges in the non-serotonergic neurons of the sensory system and corticolimbic 
pathway13,14. During the second postnatal week the 5-HTT expression in non-serotonergic 
neurons ends rapidly14. The functional implication of the transient 5-HTT expression is not 
completely clear. It has been proposed that it may serve to obtain the appropriate 5-HT levels 
important for developmental processes.
 A common variation in the promoter region of SLC6A4, encoding 5-HTT, is the 
serotonin transporter promoter-linked polymorphic region (5-HTTLPR), which is associated 
with a variety of neuropsychiatric disorders. The short allelic variant (S-allele) of this variation 
is associated with reduced 5-HTT protein availability and function15 compared with the 
long (L) form. S-allele carriers have an increased risk for developing depression16, anxiety17, 
substance abuse18 and neurodegenerative disorders19. Because of the more widespread 
expression of 5-HTT in early-life and the developmental role of 5-HT, dysregulation of 5-HT in 
early-life might account for (additional) developmental problems. Indeed, the 5-HTTLPR has 
been shown to affect establishment of neuronal connectivity between brain regions, amongst 
others, the mPFC and the amygdala20,21, possibly caused by disturbed 5-HT-dependent 
neurodevelopmental processes such as neurite outgrowth8,11,22,23. 
In order to study the effects of reduced 5-HTT expression in more detail, 5-HTT 
knockout (5-HTT-/-) rats and mice have been developed24,25. These knockout rodents show a 
rather mild phenotype, i.e. they reach normal age (Homberg, unpublished findings), show 
normal coat conditions26 and phenotype differences are not often readily apparent at first 
glance. However, 5-HTT-/- rodents show increased extracellular 5-HT levels24, increased 5-HT 
innervation of the mPFC8 and phenotype differences become apparent in several behavior 
tasks. These rodents display increased anxiety27,28, depression-like behavior28,29 and compulsive 
cocaine self-administration behavior at adulthood18. In addition, 5-HTT-/- rats show a delay 
in development compared to 5-HTT+/+ rats, with the strongest effects observed in reflex 
development and motor-related behavior30. Furthermore, 5-HTT-/- mice show abnormally 
distributed interneurons10 and altered neocortical cell density and layer thickness8,31, caused 
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by disrupted  migration of neurons during development10. The altered brain cytoarchitecture 
as a consequence of neurodevelopmental 5-HT dysregulation might be an important cause of 
the increased psychostimulant intake, anxiety and depression-like behavior observed in adult 
5-HTT-/- rodents. In conclusion, human and rodent data show that a reduction in functional 
5-HTT during development has (negative) consequences for early-life development and can 
enhance the risk of developing anxiety, depression and drug addiction in adulthood. 
The prefrontal cortex (PFC), a brain region involved in the execution of cognitive 
and emotional functions32-36, has an extensive serotonergic innervation37,38 and has been 
implicated in neuropsychiatric disorders like anxiety, depression and drug addiction39-41. The 
PFC is one of the latest maturing brain regions, showing substantial changes during postnatal 
development42,43. From around birth till the second postnatal week 5-HTT is transiently 
expressed in non-serotonergic neurons in the PFC14. After the second postnatal week 5-HTT is 
only expressed in the serotonergic neurons from the raphe nucleus. That is, Slc6a4 (encoding 
5-HTT) transcription and translation takes place in raphe serotonergic cell bodies and 5-HTT 
protein is only present at the axon terminals which protrude to, amongst others, the PFC. In 
5-HTT-/- rats 5-HTT protein is absent in the PFC (as well as all other non-raphe regions in the 
brain)24 resulting in increased 5-HT innervation8. In explant cultures from developing 5-HTT-
/- rat brains (embryonic day 16.5), 5-HT projections from the median raphe became strongly 
attracted by the medial PFC (mPFC) instead of being repelled by the mPFC, suggesting that 
5-HT levels can influence connectivity in the mPFC8. In addition, the number of a class of 
callosal projection neurons was decreased in the developing 5-HTT-/- mPFC compared to 
5-HTT+/+ mPFC8. Furthermore, mPFC-regulated behavior, e.g. fear extinction44 and cognitive 
flexibility45,46, is disturbed in 5-HTT-/- rats. In humans, the 5-HTTLPR polymorphic region is 
associated with abnormalities in the mPFC. Children and adolescents carrying a homozygous 
S-allele (S/S) showed weaker connectivity in the superior mPFC compared to L-allele carriers20. 
The 5-HTTLPR is also associated with differences in mPFC-related behavior, like sustained 
attention47, cognitive flexibility48 and decision making49, which might be a consequence of 
disturbed mPFC connectivity. However, to what extent dysregulation of the serotonergic 
system affects brain development in general and mPFC development in particular and 
whether disturbances during development predispose to the anxiety and depression-like 
behavior at adulthood is still unclear. 
Neurodevelopment is a highly complex and strictly regulated process which is 
dependent on the precisely timed and coordinated expression of thousands of genes. 
Each specific neurodevelopmental process requires a different set of genes to be, spatially-
defined, expressed at a specific time frame during development. There are several studies 
that investigated the influence of dysregulated 5-HT signaling on gene expression and they 
show altered expression of genes linked to the inflammatory system, the hypothamalus-
pituitary-adrenal axis, neurotrophic factors, myelination and neurotransmitter systems50-52. 
However, most of these studies focussed on the effect in adulthood and studies on gene 
expression during neurodevelopment are limited. While several studies reported behavioral 
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and structural consequences of 5-HTT down-regulation during development, the molecular 
underpinnings contributing to these developmental changes are poorly understood. Studying 
genome-wide gene expression during development might reveal important new insights and 
might potentially lead to new targets for treatment of 5-HT-related disorders.
Gene expression can be regulated by epigenetic mechanisms, such as DNA (de)
methylation, which is linked to gene regulation and developmental processes53-57. DNA 
methylation of cytosines at CpG sequences is catalyzed by a family of DNA methyltransferases 
(DNMTs), which show a spatiotemporal distribution during neurodevelopment. 
5-hydroxymethylcytosine (5hmC), created by oxidation of 5-methylcytosine (5mC) by TET 
proteins, is thought to be an intermediate step in the active demethylation process58. However, 
more recent studies have indicated that 5hmC does not only serve as a DNA demethylation 
intermediate but also functions as a stable epigenetic mark59,60. Dysregulation of DNA 
methylation is seen in 5-HT-related neurodevelopmental and neuropsychiatric disorders, like 
autism spectrum disorder56,61, schizophrenia62, bipolar disorder63, anxiety64 and depression65. 
Whether the DNA methylation changes are a cause or consequence of these diseases and 
whether 5-HT dyregulation is involved in the methylation changes is unknown. Genome-
wide gene expression and DNA (hydroxy)methylation changes during neurodevelopment 
as a consequence of reduced functional 5-HTT is a totally unexplored topic and might give 
important new insights.
To unravel the molecular mechanisms contributing to the structural and behavioral 
changes in the mPFC related to inherited 5-HTT deficiency, we studied genome-wide gene 
expression using transcriptome analysis (RNA-sequencing, RNA-seq) in the mPFC of 5-HTT+/+ 
and 5-HTT-/- rats sacrificed at postnatal day (PND) 8, 14, 21, 35 and 70. We performed pair-
wise comparisons and observed most differentially expressed genes during early postnatal 
life (PND8), with an enrichment for genes involved in neurotransmission and cell migration. 
Furthermore, several genes involved in myelination showed differential expression at 
multiple ages across development. In addition, we measured genome-wide DNA (hydroxy)
methylation in mPFC tissue from 5-HTT+/+ and 5-HTT-/- rats sacrificed at PND8, 14, 21, 35 and 
70. We observed a significant increase in 5hmC levels in the 5-HTT-/- rats compared to the 
5-HTT+/+ rats at PND35. This, however, is not reflected in a higher number of differentially 
regulated genes between the two genotypes at this time point.
Materials and methods
Animals
5-HTT-/- rats (Slc6a41Hubr) were generated by ENU-induced mutagenesis66. Rats were housed 
in individually ventilated cages (40 x 35 x 23 cm, Greenline, Tecniplast, West Chester, USA) in 
temperature-controlled rooms (21 °C ± 1 °C) under standard 12-h light/dark cycle (lights on 
at 7:00 A.M.) with food (Sniff, long cut pellet, Bio Services, Uden, The Netherlands) and water 
available ad libitum. Pups were weaned at PND22. Rats were sacrificed by decapitation at five 
different time points; PND8, PND14, PND21, PND35 and PND70. For group 1, ten wild-type 
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(5-HTT+/+) and ten 5-HTT-/- rats were sacrificed from three different nests per genotype per 
time point and were used for genome-wide expression analysis and Quantitative Reverse 
Transcription PCR (RT-qPCR) experiments. Half of the rats (n=5 rats/genotype/time point) 
were used for RNA-seq and RT-qPCR and the other half (n=5 rats/genotype/time point) only 
for RT-qPCR validation. For group 2 five rats were sacrificed per genotype per time point and 
used for genome-wide DNA (hydroxy)methylation analysis. Group 3 was used for validation 
of the results from group 2 and consisted of ten 5-HTT-/- and ten 5-HTT+/+ rats sacrificed at 
PND35. All experiments were carried out according to the guidelines for the Care and Use of 
Mammals in Neuroscience and Behavioral Research (National Research Council 2003), the 
principles of laboratory animal care, as well as the Dutch law concerning animal welfare.
RNA extraction and double-stranded cDNA synthesis
Five samples per genotype per time point were used for RNA extraction. mPFC tissue was 
dissected from seven (PND8 and 14) or eight (PND21, 35 and 70) consecutive slices of 200 
µm using a 2 mm punch needle and included the prelimbic and infralimbic cortex. For more 
details about the punching see Kroeze and colleagues67. Total RNA was isolated with QIAzol 
(RNeasy lipid tissue kit; QIAGEN, Venlo, The Netherlands) according to the manufacturer’s 
recommendations. From each sample 2.5 µg RNA was used for rRNA depletion using the Ribo-
Zero rRNA Removal Kit (Human/Mouse/Rat, Epicentre, Madison, Wisconsin, USA) according 
to the manufacturer’s recommendations. RNA fragmentation reactions were performed 
using fragmentation buffer (5x; 200 mM Tris-Acetate, 500 mM potassium-Acetate, 150 
mM magnesium-Acetate, pH 8.2) in a final concentration of 1x per reaction. Fragmentation 
reactions were incubated at 95°C for 4 min on a thermal cycler and placed on ice for 10 min. 
Fragmented rRNA-depleted RNA was purified using ethanol precipitation. First and second 
strand synthesis was performed as described by Kouwenhoven and colleagues68. 
Sequencing
DNA samples were prepared for sequencing by end repair of 5 ng total DNA as measured 
by Qubit dsDNA HS (Invitrogen). NEXTflex adaptors (Bioo Scientific, Austin, Texas, USA) were 
ligated to the DNA fragments, followed by post-ligation clean-up using Agencourt AMPure XP 
beads (Beckman Coulter, Woerden, The Netherlands), library amplification by PCR (10 cycles) 
and size selection (∼300 bp) using Agencourt AMPure XP beads (Beckman Coulter). Quality 
control of DNA libraries prepared for sequencing was performed by qPCR and by running 
the products on a Bioanalyzer (Bio-Rad, Veenendaal, The Netherlands). Cluster generation 
and sequencing (50 bp, single end reads) were performed with the Illumina HiSeq 2000 
sequencer according to standard Illumina protocols. Samples were sequenced to a depth of 
approximately 29 million reads per sample. 
RNA-seq data processing 
Reads were aligned to the rn4 rat genome assembly using the gsnap program69, version 
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2012-07-20. Transcript quantification analysis was done with Cufflinks70 using the rat Ensembl 
transcriptome (version 69). Cufflinks quantifies gene expression as FPKM (fragments per 
kilobase per million mapped reads), which corrects for different transcript lengths and sample 
sequencing depths. Short genes (5201 genes shorter than 200 base pairs, including small 
nuclear RNAs, small nucleolar RNAs, microRNAs and miscellaneous RNAs) were removed. 
This is because FPKMs of short genes tend to be more affected by background noise, since the 
correction for gene length gives more weight to the reads on short genes, thereby possibly 
increasing the FPKM to biologically irrelevant levels. To check for possible mistakes and errors 
during the sequencing of the RNA, the reads were assessed for the quality of calling the 
nucleotides in the reads quantified by Phred scores and the enrichment of not-called bases 
at specific locations in the reads71. The FPKMs calculated by Cufflinks were used to perform 
a principal component analysis (PCA) to look at variance between the samples72. PCA was 
performed on log10 transformed FPKM values. 
Differential expression analysis, clustering and gene function
Differential expression analysis was performed using the CuffDiff program73 version 2.2.1, 
using the Ensembl database74 version 69 rat transcriptome annotation. The expression values 
from Cufflinks were further normalized by CuffDiff across the samples in the experiment by 
scaling them according to the geometric mean of the samples. Based on these expression 
data, CuffDiff calculates differentially expressed genes (p<0.01, FPKM>1, fold change>1.2) 
between the 5-HTT-/- and 5-HTT+/+ rats for all five time points, taking replicates per genotype 
into account. The differentially expressed genes were clustered based on the standardized 
log10 transformed FPKMs (Z-scores) with hierarchical clustering using Multiexperiment 
Viewer75. The Pearson correlation coefficient was used as a measurement of distance in 
the hierarchical clustering. Gene ontology (GO) analysis was performed using the DAVID 
website76. DAVID calculates modified Fisher Exact p-values, EASE Scores, for each gene 
category77. Ingenuity Pathway Analysis software package (Ingenuity systems, www.ingenuity.
com) was used for pathway analysis and analysis of Top Diseases and Bio Functions. Ingenuity 
calculates p-values for the enrichment of each gene category using the right-tailed Fisher 
exact test, taking into consideration both the total number of molecules from the analyzed 
data set and the total number of molecules linked to the same gene category according 
to the Ingenuity Knowledge Base. We generated a molecular network by integrating the 
results of the bioinformatics analyses from PND8 with systematic literature searches. For 
all genes linked to one of the five most significantly enriched GO-terms and genes linked 
to one of the five most significantly enriched Ingenuity pathways (except Hepatic Fibrosis 
/ Hepatic Stellate Cell Activation), we looked at the available information in the NCBI Gene 
database and subsequently we searched PubMed using the search terms ‘prefrontal cortex’, 
‘neurodevelopment’, ‘signal transduction’, ‘serotonin’, ‘gutamate’, in combination with the 
name of each candidate gene or their protein name. Guided by the literature we found, 
we also searched PubMed for functional interactions between the candidate genes/encoded 
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proteins.
Quantitative Reverse Transcription PCR (RT-qPCR) 
RNA-seq validation was performed by RT-qPCR analysis of ten selected genes. Primers 
were designed using Primer3 online software (http://frodo.wi.mit.edu). See Supplementary 
Table 1 for primer sequences. Complementary DNA (cDNA) was synthesized using 500 ng 
of total RNA in a reverse transcription reaction using iScript cDNA Synthesis Kit according 
to manufacturer’s protocol (Bio-Rad, Veenendaal, The Netherlands). qPCR reactions were 
performed in a 7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA, USA) 
using the SYBR Green fluorescence quantification system (GoTaq® qPCR Master Mix, Promega 
Benelux BV, Leiden, The Netherlands). Thermal cycling was initiated with incubation at 95°C 
for 10 min followed by 40 cycles of 95°C for 30 sec and 60°C for 1 min. To normalize the 
cDNA content of the samples, we used the comparative threshold cycle (CT) method78, which 
consists of the normalization of the number of target gene copies versus an endogenous 
reference gene Gabbr1 (stable gene in the RNA-seq dataset throughout all ages based on the 
Coefficient of Variation (CV = stddev/mean). 
Genome wide DNA (hydroxy)methylation
DNA of mPFC tissue was isolated using the ReliaPrep gDNA Tissue miniprep system (Promega, 
Leiden, The Netherlands) according to the manufacturer’s recommendations. 200 ng of 
DNA was degraded into individual nucleosides using DNA degradase plus (Zymo Research, 
Irvine, CA). 5mC and 5hmC levels were measured as described by Kroeze et al58. In short, 
the individual nucleosides (dG, mdC and hmdC) were measured using a high-performance 
liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) system (Waters, Milford, 
MA, USA). Calibration standards containing internal standard solutions were measured to 
obtain area-based linear regression curves for quantification. The 5mC and 5hmC levels 
were calculated as a concentration percentage ratio of % 5-methyl-2′-deoxycytidine/2′-
deoxyguanosine (%mdC/dG) and % 5-hydroxymethyl-2′-deoxycytidine/2′-deoxyguanosine 
(%hmdC/dG), respectively. 
Statistical analysis 
Statistical analysis of RT-qPCR and 5(h)mC data was carried out using the IBM Corporation 
Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM Corp, Armonk, NY, USA). 
Data were analyzed using independent samples t tests (corrected p-value was used when 
equal variance was not assumed). Outliers (data points further than 3 interquartile ranges 
from the nearer edge of the box plot) were excluded from the analysis. Independent samples 
t tests were performed two-sided and the level of statistical significance was set at p<0.05. 
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Results
Validation of the knockout model and general differences between PFC samples
RNA-seq was performed and the reads were aligned to the rn4 rat genome assembly. To 
validate our knockout model, reads spanning the third exon of the Slc6a4 gene, corresponding 
to chromosome 10 position 67152790 to 67153009 from the Brown Norway rat genome 
(rn4 assembly79), were extracted and examined for the described mutation by calling 
differences between the extracted reads and the reference genome80. In the 5-HTT-/- rats 
this third exon should contain a C to A transversion at nucleotide 3924 (c.3924C>A, based 
on ENSRNOG0000003476), resulting in a premature stop codon (p.C1308X)24. All 5-HTT+/+ 
and 5-HTT-/- replicates were pooled because the coverage of the 5-HTT gene by individual 
samples was too low. The third exon was more extensively covered in the 5-HTT+/+ samples 
(23 reads) compared to the 5-HTT-/- samples (9 reads). Indeed, the 5-HTT-/- rat differed from 
the 5-HTT+/+ rat and the reference at nucleotide position 3924, matching the described 
mutation by Homberg and colleagues24. It should be noted that this variant was based on 
only a single read that covers this genomic region (Figure 1A). In addition, the 5-HTT+/+ and 
5-HTT-/- sequences both differed from the reference at nucleotide position 3891, indicating 
a single nucleotide polymorphism (rs8154473, encoding for the same amino acid) between 
the reference (Brown Norway rat) and our Wistar rats (Figure 1A, deviations highlighted in 
orange). 
Differential expression analysis with CuffDiff70 was performed to obtain the normalized 
gene expression values (FPKM values). A PCA was performed on log10 transformed FPKM 
values to examine variations between the samples. Principal component 1 (PC1) (19.2%) 
seems to separate samples according to age, with the PND8 samples on the left side and the 
PND70 samples on the right side (Figure 1B). PC2 (6.7%) separated 4 samples from the rest. 
Because these 4 samples were from different time points and from both 5-HTT+/+ and 5-HTT-
/- rats these might be potential outliers and therefore we decided to exclude them for further 
analyses. Samples of 5-HTT+/+ and 5-HTT-/- rats are not separated in this analysis, indicating 
small gene expression differences in mPFCs between 5-HTT+/+ and 5-HTT-/- rats.
Differential expression analysis and clustering
For each time point differentially expressed genes (p<0.01, FPKM>1, fold change>1.2) 
between 5-HTT-/- and 5-HTT+/+ rats were determined using five samples per genotype. The 
highest number of differentially expressed genes between 5-HTT-/- and 5-HTT+/+ rats was 
found at PND8 (615 genes). The other time points showed lower numbers of differentially 
expressed genes, namely 135 genes for PND14, 126 genes for PND21, 97 genes for PND35 and 
115 genes for PND70 (Figure 2A, Online Supplementary Table 2). The Slc6a4 gene (encoding 
for 5-HTT) showed differential expression only at PND8 (Figure 2B). 5-HTT is hardly expressed 
at the other time points. As a consequence no significant differences were observed at these 
time points. Of the differentially expressed genes, 123 genes were differentially expressed 
at more than one time point. None of these genes showed differential expression at all five
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Figure 1. Comparison of 5-HTT+/+ and 5-HTT-/- samples to the reference genome and principal component 
analysis. A: Comparison of reads from 5-HTT+/+ and 5-HTT-/- samples to the reference Slc6a4 gene. The number 
of reads that span a position in the third exon of the Slc6a4 gene is depicted on the y-axis in the graph. The x-axis 
depicts the nucleotide position based on the ensembl gene ENSRNOG0000003476. 5-HTT+/+ is indicated by the red 
line and 5-HTT-/- is indicated by the pink line. Sequences deviating from ENSRNOG0000003476 (based on the Brown 
Norway rat, rn4 assembly79) are shown under the graph. The highlighted nucleotides correspond to the locations in 
the graph. B: Principle component analysis (PCA). PCA was performed on log10 transformed Fragments Per Kilobase 
per Million mapped reads (FPKM) values (a pseudocount of 0.01 was added to avoid infinite values) and small genes 
were excluded. The axes are labelled by the principal component they represent and the percentage of explained 
variance by the principal component. Circles represent 5-HTT-/- samples and triangles represent 5-HTT+/+ samples. 
Red represents PND8, orange represents PND14, yellow represents PND21, green represents PND35 and blue 
represents PND70. Explanation sample numbers: WT (wild-type) = 5-HTT+/+, KO (knockout) = 5-HTT-/-. Genotype is 
followed by postnatal day, litter number and number of the rat in the litter.
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time points (Supplementary Online Table 2). Manual checking for genes with overlapping 
function revealed four genes involved in myelination (Cldn11, Plp1, Mag, Mbp81), which is 
a process that has been associated with 5-HT signaling before51,82,83. All four genes showed 
differential expression (p<0.01) between 5-HTT-/- and 5-HTT+/+ rats at more than one time 
point and all showed a similar expression pattern (Figure 2C-F). Although the difference in 
expression of these genes between 5-HTT-/- and 5-HTT+/+ rats did not reach significance at 
every specific time point, in general we observed a lower expression of myelin-related genes 
in 5-HTT-/- rats compared to the 5-HTT+/+ rats at PND8, 21 and 70 and a higher expression in 
5-HTT-/- compared to 5-HTT+/+ rats at PND14 (Figure 2C-F).
The differentially expressed genes (all time points combined) were clustered with 
hierarchical clustering based on Z-scores (Figure 3). The 5-HTT+/+ and 5-HTT-/- cluster together 
per age, indicating that in the group of differentially expressed genes between the 5-HTT+/+ 
and 5-HTT-/- mPFC samples, the differences in time were larger than the differences between 
genotypes. In addition, gene expression patterns seem to differ most between early (PND8 
and 14) and later ages (PND21, 35 and 70). These results are consistent with the data from 
the PCA (Figure 1).
In conclusion, most differences in gene expression in the mPFC were observed at the 
earliest time point measured in this study, PND8. These expression differences might affect 
developmental processes which can result in lifelong consequences for brain functioning.???? ????? ????? ????? ????????????????????????????????????????????? ???? ????? ????? ????? ????????? ????????????????????????????????????????? ???? ????? ????? ????? ???????????????? ????????????????? ? ? ????????????????????????????? ????? ????? ????? ?????????????????? ????????????????? ???????????????????????? ???? ????? ????? ????? ??????????????? ??????????????????????????????????????? ???? ????? ????? ????? ?????????????????? ????????????????? ??????????????????????? ? ?? ? ?
Figure 2. Differential expression analysis in prefrontal cortex RNA of 5-HTT-/- and 5-HTT+/+ rats. (A) The number 
of differentially expressed genes per time point. (B-F) Graphs of expression patterns of the serotonin transporter 
gene (Slc6a4) and four myelin-related genes. Fragments Per Kilobase per Million mapped reads (FPKM) at five 
developmental time points in 5-HTT-/- and 5-HTT+/+ medial prefrontal cortex are shown. (B) Slc6a4, (C) Cldn11, (D) 
Plp1, (E) Mag, (F) Mbp. *p<0.01 based on RNA-seq statistical analysis.
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Gene ontology and pathway analysis 
To functionally categorize the differentially expressed genes, GO analysis was performed. 
The most significantly enriched GO-terms for the different time points were transmission 
of nerve impulse (PND8), gas transport (PND14), response to organic substance (PND21), 
translational elongation (PND35) and response to nicotine (PND70). See Table 1 for the top 
five GO-terms per time point. For a complete list of GO terms, see Online Supplementary 
Table 2. In addition, we used Ingenuity which is a tool that models, analyzes, and understands 
complex biological systems by linking incoming data with known information regarding 
molecular interactions, cellular phenotypes, and disease processes. Ingenuity core analysis 
was used to look for significantly enriched pathways. The most significantly enriched 
pathways for the different time points were G protein coupled receptor signaling (PND8), 
neuroprotective role of THOP1 in alzheimer’s disease (PND14), chondroitin sulfate 
degradation (Metazoa) (PND21), EIF2 signaling (PND35) and growth hormone signaling 
(PND70) (Table 2). Since at PND14, 21, 35 and 70 a relative low number of differentially 
expressed genes (n<135) were found, the pathway analysis showed higher p-values and was 
therefore less reliable for these time points compared to PND8. 
 As we observed most expression changes between 5-HTT-/- and 5-HTT+/+ rats 
at PND8 and GO and pathway analysis showed most reliable results in subsequent 
analysis, we focused on gene expression data of PND8. For PND8, three of the top five 
most significantly enriched GO-terms using DAVID were involved in neurotransmission 
(transmission of nerve impulse, synaptic transmission and cell-cell signaling), with 
24 genes that were linked to all three GO-terms (Supplementary Table 3). In addition, 
neuropeptide signaling pathway is in the top five GO-terms, which contains peptides 
involved in a variety of neurodevelopmental processes like cell adhesion (e.g. Gpr56) and 
cell migration/axon guidance (e.g. Sstr2). Furthermore, cell migration, a process important 
in brain development, is in the top five GO-terms and includes several factors and receptors 
involved in cell migration and axon guidance (e.g. Ntn1, Nrp2, Dcc, Sema3c). Three of the 
top five Ingenuity pathways for PND8 were involved in signal transduction; that is G protein 
coupled receptor signaling, cAMP-mediated signaling and Gi signaling. The G protein 
coupled receptor signaling pathway included several serotonergic receptors (Htr4, Htr7, 
Htr2a and Htr2c) and also showed substantial overlap with the cAMP-mediated signaling 
pathway (15 genes) and the Gi signaling pathway (9 genes) (Supplementary Table 4). 
Based on the results of DAVID (genes linked to neurotransmission), Ingenuity (genes 
linked to signal transduction) and systematic literature search we built a potential network 
involving 5-HT and glutamate signaling in the mPFC (Figure 4). Among the receptors showing 
differential expression at PND8 is the 5-HT receptor gene Htr2a, which upon activation can 
stimulate glutamate release84. Several genes encoding for glutamatergic receptors (Grm2, 
Grm4, Gria4, Grin2a) were also differentially expressed in the mPFC. In addition, certain 
genes involved in synthesis (Ddc), vesicular transport (Slc17a785, Sv2b86, Dynll187, Syn288) and 
release (Vamp289, Cplx390) of neurotransmitters and genes involved in downstream signal 
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transduction pathways (Rgs491, Gng392, Prkcb93) were downregulated in the 5-HTT-/- mPFC, 
suggesting an overall decrease in neurotransmission. Glutamic acid decarboxylases, encoded 
by Gad1 and Gad294, catalyzing the synthesis of gamma-aminobutyric acid (GABA) from 
glutamate, were upregulated in the 5-HTT-/- mPFC. 
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Figure 3. Hierarchical clustering of the differentially expressed genes between 5-HTT-/- and 5-HTT+/+ mPFC 
samples. The genes are log10 transformed (a pseudocount of 0.01 was added to avoid infinite values), standardized 
per gene (Z-scores) and clustered with the Pearson correlation factor as a measure of distance. Red indicates above 
average expression and blue indicates below average expression.  
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Table 1. Significantly enriched GO-terms (biological process) affected by 5-HTT-/- in the 
medial prefrontal cortex
 GO-term Nr of genes Example genes p-value
PND8 Transmission of nerve impulse 29   Slc6a4, Svb2, Vamp2, Grm2 3.63E-08
Neuropeptide signaling pathway 14   Cartpt, Nmur2, Sstr2, Pdyn 1.77E-07
Synaptic transmission 24   Slc6a4, Svb2, Vamp2, Grm2 2.13E-07
Cell-cell signaling 30   Slc6a4, Svb2, Vamp2, Grm2 2.70E-07
 Cell migration 26   Gja1, Smo, Vamp2, Met 3.21E-07
PND14 Gas transport 5    Hba-a2, Hbb, Aqp1, Loc689064 6.16E-06
Oxygen transport 4    Hba-a2, Hbb, Loc360504, Loc689064 6.80E-05
Regulation of acute inflammatory 
response
4 
   
Npy5r, Anxa1, Cd46, Cr1l 1.26E-03
Cell adhesion 11    Cntnap5b, Mag, Cldn11, Ctgf 1.34E-03
 Biological adhesion 11   Cntnap5b, Mag, Cldn11, Ctgf 1.34E-03
PND21 Response to organic substance 18   P2rx4, Gng7, Igf2, Fos 3.37E-05
Chemical homeostasis 13   Cartpt, Vgf, Egr2, Cldn11 3.96E-05
Regulation of action potential in 
neuron
6 
   
Cldn11 Mbp, Pllp, Mal 5.38E-05
Response to extracellular stimulus 10   Cartpt, Igf2, Fos, A2m 8.92E-05
 Homeostatic process 15   Cartpt, Vgf, Egr2, Cldn11 9.20E-05
PND35 Translational elongation 5    Rpl10, Rpl19, Rps16, Rps7 1.03E-03
Regulation of blood pressure 4    Cyp11b1, Ptgs2, Calca, Ephx2 1.36E-02
Translation 7    Rpl27a, rpl10, Rpl19, Rps16 1.50E-02
Response to glucocorticoid stimulus 4    Fos, Ptgs2, Dusp1, Plat 2.06E-02
 Response to corticosteroid stimulus 4    Fos, Ptgs2, Dusp1, Plat 2.38E-02
PND70 Response to nicotine 3    Igf2, Htr2c, Chrna5 1.01E-02
Fatty acid metabolic process 5    Crem, Acsm3, Plp1, Decr1 1.93E-02
Cell adhesion 7    Pcdhga1, Hapln4, Nlgn2, Cldn11 4.01E-02
Biological adhesion 7 Pcdhga1, Hapln4, Nlgn2, Cldn11 4.01E-02
Behavioral response to nicotine 2 Htr2c, Chrna5 4.29E-02
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RNA-seq validation by RT-qPCR 
To validate the RNA-seq experiment at PND8, we selected five up- and five down-regulated 
genes for RT-qPCR validation in the RNA-seq samples (five per genotype) and in five independent 
samples per genotype. Using the RNA-seq samples, four out of the five genes downregulated 
in 5-HTT-/- rats by RNA-seq were significantly downregulated when assessed by RT-qPCR as 
well (Slc6a4 (t
(1,4.39)
=5.20;p<0.05); Car4 (t
(1,4.07)
=3.90;p<0.05); Calb2 (t
(1,7)
=3.93;p<0.05); Kcnh5 
(t
(1,7)
=3.17;p<0.05)) and Htr2a showed a trend (t
(1,7)
=2.18;p<0.1). Four out of the five genes 
upregulated in the 5-HTT-/- rats by RNA-seq were significantly upregulated when validated 
by RT-qPCR (Htr2c (t
(1,7)
=2.60;p<0.05); Bcl11b (t
(1,3.29)
=3.21;p<0.05); Kctd8 (t
(1,5)
=3.80;p<0.05); 
Dcc (t
(1,7)
=2.83;p<0.05)) and Scn5a showed a trend (t
(1,3.07)
=3.02; p<0.1) in the right direction 
(Figure 5A). We repeated the RT-qPCR in independent samples. Slc6a4 (t
(1,7)
=5.37; p<0.05), 
Car4 (t
(1,3.22)
=5.95;p<0.05) and Htr2a (t
(1,7)
=2.62;p<0.05) were all significantly downregulated 
in the 5-HTT-/- rats. Bcl11b (t
(1,7)
=5.51;p<0.05) was significantly upregulated and Dcc showed a 
trend for upregulation in the 5-HTT-/- rats (t
(1,7)
=2.04;p<0.1). The other genes do not reach the 
threshold of significance, but all genes showed a change in the same direction as observed in 
the RNA-seq experiment (Figure 5B). 
Genome-wide DNA (hydroxy)methylation
5mC and 5hmC levels were measured in mPFC DNA of five samples per genotype for each 
time point. No significant differences were found in 5mC levels between 5-HTT-/- and 5-HTT+/+ 
rats (Figure 6A). For the 5hmC levels we found a significant increase in 5-HTT-/- compared to 
5-HTT+/+ rats at PND35 (t
(1,8)
=6.29;p<0.05) (Figure 6B). In addition, 5hmC levels increased during 
development from 0.38% 5hmC/G at PND8 to 0.71% 5hmC/G at PND70 in both genotypes. 
Validation of the increase in 5hmC levels at PND35 was performed in an independent group 
of biological replicates (group 3). In this group, 5hmC levels in mPFC tissue were again 
increased in the 5-HTT-/- rats compared to the 5-HTT+/+ rats (t
(1,18)
=2.28;p<0.05) (Figure 6B). No 
significant expression changes were observed in genes involved in DNA (hydroxy)methylation 
(Tet and Dnmt genes) at PND35, nor at the other time points (Supplementary Figure 1).
Discussion
In this study, we demonstrate that a lack of functional 5-HTT affects postnatal gene expression 
in the mPFC particularly during the first postnatal week (PND8, earliest time point measured), 
with 615 differentially expressed genes between 5-HTT-/- and 5-HTT+/+ rats for PND8 and less 
than 140 differentially expressed genes for the other time points (PND14, 21, 35 and 70). GO 
analysis showed that genes differentially expressed in the mPFC of HTT-/- rats at PND8 are 
mainly involved in neurotransmission and neurodevelopmental processes, while GO-terms 
enriched at other time points are less specific for neuronal-related processes. Furthermore, 
several genes involved in myelination show a decrease in expression in the 5-HTT-/- compared 
to the 5-HTT+/+ mPFC at multiple ages across development. 
Expression of Slc6a4 (encoding for 5-HTT itself) is in general low in the mPFC
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because the cell soma (where most of the RNA translation takes place113) of the serotonergic 
neurons is located in the raphe nuclei, while the axons (containing 5-HTT protein) reach the 
mPFC. We do see higher levels of Slc6a4 mRNA at early postnatal time points (PND8 and 
PND14), which can be explained by the fact that at early postnatal stages 5-HTT is not only 
expressed by serotonergic neurons from the raphe nuclei, but also by other types of neurons
, 
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Figure 5. Medial prefrontal cortex RNA expression levels in 5-HTT-/- and 5-HTT+/+ rats by RT-qPCR. Validation of 
RNA-seq results by quantitative RT-PCR (RT-qPCR) analysis in RNA-seq samples (A) and in independent biological 
replicates (B). RT-qPCR analysis was performed on medial prefrontal cortex RNA of 5-HTT-/- and 5-HTT+/+ rats sacrificed 
at PND8. Based on RNA-seq data, five genes upregulated (left side in figure) and five genes downregulated (right 
side in figure) in 5-HTT-/- samples compared to 5-HTT+/+ samples were selected for validation. Data are normalized for 
Gabbr1 RNA levels and are presented as mean + S.E.M. of relative gene expression (% of 5-HTT+/+ group). *p<0.05 
#p<0.1. ???? ????? ????? ????? ??????????? ???????????????????????? ???? ????? ????? ????? ????????????????? ???????????????????????????????????????????? ??????????? ? ??????????
Figure 6. 5(h)mC measurements in medial prefrontal cortex DNA of 5-HTT-/- and 5-HTT+/+ rats. (A) 5mC levels in 
5-HTT-/- and 5-HTT+/+ rats measured at five time points (n=5/genotype/time point). 5mC levels were calculated as a 
concentration percentage ratio of % 5-methyl-2’-deoxycytidine/2’-deoxyguanosine (%mdC/dG). (B) 5hmC levels in 
5-HTT-/- and 5-HTT+/+ rats measured at five time points (n=5/genotype/time point). 5hmC levels were calculated as 
a concentration percentage ratio of % 5-hydroxymethyl-2’-deoxycytidine/2’-deoxyguanosine (%hmdC/dG). 5hmC 
levels at PND35 were validated using an independent group of rats, depicted as 5-HTT-/- extra and 5-HTT+/+ extra 
(n=10/genotype). *p<0.05.
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in, amongst others, the mPFC (as mentioned in the introduction)14. We see a decrease in 
expression of the mutated Slc6a4 gene in the 5-HTT-/- mPFC at PND8, most likely because the 
RNA containing the point mutation is degraded by nonsense mediated decay114.
PCA and cluster analysis demonstrated that 5-HTT+/+ and 5-HTT-/- samples cluster 
together per age, showing that the differences between the developmental time points 
were larger than the differences between genotypes. The stronger difference between time 
points is not surprising given the tremendous changes in the brain that occur from the early 
postnatal period up to adulthood compared to the relatively mild phenotype observed in the 
5-HTT-/- rats. We also observed a clear gene expression separation between early (PND8, 14 
and 21) and late (PND35 and 70) ages in the PCA, possibly indicating a genetic switch from 
PFC development at early postnatal life to maintenance of neural networks in adulthood. 
This shift from development to maintenance between PND21 and 35 was shown in our wild-
type PFC samples67 and coincides with the sharp increase of synapse formation during early 
brain development, which stabilizes around adolescence32,115. However, per time point we do 
see differences in gene expression between 5-HTT+/+ and 5-HTT-/- mPFC samples. There are 
123 genes showing differential expression at more than one time point, amongst others the 
myelin-related genes Cldn11, Plp1, Mbp and Mag. Overall we see a decrease in expression 
of myelin genes in 5-HTT-/- compared to 5-HTT+/+ rats, potentially resulting in decreased or 
abberant myelin sheats, which fits with our previous work showing that a lack of functional 
5-HTT (blocking 5-HTT by selective serotonin reuptake inhibitors) early in life results in down-
regulation of genes linked to myelin51 as well as with work of others showing a disturbed 
myelin sheath formation after blocking 5-HTT perinatally82. Why we observe an opposite 
effect at PND14 is unclear. In both 5-HTT-/- and 5-HTT+/+ rats the highest expression of myelin-
related genes was observed around PND21. It has been documented that myelin formation in 
the brain starts around PND10 in the rat and that the maximum rate of myelin accumulation 
occurs around PND20. Myelin accumulation does continue into adulthood, albeit at a 
decreasing rate116,117. This matches with the peak of mRNA expression we see around PND20. 
Most differences in mPFC gene expression between 5-HTT-/- and 5-HTT+/+ rats were 
found at PND8. At PND8 we found mainly GO-terms and pathways involved in cell migration, 
neurotransmission and signal transduction (See Table 1 and 2). Cell migration, a process 
important for proper formation of cell layers and cell connections in the brain, is in line 
with literature showing that 5-HT is involved in migration of neurons and connectivity in the 
brain9,10,118. In addition, studies have shown that cell migration and connectivity are disturbed 
in 5-HTT-/- mice and S-allele carriers, respectively10,20. Furthermore, cell migration is affected in 
5-HT-related neuropsychiatric disorders as autism spectrum disorder and bipolar disorder119. 
In the neurotransmission-related GO-terms and signal transduction pathways enriched at 
PND8, several genes involved in synthesis and transmission of glutamate were found. The 
differentially expressed 5-HT2A receptor is a serotonergic receptor present on glutamatergic 
pyramidal cells in deep cortical layers (V and VI) in the PFC, which, upon activation, can trigger 
glutamate release from the pyramidal cells (Figure 4)84. In addition, studies have shown that 
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5-HTT (encoded by Slc6a4) and the vesicular monoamine transporter (encoded by Slc18a2), 
which are both differential expressed at PND8, are transiently expressed on glutamatergic 
pyramidal neurons in early postnatal development, suggesting that 5-HT can be taken up by 
glutamatergic neurons and can be released upon activation111,112. Extracellular glutamate can 
activate glutamate receptors on layer V pyramidal cells84. The down-regulation of several genes 
involved in vesicular transport of neurotransmitters and in downstream signaling pathways in 
the 5-HTT-/- rats suggests a reduction in synaptic transmission in these rats. During postnatal 
development NMDA receptors (encoded by, amongst others, Grin2a) and AMPA receptors 
(encoded by, amongst others Gria4) are involved in neurite outgrowth and the formation, 
stabilization, maturation and elimination of synapses120-125. Although the involvement 
of mGlu receptors (encoded by amongst others, Grm2 and Grm4) in such processes is 
largely unknown, it has been recently suggested that they may also participate in synapse-
stabilizing responses126. This suggests that altered expression of these glutamate receptors 
in the early postnatal PFC, as shown in our RNA-seq experiment, result in dysregulation of 
neurite outgrowth and synaptogenesis. Whether this dysregulation at PND8 can also result in 
neuropsychiatric disorders later in life is not clear. However, it has been shown that alterations 
in the serotonergic 5-HT2A and glutamatergic receptors are associated with neuropsychiatric 
disorders. Interactions between Htr2a polymorphisms and Slc6a4 polymorphisms or SSRI 
treatment (blocking Slc6a4) were shown to predict treatment response in anxiety and 
depression127-131. Furthermore, studies showed that 5-HT2A receptor signaling is reduced in 
adult 5-HTT-/- mice which show depression-like behavior95,96. Altered Grin2a expression is 
linked to depression-like behavior in rats132. In addition, the mGlu2 receptor, encoded by 
Grm2, has been shown to be altered in both animal models of depression and in postmortem 
brain tissue of subjects with major depressive disorder133,134. Recent studies have shown that 
5-HT2A and mGlu2 receptors can form a functional receptor heterocomplex, which is shown 
to be dysregulated in the frontal cortex of schizophrenic patients93,97,104,135. 
Another Ingenuity pathway showing a strong enrichment at PND8 is hepatic 
fibrosis / hepatic stellate cell activation, which contains, amongst others, several collagen 
genes. Upon activation hepatic stellate cells secrete collagens resulting in liver fibrosis136. 
There is indeed evidence that 5-HT plays a role in hepatic stellate cell function137. Others 
also showed that serotonin can enhance collagen production138, suggesting that collagens 
might be a downstream target of the serotonin pathway. In the brain collagen genes play a 
role in e.g. axonal growth and guidance and formation of the neuromuscular junction during 
neurodevelopment139. To our knowledge we are the first to describe a link between 5-HT and 
collagens in the brain. 
The differences found in gene expression between 5-HTT-/- and 5-HTT+/+ rats might 
influence (neuro)development and behavior. We previously demonstrated that the 5-HTT-/- rats 
show a delay in development30. One of the main differences we observed was reduced motor 
coordination and muscle strength in the 5-HTT-/- rats in infancy. The underlying mechanism 
causing this aberrant development is still unknown, but it might be caused by disturbed gene 
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expression. In our Ingenuity Top Diseases and Bio Functions list from PND8 (Supplementary 
Table 5) we see the highest enrichment for genes linked to neurological diseases and also 
a high enrichment for skeletal and muscular disorders. Within the neurological diseases 
category we see only motor and muscle related diseases in the top three of the list, namely 
seizure disorder, movement disorders and dyskinesia (Supplementary Table 6). This suggests 
that several differentially expressed genes at PND8 might be associated with the defects in 
muscle and motor function we found in young 5-HTT-/- rats. From the genes we used for 
qPCR validation, Htr2a, Htr2c, Scn5a, Bcl11b, Dcc, Car4 and Slc6a4 are linked to the Ingenuity 
term movement disorders140-146. Studies have shown that regulation of expression of the 
serotonergic 5-HT2A receptor gene (Htr2a) can influence motor control
147,148. Htr2a promoter 
methylation, associated with reduced expression, is linked to a reduced quality of movement 
in infants147. In addition, polymorphisms in the Htr2a gene are linked to movement related 
diseases like tardive dyskinesia143 and Parkinson’s disease149. We have to keep in mind that 
we focused on expression changes in the mPFC, which is not a main motor control region35. 
Nonetheless, gene expression changes observed in the mPFC do not have to be PFC-specific. 
More functional research (e.g. in muscles or the motor cortex) is needed to elucidate the link 
between the expression of these genes and the behavioral differences found in 5-HTT-/- rats. 
We have to keep in mind that 5-HTT expression starts prenatally. Therefore, the 
expression differences found in the 5-HTT-/- rats postnatally can be a secondary effect of 
the changes occurring prenatally. Gene expression at postnatal stage can be different in the 
5-HTT-/- rats compared to the 5-HTT+/+ rats due to a different cell composition of the punch 
area caused by prenatal effects on developmental processes, e.g. cell migration. In addition, 
the expression differences in the 5-HTT-/- rats at postnatal time points can be a compensatory 
mechanism for the expression changes occurring prenatally. Genome-wide gene expression 
data from prenatal stages would give valuable new insights. 
We did not find any differences in global 5mC in the mPFC, but we found an increase 
in 5hmC in the mPFC across development. This is consistent with previous findings showing 
that 5hmC is highly abundant in the brain150 and levels increase during pre- and postnatal 
neurodevelopment55,151. DNA methylation plays an important role in neurogenesis, neuronal 
maturation and plasticity53,54 and is linked to 5-HT-related diseases such as depression and 
anxiety64,152. So far, only one study showed that 5-HT can influence DNA methylation; 5-HT 
induces methylation of a conserved CpG island in the promoter region of the CREB2 gene, 
serving synaptic plasticity153. We observed a significant increase in global 5hmC in 5-HTT-
/- compared to 5-HTT+/+ rats at PND35. However, the difference in 5hmC between 5-HTT-/- 
and 5-HTT+/+ rats at PND35 does not coincide with differences in gene expression; we did 
not observe a sudden increase in the number of differentially expressed genes between the 
5-HTT-/- and 5-HTT+/+ rats at PND35. Also no differences in Tet1, Tet2 and Tet3 expression 
were observed (Supplementary Figure 1). Further research is needed to unravel the exact 
consequences of increased 5hmC during adolescence. In addition, it should be noted that we 
measured 5(h)mC at a global level, which means that methylation changes on specific genes 
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can still be present despite the lack of an overall effect. 
In conclusion, we provide a comprehensive overview of differentially expressed 
genes in the mPFC of 5-HTT-/- rats compared to 5-HTT+/+ rats across postnatal development. 
This dataset can be used to study potential new targets for treatment of 5-HT-related 
disorders. We showed that reduced functional 5-HTT expression affects gene expression in 
the mPFC mainly during early postnatal life (PND8). These changes in gene expression can 
affect neurodevelopmental processes resulting in aberrant brain wiring which can influence 
behavior during infancy, but also can result in lifelong consequences on brain functioning 
potentially leading to neuropsychiatric disorders in adulthood. While mainly adult rats were 
used to unravel the mechanisms behind 5-HT-related neuropsychiatric disorders, we propose 
that studying early-life stages might give more insight in the developmental dysregulation 
that might predispose to 5-HT-related neuropsychiatric disorders in adulthood.
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Supplementary information
Supplementary Table 1. Primers used for quantitative RT-PCR
Gene symbol Ensembl number Forward primer Reverse primer
Htr2c ENSRNOG00000030877 ACGCACGTGGTGTTATTCAC ATGAAGATTGCCATCGTTTG
Slc32a1 ENSRNOG00000015393 CACGACAAACCCAAGATCAC GAGGATGGCGTAGGGTAGAC
Kctd8 ENSRNOG00000026472 GACGACAAGATCTGGAGCAG GCAGGAAGTCCCACTCTCAC
Scn5a ENSRNOG00000015049 TTCTGGATGATGTCGGAGAG TGCGCCACTATTACTTCACC
Dcc ENSRNOG00000033099 GTCTGGGAGAGGAACCTCAG CAGACACCATAAACCGGATG
Slc6a4 ENSRNOG00000003476 CTGTGGGTGTTTCAGGAGTG GCTACTGCATAGGGATGTCG
Car4 ENSRNOG00000002916 TCGTTGGCTATGACCAAAAG CAGGTGTAACTGTATGGCCTTG
Calb2 ENSRNOG00000016977 GCCATCTCAATTTTCCCATC AAGGCCAGGAAAGGTTCTG
Kcnh5 ENSRNOG00000009542 CACATACCAGGAGCACAAGG CAATGCCTTTGAAAATGTGG
Htr2a ENSRNOG00000010063 GTTTCCTTGTCATGCCTGTG TGATGGATGCCGTAGAAAAG
Gabbr1 ENSRNOG00000000774 TTTTCAGCCGCTTGGTTAG ACATCACCACGGAGATTGTC
Supplementary Table 2 will be available online after publishing
Supplementary Table 3. Differentially expressed genes (PND8) linked to three GO-terms: 
Transmission of nerve impulse, cell - cell signaling and synaptic transmission
Gene Log2 Ratio Fold change p-value FPKM
Cartpt 0.90 1.86 5.00E-05 42.233
Cplx3 -0.73 0.60 1.00E-04 2.515
Slc6a4 -1.88 0.27 5.00E-05 1.479
Sv2b -0.31 0.81 9.00E-04 117.867
Pnoc 0.76 1.69 8.00E-04 5.065
Vamp2 -0.27 0.83 4.65E-03 80.164
Sptbn2 -0.26 0.83 5.35E-03 195.726
Shc3 -0.42 0.75 1.00E-04 38.991
Grm2 -0.75 0.59 5.00E-05 2.862
Syn2 -0.32 0.80 1.15E-03 47.932
P2rx2 -0.48 0.72 8.80E-03 4.430
Pdyn 0.63 1.54 5.00E-05 6.293
Thbs2 0.91 1.88 5.00E-05 1.781
Hap1 0.42 1.34 5.00E-05 66.095
Gria4 0.28 1.21 4.80E-03 55.424
Gad2 1.14 2.20 5.00E-05 53.588
Dynll1 -0.28 0.82 3.20E-03 337.976
Grin2a -0.34 0.79 3.10E-03 10.231
Gad1 0.70 1.63 5.00E-05 61.382
Gabrg1 0.27 1.21 9.60E-03 45.799
Slc17a7 -0.38 0.77 2.00E-04 165.800
Chrm1 -0.56 0.68 5.00E-05 17.832
Slc22a3 -0.76 0.59 5.00E-05 8.515
Slc5a7 0.45 1.36 1.15E-03 4.518
214
Chapter 6
Supplementary Table 4. Differentially expressed genes (PND8) linked to the G protein 
coupled receptor signaling pathway in Ingenuity
Gene Log2 Ratio Fold change p-value FPKM Ingeniuty pathway
Atf4 -0.31 0.80 9.50E-04 187.949 GPCR, cAMP
Chrm1 -0.56 0.68 5.00E-05 17.832 GPCR, cAMP
Dusp4 0.53 1.44 4.00E-04 13.146 GPCR, cAMP
Grm2 -0.75 0.59 5.00E-05 2.862 GPCR, cAMP, GI
Grm4 0.60 1.51 3.70E-03 3.098 GPCR, cAMP, GI
Hrh3 -0.47 0.72 4.30E-03 4.836 GPCR, cAMP, GI
Htr4 0.78 1.71 1.25E-03 3.186 GPCR, cAMP, SERT
Htr7 0.69 1.61 5.00E-05 5.535 GPCR, cAMP, SERT
Htr1f 1.03 2.04 4.00E-03 1.374 GPCR, cAMP, GI
Mc4r 0.97 1.96 6.50E-04 2.759 GPCR, cAMP
Npr3 -0.30 0.81 9.25E-03 25.496 GPCR, cAMP, GI
Npy1r -0.38 0.77 8.00E-04 18.629 GPCR, cAMP, GI
Oprk1 1.00 1.99 5.00E-05 2.150 GPCR, cAMP, GI
Pde8b 0.56 1.48 4.50E-04 5.496 GPCR, cAMP
Rgs4 -0.52 0.70 5.00E-05 146.125 GPCR, cAMP, GI
Htr2a -0.38 0.77 1.10E-03 11.042 GPCR, SERT
Htr2c 1.47 2.76 5.00E-05 19.846 GPCR, SERT
Sos2 -0.40 0.76 1.00E-04 16.180 GPCR, GI
Adra1d -0.70 0.62 5.00E-05 2.751 GPCR
Prkcb -0.28 0.82 1.80E-03 186.166 GPCR
Abbreviations: GPCR = G protein coupled receptor signaling, cAMP = cAMP mediated signaling and SERT = serotonin 
mediated signaling
Supplementary Table 5. Top Disease and Bio Functions affected by 5-HTT-/- in the medial 
prefrontal cortex
 Pathway Top p-value Genes 
PND8 Neurological Disease  8.13E-14 142 
Psychological Disorders 2.03E-12 103 
Hereditary Disorder 2.37E-12 71 
Skeletal and Muscular Disorders 2.37E-12 106 
 Cancer 1.83E-11 409 
Supplementary Table 6. Top Neurological Diseases affected by 5-HTT-/- in the medial 
prefrontal cortex
 Pathway p-value Genes (nr and examples)
PND8 Seizure disorder 8.13E-14 46 (e.g. Kcnh3, Kcnj9, Galr1, Gng3, Pnoc) 
Movement Disorders 1.55E-13 69 (e.g. Htr2a, Htr2c, Bcl11b, Dcc, Scn5a)
Dyskinesia 1.34E-12 44 (e.g. Hpca, S100a10, Grin2a, Sst, Tnnt1)
Seizures 1.38E-12 40 (e.g. Kcnh3, Kcnj9, Galr1, Gng3, Pnoc)
 Disorder of basal ganglia 2.03E-12 50 (e.g. Syn2a, Penk, Gpr88, Ptpn3, Hpca)
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Supplementary Figure 1. Expression of genes involved in DNA methylation. A-C: Expression of DNA 
methyltransferases (Dnmt) across mPFC development. Dnmt2 gene is not annotated in the used reference genome 
(rn4). D-F: Expression of Ten-eleven translocation (Tet) methylcytosine dioxygenases across mPFC development. 
Y-axis shows expression values in fragments per kilobase per million mapped reads (FPKM). Data are presented as 
mean ± S.E.M. of FPKM. 
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Thesis objective
Affective disorders are among the leading causes of burden worldwide. Aberrant serotonin 
(5-HT) signaling is involved in several affective disorders and drugs used for the treatment of 
affective disorders are often targeting the 5-HT system. It is known that 5-HT is involved in 
pathophysiology of affective disorders, but it is still unclear how (changes in) 5-HT signaling 
can affect behavior. Better understanding of the pathways affected by 5-HT will provide new 
insights in affective disorders, the working mechanism of drugs targeting 5-HT and might lead 
to potential new therapeutic targets. The aims of my thesis were to unravel the molecular 
processes occurring across postnatal medial prefrontal cortex (mPFC) development and 
to unravel the behavioral and molecular consequences of aberrant 5-HT signaling across 
development in the absence of adverse environmental conditions.
In chapter 2 we summarized the existing literature about the effects of selective 
serotonin reuptake inhibitor (SSRI) treatment, resulting in increased extracellular 5-HT 
levels, on gene expression in the brain. The main groups of genes affected by SSRIs are 
genes encoding 5-HT receptors, components of non-serotonergic neurotransmitter systems, 
neurotrophic factors, hypothalamic hormones and inflammatory factors. To study the 
long-term effects of SSRIs we performed a genome-wide gene expression analysis in the 
hippocampus of rats 40 days after chronic fluoxetine treatment (chapter 3). We showed that 
mRNA levels of myelination-related genes were significantly upregulated in the hippocampus 
of SSRI-exposed rats compared to vehicle-exposed rats. In addition, the paradoxical effects of 
SSRI exposure during early-life and adulthood on adult anxiety and depression-like behavior 
would suggest that adult gene expression is affected in opposite direction after early-life 
SSRI exposure compared to adult SSRI exposure. In chapter 3 we confirmed this hypothesis 
by showing that expression of myelination-related genes in the hippocampus of adult rats 
postnatally exposed to SSRIs was significantly decreased, while expression of myelination-
related genes was increased after adult SSRI-exposure. In chapter 4 we observed that both 
pharmacological and genetic inactivation of the 5-HT transporter (5-HTT) resulted in a 
developmental delay. Except for hypolocomotion, most of the observed early-life effects were 
normalized later in life. In chapter 5, we examined genome-wide expression in the developing 
mPFC and provided a data resource of temporal coding-gene expression, long intergenic non-
coding RNA expression and alternative exon usage from infancy to adulthood. In addition, 
we showed that gene expression is dynamic during postnatal development and we identified 
a clear genetic switch from neuronal network establishment in infancy to maintenance in 
adulthood. This chapter provides a basis for studying mPFC-related molecular mechanisms in 
5-HT related diseases. In chapter 6, we examined genome-wide expression in the developing 
mPFC of 5-HTT-/- rats compared to 5-HTT+/+ rats at five developmental time points. We 
observed most gene expression changes in the mPFC during early postnatal life (postnatal 
day (PND)8) and found an enrichment of genes linked to neuronal and developmental 
processes like neurotransmission, neuropeptide signaling pathway and cell migration on 
PND8. In addition, we observed a global increase in 5-hydroxymethylcytosine (5hmC) in the 
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mPFC during development in both genotypes and a significant increase in global 5hmC in the 
5-HTT-/- rats compared to 5-HTT+/+ rats on PND35, which might influence gene expression.
Processes affected by blocking 5-HTT during adulthood 
Decades ago SSRIs were used for treatment of affective disorders without knowing their 
exact mechanism of action. Nowadays there is data available from multiple studies showing 
that SSRIs increase extracellular 5-HT levels and that 5-HT can affect several pathways which 
might contribute to the therapeutic effect of SSRIs. There is strong evidence that besides 
5-HT signaling other neurotransmitter systems, the immune system, neurotrophic factors 
and the HPA axis are affected by SSRIs. Effects are seen on both the gene expression1 
and the protein level2-4. Besides these pathways, we were the first to show that SSRIs can 
increase gene expression of myelin-related genes5. Others showed that expression of myelin-
related genes was decreased in depressed patients6-10, which nicely fits with the fact that 
treatment of depression with SSRIs results in upregulation of myelin genes. In addition, 
MRI studies showed alterations in white matter (composed of bundles of myelinated cell 
projections) in several brain regions in depressed patients which were (partly) normalized 
after SSRI treatment11,12. Non-serotonergic compounds acting on the immune system (e.g. 
anti-inflammatory drugs)13, the HPA axis (e.g. CRH1 antagonists)14,15, neurogenesis (e.g. BDNF 
infusion)16 and myelination (e.g. antimuscarinic compound that enhances myelination)17, also 
reduce affective behavior (mainly tested in animals), confirming that these pathways actually 
contribute to the treatment of affective disorders and are not just side effects of SSRIs.  
Most studies focused on the short-term effect of chronic SSRI treatment (24 
hours after the last SSRI treatment), but we studied the long-term effects of chronic SSRI 
treatment and found myelination to be affected at gene expression level 40 days after the last 
treatment. Effects on neurotransmitter systems, the immune system, neurotrophic factors 
and the HPA axis were not visible in our study and might represent acute/short term effects. 
However, these pathways can still be affected at other levels. For instance, protein levels 
could be altered, or further downstream structural changes could have taken place, which 
can contribute to the therapeutic effects of SSRIs. Information about the long-term effects 
on protein and structural changes after cessation of SSRI treatment is very limited. One study 
showed that chronic SSRI treatment caused a persistent decrease in brain dopamine levels 
for 7-14 days after cessation of treatment, depending on the dose used18. Others showed 
that chronic SSRI treatment in olfactory bulbectomized rats (model of depression) results 
in changes in open field activity, one and two weeks after treatment cessation19. Since a 
relatively high number of affective disorder patients experiences a relapse20,21, it would 
be interesting to investigate whether long-term SSRI-induced changes, e.g. myelination 
changes, are normalized at the time of a relapse and whether this can be used as a potential 
(predictive) marker for development of a relapse. In addition, we have to be aware that the 
effects of SSRI treatment are influenced by several factors such as type of SSRI, brain region, 
treatment length, animal/strain, sex and environmental factors which might account for the 
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differences seen between studies.
Processes affected by blocking 5-HTT during the perinatal 
period 
Pharmacological (SSRI exposure) and genetic (5-HTTLPR S-allele carriers, 5-HTT-/-) reduction 
of functional 5-HTT during development have been associated with negative effects on 
development and behavior. The pathways affected by developmental 5-HTT reduction 
depend on the time point of SSRI exposure, the length of exposure, the type of SSRI, the brain 
region of interest and the time point of measuring the effect. We here discuss the effects of 
perinatal (pre and/or postnatal) reduction of functional 5-HTT on brain development.
The most reported early postnatal effects in children perinatally exposed to SSRIs 
are neonatal withdrawal symptoms, which usually disappear within 2 weeks after birth22. In 
addition, perinatal exposure is linked to teratogenic effects (e.g. congenital heart defects) 
and developmental delay, which in most studies reflects a delay in gross motor function 
milestones. Furthermore, autism spectrum disorder (ASD) is a developmental disorder that is 
associated with SSRI exposure during pregnancy in humans23-25. Also in rodents ASD-related 
behavior has been found after perinatal SSRI exposure26. The delay in social-sensory and 
motor development observed in perinatally SSRI-exposed rats in this thesis, and the decreased 
sociability found in these rats27 are comparable to ASD-related phenotypes28. SSRI exposure 
leads to 5-HTT inhibition and thereby a rise in 5-HT levels. This condition is exacerbated in 
5-HTT-/- rats and, accordingly, we observed that social-sensory and motor development were 
delayed with greater intensity in 5-HTT-/- rats compared to perinatally SSRI-exposed rats. 
Additionally, we showed that 5-HTT-/- rats, compared to 5-HTT+/+ controls, displayed increased 
repetitive (object directed) behavior and an increase in brain/body mass index, both of which 
have been linked to ASD29. In contrast to the clinical symptoms, the early postnatal effects on 
gene expression or structural changes in the brain after perinatal reduction of functional 5-HTT 
are hardly investigated. No gene expression studies investigating early postnatal changes in 
S-allele carriers or after perinatal SSRI exposure are available. We investigated early postnatal 
gene expression in the mPFC of 5-HTT-/- and 5-HTT+/+ rats and showed that expression of 
genes involved in cell migration, neurotransmission and signal transduction was affected on 
PND8 in the 5-HTT-/- rats. Whether these pathways contribute to the observed clinical effects 
is not clear. However, there are several links between differentially expressed genes and 
behavior phenotypes. Differentially expressed genes in 5-HTT-/- rats on PND8 were strongly 
enriched for genes linked to diseases with muscle and motor dysfunction (e.g. movement 
disorders), showing a link with the delay in development of motor functions as observed in 
SSRI exposure children30-32 and in our 5-HTT-/- and perinatal SSRI-exposed rats. Furthermore, 
dysregulation of cell migration might result in aberrant brain wiring, which can influence 
behavior during infancy, but can also result in lifelong consequences on brain functioning. 
Defects in cell migration are often found in ASD33. In addition, within the neurotransmission 
gene category we found a number of genes related to glutamate signaling, which is a process 
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that is shown to be dysregulated in a group of ASD patients34.
  Frequently reported effects of perinatal reduction of 5-HTT observed at adulthood are 
anxiety and depression-like symptoms as well as substance abuse. These effects are observed 
in models of lifelong 5-HTT reduction such as S-allele carriers35-37 and 5-HTT-/- rodents38,39, but 
also in rodents exposed to SSRIs during the perinatal27,40,41 and, to a lesser extent, adolescent42 
period, suggesting that the effects at adulthood are a consequence of developmental 5-HTT 
reduction. Studies investigating adult effects of early-life reduction of functional 5-HTT on 
gene expression and structural changes in the brain are limited. In postnatally SSRI-exposed 
rats we observed a decrease in the expression of myelin-related genes at adulthood. Also 
in the 5-HTT-/- rats we observed a decrease in expression of some myelin genes (Cldn11, 
Plp1) at adulthood. Based on the similarity of these results with the results in postnatal SSRI-
exposed rats, we assume that in the 5-HTT-/- rats this effect on myelin gene expression is 
also caused by early-life 5-HTT inactivation. Others observed structural changes of myelin, 
such as a disturbed myelin sheath formation, at adulthood after SSRI exposure during brain 
development43. Furthermore, postnatal SSRI exposure was found to cause downregulation 
of brain derived neurotrophic factor IV (Bdnf IV) gene expression in the hippocampus44 and 
long-term sex-dependent effects on hippocampal plasticity at adulthood45. Moreover Npas4, 
one of the transcription factors regulating Bdnf gene expression, was significantly decreased 
in the hippocampus of adult rats prenatally exposed SSRIs46. In summary, only a few studies 
focused on the long-term molecular and structural effects of early-life reduction in functional 
5-HTT and more research is needed to understand the underlying mechanisms involved in 
the anxiety and depression-like behavior.
 mPFC development and changes in 5-HT signaling
We investigated gene expression across postnatal development in the mPFC, which is one 
of the latest maturing brain regions. The mPFC has an extensive serotonergic innervation47,48 
and has been implicated in neuropsychiatric disorders like anxiety, depression and drug 
addiction49-51. In our developmental expression timeline in the mPFC of wildtype rats (chapter 
5) we showed a clear switch from genes involved in neuronal network establishment in 
infancy to those involved in neuronal homeostasis and maintenance in adulthood. Moreover, 
we showed that in these wildtype rats most expression changes occur in infancy and the 
number of differentially expressed genes reduces toward adulthood. In addition, we found 
the highest number of differentially expressed genes between 5-HTT-/- and 5-HTT+/+ rats on 
PND8 (chapter 6), showing that manipulating 5-HT levels causes the strongest effects in 
the period with the highest gene expression dynamics. As shown in chapter 5, this early 
postnatal period is important for synaptogenesis and network establishment and the high 
number of differentially expressed genes in the 5-HTT-/- rats in this period fits with the 
important role of 5-HT in developmental processes such as neuronal migration and network 
formation in the mPFC52-55. Several genes proven to be involved in prefrontal developmental 
events are associated with neurodevelopmental diseases and show differential expression 
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between consecutive time points in wildtype rat mPFC tissue (chapter 5, table 1). We were 
able to show that some of these genes, e.g. Gad1 (Glutamate decarboxylase 1) and Nrp2 
(Neuropilin 2, involved in axon guidance), are differentially regulated in PND8 mPFC tissue of 
5-HTT-/- rats compared to 5-HTT+/+ rats as well. These findings support the existing literature 
about involvement of 5-HT dysregulation in neurodevelopmental diseases, such as autism 
spectrum disorder26. Furthermore, we found multiple differentially expressed lincRNAs and 
genes showing alternative exon usage during postnatal mPFC development in wildtype rats. 
Similar analysis can be done using our 5-HTT-/- and 5-HTT+/+ RNA-seq data and might provide 
additional information about the role of 5-HT signaling on transcriptional changes across 
postnatal mPFC development. 
Paradoxical effects of SSRIs
There is increasing evidence that early-life SSRI exposure results in paradoxical behavioral 
and molecular effects compared to adult SSRI exposure. While adult SSRI treatment induces 
antidepressive and anxiolytic effects, perinatal SSRI exposure results in increased anxiety 
and increased depression-like symptoms. Furthermore, teenagers and adults with ASD may 
benefit from SSRIs56, while SSRI exposure during the perinatal period increased the risk for 
ASD24-26. It is likely that similar molecular pathways are affected in both cases, since adult SSRI 
exposure can alleviate the behavioral effects induced by adolescent42 and neonatal57 SSRI 
exposure. Indeed, studies, so far, revealed two pathways showing opposite effects, namely 
neurogenesis and myelination. We showed that adult SSRI exposure can increase gene 
expression of myelin-related genes, which might restore the reduced expression of myelin 
genes found in depressed patients6. Opposite effects were observed in adult rodents after 
developmental SSRI exposure, namely decreased expression of myelin-related genes (this 
thesis), disturbed myelin sheath formation and reduced callosal connectivity43. Neurogenesis 
is also showing paradoxical effects. Chronic administration of SSRIs in adult rodents leads to 
increased hippocampal neurogenesis58 and increased expression of the neurotrophic factor 
BDNF59. However, there are also studies showing opposite or no effects60-62. Developmental 
SSRI exposure caused a decrease in hippocampal plasticity45 and reductions in mRNA of 
Bdnf IV44, Npas4, (transcription factor regulating Bdnf)46 and Erk2 and Creb (downstream 
targets of Bdnf)63 at adulthood. The finding that neurogenesis and myelination are showing 
opposite effects suggest that these pathways are involved in the ”SSRI paradox”. By finding 
opposite effects on gene expression we are now one step further in understanding the 
opposite behavior effects, but it still remains to be elucidated why the direction of an effect is 
dependent on the time point of SSRI exposure. Two factors that contribute to different effects 
during development are the transient wide-spread expression of 5-HTT during development 
and the effects of 5-HT on neurodevelopmental processes such as cell proliferation, cell 
differentiation, neuronal migration and network formation52-54. The downstream pathways 
of 5-HT during developmental time points may differ from the pathways at adulthood in 
order to be able to help building the brain. These different downstream pathways potentially 
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account for 5-HTs neurotrophic functions, but might also be involved in the opposite effects 
on myelination, neurogenesis and behavior. Given the transient wide-spread expression 
of 5-HTT and the neurotrophic function of 5-HT, different effects during development are 
expected, however it is interesting, but still unclear, why several pathways show opposite 
effects compared to adulthood. 
Depression versus SSRIs during pregnancy
The best way to investigate the risks of SSRI use during pregnancy in comparison to women 
who have the same severity of depressive symptoms but are not receiving SSRI treatment 
during pregnancy, would be conducting randomized, double-blind, placebo-controlled 
studies in pregnant mothers. However, this is seen as unethical due to the potentially 
negative impact on the fetus. As a consequence the available data about the effects of SSRI 
treatment and untreated depression (and also anxiety and stress64) on the (un)born child 
and the available treatment guidelines65-67 are based on retrospective case-control studies, 
smaller prospective control studies and animal studies (like this thesis). This thesis increases 
the knowledge about the effects of SSRIs, by showing a delay in development and altered 
myelin gene expression at adulthood, but based on the data in this thesis alone we cannot 
give a good advice to pregnant mothers about SSRI use during pregnancy. Together with the 
available literature we can speculate about the benefits and disadvantages of SSRI exposure 
and maternal depression during gestation. SSRI use during pregnancy has several negative 
effects on the developing child, like neonatal withdrawal symptoms, developmental delay, 
teratogenic effects and an increased risk of developing neuropsychiatric disorders such as 
ASD, depression and anxiety. In contrast, depression itself can also have a major impact 
on the development of the (unborn) child, like preterm birth, lower birth weight, delayed 
cognitive and motor development, higher impulsivity, maladaptive social interactions, and 
behavioral and emotional difficulties64,68,69. Both, depression and its treatment, cause very 
similar negative effects on the offspring, making the decision to discontinue treatment or to 
wait with initiating treatment rather difficult. For both conditions most effects on the offspring 
are transient and only a few effects might last into childhood, adolescence and adulthood (as 
we also show in chapter 4). Studying long-term effects in humans is hampered by variability 
in e.g. depression severity, treatment period, treatment length and environmental factors. 
Therefore, evidence for long-term effects, e.g. anxiety and depression, is mainly based on 
animal studies (under well-controlled environmental conditions). The most recent meta-
analyses and reviews suggest that the risks of SSRI intake during pregnancy for poor fetal 
outcome overall are small to moderate70. However, untreated depression has similar risks 
for fetal outcome and, in addition, untreated depression during pregnancy also increases 
maternal risks like hypertension, suicide and unhealthy behaviors as smoking and the use of 
drugs and alcohol70,71. Current best practice is to make a decision based on a personalized 
risk-benefit analysis. If mood has been stable for a long period of time discontinuation of 
SSRIs during pregnancy might be considered. Psychotherapy should also be considered 
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as treatment and might especially be beneficial for mild to moderate depression72. For 
severe (recurrent) depression psychotherapy alone is not recommended but can be used in 
combination with antidepressants. When using SSRIs during pregnancy it is recommended 
to use one drug (monotherapy), to use an SSRI with a relatively low placental transfer (e.g. 
fluvoxamine)73, to not change medication during pregnancy and to use the lowest effective 
dose. The extent of fetal exposure during pregnancy is also relevant to those women who 
choose to breast feed. If a woman takes an SSRI in pregnancy, concerns about breast feeding 
exposure are not warranted, since pregnancy exposure is magnitudes of order greater than 
breast feeding exposure67. 
Potential new therapeutic options 
SSRIs are currently the first line treatment for affective disorders. Adult SSRI exposure reveals 
favorable effects on affective disorders, but also has adverse effects, like sexual dysfunction74, 
suppression of rapid eye movement sleep75, nausea76,77, decreased appetite78 and aggression/
violence79,80. In addition, it takes weeks of treatment before clinical effects are noticed. 
Furthermore, as mentioned above, SSRI exposure during development has many (negative) 
consequences on brain development and behavior. These adverse effects emphasize that 
further optimization of chronic treatment of affective disorders is needed. 
 Pathways affected by SSRIs potentially contribute to their efficacy and targeting 
these pathways might augment the therapeutic response or reduce adverse effects. Based 
on our review about the effects of SSRIs on gene expression and our RNA-seq experiment 
in SSRI-exposed rats, we can propose several directions for the treatment of effective 
disorders in adulthood, namely; 5-HT receptors, non-serotonergic neurotransmitter systems, 
neurotrophic factors, hypothalamic hormones, inflammatory factors and components 
involved in myelination. Several of these directions are already under investigation. In addition, 
the genes and pathways mentioned in chapter 5 (neurodevelopmental genes) and chapter 6 
(genes affected by genetic inactivation of 5-HTT), can be used for development of therapeutic 
targets for treatment of 5-HT related diseases. One strategy to improve therapeutic response is 
to refine and expand on the monoamine mechanisms. Augmenting strategies are investigated 
for several years already and include adjuvant therapy with atypical antipsychotics, which act 
by their antagonistic effect on 5-HT
2A/2C
, and treatment with multimodal drugs targeting 5-HT 
receptors in combination with 5-HTT inhibition in one molecule81. There are a few multimodal 
and atypical antipsychotics drugs approved for treatment of depression and several 
new drugs are under investigation81. In addition, adjunct treatment with the slow release 
5-hydroxytryptophan (5-HT precursor) in mice can safely and effectively elevate 5-HT beyond 
the SSRI effect and might represent a novel treatment for treatment-resistant depression82. 
Other research is focusing on mechanisms that go beyond the monoamine system. There is 
an increasing interest in targeting glutamate neurotransmission. The N-methyl-D-aspartate 
(NMDA) receptor antagonist ketamine is able to produce an immediate and long-lasting 
antidepressant effect in patients with treatment-resistant depression83 and is now used as a 
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treatment option for this group of patients84. Blockade of NMDA receptors by ketamine will 
lead to an increase in extracellular glutamate, which is thought to mediate antidepressant 
effects by activating pathways involved in neuronal plasticity and synaptogenesis85-87. However, 
ketamine also has adverse effects, like psychotomimesis and abuse liability88, which prevent 
its use as a first-line treatment for affective disorders. In addition, compounds targeting other 
glutamate receptors, e.g. metabotropic glutamate receptors89,90, are currently investigated 
in clinical trials. Furthermore, compounds acting on neuroinflammation have been tested. 
Cyclooxygenase-2 inhibitors showed antidepressant efficacy as an add-on therapy to SSRIs91,92 
and a TNF alpha antibody showed a trend towards antidepressant activity in a group of 
depressed patients with elevated levels of pro-inflammatory cytokines93. A few compounds 
involved in the HPA-axis have been tested. CRF1 receptor antagonists have shown anxiolytic-
like effects in animals, but showed mixed effects on antidepressant behavior and no CRF1 
antagonist has successfully completed a Phase III clinical trial in humans yet94. Also research 
around neurotrophic factors is ongoing. Especially BDNF and its TrkB receptor are the focus 
of several studies. In rats infusion of BDNF into the dentate gyrus produced antidepressant 
effects16. No CNS drug-like molecule is available yet, but attempts to transfer BDNF or TrkB 
ligands across the blood-brain barrier using liposomes or by conjugation with a protein 
transduction domain are being made95-98, also in our lab.  Lastly, we found an increase in 
the expression of myelin-related genes, which fits with the findings of Aston and colleagues 
who reported a decrease in the expression of myelin-related genes in depressed patients6. 
Myelination would be an interesting new direction for drug development. We showed long-
term effects of SSRI exposure on myelination, which suggests that changes in myelination 
might be more stable changes and targeting myelination might potentially reduce the 
chances of developing a relapse after discontinuation of SSRI treatment. So far, there is one 
animal study that supports the finding that increasing myelination can decrease depression-
like symptoms. Oral clemastine treatment (associated with enhanced oligodendrocyte 
progenitor differentiation) rescued the impaired myelination in mice undergoing prolonged 
social isolation and reversed the depression-like social avoidance behavior in these mice17. 
More research is needed to explore the opportunities of myelinating agents as a treatment 
for affective disorders. 
 While a lot of research is focusing on new compounds for the treatment of affective 
disorders, none of these compounds have been tested in the developmental period yet. 
Testing safety and efficacy during development is important, because drugs can have 
a completely different effect during development as a consequence of differences in e.g. 
metabolism and hormone levels during development and potential detrimental effects of 
the drug on neurodevelopmental processes. Since developmental SSRI exposure can have 
negative outcomes, development of new drugs for the pediatric population and for use during 
pregnancy is highly needed. Since blocking 5-HTT during development can result in negative 
effects later in life, it may be worthwhile to explore non-serotonergic compounds, e.g. related 
to non-serotonergic neurotransmitter systems, neurotrophic factors, hypothalamic hormones, 
227
General discussion and future perspectives
7
inflammatory factors and myelination. Another approach would be the development of SSRIs 
with a lower placental transfer. 
Future perspectives for studying the effects of reduced 
functional 5-HTT in rodents 
In the paragraphs above we already proposed several interesting directions for future 
research. In addition, we would like to discuss a few more directions based on this thesis 
specifically. In our gene expression studies we chose to look at the overall effect of reduced 
5-HTT in a brain region. We have investigated gene expression in the hippocampus and mPFC 
in a mixture of cell types. Using this approach, we did observe differences in gene expression 
which contribute to mPFC development and 5-HT related neurodevelopmental and behavioral 
phenotypes, but we do not know whether these differences are a consequence of altered 
gene expression within a cell type or a consequence of a different composition of cells in the 
investigated area. Furthermore, 5-HTT expression starts prenatally, therefore in the 5-HTT-/- 
rats the mRNA expression differences we found postnatally can be a secondary effect of the 
changes occurring prenatally. For example, the gene expression observed at postnatal time 
points can be a compensatory mechanism for the expression changes occurring prenatally 
and gene expression at postnatal stage can be different due to a different cell composition 
of the punch area caused by prenatal effects on e.g. cell migration. In addition to our gene 
expression data, information from prenatal stages and gene expression per cell type would 
give valuable new insights in the effects of a reduction in functional 5-HTT, which might help in 
defining potential drug targets. In order to obtain expression data per cell type, fluorescence-
activated cell sorting (FACS)99 followed by RNA-seq would be a good approach. Potential cell 
types to focus on would be oligodendrocytes (based on the myelin-related effects shown 
in chapter 3 and 6) and glutamatergic pyramidal cells (based on gene expression changes 
observed in the 5-HTT-/- rats on PND8 in chapter 6, Figure 4).
 We have shown several processes that are dysregulated on gene expression level by 
a reduction in functional 5-HTT. It would be relevant to investigate whether these processes 
are dysregulated on protein or structural level as well. For instance, investigating myelin 
protein expression or myelin structure by performing immunohistochemistry and electron 
microscopy, respectively. In addition, it would be interesting to investigate whether part of 
the gene expression observed in 5-HTT-/- rats can be normalized by injecting 5-HTT constructs 
into 5-HTT-/- rat embryos by in utero electroporation. With this technique various constructs, 
either up- or downregulating the gene of interest, can be microinjected into the lateral 
ventricles of the developing embryonic brain. The construct is then incorporated into the 
ventricular surface by electroporation using a series of unipolar square wave pulses, driving 
expression into specific brain areas defined by the position of the electrodes100. Besides 
normalizing 5-HTT itself, this technique can also be used to investigate whether normalizing 
one or combinations of the differentially expressed genes can rescue a particular behavior 
defect. 
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Another direction for follow-up research is looking into epigenetic changes caused by 
altered 5-HTT expression. Up to now we only investigated global DNA (hydroxy)methylation 
(5(h)mC) changes, but it would be interesting to also look at genome-wide, gene-specific, 
5(h)mC in 5-HTT-/- rats or in SSRI-exposed rats since aberrant DNA methylation patterns in 
the brain, in saliva and in blood are linked to affective disorders101-105. Investigating genome-
wide 5(h)mC differences in the 5-HTT-/- rats and analyzing whether these changes fit with 
the observed gene expression changes will result in valuable new information about the 
downstream effects of 5-HT signaling and the working mechanisms of SSRIs. In addition, 
histone modifications have been linked to affective disorders, especially acetylation106-110. 
Studying histone modifications using chromatin immuno-precipitation followed by 
sequencing (ChIP-seq) in our 5-HTT-/- rats will complement the gene expression (and DNA 
methylation) data. 
Performing the same gene expression and behavior experiments in 5-HTT+/- rats, 
which more resemble the S-allele carriers in terms of 5-HTT protein expression, would be of 
great interest as well. So far results in the 5-HTT+/- rats are mixed, which might depend on the 
environmental conditions (see below). They sometimes behave like the 5-HTT-/- rats111 and 
sometimes their behavior is similar as observed in the 5-HTT+/+ rats112. 
Furthermore, models of reduced 5-HTT expression (5-HTT-/-, 5-HTT+/-, SSRI exposure) 
have been associated with increased susceptibility to environmental conditions, which can 
result in favorable effects when exposed to positive environmental conditions and may result 
in negative effects when exposed to negative environmental conditions (e.g. stress)113-115. 
Positive effects observed in adult S-allele carriers and 5-HTT−/− rodents are enhancement of 
cognitive functions, including better decision-making skills116-118, inhibitory control112, and 
reversal learning119,120. Prenatal SSRI exposure is associated with improved spatial learning121. 
So far these studies focused on adult rats. Are there favorable effects in models of reduced 
5-HTT expression during development as well? Investigating the influence of stress is beyond 
the scope of this thesis (investigating the effects of dysregulated 5-HT signaling in the 
absence of adverse environmental conditions), but it has been shown by others that stress, 
as a negative environmental condition, can differentially effect adult behavior and gene 
expression in models of reduced 5-HTT expression compared to non-stressed groups122-124. 
Investigating whether exposure of 5-HTT-/-  and SSRI-exposed rats to negative environmental 
conditions, such as stress, results in differential effects on behavior and gene expression 
during development, compared to non-stressed conditions, might be a possible future 
direction. 
Conclusion
Overall with this thesis we have come to a further understanding of the effects of 5-HT on 
behavior and gene expression across development. In chapter 4  we extended the studies 
from Olivier and colleagues27,38, which showed effects of perinatal SSRI exposed rats and 
5-HTT-/- rats on adult behavior, by showing a delay in development in perinatal SSRI exposed 
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rats and 5-HTT-/- rats, with the strongest effects on motor behavior. On the transcriptional 
level, we explored genome-wide transcriptional changes in the wildtype medial PFC during 
development (chapter 5) and we were the first to investigate changes in gene expression 
in this brain region in the 5-HTT-/- rats across development (chapter 6), resulting in datasets 
which can be used as a resource for investigators interested in the basic developmental 
processes of the mPFC, the mechanisms of neurodevelopmental and neuropsychiatric 
disorders and for selecting potential new targets for treatment of 5-HT-related disorders. We 
found several pathways to be affected in the 5-HTT-/- rats on PND8, including genes involved 
in motor diseases, which complement the observed delay in motor behavior in these rats. In 
chapter 2 we summarize the existing literature about the effect of SSRIs on gene expression 
and concluded that information about the long-term effects of SSRIs (>24 hours after last 
exposure) and about gene expression changes by perinatal SSRI exposure was lacking. In 
chapter 3 we focused on these gaps and showed that myelin genes are upregulated 40 days 
after the last SSRI exposure. In addition, we showed that SSRI exposure results in opposite 
effects on expression of myelination-related genes after perinatal SSRI exposure, which 
correlated with (opposite) anxiety and depression-like behavior and brings us a step further 
in unraveling the mechanisms behind the frequently reported paradoxical effects of perinatal 
versus adult SSRI exposure on behavior125 .
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English Summary
Affective disorders are psychiatric disorders characterized by disturbances in mood and 
emotions in such a way that normal functioning is hampered. Examples of such disorders 
are depression, anxiety-related disorders and bipolar disorders. Affective disorders are 
frequently occurring diseases caused by a combination of genetic and environmental factors. 
An important molecule involved in affective disorders is serotonin (5-hydroxytryptamine, 
5-HT). Serotonin is a neurotransmitter (a messenger which transmits information between 
neurons) produced in serotonergic neurons which plays an important role in processes such 
as mood, sleep, sexual activity, emotion and appetite. Serotonin is released in the extracellular 
space via vesicles and can bind to serotonin receptors present on other neurons, and 
activate a variety of downstream processes. Serotonin transporters (5-hydroxytryptamine 
transporter, 5-HTT) present on the serotonergic neurons regulate the amount of available 
extracellular serotonin by facilitating the reuptake of serotonin in the neuron. Decades ago 
it was shown that low extracellular serotonin levels in the brain are associated with affective 
disorders, such as depression. Furthermore, studies showed that genetic variations (such 
as polymorphisms; natural variations in the DNA sequence which occur with relative high 
frequency in the population) in serotonin genes are associated with affective disorders. A 
well-studied polymorphism is the 5-HTT-linked polymorphic region (5-HTTLPR) polymorphism 
located in the part of the DNA that regulates the expression of the serotonin transporter. The 
short variant (S-allele; contains less repeats of a repetitive sequence) is associated with lower 
levels of the serotonin transporter and people carrying this variant have an increased risk of 
developing depression and anxiety-related disorders. 
The serotonin system is an important target for a variety of drugs prescribed for 
treatment of affective disorders. The most frequently prescribed drugs for the treatment 
of affective disorders are selective serotonin reuptake inhibitors (SSRIs). SSRIs block the 
serotonin transporter and thereby the reuptake of serotonin in the neuron, resulting in 
increased extracellular serotonin levels. SSRIs are mostly known as antidepressants, but 
are also prescribed for, amongst others, anxiety-related disorders. Despite many positive 
effects, clinical studies also showed several adverse effects of SSRIs, namely nausea, reduced 
appetite, aggression/violence, suppression of rapid eye movement (REM) sleep and sexual 
dysfunction. Another disadvantage is that it often takes weeks of treatment with SSRIs before 
clinical effects are noticed.
 The highest risk for women to suffer from depression is during their childbearing 
years. To treat depressed pregnant women, SSRIs are frequently prescribed. Studies have 
shown that SSRIs can reach the unborn child by crossing the placenta and that SSRIs can be 
transferred by breastfeeding. It has been shown that this early-life SSRI exposure can have 
negative effects on the development of the child, such as preterm birth, low birth weight, 
neonatal withdrawal symptoms, defects in motor behavior, autistic-like behavior, increased 
blood pressure in the lungs (pulmonary hypertension) and congenital heart defects. In 
addition, mainly in animal studies it is shown that perinatal SSRI exposure increases the risk 
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of developing anxiety and depression-like symptoms in adulthood. It is striking that SSRI 
exposure during development is associated with an increased risk of developing anxiety and 
depression-like symptoms, while exposure in adulthood suppresses these symptoms (age-
dependent effect). It is important to mention here that untreated affective disorders of the 
mother can also have negative consequences on the (unborn) child. In summary, SSRIs show 
age-dependent effects, with negative outcomes after early-life exposure. Of special interest is 
the opposite age-dependent effect on anxiety and depression-like behavior. In addition, SSRI 
use in adulthood can result in several adverse effects, despite their positive effect on anxiety 
and depression-like behavior. Taken together, this shows that increasing the knowledge about 
the cause of affective disorders and the effects of serotonin and SSRI exposure in adulthood 
as well as during development is necessary to improve treatment of affective disorders. 
 In this thesis we focused on the molecular changes occurring in the brain as a 
consequence of increased extracellular serotonin levels during postnatal development as well 
as in adulthood. In addition, we looked into the behavioral effects of increased extracellular 
serotonin levels from early postnatal age till adulthood. 
In chapter 2, we summarized the literature available at the beginning of my PhD 
about the effects of SSRI treatment, resulting in increased extracellular 5-HT levels, on gene 
expression in the brain. The majority of the genes affected by SSRIs are genes encoding 5-HT 
receptors, components of non-serotonergic neurotransmitter systems, neurotrophic factors 
(factors which stimulate cell division, development and survival), hypothalamic hormones 
and inflammatory factors. We noticed that most studies focused on gene expression 24 hours 
after the last SSRI exposure, while research about the long-term effects of SSRIs can bring 
valuable additional information about the working mechanisms of SSRIs. In addition, there is 
hardly any information about the effects of perinatal SSRI exposure on gene expression. 
Therefore, in chapter 3 we focused on the long-term effects of SSRI exposure in adulthood 
and around birth on gene expression in the hippocampus. The hippocampus is a brain region 
implicated in psychiatric disorders and mainly involved in memory formation. We 
demonstrated in adult rats that the expression of several genes involved in myelination is 
increased in the hippocampus 40 days after the last SSRI administration in comparison to a 
control group that was not treated with SSRIs. Myelination is the formation of myelin around 
axons, which enhances the speed of the transmission of information encoded in action 
potentials. Furthermore, we showed a negative correlation in these rats between the 
expression levels of myelin genes and anxiety levels investigated with a behavior test; the 
increased expression of myelin genes correlated with lower anxiety levels. It would be 
interesting to investigate whether the increased gene expression will decline at the time of a 
relapse and whether myelination can be used as a potential (predictive) marker for 
development of a relapse. In addition, we showed in this chapter that postnatal SSRI exposure 
results in a decrease in expression of myelin genes in the hippocampus when the rats are 
grown-up. This gene expression also shows a negative correlation with the level of anxiety; a 
lower expression of myelin genes correlates with increased anxiety levels. In summary, 
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expression of myelin genes is increased after adult exposure and decreased after perinatal 
exposure. This opposite age-dependent effect of SSRI exposure on expression levels of myelin 
genes fits very well with the opposite effects of perinatal versus adult SSRI exposure on 
anxiety and depression-like behavior which have been frequently described in the literature. 
In chapter 4, we investigated the effects of changes in the serotonin system, namely increased 
extracellular serotonin levels, on development of behavior. There are already several early 
behavioral effects of SSRI exposure on young age described in the literature, but the effects 
during later development of the animals were still unknown. Furthermore, there were no 
studies that have investigated behavior across developmental stages in 5-HTTLPR S-allele 
carriers. To elucidate this, we used rat models and we observed that rats perinatally exposed 
to SSRIs as well as rats lacking the serotonin transporter their whole life (so-called serotonin 
transporter knockout rats, a model for 5-HTTLPR S-allele carriers) show a delay in development, 
especially on motor coordination and reflex development. With the exception of 
hypolocomotion, most behavior differences where normalized around adolescence. Around 
adolescence and adulthood, we observed reduced interest in novel objects and an increase 
in object directed, repetitive, behavior in the serotonin transporter knockout rats. This 
behavior was not seen in the SSRI-exposed rats and might be related to the differences in 
exposure period and the degree of loss of function of the serotonin transporter; the serotonin 
transporter knockout rats are characterized by a life-long total absence of the serotonin 
transporter, while in rats perinatally exposed to SSRIs the serotonin transporter knockout is 
only blocked during the period of exposure. The effects of perinatal SSRI exposure on behavior 
as described in this chapter are important to take along in the decision about prescribing 
SSRIs during pregnancy. The fact that most of the behavioral differences we measured were 
normalized around adolescence and hardly any consequences of perinatal SSRI exposure 
were observed in adulthood is very positive. Obviously we measured only a small part of the 
wide range of behaviors an individual can express (e.g. no anxiety and depression-like 
behavior) and especially the presence of potential long-term effects needs further 
investigation in the future. In chapter 5 and 6, we investigated changes in genome-wide gene 
expression in the medial prefrontal cortex (mPFC) in rats with a functionally intact serotonin 
transporter (wildtype rats) and in serotonin transporter knockout rats. We measured gene 
expression at 5 different developmental time points, from 8 days after birth (postnatal day 
(PND) 8) till adulthood. The mPFC is a brain region with a high innervation (supplying a region 
with nerves) of serotonergic neurons which is involved in, amongst others, the regulation of 
emotion and its function is reduced in affective disorders. In chapter 5, we showed that gene 
expression in the mPFC is dynamic across postnatal development and we showed a clear 
switch around (early-) adolescence from expression of genes involved in neuronal network 
establishment to genes involved in homeostasis. Homeostasis is the ability of maintaining 
internal stability regarding chemical and physiological processes in the body. Besides 
expression of protein-coding genes we also mapped the expression of parts of the DNA which 
are not coding for proteins itself, but are involved in the regulation of protein-coding genes; 
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so-called non-coding RNAs. The resource we generated with expression changes across 
development can be used by other research groups interested in prefrontal cortex 
development or neurodevelopmental disorders. This resource also provides a good baseline 
for studying gene expression changes in the mPFC in serotonin-related disorders. As a follow-
up to this, we investigated in chapter 6 the gene expression in the mPFC across development 
in serotonin transporter knockout rats and we compared the expression with the gene 
expression found in wildtype rats (from chapter 5). We observed most gene expression 
changes at the earliest time point measured in this study, PND8. At this age we found an 
enrichment of expression changes in genes involved in neuronal and developmental 
processes, such as neurotransmission and cell migration. These gene expression changes 
might cause a dysregulation in neurotransmission and changes in brain development caused 
by cell migration problems, which might be the underlying cause of the aberrant behavior. In 
addition, among the genes showing expression changes at PND8 we observed several genes 
involved in muscle diseases and movement disorders. These genes might play a role in the 
reduced motor coordination in young serotonin transporter knockout rats observed in 
chapter 4. More research is needed to confirm this. Furthermore, several genes involved in 
myelination showed gene expression changes (in general a decrease in expression) in the 
serotonin transporter knockout rats across development. Our resource with gene expression 
changes in the serotonin transporter knockout rat can be used for future research into the 
effects of increased extracellular serotonin levels during development. Finally, we looked into 
DNA (hydroxy)methylation in the mPFC. The level of DNA (hydroxy)methylation plays a role in 
the regulation of gene expression and might underlie the observed changes in gene 
expression. We showed that hydroxymethylation levels increase during postnatal development 
in the wildtype rats as well as in the serotonin transporter knockout rats.  Moreover, we 
showed an increase in hydroxymethylation at PND35 in de serotonin transporter knockout 
rats compared to wildtype rats. More research into the meaning of these hydroxymethylation 
changes is necessary. In chapter 7, we provided an extensive discussion of the research 
findings summarized above and we proposed directions for future research. The findings in 
this thesis contribute to an increased insight into the effects of serotonin during different 
developmental periods. We showed that increased extracellular serotonin levels influence 
the expression of myelin genes and we showed that the direction of these expression changes 
is dependent on the time point at which the change in the serotonin system takes place. We 
showed that both perinatal SSRI exposure and a life-long absence of the serotonin transporter 
result in a delay in reflex development and development of motor-related behavior. Moreover, 
we created several resources containing gene expression changes occurring in the 
hippocampus as a consequence of SSRI treatment in adult rats (chapter 3) and expression 
changes  occuring during mPFC development in wildtype rats (chapter 5) and in serotonin 
transporter knockout rats (chapter 6). These resources can be used for future research into 
prefrontal cortex development, neurodevelopmental disorders, the working mechanisms of 
serotonin and new targets for treatment of affective disorders.
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Stemmingsstoornissen zijn psychische aandoeningen waarbij iemands gemoedstoestand 
dusdanig is verstoord dat diens normale functioneren hierdoor wordt belemmerd. Voorbeelden 
van dergelijke stoornissen zijn depressie, angststoornissen en bipolaire stoornissen. 
Stemmingsstoornissen zijn veel voorkomende ziektes in de hersenen waarvan de oorzaak ligt 
in een combinatie van genetische factoren en omgevingsinvloeden. Een belangrijk molecuul 
in de hersenen dat betrokken is bij het ontstaan van stemmingsstoornissen is serotonine. 
Serotonine (ook wel genoemd 5-hydroxytryptamine, 5-HT) is een neurotransmitter (een 
boodschapper die zorgt voor informatieoverdracht tussen zenuwcellen) geproduceerd in 
serotonerge neuronen, die een belangrijke rol speelt bij processen als stemming, slaap, 
seksuele activiteit, emotie en eetlust. Serotonine wordt via blaasjes vrijgelaten in de 
extracellulaire ruimte en kan dan binden aan serotonine receptoren op andere neuronen 
om zo verschillende processen te activeren. Serotonine transporters (5-hydroxytryptamine 
transporter, 5-HTT) gelegen op de serotonerge neuronen kunnen serotonine heropnemen 
in het neuron en hiermee de hoeveelheid beschikbare, extracellulaire serotonine regelen. 
Decennia geleden is er aangetoond dat een verlaagd extracellulair serotonine niveau in 
de hersenen geassocieerd is met stemmingsstoornissen zoals depressie. Daarnaast is ook 
aangetoond dat genetische variatie (zoals polymorfismen; natuurlijke variaties in de DNA 
sequentie die met relatief hoge frequentie voorkomen in de populatie) in serotonine genen 
geassocieerd is met stemmingsstoornissen. Een veel bestudeerd polymorfisme is het 
5-HTTLPR (5-HTT-linked polymorphic region) polymorfisme gelegen in het stukje DNA dat 
de expressie van de serotonine transporter regelt. De korte variant van dit polymorfisme 
(S (short) allel; bevat minder herhalingen van een repeterende stukje DNA) is geassocieerd 
met lagere niveaus van de serotonine transporter en mensen met deze variant hebben een 
verhoogde kans op depressie en angststoornissen.  
 Het serotonine systeem is een erg belangrijk aangrijpingspunt voor veel medicijnen 
die voorgeschreven worden bij stemmingsstoornissen. De medicijnen die het meest worden 
voorgeschreven voor stemmingsstoornissen zijn selectieve serotonine heropname remmers 
(selective serotonin reuptake inhibitors, SSRIs). SSRIs blokkeren de serotonine transporter en 
daarmee de heropname van serotonine in het neuron, wat resulteert in hogere extracellulaire 
serotonine niveaus. SSRIs zijn vooral bekend als antidepressiva, maar ze worden daarnaast 
ook voorgeschreven voor o.a. angststoornissen. Ondanks de vele positieve effecten hebben 
klinische studies aangetoond dat SSRIs ook verschillende bijwerkingen kunnen hebben, zoals 
misselijkheid, verminderde eetlust, agressie/geweld, verstoorde rapid eye movement (REM)-
slaap en stoornissen op seksueel gebied. Een ander nadeel is dat het vaak weken duurt 
voordat de klinische effecten van SSRIs merkbaar zijn. 
Depressie komt relatief vaak voor tijdens de zwangerschap en SSRIs worden in deze 
periode veel voorgeschreven. Studies hebben aangetoond dat SSRIs via de placenta het 
ongeboren kind kunnen bereiken en na de geboorte via de moedermelk kunnen worden 
overgebracht. Er is aangetoond dat deze vroege blootstelling aan SSRIs nadelige effecten 
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kan hebben op de ontwikkeling van het kind, zoals verhoogde kans op vroeggeboorte, laag 
geboortegewicht, serotonerge onttrekkingsverschijnselen van de pasgeborene, defecten in 
motoriek, autistisch gedrag, verhoogde bloeddruk in de longen (pulmonaire hypertensie) 
en aangeboren hartafwijkingen. Daarnaast is met name in dierstudies aangetoond dat SSRI 
blootstelling rond de geboorte een verhoogde kans op stemmingsstoornissen op volwassen 
leeftijd met zich meebrengt. SSRI blootstelling op jonge leeftijd verhoogd dus de kans 
op angst en depressieve symptomen op volwassen leeftijd, terwijl SSRI behandeling op 
volwassen leeftijd deze symptomen juist onderdrukt. Belangrijk is om hierbij te vermelden 
dat onbehandelde stemmingsstoornissen van de moeder ook nadelige effecten kunnen 
hebben op het (ongeboren) kind. Samenvattend, SSRIs laten leeftijdsafhankelijke effecten 
zien met negatieve gevolgen bij blootstelling op jonge leeftijd. Interessant daarbij is het 
tegengestelde leeftijdsafhankelijke effect op het gebied van angst en depressie. Daarnaast 
zien we bij gebruik op volwassen leeftijd nog relatief veel bijwerkingen. Dit alles geeft aan dat 
er meer kennis over de oorzaak van stemmingsstoornissen en de effecten van serotonine en 
SSRIs op zowel volwassen leeftijd als tijdens de ontwikkeling nodig is om de behandeling van 
stemmingsstoornissen te verbeteren. 
 In dit proefschrift hebben we ons gericht op de moleculaire veranderingen die 
plaatsvinden in de hersenen als gevolg van het verhogen van de extracellulaire serotonine 
niveaus, zowel tijdens de postnatale (na de geboorte) ontwikkeling als op volwassen leeftijd. 
Daarnaast hebben we gekeken naar effecten van het verhogen van de extracellulaire 
serotonine niveaus op jonge leeftijd op het gedrag vanaf vlak na de geboorte tot aan 
volwassen leeftijd.
In hoofdstuk 2 hebben we een samenvatting gegeven van de effecten van SSRI 
behandeling op genexpressie in de hersenen die beschreven waren in de beschikbare 
literatuur aan het begin van mijn promotietraject. De meerderheid van de genen waarvan de 
expressie beïnvloed wordt door SSRIs zijn genen die coderen voor de serotonine receptoren, 
componenten van niet-serotonerge neurotransmitter systemen, neurotrofe factoren 
(factoren die een bevorderende werking hebben op celdeling, ontwikkeling en overleving), 
hormonen van de hypothalamus en ontstekingsfactoren. Verder viel op dat de meeste studies 
gekeken hebben naar genexpressie 24 uur na de laatste SSRI behandeling, terwijl onderzoek 
naar de lange termijneffecten waardevolle aanvullende informatie kan opleveren over de 
werkingsmechanismen van SSRIs. Daarnaast is er nauwelijks onderzoek gedaan naar de 
effecten van SSRI blootstelling rond de geboorte op genexpressie. In hoofdstuk 3 hebben we 
dan ook gekeken naar de lange termijneffecten van SSRI behandeling op genexpressie in de 
hippocampus, zowel na SSRI blootstelling op volwassen leeftijd als na SSRI blootstelling rond 
de geboorte. De hippocampus is een hersengebied dat is aangetast bij stemmingsstoornissen 
en voornamelijk betrokken is bij het opslaan van herinneringen. Wij hebben in volwassen 
ratten aangetoond dat de expressie van verschillende genen betrokken bij myelinatie 
verhoogd is in de hippocampus 40 dagen na de laatste SSRI behandeling in vergelijking met 
een controle groep die geen SSRIs kreeg. Myelinatie is het vormen van myeline rondom 
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axonen wat ervoor zorgt dat signalen sneller worden doorgegeven. Verder hebben we laten 
zien dat deze genexpressie niveaus in deze ratten negatief correleren met de mate van angst 
getest m.b.v. een gedragstest; de hogere expressie van deze myelinatie genen correleerde 
met een lager angstniveau. Verder onderzoek zou moeten uitwijzen of deze verhoogde 
genexpressie weer omlaag gaat bij een terugkeer van de depressieve klachten en of myelinatie 
een mogelijke diagnostische marker zou kunnen zijn voor het voorspellen van de kans op een 
terugval. Verder hebben we in dit hoofdstuk aangetoond dat bij SSRI blootstelling vlak na de 
geboorte de expressie van genen betrokken bij myelinatie juist verlaagd is in de hippocampus 
als deze dieren volwassen zijn en dat deze expressie ook negatief correleert met de mate van 
angst; de lagere expressie van de myelinatie genen correleerde met een hoger angstniveau. 
Samengevat zien we een verhoogde expressie van myelinatie genen na volwassen blootstelling 
en een verlaagde genexpressie naar blootstelling rond de geboorte. Dit tegengestelde 
leeftijdsafhankelijke effect van SSRIs op expressie niveaus van myelinatie genen past goed bij 
de tegengestelde effecten op angst en depressief gedrag die al veelvuldig in de literatuur 
beschreven zijn. In hoofdstuk 4 hebben we onderzocht wat de effecten van veranderingen in 
het serotonine systeem, namelijk verhoogde serotonine niveaus, zijn op de (gedrags)
ontwikkeling. Er zijn al enkele vroege gedragseffecten van SSRI blootstelling op jonge leeftijd 
beschreven in de literatuur, maar de effecten op de verdere ontwikkeling van de dieren waren 
nog onbekend. Daarnaast was er nog geen onderzoek gedaan naar de effecten van het 
hebben van de korte variant (S-allel) van het serotonine transporter polymorfisme op de 
(gedrags)ontwikkeling. We hebben dit verder onderzocht in diermodellen en zagen dat zowel 
ratten die perinataal (rond de geboorte) waren blootgesteld aan SSRIs, als ratten die hun hele 
leven lang de serotonine transporter misten (zogenaamde serotonine transporter knockout 
ratten, een model voor 5-HTTLPR S-allel dragers), een vertraging in ontwikkeling vertonen, 
met name op het gebied van motorcoördinatie en reflexontwikkeling. Met uitzondering van 
verminderd voortbewegen (hypolocomotion), waren rond adolescentie de meeste verschillen 
in de ontwikkeling weer verdwenen. Op adolescente en volwassen leeftijd zien we in de 
serotonine transporter knockout ratten verminderde interesse in nieuwe objecten en meer 
object-gericht, repetitief, gedrag. Dit gedrag werd echter niet waargenomen in de ratten 
blootgesteld aan SSRIs en zou gerelateerd kunnen zijn aan de verschillen in de periode en de 
mate van functieverlies van de serotonine transporter; de serotonine transporter knockout 
ratten worden gekenmerkt door levenslange totale afwezigheid van de serotonine transporter 
en in de ratten die perinataal zijn blootgesteld aan SSRIs is de serotonine transporter alleen 
tijdens blootstelling geblokkeerd. De in dit hoofdstuk gevonden gedragseffecten zijn belangrijk 
om mee te nemen in de beslissing over het al dan niet voorschrijven van SSRIs tijdens de 
zwangerschap. Het feit dat de meeste door ons gemeten verschillen in gedrag weer zijn 
verdwenen rond adolescente leeftijd en er op volwassen leeftijd nauwelijks gevolgen te zien 
zijn van SSRI blootstelling is positief. Wij hebben uiteraard maar een klein deel van het gedrag 
bestudeerd (o.a. geen angst en depressief gedrag) en met name de aanwezigheid van 
eventuele lange termijneffecten van perinatale SSRI blootstelling moet in de toekomst nog 
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uitgebreider worden onderzocht. In hoofdstuk 5 en 6 hebben we gekeken naar veranderingen 
in genoom-brede genexpressie in de mediale prefrontale cortex (mPFC) in ratten met een 
intacte serotonine transporter expressie (wildtype ratten) en in serotonine transporter knock-
out ratten. Genexpressie hebben we gemeten op 5 verschillende tijdspunten tijdens de 
ontwikkeling, vanaf dag 8 na de geboorte tot volwassen leeftijd. De mPFC is een hersengebied 
met een hoge innervatie (voorziening van het gebied met zenuwen) van serotonerge 
neuronen dat betrokken is bij onder andere emotieregulatie en minder goed lijkt te 
functioneren bij verschillende stemmingsstoornissen. In hoofdstuk 5 hebben we laten zien 
dat genexpressie dynamisch is tijdens de postnatale ontwikkeling van de hersenen en dat er 
een duidelijke omschakeling plaatsvindt rond (jong-)adolescente leeftijd van expressie van 
genen betrokken bij het vormen van neuronale netwerken, naar genen betrokken bij 
homeostase. Homeostase is het in evenwicht houden van de chemische en fysiologische 
processen in het lichaam. Naast genen die daadwerkelijk coderen voor eiwitten hebben we 
ook de expressie in kaart gebracht van stukjes erfelijk materiaal die zelf niet coderen voor 
eiwitten, maar betrokken zijn bij de regulatie van eiwit-coderende genen; de zogenaamde 
niet-coderende RNAs. We hebben een dataset gecreëerd met expressieveranderingen tijdens 
de ontwikkeling welke gebruikt kan worden door andere onderzoekers die geïnteresseerd zijn 
in prefrontale cortex ontwikkeling of neuronale ontwikkelingsstoornissen. Daarmee vormt 
hoofdstuk 5 een goede basis voor het bestuderen van veranderingen in genexpressie in de 
mPFC bij serotonine gerelateerde ziektes. Als vervolg hierop hebben we in hoofdstuk 6 
gekeken naar expressie in de mPFC tijdens de ontwikkeling in serotonine transporter knock-
out ratten en deze expressie hebben we vergeleken met de genexpressie in ratten met een 
intacte serotonine transporter (uit hoofdstuk 5). We zagen de meeste genexpressie 
veranderingen op de jongste leeftijd die we gemeten hadden, 8 dagen na de geboorte. Op 
die leeftijd vonden we een verrijking aan expressie veranderingen (zowel verhoogde als 
verlaagde expressie) in genen betrokken bij neuronale en ontwikkelingsprocessen zoals 
neurotransmissie en celmigratie. Deze veranderingen in genexpressie zouden kunnen zorgen 
voor een afwijkende signaaloverdracht tussen zenuwen (neurotransmissie) en afwijkingen in 
de hersenontwikkeling door problemen met celmigratie, die mogelijk de onderliggende 
oorzaak zijn van het afwijkend gedrag. Onder de genen die expressieveranderingen lieten 
zien 8 dagen na de geboorte zagen we ook veel genen die betrokken zijn bij spierziekten en 
bewegingsstoornissen. Deze genen zouden een rol kunnen spelen bij de in hoofdstuk 4 
beschreven verminderde motorcoördinatie in jonge serotonine transporter knockout ratten. 
Om dit te bevestigen is meer onderzoek nodig. Daarnaast bleken enkele genen betrokken bij 
myelinatie veranderingen in genexpressie te laten zien (over het algemeen verlaagde 
expressie) in de serotonine transporter knockout ratten gedurende de gehele ontwikkeling. 
Onze dataset met veranderingen van genexpressie in de serotonine transporter knockout 
ratten kan gebruikt worden voor verder onderzoek naar de effecten van verhoogde 
extracellulaire serotonine niveaus tijdens de ontwikkeling. Tot slot hebben we gekeken naar 
DNA (hydroxy)methylatie in de mPFC. De mate van DNA (hydroxy)methylatie speelt een rol bij 
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de regulatie van genexpressie en zou daarmee ten grondslag kunnen liggen aan de 
waargenomen veranderingen in genexpressie. We hebben aangetoond dat het 
hydroxymethylatie niveau toeneemt gedurende de postnatale ontwikkeling zowel in de 
wildtype als in de serotonine transporter knockout ratten. Daarnaast zagen we een toename 
in hydroxymethylatie in 35 dagen oude serotonine transporter knockout ratten in vergelijking 
met de wildtype ratten. Verder onderzoek is nodig naar de betekenis van deze veranderingen 
in hydroxymethylatie niveaus. In hoofdstuk 7 hebben we onze resultaten uitgebreid 
bediscussieerd en daarnaast hebben we vervolgexperimenten voorgesteld. De bevindingen 
in dit proefschrift hebben een belangrijke bijdrage geleverd aan het verkrijgen van meer 
inzicht in de effecten van serotonine tijdens de verschillende fasen van de ontwikkeling. We 
hebben aangetoond dat verhoogde extracellulaire serotonine niveaus effect hebben op de 
expressie van myelinatie genen en dat de richting van dit effect afhankelijk is van de leeftijd 
waarop de verandering in het serotonine systeem plaatsvindt. We hebben laten zien dat 
zowel SSRI blootstelling op jonge leeftijd als het levenslang uitschakelen van de serotonine 
transporter zorgt voor een tijdelijke achterstand in ontwikkeling van motorcoördinatie en 
reflexen. We hebben daarnaast verschillende genexpressie datasets gecreëerd met 
expressieveranderingen die optreden in de hippocampus als gevolg van SSRI behandeling in 
volwassen ratten (hoofdstuk 3) en expressieveranderingen die optreden tijdens mPFC 
ontwikkeling in wildtype ratten (hoofdstuk 5) en in serotonine transporter knockout ratten 
(hoofdstuk 6) . Deze datasets kunnen gebruikt worden voor verder onderzoek naar prefrontale 
cortex ontwikkeling, neuronale ontwikkelingsziekten, de werkingsmechanismen van 
serotonine en nieuwe aangrijpingspunten voor medicatie voor stemmingsstoornissen.
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Dankwoord
Het is zover, mijn proefschrift is klaar! Een mooi resultaat van een onvergetelijke tijd. Dit werk 
had ik niet kunnen doen zonder de steun van vele mensen om mij heen. 
Allereerst wil ik mijn promotor Hans en mijn co-promotoren Judith en Jo bedanken. 
Judith, bedankt dat je mij de mogelijkheid hebt geboden om dit promotieonderzoek uit te 
voeren. Hoe druk je ook was, ik kon altijd bij je binnen lopen om te overleggen. Superfijn hoe 
snel jij altijd alles had nagekeken. Ook al stuurde ik ‘s avonds na 11 uur een manuscript dan 
was deze vaak de volgende ochtend (lees: doorgaans voor 7 uur ‘s ochtends) nagekeken. Ik 
heb veel bewondering voor je gedrevenheid en doorzettingsvermogen. Daarnaast heb ik ook 
veel gehad aan jouw altijd positieve kijk op mijn project. Ondanks dat mijn project niet altijd 
even soepel verliep, bleef jij positief en zag je vaak meteen weer nieuwe mogelijkheden. Ik 
heb me al die jaren erg thuis gevoeld in je groep. Bedankt voor alles!
Jo, bedankt voor al je hulp en enthousiasme de afgelopen jaren. Je directe manier van 
communiceren was even wennen voor me in het begin, maar ik ben hem inmiddels 
enorm gaan waarderen. Ik kon altijd bij je terecht met moleculaire vragen en als ik nieuwe 
resultaten liet zien was je altijd meteen enthousiast en kwam je gelijk met ideeën over 
vervolgexperimenten met mijn ratjes. Het heeft een tijdje geduurd maar uiteindelijk is het 
je zelfs gelukt om ratten en muizen niet meer door elkaar te halen geloof ik;). Ondanks dat ik 
het grootste deel van mijn PhD op het dierenlab heb doorgebracht, betrok je me altijd bij je 
groep. Ik heb erg genoten van de verschillende etentjes, het uitje naar het openluchtmuseum 
en elk jaar met kerst een klein cadeautje voor het harde werken. 
Hans, bedankt voor het meedenken en je kritische blik tijdens alle besprekingen. Ondanks 
je drukke schema was je erg betrokken bij mijn PhD project. Tijdens de besprekingen viel 
het me altijd weer op hoe goed je met een soort helicopterview over mijn PhD project kon 
kijken en mij daardoor weer de juiste richting op kon sturen als ik, onbewust, een zijpad was 
ingeslagen.
Marloes en Deborah, wat ben ik blij dat jullie naast mij staan op deze belangrijke dag. Bedankt 
voor alle hulp en gezelligheid de afgelopen jaren. Voor mij zijn jullie veel meer dan alleen 
collega’s. 
Lieve Deborah, begonnen als mijn student en nu paranimf bij mijn promotie, wat gaat de 
tijd snel. Je hebt tijdens je stage keihard gewerkt, wat heeft geresulteerd in mooie data voor 
hoofdstuk 3 van dit proefschrift en een mooie publicatie voor ons allebei! Tussen het harde 
werken door was het erg gezellig en ik vond het dan ook heel leuk dat we 1,5 jaar later PhD 
collega’s werden. Je vond de vele uurtjes gaptest in het donker vast zo leuk dat je graag 
terug wilde komen ;). Ik vond het heel fijn dat ik altijd bij je terecht kon voor vragen over 
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werk, maar ook voor een gezellig of serieus gesprek. En ook naast het werk hebben we veel 
lol gehad tijdens onze shopavondjes, bakavondjes, filmavondjes, dansavondjes en nog veel 
meer. Dit houden we erin!! En niet te vergeten, bedankt voor al die keren dat je mijn haren 
hebt gedaan voor feestjes, wat een luxe zo’n persoonlijke kapster. 
Lieve Marloes, ik heb je pas halverwege mijn PhD leren kennen en ik kan me herinneren dat 
ik vooral erg onder de indruk was (en nog steeds ben!) van wat je al had bereikt als jonge 
onderzoeker. Naast een gedreven onderzoeker bleek je ook al snel een hele leuke collega. Je 
was ondanks je eigen drukke planning altijd bereid mee te denken met mijn experimenten, 
artikelen en figuren. Ik heb dan ook regelmatig een beroep op je gedaan om eens kritisch 
naar een stuk tekst te kijken, waarop ik dan een mailtje terug kreeg met: “als je graag veel 
commentaar wilt, dan krijg je het ook ;)”. Waar ik, ondanks de soms lichte frustratie tijdens 
het verwerken van het commentaar, erg blij mee was! Ook buiten het werk is het altijd erg 
gezellig. Jij hebt mij enthousiast gemaakt voor de sportschool, wat heeft geresulteerd in 
vele fietstochtjes naar Wijchen en Beuningen, samen eten, samen sporten en de volgende 
dag samen klagen over spierpijn. Hopelijk gaan er nog heel veel sportlesjes (inmiddels in 
Nijmegen) en andere uitjes volgen! Bedankt dat ik altijd bij je terecht kan op leuke en op 
moeilijke momenten! Jij hebt me geleerd dat altijd alles goed komt. Al vergeet ik dat zo af en 
toe toch nog weer eventjes;) 
Collega’s van groep Homberg, bedankt voor al jullie hulp bij de experimenten, het bouwen 
van opstellingen, het meedenken met mijn onderzoek en vooral voor de leuke en gezellige 
tijd samen. Door jullie ging ik altijd met heel veel plezier naar het werk. Anthonieke (Piekjes), 
zonder al jouw hulp in het CDL en in Oss was ik nu nog lang niet klaar geweest. Ik heb veel 
van je geleerd de afgelopen jaren! En bedankt voor de gezellige daagjes in Veenendaal, aan 
mijn pianokwaliteiten moeten we nog wat verder gaan werken! Sjef, bedankt voor al je hulp 
bij praktische en technische klusjes op het CDL. Je was altijd bereid me te helpen als ik weer 
eens ruzie had met het aansluiten van de old-school video recorders. Vaak bood jouw extra 
voorraad ‘pielekes’ dan de uitkomst om verder te kunnen bouwen. Lourens en Michel, voor 
mij waren jullie de ervaren onderzoekers op de afdeling en ik heb dan ook regelmatig gebruik 
gemaakt van jullie expertise op het gebied van wetenschap en houtje-touwtje bouwkunsten, 
bedankt! Annemarie, al was ik in de tijd dat jij onze groep kwam versterken al voornamelijk 
op kantoor aan het schrijven, je leefde toch altijd erg mee met de vorderingen van mijn PhD. 
Bedankt voor het regelen van vele zaken op het CDL en de gezellige pauzes samen. Waar is 
die tijd gebleven dat iedere week iemand wat lekkers meenam voor de lunch?  
Mede-PhD collega’s bedankt voor alle hulp op het lab en op kantoor en ook voor de nodige 
gezelligheid na werktijd. Piet, Rick en Noortje het was erg gezelligheid tijdens het SFN-congres 
in San Diego. De nachtelijke zwemavonturen, Piets 10 cm dikke omeletten en onze roadtrip 
door West-Amerika zal ik niet snel vergeten. Peter bedankt voor het introduceren van de 
speciaal biertjes en je hulp bij het kiezen van een geschikt biertje voor mij. Foreign colleagues 
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Giuseppe, Sandra, Chao, Mina, Danielle, Yacine and Elisavet, first of all thanks a lot for all the 
delicious foreign food (Italian pasta, Chinese dumplings (and the fun to make them), Greek 
Moussaka, Algerian sweets, Spanish tortilla de patatas)! Elisavet, thanks for showing me (and 
others) your country, it was a very nice short holiday with a lot of great Greek food. Giuseppe 
it was nice talking about sports and swimming pools;). I still need to practice a bit more to be 
able to beat you and Chao with table tennis. And Sicily is still on my bucket list, I would love 
to try out the swimming pools there, haha! Ling, my epigenetics colleague, thanks for helping 
me with the molecular experiments. It was a pleasure to come to Amsterdam and, despite of 
being too late (oops!), attend a part of your thesis defense. Verder is dankzij velen van jullie 
mijn schaarse filmkennis significant verbreed tijdens de gezellige movie nights! Daarnaast 
waren de vele etentjes, aesculaafjes (a.k.a. Scooluf for the Spanish people) with my dear 
friend ‘Carolus’, dansavondjes en de jaarlijkse vierdaagse feesten altijd een groot succes. 
Sabrina, Deborah, Marloes, Piekjes en Elisavet: de leuke shopavondjes, dansvoorstellingen 
en high tea waren erg geslaagd, dit houden we erin! 
Mijn moleculaire collega’s. Evelyn en Tom, bedankt voor het overdragen van jullie RNA-seq en 
ChIP-seq kennis, de praatjes tijdens de vele wachtstappen en de gezelligheid bij het congres 
in Heidelberg, de vierdaagse feesten, de Kuukse kroegentocht (Yvet en carnaval vieren is 
zeer uitzonderlijk; dat is jullie toch maar mooi gelukt) en de dagjes uit! Kriti thanks for the 
discussions during the meetings and the fun during the dinners. Good luck with finishing 
your PhD. Astrid, in de eerste weken van mijn PhD heb ik je geloof ik iedere dag bestookt met 
vragen over RNA isolatie, RNA-seq procedures en het bestellen van kitjes en altijd stond je 
klaar om me te helpen, heel fijn. Ook later kon ik voor het leren van Western blotten weer bij 
je terecht, bedankt! Ellen, zonder jouw pipetteerkunsten was hoofdstuk 5 niet gepubliceerd! 
Eduardo, Eva and Kim, thanks for helping me with the RNA-seq experiments at the RIMLS. 
Martin, thanks for all the bioinformatic analyses and for co-writing the last two chapters. You 
are an outstanding and very dedicated researcher. Even from Brazil you were willing to help 
me with the analysis of the RNA-seq data, often in the evenings and in the weekends, thanks 
a lot! Willem, bedankt voor het meedenken met mijn project tijdens de vrijdagbesprekingen. 
Ook veel dank gaat uit naar mijn andere CNS collega’s. Benno, Gerard en Sharon, bedankt 
voor het meedenken met de verschillende moleculaire experimenten. Jos en Bram 
(officieel Anatomie), bedankt voor jullie hulp tijdens die keren dat ik mij heb gewaagd aan 
een immunokleuring. Renee, Ellen, Marieke, Inge, Aron, Nikkie, Piray, Lidiane, Erika and 
Annemieke thanks for the help in- and outside the lab, the work-related discussions and the 
fun during BBQs, pizza’s and beers!
Collega’s van het dierenlab, bedankt voor jullie hulp bij al het dierwerk. Fijn dat ik op jullie kon 
rekenen, vooral tijdens de vele weekenden dat er medicatie toegediend moest worden. Karin 
(ja met een K), vooral jij toonde altijd bijzonder veel interesse in alle onderzoeken, erg leuk! 
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De studenten die ik heb mogen begeleiden tijdens mijn promotieonderzoek. Alexander, Max, 
Stefan, Bart, Marijke en Ramona, bedankt voor jullie hulp bij de experimenten en veel succes 
met jullie carrières.
Naast iedereen die betrokken was bij mijn promotietraject zijn er nog veel meer mensen die 
belangrijk voor mij zijn geweest de afgelopen jaren.
Esmé en Casandra, jullie hebben me tijdens mijn stages enthousiast weten te maken voor de 
wetenschap en bij jullie heb ik de beginselen geleerd van de (epi)genetica, bedankt!
Mijn collega’s van het PDRC, Karin, Nienke, Ingrid, Anke, Patricia, Wendy, Regine, Nicole, 
Mariette, Martine, Maroeska en Jos. Wat fijn hoe jullie meeleefden met de laatste loodjes 
van mijn promotietraject. Ik heb veel van jullie geleerd de aflopen tijd: van serieuze 
vakinhoudelijke kennis, mooie uitspraken en levenslessen (misschien kun je ze bundelen in 
een boek Karin?), tot het knutselen van rupsen en vlinders (houdt je jong hè Ingrid? En het 
is niet voor niks een kinderafdeling!). Daarnaast heb ik onder jullie meerdere ‘lotgenoten’ 
gevonden die houden van een beetje zoetigheid. Die chocoladetaartjes houden we erin hoor 
Wendy en Nienke, ook al moeten we daarvoor het hele ziekenhuis door! Bedankt voor jullie 
betrokkenheid, gekheid en vele lovende woorden; dit gaf mij de energie om na een werkdag 
weer verder te schrijven aan mijn proefschrift. Het is nu eindelijk zo ver, mijn boekje is af, 
tijd voor een feestje! Dus ga maar vast beginnen met dat ABCtje dat jullie hadden beloofd ;)
Lieve Marcia en Manon, bedankt voor de vele gezellige, grappige en serieuze gesprekken. Als 
mede-medische biologen begrijpen jullie als geen ander hoe het er op een lab aan toe gaat. 
Inmiddels zitten we wat meer verspreid over Nederland en zijn de wekelijkse etentjes wat 
minder frequent geworden, maar zeker zo gezellig!! Ook onze weekendjes weg en andere 
activiteiten zijn altijd gezellig, erg lachwekkend en vol onverwachte wendingen (denk alleen 
al aan onze stuurkunsten in Giethoorn;)). Dat we nog maar veel meer leuke dingen samen 
gaan doen! 
Lieve Maron, we hebben elkaar leren kennen via turnen en staan inmiddels al heel wat jaartjes 
samen in de turnhal. Ik heb in al die jaren al vele bijnamen gehad, maar vanaf nu ben ik dus 
gepromoveerd van Kievit, Yellowfish en Intermediate sis, naar dr. Kroeze. Goed onthouden 
hè! Ook buiten de turnhal is het altijd supergezellig tijdens onze vakanties, stedentrips en 
avondjes bankhangen. Gelukkig hebben we nog heel veel leuke vakantiebestemmingen op 
ons lijstje staan voor de toekomst. Fijn dat ik zowel leuke en grappige dingen, als domme 
acties en moeilijke momenten met je kan delen; dankjewel dat je bent wie je bent! 
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Lieve Chantal, ook wij kennen elkaar inmiddels al heel wat jaartjes. Het is altijd erg gezellig 
om even bij te kletsen of er op uit te gaan voor een geocache. Tijdens onze stedentrips was je 
mijn maatje in het maken van ‘slimme’ opmerkingen. Iets met geocachen, Rome en stromend 
water? Dit heb ik de afgelopen vakanties wel gemist hoor! 
Maaike en Niels, Chantal en Mike en kleine Lune en nogmaals Maron (alias de ‘date’ groep). 
Jullie zorgden voor de broodnodige Twentse gezelligheid in de weekenden. Van escaperooms 
tot weekendjes weg, het was altijd gezellig. Op naar nog heel veel meer leuke uitjes! Daarnaast 
bedankt voor jullie interesse in mijn onderzoek de afgelopen jaren. Ik heb geprobeerd om de 
ratjes te trainen tot kleine Zonderlandjes en Wevertjes, maar tevergeefs… De oefeningen op 
de rekstok en evenwichtsbalk moeten ze toch nog wat harder oefenen. Nu is eindelijk mijn 
lang verwachte boekje klaar en is het tijd voor een feestje! 
Daarnaast wil ik ook graag Kris, Dennis, Marloes, Hanny, Saskia en de vrijdag turngroep van 
RSV Renata bedanken, met wie het altijd gezellig is om weer even bij te kletsen tijdens een 
kopje thee, een etentje, geocachen of het turnen.
En tot slot natuurlijk mijn familie. Familie Nijhuis en Kroeze bedankt voor jullie interesse (en 
nieuwsgierigheid) in mijn promotieonderzoek. Ik kreeg regelmatig de vraag wat ik nu precies 
met de ratjes deed en ik heb dus alvast een beetje kunnen oefenen voor mijn lekenpraatje. 
Lieve pap en mam, als ik in het weekend in Borne kwam stonden jullie altijd voor me klaar. 
Eten maken, op halen van het station of een wasje niets was te veel gevraagd in, zoals jullie 
het zelf noemen, ‘Hotel Kroeze’. Daarnaast toonden jullie altijd bijzonder veel interesse in 
mijn promotie onderzoek en mijn belevenissen in Nijmegen. Leonie, jij weet als geen ander 
wat het is om een promotieonderzoek te doen en ik kon dan ook altijd bij je terecht voor 
hulp bij experimenten/ analyses en om mooie resultaten of juist frustraties over mislukte 
experimenten te delen. Leuk dat we voor hoofdstuk 6 van dit proefschrift samen hebben 
mogen werken. En hoewel ik er eerst een beetje op tegen was, is het toch wel handig en 
gezellig dat je nu in dezelfde flat woont. Bedankt voor al jullie steun en liefde!
Yvet
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Curriculum Vitae
Yvet Kroeze werd geboren op 19 oktober 1985 te Almelo. Ze groeide op in Borne en behaalde 
in 2004 haar VWO-diploma aan Scholengemeenschap De Grundel te Hengelo. Hierna begon 
ze aan haar Bachelor Biologie en Medisch laboratorium onderzoek aan de Saxion Hogeschool 
te Enschede, welke werd afgerond in augustus 2007 (Cum laude). Hierna begon ze aan de 
Master Medische Biologie aan de Radboud Universiteit Nijmegen. Tijdens haar Master 
programma heeft ze twee wetenschappelijke stages gedaan. Haar eerste wetenschappelijke 
stage heeft ze gelopen bij de afdeling Nierziekten van het Radboudumc. Onder begeleiding 
van Dr. Casandra van Bavel en Dr. Johan van der Vlag heeft ze onderzoek uitgevoerd naar 
histon modificaties bij de auto-immuunziekte systemische lupus erythematosus. Tijdens 
haar tweede Masterstage, bij de afdeling Genetica op het Radboudumc, heeft ze onderzoek 
gedaan naar de betrokkenheid van het gen BTG1 bij het ontstaan van acute lymfatische 
leukemie bij kinderen onder begeleiding van Dr. Esme Waanders en Dr. Roland Kuiper. Na het 
behalen van haar Master diploma in 2010 (bene meritum) is ze begin 2011 begonnen aan haar 
promotieonderzoek binnen de afdeling Cognitieve Neuroscience van het Donders institute 
for Brain, Cognition and Behaviour en de afdeling Genetica van het Radboudumc onder 
leiding van Judith Homberg, Huiqing Zhou en Hans van Bokhoven. Tijdens dit promotietraject 
heeft ze onderzoek gedaan naar de  effecten van het serotonine systeem op gedrag en gen 
expressie. De resultaten van het onderzoek zijn beschreven in dit proefschrift en daarnaast zijn 
de bevindingen gepresenteerd op verschillende (inter)nationale congressen, zoals de Society 
for Neuroscience, Donders Discussions, Dutch Neuroscience meeting en het symposium van 
de Nederlandse Vereniging voor Farmacologie. Tijdens haar promotieonderzoek heeft ze 
verschillende cursussen gevolgd waaronder Statistiek voor promovendi en Writing course 
“On papers and publishing”. Na haar promotieonderzoek is ze gaan werken bij de afdeling 
Kindergeneeskunde waar ze zich bezig houdt met datamanagement van klinische trials in 
met name de kinderoncologie. 
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5-HT  5-hydroxytryptamine; serotonin
5-HTT 5-hydroxytryptamine transporter; serotonin 
transporter 
5-HTTLPR  5-hydroxytryptamine transporter-linked   
                  polymorphic region
5hmC 5-hydroxymethylcytosine 
5mC 5-methylcytosine
AC  Adenylyl cyclase 
ACC Anterior cingulate cortex
ACTH  Adrenocorticotropic hormone 
AD(H)D  Attention deficit (hyperactivity) disorder 
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazole propionic  
  acid 
ANOVA Analysis of variance
ASD Autism spectrum disorder
Avp  Arginine vasopressin 
BDNF  Brain-derived neurotrophic factor
CA Cornu Ammonis 
cDNA Complementary deoxyribonucleic acid
ChIP-seq Chromatin immuno-precipitation followed by        
  sequencing 
CMS Chronic mild stress 
CNS Central nervous system
COMT  Catechol-O-methyltransferase
CpG Cytosine-phosphate-guanine 
CREB  cAMP-response element-binding protein
CRF  Corticotrophin releasing factor 
CSF Cerebrospinal fluid 
D2 Discrimination index 
DA Dopamine 
DAVID  Database for Annotation, Visualization and 
  Integrated Discovery
DG Dentate gyrus 
DLPFC Dorsolateral prefrontal cortex
DNMT DNA methyltransferases 
DRN Dorsal raphe nucleus 
DSM-5 Diagnostic and Statistical Manual of Mental 
 Disorders, fifth revision
E(2) Estradiol 
ES cell Embryonic stem cell
FACS Fluorescence-activated cell sorting 
FPKM Fragments Per Kilobase per Million mapped reads
GABA  Gamma-aminobutyric acid 
Gap-43  Growth-associated protein-43
GD Gestational day 
GO Gene ontology 
GR  Glucocorticoid receptor 
GSK3B  Glycogen synthase kinase-3beta 
GWAS Genome-wide association studies 
HDAC Histone deacetylase  
HPA-axis  Hypothalamus-pituitary-adrenal axis
HTR  Hydroxytryptamine receptor
ID Intellectual disability 
IDO  Indoleamine 2,3-dioxygenase 
LCLs  Lymphoblastoid cell lines
lincRNA Long intergenic non-coding RNA
MAOI Monoamine oxidase inhibitor
MDD  Major depressive disorder
miRNA micro ribonucleic acid
mPFC Medial prefrontal cortex
MR  Mineralocorticoid receptor 
mRNA messenger ribonucleic acid
mTOR  Mechanistic target of rapamycin
ncRNA non-coding ribonucleic acid
NE Norepinephrine 
NMDA  N-Methyl-D-aspartic acid
NOR novel object recognition 
NPY  Neuropeptide Y
NRI Norepinephrine reuptake inhibitor
NSFT Novelty-suppressed feeding test
OCD Obsessive compulsive disorder
ODB Object directed behavior 
OFC Orbitofrontal cortex
OFCo  Time spent in the corner
OFCe  Time spent in the center
OFT Open field test 
OPC Oligodendrocyte progenitor cell
Oxt  Oxytocin 
PC Principal component
PCA principal component analysis 
PCC Pearson correlation coefficient 
PCR Polymerase chain reaction
PDE  cAMP-specific phosphodiesterases 
PFC Prefrontal cortex 
PKA  Protein kinase A
PKC Protein kinase C 
PLC Phospholipase C 
PND Postnatal day
POMC  Proopiomelanocortin 
PPHN Persistent pulmonary hypertension 
PPI  Prepulse inhibition
PTSD Post-traumatic stress disorder
PVN Paraventricular nucleus 
qPCR Quantitative polymerase chain reaction
REM  Rapid eye movement
RNA  Ribonucleic acid
RNA-seq  Ribonucleic acid sequencing
RT Reverse transcription
SCZ Schizophrenia 
S.E.M  Standard error of the mean
SGZ Subgranular zone 
siRNA Small interfering ribonucleic acid
SNP  Single nucleotide polymorphism
SNRI Serotonin-norepinephrine reuptake inhibitor
SPSS Statistical Package for the Social Sciences
SSRIs  Selective serotonin reuptake inhibitors 
TCA  Tricyclic antidepressant
TCAs  Thalamocortical axons 
tPA  Plasminogen activator
Tph  L-tryptophan hydroxylase 
VEGF  Vascular endothelial growth factor 
VLPFC Ventrolateral prefrontal cortex 
VZ Ventricular zone 
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Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established the 
Donders Graduate School for Cognitive Neuroscience (DGCN), which was officially recognised 
as a national graduate school in 2009. The Graduate School covers training at both Master’s 
and PhD level and provides an excellent educational context fully aligned with the research 
programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in biology, 
physics, psycholinguistics, psychology, behavioral science, medicine and related disciplines. 
Selective admission and assessment centers guarantee the enrolment of the best and most 
motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni show 
a continuation in academia with postdoc positions at top institutes worldwide, e.g. Stanford 
University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, Hanyang 
University in South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.. Positions outside 
academia spread among the following sectors: specialists in a medical environment, mainly 
in genetics, geriatrics, psychiatry and neurology. Specialists in a psychological environment, 
e.g. as specialist in neuropsychology, psychological diagnostics or therapy. Positions in higher 
education as coordinators or lecturers. A smaller percentage enters business as research 
consultants, analysts or head of research and development. Fewer graduates  stay in a 
research environment as lab coordinators, technical support or policy advisors. Upcoming 
possibilities are positions in the IT sector and management position in pharmaceutical 
industry. In general, the PhDs graduates almost invariably continue with high-quality positions 
that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/
